INSERT INTO `brands` (`id`, `brand_name`, `unit_price`, `strength`, `generic_id`, `dosage_id`, `company_id`, `created_at`, `updated_at`) VALUES
(22724, 'Z-sil', '25.17', '10 mg/5 ml (100 ml bottle)', '1124', '59', '174', '2022-09-09 18:47:42', '2022-09-09 18:47:42'),
(22725, 'Z-sil', '48.33', '10 mg/5 ml (200 ml bottle)', '1124', '59', '174', '2022-09-09 18:50:28', '2022-09-09 18:50:28'),
(22726, 'Zeal', '30.15', '10 mg/5 ml', '1124', '59', '98', '2022-09-09 18:51:16', '2022-09-09 18:51:16'),
(22727, 'Zedex', '1.51', '20 mg', '1124', '13', '43', '2022-09-09 18:51:38', '2022-09-09 18:51:38'),
(22728, 'Zedex DS', '30.00', '10 mg/5 ml', '1124', '59', '43', '2022-09-09 18:52:41', '2022-09-09 18:52:41'),
(22729, 'Zedex Max', '55.00', '20 mg/5 ml', '1124', '59', '43', '2022-09-09 18:53:28', '2022-09-09 18:53:28'),
(22730, 'Zee-1', '30.00', '4.05 mg/5 ml', '1124', '59', '90', '2022-09-09 19:26:10', '2022-09-09 19:26:10'),
(22731, 'Zee-2', '50.00', '10 mg/5 ml', '1124', '59', '90', '2022-09-09 19:26:58', '2022-09-09 19:26:58'),
(22732, 'Zeenee', '30.00', '10 mg/5 ml', '1124', '59', '51', '2022-09-09 19:27:50', '2022-09-09 19:27:50'),
(22733, 'Zeenk', '32.00', '10 mg/5 ml', '1124', '59', '54', '2022-09-09 19:28:25', '2022-09-09 19:28:25'),
(22734, 'Zemin', '30.00', '10 mg/5 ml', '1124', '59', '73', '2022-09-09 19:29:10', '2022-09-09 19:29:10'),
(22735, 'Zemin', '2.70', '20 mg', '1124', '13', '73', '2022-09-09 19:31:13', '2022-09-09 19:31:13'),
(22736, 'Zemin DS', '55.00', '20 mg/5 ml', '1124', '59', '73', '2022-09-09 19:32:12', '2022-09-09 19:32:12'),
(22737, 'Zep', '35.11', '20 mg/5 ml', '1124', '59', '23', '2022-09-09 19:33:03', '2022-09-09 19:33:03'),
(22738, 'Zep Junior', '35.11', '10 mg/5 ml', '1124', '59', '23', '2022-09-09 19:33:42', '2022-09-09 19:33:42'),
(22739, 'Zesup', '35.11', '10 mg/5 ml', '1124', '59', '179', '2022-09-09 19:34:32', '2022-09-09 19:34:32'),
(22740, 'Zico', '32.00', '10 mg/5 ml', '1124', '59', '78', '2022-09-09 19:35:14', '2022-09-09 19:35:14'),
(22741, 'Zido', '35.11', '10 mg/5 ml', '1124', '59', '130', '2022-09-09 19:36:04', '2022-09-09 19:36:04'),
(22742, 'Ziflu', '1.50', '20 mg', '1124', '13', '92', '2022-09-09 19:36:48', '2022-09-09 19:36:48'),
(22743, 'Zilfu', '30.00', '10 mg/5 ml', '1124', '59', '92', '2022-09-09 19:37:41', '2022-09-09 19:37:41'),
(22744, 'Zifort', '30.00', '10 mg/5 ml', '1124', '59', '72', '2022-09-09 19:39:26', '2022-09-09 19:39:26'),
(22745, 'Zikid', '35.00', '10 mg/5 ml', '1124', '59', '82', '2022-09-09 19:40:18', '2022-09-09 19:40:18'),
(22746, 'Zimon', '1.75', '20 mg', '1124', '13', '196', '2022-09-09 19:40:45', '2022-09-09 19:40:45'),
(22747, 'Zimon', '1.75', '20 mg', '1124', '13', '196', '2022-09-09 19:40:55', '2022-09-09 19:40:55'),
(22748, 'Zimon', '1.75', '20 mg', '1124', '13', '196', '2022-09-09 19:40:55', '2022-09-09 19:40:55'),
(22749, 'Zimon', '30.00', '10 mg/5 ml', '1124', '59', '196', '2022-09-09 19:43:53', '2022-09-09 19:43:53'),
(22750, 'Zinc Kid', '20.00', '20 mg', '1124', '13', '22', '2022-09-09 19:44:40', '2022-09-09 19:44:40'),
(22751, 'Zinc Sulphate', '30.00', '10 mg/5 ml', '1124', '59', '30', '2022-09-09 19:45:26', '2022-09-09 19:45:26'),
(22752, 'Zinc-AG', '52.00', '10 mg/5 ml', '1124', '59', '173', '2022-09-09 19:46:10', '2022-09-09 19:46:10'),
(22753, 'Zinc-R', '2.75', '20 mg', '1124', '13', '156', '2022-09-09 19:47:00', '2022-09-09 19:47:00'),
(22754, 'Zinc-S', '25.00', '10 mg/5 ml', '1124', '59', '27', '2022-09-09 19:47:48', '2022-09-09 19:47:48'),
(22755, 'Zinca', '35.00', '10 mg/5 ml', '1124', '59', '32', '2022-09-09 19:48:38', '2022-09-09 19:48:38'),
(22756, 'Zincare', '2.00', '20 mg', '1124', '13', '98', '2022-09-09 19:49:46', '2022-09-09 19:49:46'),
(22757, 'Zincase', '27.00', '10 mg/5 ml', '1124', '59', '159', '2022-09-09 19:50:28', '2022-09-09 19:50:28'),
(22758, 'Zincep', '30.00', '10 mg/5 ml', '1124', '59', '62', '2022-09-09 19:51:13', '2022-09-09 19:51:13'),
(22759, 'Zincoral', '30.00', '10 mg/5 ml', '1124', '59', '197', '2022-09-09 19:52:03', '2022-09-09 19:52:03'),
(22760, 'Zincoral DT', '2.00', '20 mg', '1124', '13', '197', '2022-09-09 19:52:55', '2022-09-09 19:52:55'),
(22761, 'ZincTab', '2.75', '20 mg', '1124', '13', '91', '2022-09-09 19:53:47', '2022-09-09 19:53:47'),
(22762, 'Zinga', '35.00', '10 mg/5 ml', '1124', '59', '45', '2022-09-09 19:54:31', '2022-09-09 19:54:31'),
(22763, 'Zinga', '2.00', '20 mg', '1124', '13', '45', '2022-09-09 19:55:16', '2022-09-09 19:55:16'),
(22764, 'Zinofa', '30.00', '10 mg/5 ml', '1124', '59', '117', '2022-09-09 19:56:08', '2022-09-09 19:56:08'),
(22765, 'Zinon', '1.48', '20 mg', '1124', '13', '112', '2022-09-09 19:56:59', '2022-09-09 19:56:59'),
(22766, 'Zinon', '34.00', '10 mg/5 ml', '1124', '59', '112', '2022-09-09 19:57:50', '2022-09-09 19:57:50'),
(22767, 'Zinpro', '30.00', '10 mg/5 ml', '1124', '59', '102', '2022-09-09 19:59:15', '2022-09-09 19:59:15'),
(22768, 'Zins', '26.00', '10 mg/5 ml', '1124', '59', '93', '2022-09-09 20:00:00', '2022-09-09 20:00:00'),
(22769, 'Zinsul', '28.00', '4.05 mg/5 ml', '1124', '59', '64', '2022-09-09 20:00:54', '2022-09-09 20:00:54'),
(22770, 'Zinta-20', '50.00', '20 mg/5 ml', '1124', '59', '120', '2022-09-09 20:01:45', '2022-09-09 20:01:45'),
(22771, 'Zinton', '35.00', '10 mg/5 ml', '1124', '59', '116', '2022-09-09 20:02:31', '2022-09-09 20:02:31'),
(22772, 'Zipol', '32.00', '10 mg/5 ml', '1124', '59', '31', '2022-09-09 20:03:14', '2022-09-09 20:03:14'),
(22773, 'Ziqui', '35.00', '10 mg/5 ml', '1124', '59', '119', '2022-09-09 20:04:11', '2022-09-09 20:04:11'),
(22774, 'Zis-DS', '38.11', '10 mg/5 ml', '1124', '59', '19', '2022-09-09 20:05:39', '2022-09-09 20:05:39'),
(22775, 'Zismo', '35.00', '10 mg/5 ml', '1124', '59', '101', '2022-09-09 20:06:32', '2022-09-09 20:06:32'),
(22776, 'Zisul', '25.00', '10 mg/5 ml', '1124', '59', '111', '2022-09-09 20:07:16', '2022-09-09 20:07:16'),
(22777, 'Zisulmet', '30.00', '10 mg/5 ml', '1124', '59', '113', '2022-09-09 20:07:54', '2022-09-09 20:07:54'),
(22778, 'Ziton', '30.10', '10 mg/5 ml', '1124', '59', '65', '2022-09-09 20:08:33', '2022-09-09 20:08:33'),
(22779, 'Zixol', '30.00', '10 mg/5 ml', '1124', '59', '190', '2022-09-09 20:09:21', '2022-09-09 20:09:21'),
(22780, 'Zixol', '2.00', '20 mg', '1124', '13', '190', '2022-09-09 20:10:23', '2022-09-09 20:10:23'),
(22781, 'ZMS', '35.00', '10 mg/5 ml', '1124', '59', '170', '2022-09-09 20:11:07', '2022-09-09 20:11:07'),
(22782, 'Zn', '35.00', '10 mg/5 ml', '1124', '59', '28', '2022-09-09 20:11:51', '2022-09-09 20:11:51'),
(22783, 'Zs', '30.00', '10 mg/5 ml', '1124', '59', '60', '2022-09-09 20:12:35', '2022-09-09 20:12:35'),
(22784, 'ZT', '1.51', '20 mg', '1124', '13', '39', '2022-09-09 20:13:23', '2022-09-09 20:13:23'),
(22785, 'Zym', '30.00', '4.05 mg/5 ml', '1124', '59', '88', '2022-09-09 20:14:31', '2022-09-09 20:14:31'),
(22786, 'Zym DS', '35.00', '10 mg/5 ml', '1124', '59', '88', '2022-09-09 20:15:13', '2022-09-09 20:15:13'),
(22787, 'Zipradon', '5.00', '20 mg', '1125', '16', '65', '2022-09-09 20:19:49', '2022-09-09 20:19:49'),
(22788, 'Zipradon', '10.00', '40 mg', '1125', '16', '65', '2022-09-09 20:20:36', '2022-09-09 20:20:36'),
(22789, 'Acidron', '5000.00', '4 mg/5 ml', '1126', '50', '18', '2022-09-09 20:21:24', '2022-09-09 20:21:24'),
(22790, 'Drometa', '5000.00', '4 mg/5 ml', '1126', '50', '92', '2022-09-09 20:22:08', '2022-09-09 20:22:08'),
(22791, 'Ostometa', '5000.00', '4 mg/5 ml', '1126', '50', '185', '2022-09-09 20:22:47', '2022-09-09 20:22:47'),
(22792, 'Xoleron', '5000.00', '4 mg/5 ml', '1126', '50', '39', '2022-09-09 20:23:25', '2022-09-09 20:23:25'),
(22793, 'Zerlinda', '7800.00', '4 mg/5 ml', '1126', '50', '47', '2022-09-09 20:24:09', '2022-09-09 20:24:09'),
(22794, 'Zoclast', '6500.00', '4 mg/5 ml', '1126', '50', '89', '2022-09-09 20:24:44', '2022-09-09 20:24:44'),
(22795, 'Zometa', '30113.60', '4 mg/5 ml', '1126', '50', '128', '2022-09-09 20:25:32', '2022-09-09 20:25:32'),
(22796, 'Aclasta', '33927.98', '5 mg/100 ml', '1127', '50', '167', '2022-09-09 20:26:29', '2022-09-09 20:26:29'),
(22797, 'Bonizol', '6000.00', '5 mg/100 ml', '1127', '50', '179', '2022-09-09 20:27:05', '2022-09-09 20:27:05'),
(22798, 'Zoledron', '5950.00', '5 mg/100 ml', '1127', '50', '136', '2022-09-09 20:28:34', '2022-09-09 20:28:34'),
(22799, 'Zolenic', '6000.00', '5 mg/100 ml', '1127', '50', '92', '2022-09-09 20:29:13', '2022-09-09 20:29:13'),
(22800, 'Zoltero', '7000.00', '5 mg/100 ml', '1127', '50', '43', '2022-09-09 20:30:02', '2022-09-09 20:30:02'),
(22801, 'Miotrol', '17.00', '2.5 mg', '1128', '13', '65', '2022-09-09 20:30:48', '2022-09-09 20:30:48'),
(22802, 'Nomi', '25.17', '2.5 mg', '1128', '13', '179', '2022-09-09 20:31:34', '2022-09-09 20:31:34'),
(22803, 'Nomiten', '20.00', '2.5 mg', '1128', '13', '162', '2022-09-09 20:32:28', '2022-09-09 20:32:28'),
(22804, 'Zolmit', '25.00', '2.5 mg', '1128', '13', '43', '2022-09-09 20:33:05', '2022-09-09 20:33:05'),
(22805, 'Zomitan', '25.00', '2.5 mg', '1128', '13', '92', '2022-09-09 20:33:45', '2022-09-09 20:33:45'),
(22806, 'Nitrest', '4.96', '10 mg', '1129', '13', '180', '2022-09-09 20:34:32', '2022-09-09 20:34:32'),
(22807, 'Xonimide', '15.00', '50 mg', '1130', '16', '39', '2022-09-10 01:36:26', '2022-09-10 01:36:26'),
(22808, 'Xonimide', '15.00', '50 mg', '1130', '16', '39', '2022-09-10 01:36:26', '2022-09-10 01:36:26'),
(22809, 'Xonimide', '15.00', '50 mg', '1130', '13', '39', '2022-09-10 01:36:59', '2022-09-10 01:36:59'),
(22810, 'Xonimide', '15.00', '50 mg', '1130', '13', '39', '2022-09-10 01:38:02', '2022-09-10 01:38:02'),
(22811, 'Xonimide', '15.00', '50 mg', '1130', '13', '39', '2022-09-10 01:38:03', '2022-09-10 01:38:03'),
(22812, 'Xonimide', '15.00', '50 mg', '1130', '13', '39', '2022-09-10 01:38:03', '2022-09-10 01:38:03'),
(22813, 'Imovane', '10.03', '7.5 mg', '1131', '13', '198', '2022-09-10 01:39:07', '2022-09-10 01:39:07'),
(22814, 'Imovane', '10.03', '7.5 mg', '1131', '13', '198', '2022-09-10 01:39:56', '2022-09-10 01:39:56'),
(22815, 'Imovane', '10.03', '7.5 mg', '1131', '13', '198', '2022-09-10 01:39:56', '2022-09-10 01:39:56'),
(22816, 'Alben Suspension 10 ml', '23', '200 mg.', '53', '67', '71', '2023-11-15 21:18:55', '2023-11-15 21:18:55');

-- --------------------------------------------------------

--
-- Table structure for table `categories`
--

CREATE TABLE `categories` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `cat_name` varchar(255) NOT NULL,
  `cat_image` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `categories`
--

INSERT INTO `categories` (`id`, `cat_name`, `cat_image`, `created_at`, `updated_at`) VALUES
(1, 'Medicine', '2057881846.png', '2022-02-01 07:05:58', '2022-02-05 06:03:25'),
(2, 'Instrument', '44380425.jpg', '2022-02-05 06:05:08', '2022-03-19 05:35:35'),
(3, 'Equipment', '1964382052.png', '2022-02-05 06:04:08', '2022-02-05 06:04:08'),
(4, 'Chemicals', '437507649.png', '2022-02-05 06:04:42', '2022-02-05 06:04:42'),
(5, 'Vaccines', '1389513561.jpg', '2022-02-05 06:05:08', '2022-02-10 22:02:07'),
(9, 'Gauze, Bandage & Cotton', '1484021140.jpg', '2022-02-05 06:05:08', '2022-03-19 05:36:10'),
(10, 'Furniture', '15079573.jpg', '2022-02-05 06:05:08', '2022-03-19 05:37:13'),
(11, 'Linen item', '1590973004.jpg', '2022-02-05 06:05:08', '2022-03-19 05:37:29'),
(12, 'Miscellaneous', '1002471065.jpg', '2022-02-05 06:05:08', '2022-03-19 05:37:58');

-- --------------------------------------------------------

--
-- Table structure for table `doctors`
--

CREATE TABLE `doctors` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `doctor_name` varchar(255) NOT NULL,
  `doctor_qualification` varchar(255) DEFAULT NULL,
  `department` varchar(255) DEFAULT NULL,
  `medical` varchar(255) DEFAULT NULL,
  `chamber` varchar(255) DEFAULT NULL,
  `contact_no` varchar(255) DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `doctors`
--

INSERT INTO `doctors` (`id`, `doctor_name`, `doctor_qualification`, `department`, `medical`, `chamber`, `contact_no`, `created_at`, `updated_at`) VALUES
(1, 'Brig. Gen. Prof. Dr. MHM Delwar Hossain', 'MBBS, DA, MCPS, FCPS (Anesthesiology)', 'Anesthesia', 'Combined Military Hospital (CMH), Dhaka', 'IBN SINA Diagnostic, Dhanmondi', '+8809610010615', '2022-07-05 21:08:38', '2022-07-07 06:13:07');

-- --------------------------------------------------------

--
-- Table structure for table `documents`
--

CREATE TABLE `documents` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `title` varchar(255) NOT NULL,
  `document_file` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `documents`
--

INSERT INTO `documents` (`id`, `title`, `document_file`, `created_at`, `updated_at`) VALUES
(2, 'Allopathic Drug Manufacturers', '196108735(alpha-medicare.com).pdf', '2022-01-31 01:34:05', '2022-01-31 01:34:05');

-- --------------------------------------------------------

--
-- Table structure for table `dosages`
--

CREATE TABLE `dosages` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `dosage_forms` varchar(255) NOT NULL,
  `icon_image` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `dosages`
--

INSERT INTO `dosages` (`id`, `dosage_forms`, `icon_image`, `created_at`, `updated_at`) VALUES
(10, 'Injection', '613521979.png', '2022-01-17 06:11:06', '2022-02-05 05:29:47'),
(13, 'Tablet', '893443473.jpg', '2022-02-08 07:12:07', '2022-02-14 07:31:39'),
(14, 'Tablet (Bilayer)', '1502494636.jpg', '2022-02-14 07:32:23', '2022-02-14 07:32:23'),
(15, 'Tablet (Bolus)', '1240512968.jpg', '2022-02-14 07:32:41', '2022-02-14 07:32:41'),
(16, 'Capsul', '1088958628.jpg', '2022-02-14 07:33:38', '2022-02-14 07:33:38'),
(17, 'Capsule (Blended Pellets)', '51312374.jpg', '2022-02-14 07:34:07', '2022-02-14 07:34:07'),
(18, 'Capsule (Controlled Release)', '1845920128.jpg', '2022-02-14 07:34:27', '2022-02-14 07:34:27'),
(19, 'Capsule (Delayed Release)', '1501779033.jpg', '2022-02-14 07:34:48', '2022-02-14 07:34:48'),
(20, 'Capsule (Extended Release)', '1062219053.jpg', '2022-02-14 07:35:17', '2022-02-14 07:35:17'),
(21, 'Capsule (Liquid Filled)', '130650619.jpg', '2022-02-14 07:35:43', '2022-02-14 07:35:43'),
(22, 'Capsule (Micronized)', '1174858189.jpg', '2022-02-14 07:36:04', '2022-02-14 07:36:04'),
(23, 'Capsule (Modified Release)', '1506466161.jpg', '2022-02-14 07:36:26', '2022-02-14 07:36:26'),
(24, 'Capsule (Sustained Release)', '1214424913.jpg', '2022-02-14 07:36:51', '2022-02-14 07:36:51'),
(25, 'Capsule (Time Release)', '2142144475.jpg', '2022-02-14 07:37:12', '2022-02-14 07:37:12'),
(26, 'Tablet (Chewable)', '1617082467.jpg', '2022-02-14 07:39:58', '2022-02-14 07:39:58'),
(27, 'Tablet (Chewing Ghum)', '443922052.jpg', '2022-02-14 07:40:33', '2022-02-14 07:40:33'),
(28, 'Oral Solution (Concentrated)', '1447935884.jfif', '2022-02-14 07:44:25', '2022-02-14 07:44:25'),
(29, 'Cream', '1315487341.jpg', '2022-02-14 07:56:19', '2022-02-14 07:56:19'),
(30, 'Dental Gel', '1954430265.jpg', '2022-02-14 08:14:17', '2022-02-14 08:14:17'),
(31, 'Dialysis Solution', '2015830889.jpg', '2022-02-14 08:15:54', '2022-02-14 08:15:54'),
(32, 'Ear Drop', '1499834786.jpg', '2022-02-14 08:16:10', '2022-02-14 08:16:10'),
(33, 'Effervescent Granules', '1413144780.jpg', '2022-02-14 08:16:31', '2022-02-14 08:16:31'),
(34, 'Effervescent Powder', '1177482362.jpg', '2022-02-14 08:16:59', '2022-02-14 08:16:59'),
(35, 'Effervescent Tablet', '1306434543.jfif', '2022-02-14 08:17:15', '2022-02-14 08:17:15'),
(36, 'Elixir', '1095718140.jpg', '2022-02-14 08:18:12', '2022-02-14 08:18:12'),
(37, 'Emulsion for Infusion', '49676300.jpg', '2022-02-14 08:18:45', '2022-02-14 08:18:45'),
(38, 'Eye Capsule', '799208781.jpg', '2022-02-14 08:19:02', '2022-02-14 08:19:02'),
(39, 'Eye Drops', '43910187.jpg', '2022-02-14 08:19:19', '2022-02-14 08:19:19'),
(40, 'Tablet Flash', '1612827600.jpg', '2022-02-14 08:19:36', '2022-02-14 08:19:36'),
(41, 'Gas', '765869097.jpg', '2022-02-14 08:19:56', '2022-02-14 08:19:56'),
(42, 'Gel', '1628514015.jpg', '2022-02-14 08:20:07', '2022-02-14 08:20:07'),
(43, 'Granules for Suspension', '1119415678.jpg', '2022-02-14 08:20:29', '2022-02-14 08:20:29'),
(44, 'Injection', '1899872329.jpg', '2022-02-14 08:21:30', '2022-02-14 08:21:30'),
(45, 'Injection IM', '1013611975.jpg', '2022-02-14 08:22:17', '2022-02-14 08:22:17'),
(46, 'Injection IV', '613552200.jpg', '2022-02-14 08:22:32', '2022-02-14 08:22:32'),
(47, 'Injection IM/SC/Deep SC', '1664601159.jpg', '2022-02-14 08:23:16', '2022-02-14 08:23:16'),
(48, 'Inhaler', '1943916869.jpg', '2022-02-14 08:23:41', '2022-02-14 08:23:41'),
(49, 'IV Injection', '1333422969.jpg', '2022-02-14 08:24:30', '2022-02-14 08:24:30'),
(50, 'IV Infusion', '429478035.jpg', '2022-02-14 08:24:46', '2022-02-14 08:24:46'),
(51, 'Liquid', '1179459580.jpg', '2022-02-14 08:25:02', '2022-02-14 08:25:02'),
(52, 'Mouthwash', '1441751281.jpg', '2022-02-14 08:25:31', '2022-02-14 08:25:31'),
(53, 'Nebulizer Solution', '677634650.jpg', '2022-02-14 08:27:50', '2022-02-14 08:27:50'),
(54, 'Respiratory Solution', '973816627.jpg', '2022-02-14 08:28:22', '2022-02-14 08:28:22'),
(55, 'Solution', '1548323011.jpg', '2022-02-14 08:28:37', '2022-02-14 08:28:37'),
(56, 'Solution for Inhalation', '2016868257.jpg', '2022-02-14 08:28:58', '2022-02-14 08:28:58'),
(57, 'Spray', '1064339703.jpg', '2022-02-14 08:29:13', '2022-02-14 08:29:13'),
(58, 'Suppository', '394727285.jpg', '2022-02-14 08:29:32', '2022-02-14 08:29:32'),
(59, 'Syrup', '1836649919.jpg', '2022-02-14 08:29:49', '2022-02-14 08:29:49'),
(60, 'Topical Gel', '1882115377.jpg', '2022-02-14 08:30:14', '2022-02-14 08:30:14'),
(61, 'Topical Powder', '1314556207.jpg', '2022-02-14 08:30:30', '2022-02-14 08:30:30'),
(62, 'Topical Solution', '663630124.jpg', '2022-02-14 08:30:47', '2022-02-14 08:30:47'),
(63, 'Vaginal Gel', '518987080.jpg', '2022-02-14 08:31:25', '2022-02-14 08:31:25'),
(64, 'Vaginal Suppository', '874053190.jfif', '2022-02-14 08:31:46', '2022-02-14 08:31:46'),
(65, 'Vaginal Tablet', '429235888.jfif', '2022-02-14 08:32:02', '2022-02-14 08:32:02'),
(66, 'Ophthalmic Oinment', '376550400.jpg', '2022-04-17 05:19:04', '2022-04-17 05:19:04'),
(67, 'Oral Suspension', '458354161.png', '2022-04-18 05:12:29', '2022-04-18 05:12:29'),
(68, 'IM Injection', '1244839419.jpg', '2022-04-21 06:12:53', '2022-04-21 06:12:53'),
(69, 'Ophthalmic Solution', '1254031674.jfif', '2022-04-21 18:24:07', '2022-04-21 18:24:07'),
(70, 'Pediatric Drops', '1492158157.jpg', '2022-04-23 15:14:55', '2022-04-23 15:14:55'),
(71, 'Oral Paste', '330707731.jfif', '2022-05-09 20:29:34', '2022-05-09 20:29:34'),
(73, 'Nail Lacquer', '1115803818.jpg', '2022-05-11 23:09:47', '2022-05-11 23:09:47'),
(75, 'Powder for Suspension', '1348061392.jpg', '2022-05-11 23:17:52', '2022-05-11 23:17:52'),
(76, 'Oral Powder', '1453520418.png', '2022-05-20 00:46:47', '2022-05-20 00:46:47'),
(77, 'SC Injection', '118822203.jpg', '2022-06-21 05:49:13', '2022-06-21 05:49:13'),
(78, 'IM/SC Injection', '1630638402.jpg', '2022-07-03 06:09:42', '2022-07-03 06:09:42');

-- --------------------------------------------------------

--
-- Table structure for table `failed_jobs`
--

CREATE TABLE `failed_jobs` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `uuid` varchar(255) NOT NULL,
  `connection` text NOT NULL,
  `queue` text NOT NULL,
  `payload` longtext NOT NULL,
  `exception` longtext NOT NULL,
  `failed_at` timestamp NOT NULL DEFAULT current_timestamp()
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `generics`
--

CREATE TABLE `generics` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `generic_name` varchar(255) NOT NULL,
  `category_id` int(11) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `generics`
--

INSERT INTO `generics` (`id`, `generic_name`, `category_id`, `created_at`, `updated_at`) VALUES
(21, 'Lidocaine Hydrochloride 2% (Injection)', 1, '2022-01-29 04:30:45', '2022-02-10 02:20:52'),
(22, 'List of Generic Names (Herbal)', 2, '2022-01-29 04:34:00', '2022-01-29 04:34:00'),
(23, 'List of generic name Name (v)', 3, '2022-02-01 06:31:59', '2022-02-01 06:31:59'),
(26, 'Lidocaine+Adrenaline 2% Injection', 1, '2022-02-10 02:31:48', '2022-02-10 02:31:48'),
(27, 'Aceclofenac', 1, '2022-02-10 21:57:38', '2022-02-10 21:57:38'),
(28, 'Abiraterone Acetate', 1, '2022-02-11 05:16:05', '2022-02-11 05:16:05'),
(29, 'Acemetacin', 1, '2022-02-11 05:18:28', '2022-02-11 05:18:28'),
(30, 'Acetate Formulation (Hemodialysis Solution)', 1, '2022-02-11 05:21:39', '2022-02-11 05:21:39'),
(31, 'Acetazolamide', 1, '2022-02-11 05:24:05', '2022-02-11 05:24:05'),
(32, 'Atorvastatin Calcium', 1, '2022-02-12 00:40:11', '2022-02-12 00:40:11'),
(33, 'Atenolol', 1, '2022-02-12 00:43:46', '2022-02-12 00:43:46'),
(34, 'Acetylcysteine', 1, '2022-02-14 04:06:34', '2022-02-14 04:06:34'),
(35, 'Acitretin', 1, '2022-02-14 06:20:27', '2022-02-14 06:20:27'),
(36, 'Activated Charcoal', 1, '2022-02-14 06:20:58', '2022-02-14 06:20:58'),
(37, 'Acyclovir (Injection)', 1, '2022-02-14 06:21:49', '2022-02-14 06:21:49'),
(38, 'Acyclovir (Ophthalmic)', 1, '2022-02-14 06:22:15', '2022-02-14 06:22:15'),
(39, 'Acyclovir (Oral)', 1, '2022-02-14 06:22:41', '2022-02-14 06:22:41'),
(40, 'Acyclovir (Topical)', 1, '2022-02-14 06:25:46', '2022-02-14 06:25:46'),
(41, 'Acyclovir + Hydrocortisone', 1, '2022-02-14 06:26:35', '2022-02-14 06:26:35'),
(42, 'Adalimumab', 1, '2022-02-14 06:26:56', '2022-02-14 06:26:56'),
(43, 'Adapalene', 1, '2022-02-14 06:27:22', '2022-02-14 06:27:22'),
(44, 'Adapalene + Benzoyl peroxide', 1, '2022-02-14 06:27:45', '2022-02-14 06:27:45'),
(45, 'Adefovir Dipivoxil', 1, '2022-02-14 06:28:26', '2022-02-14 06:28:26'),
(46, 'Adenosine', 1, '2022-02-14 06:29:45', '2022-02-14 06:29:45'),
(47, 'Adhatoda vasica+Cantella asiatica', 1, '2022-02-14 06:31:17', '2022-02-14 06:31:17'),
(48, 'Adrenaline', 1, '2022-02-14 06:31:56', '2022-02-14 06:31:56'),
(49, 'Adsorbed Tetanus Vaccine', 1, '2022-02-14 06:32:33', '2022-02-14 06:32:33'),
(50, 'Afatinib Dimaleate', 1, '2022-02-14 06:32:52', '2022-02-14 06:32:52'),
(51, 'Aflibercept', 1, '2022-02-14 06:33:22', '2022-02-14 06:33:22'),
(52, 'Agomelatine', 1, '2022-02-14 06:33:42', '2022-02-14 06:33:42'),
(53, 'Albendazole', 1, '2022-02-14 06:33:56', '2022-02-14 06:33:56'),
(54, 'Albumin (Human)', 1, '2022-02-14 06:34:15', '2022-02-14 06:34:15'),
(55, 'Alcaftadine', 1, '2022-02-14 06:34:34', '2022-02-14 06:34:34'),
(56, 'Alectinib', 1, '2022-02-14 06:34:52', '2022-02-14 06:34:52'),
(57, 'Alendronic Acid', 1, '2022-02-14 06:35:12', '2022-02-14 06:35:12'),
(58, 'Alendronic Acid+Vitamin D3', 1, '2022-02-14 06:35:38', '2022-02-14 06:35:38'),
(59, 'Alfacalcidol', 1, '2022-02-14 06:35:57', '2022-02-14 06:35:57'),
(60, 'Alfuzosin Hydrochloride', 1, '2022-02-14 06:36:24', '2022-02-14 06:36:24'),
(61, 'Allium cepa + Heparin + Allantoin', 1, '2022-02-14 06:36:58', '2022-02-14 06:36:58'),
(62, 'Allopurinol', 1, '2022-02-14 06:37:25', '2022-02-14 06:37:25'),
(63, 'Almitrine Bismesylate + Raubasine', 1, '2022-02-14 06:37:58', '2022-02-14 06:37:58'),
(64, 'Almotriptan', 1, '2022-02-14 06:38:14', '2022-02-14 06:38:14'),
(65, 'Alogliptin', 1, '2022-02-14 06:38:36', '2022-02-14 06:38:36'),
(66, 'Alphanate', 1, '2022-02-14 06:38:57', '2022-02-14 06:38:57'),
(67, 'Alprazolam', 1, '2022-02-14 06:39:14', '2022-02-14 06:39:14'),
(68, 'Alteplase', 1, '2022-02-14 06:39:30', '2022-02-14 06:39:30'),
(69, 'Aluminium Cl + Melaleuca Alternifolia Oil + Geothermal Water', 1, '2022-02-14 06:40:11', '2022-02-14 06:40:11'),
(70, 'Aluminium Chloride Gexahydrate', 1, '2022-02-14 06:40:46', '2022-02-14 06:40:46'),
(71, 'Aluminium Hydroxide + Magnesium Hydroxide', 1, '2022-02-14 06:41:35', '2022-02-14 06:41:35'),
(72, 'Aluminium Oxide + Magnesium Trisilicate', 1, '2022-02-14 06:42:10', '2022-02-14 06:42:10'),
(73, 'Alverine Citrate', 1, '2022-02-14 06:42:34', '2022-02-14 06:42:34'),
(74, 'Amantadine Hydrochloride', 1, '2022-02-14 06:43:01', '2022-02-14 06:43:01'),
(75, 'Ambrisentan', 1, '2022-02-14 06:43:19', '2022-02-14 06:43:19'),
(76, 'Ambroxol Hydrochloride', 1, '2022-02-14 06:43:42', '2022-02-14 06:43:42'),
(77, 'Amikacin', 1, '2022-02-14 06:43:55', '2022-02-14 06:43:55'),
(78, 'Amino Acid', 1, '2022-02-14 06:44:12', '2022-02-14 06:44:12'),
(79, 'Amino Acid + Calcium', 1, '2022-02-14 06:44:29', '2022-02-14 06:44:29'),
(80, 'Amino Acid + D-Sorbitol + Electrolytes', 1, '2022-02-14 06:45:03', '2022-02-14 06:45:03'),
(81, 'Amino Acid + Dextrose + Electrolytes', 1, '2022-02-14 06:45:28', '2022-02-14 06:45:28'),
(82, 'Amino Acid + Glucose + Electrolytes', 1, '2022-02-14 06:45:56', '2022-02-14 06:45:56'),
(83, 'Amino Acid Keto Analogues', 1, '2022-02-14 06:46:17', '2022-02-14 06:46:17'),
(84, 'Aminocaproic Acid', 1, '2022-02-14 06:46:50', '2022-02-14 06:46:50'),
(85, 'Aminophylline', 1, '2022-02-14 06:49:46', '2022-02-14 06:49:46'),
(86, 'Amiodarone Hydrochloride (Injection)', 1, '2022-02-14 06:50:10', '2022-02-14 06:50:10'),
(87, 'Amiodarone Hydrochloride (Tablet)', 1, '2022-02-14 06:50:33', '2022-02-14 06:50:33'),
(88, 'Amisulpride', 1, '2022-02-14 06:50:51', '2022-02-14 06:50:51'),
(89, 'Amitriptyline Hydrochloride + Chlordiazepoxide', 1, '2022-02-14 06:51:31', '2022-02-14 06:51:31'),
(90, 'Amlexanox', 1, '2022-02-14 06:51:51', '2022-02-14 06:51:51'),
(91, 'Amlodipine Besilate', 1, '2022-02-14 06:52:09', '2022-02-14 06:52:09'),
(92, 'Amlodipine Besilate + Atenolol', 1, '2022-02-14 06:52:30', '2022-02-14 06:52:30'),
(93, 'Amlodipine Besilate + Atorvastatin', 1, '2022-02-14 06:52:57', '2022-02-14 06:52:57'),
(94, 'Amlodipine Besilate + Benzepril Hydrochloride', 1, '2022-02-14 06:53:34', '2022-02-14 06:53:34'),
(95, 'Amlodipine Besilate + Telmisartan', 1, '2022-02-14 06:54:09', '2022-02-14 06:54:09'),
(96, 'Amlodipine Besilate + Valsartan', 1, '2022-02-14 06:54:53', '2022-05-11 00:41:24'),
(97, 'Amorolfine Hydrochloride (Cream)', 1, '2022-02-14 06:55:36', '2022-02-14 06:55:36'),
(98, 'Amorolfine Hydrochloride (Nail Lacquer)', 1, '2022-02-14 06:56:17', '2022-02-14 06:56:17'),
(99, 'Amoxicillin + Clavulanic Acid', 1, '2022-02-14 06:56:45', '2022-02-14 06:56:45'),
(100, 'Amoxicillin Trihydrate', 1, '2022-02-14 06:57:05', '2022-02-14 06:57:05'),
(101, 'Amphotericin B', 1, '2022-02-14 06:57:23', '2022-02-14 06:57:23'),
(102, 'Ampicillin Sodium', 1, '2022-02-14 06:59:10', '2022-02-14 06:59:10'),
(103, 'Anastrozole', 1, '2022-02-14 06:59:25', '2022-02-14 06:59:25'),
(104, 'Anidulafungin', 1, '2022-02-14 06:59:51', '2022-02-14 06:59:51'),
(105, 'Antazoline Hydrochloride + Tetiyzoline Hydrochloride', 1, '2022-02-14 07:00:10', '2022-02-14 07:00:10'),
(106, 'anti-Thymocyte Globulin', 1, '2022-02-14 07:00:54', '2022-02-14 07:00:54'),
(107, 'Antihemophilic Factor [ Factor VIII ]', 1, '2022-02-14 07:01:47', '2022-02-14 07:01:47'),
(108, 'Antioxidants and Micronutrients', 1, '2022-02-14 07:02:26', '2022-02-14 07:02:26'),
(109, 'Apis mellifica + Gelsemium sempervirens + Gnaphalium', 1, '2022-02-14 07:02:43', '2022-02-14 07:02:43'),
(110, 'Apixaban', 1, '2022-02-14 07:03:18', '2022-02-14 07:03:18'),
(111, 'Apremilast', 1, '2022-02-14 07:03:37', '2022-02-14 07:03:37'),
(112, 'Aprepitant', 1, '2022-02-14 07:03:54', '2022-02-14 07:03:54'),
(113, 'Arabinoxylan', 1, '2022-02-14 07:04:13', '2022-02-14 07:04:13'),
(114, 'Arformoterol Tartrate', 1, '2022-02-14 07:04:35', '2022-02-14 07:04:35'),
(115, 'Aripiprazole', 1, '2022-02-14 07:04:55', '2022-02-14 07:04:55'),
(116, 'Armodafinil', 1, '2022-02-14 07:05:14', '2022-02-14 07:05:14'),
(117, 'Artemether', 1, '2022-02-14 07:05:32', '2022-02-14 07:05:32'),
(118, 'Artemether + Lumefantrine', 1, '2022-02-14 07:05:53', '2022-02-14 07:05:53'),
(119, 'Artesunate', 1, '2022-02-14 07:06:15', '2022-02-14 07:06:15'),
(120, 'Articaine Hydrochloride + Epinephrine', 1, '2022-02-14 07:06:50', '2022-02-14 07:06:50'),
(121, 'Aspartame', 1, '2022-02-14 07:07:02', '2022-02-14 07:07:02'),
(122, 'Aspirine', 1, '2022-02-14 07:07:25', '2022-02-14 07:07:25'),
(123, 'Aspirine + Dipyridamole', 1, '2022-02-14 07:07:49', '2022-02-14 07:07:49'),
(124, 'Astaxanthin', 1, '2022-02-14 07:08:07', '2022-02-14 07:08:07'),
(125, 'Atenolol + Chlorthalidone', 1, '2022-02-14 07:09:00', '2022-02-14 07:09:00'),
(126, 'Atenolol + Nifedipine', 1, '2022-02-14 07:09:52', '2022-02-14 07:09:52'),
(127, 'Atezolizumab', 1, '2022-02-14 07:10:17', '2022-02-14 07:10:17'),
(128, 'Atomoxetine Hydrochloride', 1, '2022-02-14 07:10:38', '2022-02-14 07:10:38'),
(129, 'Atosiban Acetate', 1, '2022-02-14 07:11:33', '2022-02-14 07:11:33'),
(130, 'Atracurium Besilate', 1, '2022-02-14 07:11:55', '2022-02-14 07:11:55'),
(131, 'Atropine Sulphate', 1, '2022-02-14 07:12:15', '2022-02-14 07:12:15'),
(132, 'Avanafil', 1, '2022-02-14 07:12:32', '2022-02-14 07:12:32'),
(133, 'Axitinib', 1, '2022-02-14 07:12:53', '2022-02-14 07:12:53'),
(134, 'Azathioprine', 1, '2022-02-14 07:13:10', '2022-02-14 07:13:10'),
(135, 'Azelaic Acid', 1, '2022-02-14 07:13:31', '2022-02-14 07:13:31'),
(136, 'Azelastine Hydrochloride (Eye Drop)', 1, '2022-02-14 07:14:10', '2022-02-14 07:14:10'),
(137, 'Azelastine Hydrochloride (Nasal Spray)', 1, '2022-02-14 07:14:35', '2022-02-14 07:14:35'),
(138, 'Azelastine Hydrochloride + Fluticasone Propionate', 1, '2022-02-14 07:15:02', '2022-02-14 07:15:02'),
(139, 'Azilsartan Medoxomil', 1, '2022-02-14 07:15:28', '2022-02-14 07:15:28'),
(140, 'Azilsartan Medoxomil + Chlorthalidone', 1, '2022-02-14 07:15:50', '2022-02-14 07:15:50'),
(141, 'Azithromycin Dihydrate', 1, '2022-02-14 07:16:29', '2022-02-14 07:16:29'),
(142, 'Azithromycin Dihydrate (Ophthalmic)', 1, '2022-02-14 07:16:49', '2022-02-14 07:16:49'),
(143, 'Aztreonam', 1, '2022-02-14 07:17:08', '2022-02-14 07:17:08'),
(144, 'Bacillus Clausii spores', 1, '2022-02-15 05:25:00', '2022-02-15 05:25:00'),
(145, 'Bacitracin Zinc + Polymyxin B Sulfate', 1, '2022-02-15 05:26:01', '2022-02-15 05:26:01'),
(146, 'Baclofen', 1, '2022-02-15 05:26:32', '2022-02-15 05:26:32'),
(147, 'Balanced Salt Solution', 1, '2022-02-15 05:26:52', '2022-02-15 05:26:52'),
(148, 'Baloxavir Marboxil', 1, '2022-02-15 05:27:12', '2022-02-15 05:27:12'),
(149, 'Bambuterol Hydrochloride', 1, '2022-02-15 05:27:38', '2022-02-15 05:27:38'),
(150, 'Barium Sulfate', 1, '2022-02-15 05:27:57', '2022-02-15 05:27:57'),
(151, 'Beclometasone Dipropionate + Formoterol Fumarate', 1, '2022-02-15 05:28:14', '2022-02-15 05:28:14'),
(152, 'Beclomethasone Dipropionate (Inhaler)', 1, '2022-02-15 05:28:34', '2022-02-15 05:28:34'),
(153, 'Beclomethasone Dipropionate (Nasal Spray)', 1, '2022-02-15 05:28:56', '2022-02-15 05:28:56'),
(154, 'Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine', 1, '2022-02-15 05:29:30', '2022-02-15 05:29:30'),
(155, 'Bempedoic Acid', 1, '2022-02-15 05:30:04', '2022-02-15 05:30:04'),
(156, 'Benzalkonium Chloride', 1, '2022-02-15 05:30:26', '2022-02-15 05:30:26'),
(157, 'Benzathine Penicillin', 1, '2022-02-15 05:30:51', '2022-02-15 05:30:51'),
(158, 'Benzocaine', 1, '2022-02-15 05:31:09', '2022-02-15 05:31:09'),
(159, 'Benzocaine + Butamben + Tetracaine Hydrochloride', 1, '2022-02-15 05:31:23', '2022-02-15 05:31:23'),
(160, 'Benzocaine + Camphor + Methanol + Phenol', 1, '2022-02-15 05:31:43', '2022-02-15 05:31:43'),
(161, 'Benzoic Acid + Salicylic Acid', 1, '2022-02-15 05:32:18', '2022-02-15 05:32:18'),
(162, 'Benzoyl Peroxide', 1, '2022-02-15 05:32:36', '2022-02-15 05:32:36'),
(163, 'Benzydamine Hydrochloride', 1, '2022-02-15 05:33:05', '2022-02-15 05:33:05'),
(164, 'Benzyl Alcohol', 1, '2022-02-15 05:33:22', '2022-02-15 05:33:22'),
(165, 'Benzyl Benzoate', 1, '2022-02-15 05:33:45', '2022-02-15 05:33:45'),
(166, 'Benzyl Penicillin', 1, '2022-02-15 05:34:06', '2022-02-15 05:34:06'),
(167, 'Bepotastine Besilate', 1, '2022-02-15 05:34:25', '2022-02-15 05:34:25'),
(168, 'Besifloxacin', 1, '2022-02-15 05:34:51', '2022-02-15 05:34:51'),
(169, 'Betacarotene + Vitamin C + Vitamin E', 1, '2022-02-15 05:35:11', '2022-02-15 05:35:11'),
(170, 'Betahistine Dihydrochloride', 1, '2022-02-15 05:35:51', '2022-02-15 05:35:51'),
(171, 'Betahistine Mesylate', 1, '2022-02-15 05:36:23', '2022-02-15 05:36:23'),
(172, 'Betamethasone', 1, '2022-02-15 05:36:35', '2022-02-15 05:36:35'),
(173, 'Betamethasone + Calcipotril', 1, '2022-02-15 05:37:13', '2022-02-15 05:37:13'),
(174, 'Betamethasone + Clotrimazole', 1, '2022-02-15 05:39:03', '2022-02-15 05:39:03'),
(175, 'Betamethasone + Clotrimazole + Gentamicin', 1, '2022-02-15 05:39:45', '2022-02-15 05:39:45'),
(176, 'Betamethasone + Gentamicin', 1, '2022-02-15 05:40:14', '2022-02-15 05:40:14'),
(177, 'Betamethasone + Neomycin Sulphate (E/E)', 1, '2022-02-15 05:40:38', '2022-02-15 05:40:38'),
(178, 'Betamethasone + Neomycin Sulphate (Topical)', 1, '2022-02-15 05:40:56', '2022-02-15 05:40:56'),
(179, 'Betamethasone + Phenylephrine + Lignocaine', 1, '2022-02-15 05:41:14', '2022-02-15 05:41:14'),
(180, 'Betamethasone Dipropionate', 1, '2022-02-15 05:42:27', '2022-02-15 05:42:27'),
(181, 'Betamethasone Dipropionate + Salicylic Acid', 1, '2022-02-15 05:54:03', '2022-02-15 05:54:03'),
(182, 'Betamethasone Sodium Phosphate', 1, '2022-02-15 05:54:32', '2022-02-15 05:54:32'),
(183, 'Metamethasone Valerate', 1, '2022-02-15 05:54:53', '2022-02-15 05:54:53'),
(184, 'Betaxol Hydrochloride', 1, '2022-02-15 05:56:00', '2022-02-15 05:56:00'),
(185, 'Betrixaban', 1, '2022-02-15 05:56:21', '2022-02-15 05:56:21'),
(186, 'Bevacizumab', 1, '2022-02-15 05:56:43', '2022-02-15 05:56:43'),
(187, 'Bicalutamide', 1, '2022-02-15 05:57:01', '2022-02-15 05:57:01'),
(188, 'Bicarbonate Component [HCO3 Hemodialysis Solution]', 1, '2022-02-15 05:57:19', '2022-02-15 05:57:19'),
(189, 'Bilastine', 1, '2022-02-15 05:57:46', '2022-02-15 05:57:46'),
(190, 'Bimatoprost', 1, '2022-02-15 05:58:07', '2022-02-15 05:58:07'),
(191, 'Bimatoprost + Timolol', 1, '2022-02-15 05:58:36', '2022-02-15 05:58:36'),
(192, 'Biphasis Insulin Aspart [rDNA]', 1, '2022-02-15 05:59:17', '2022-02-15 05:59:17'),
(193, 'Bisacodyl', 1, '2022-02-15 05:59:58', '2022-02-15 05:59:58'),
(194, 'Bismuth Subsalicylate', 1, '2022-02-15 06:00:22', '2022-02-15 06:00:22'),
(195, 'Bisoprolol Fumarate + Amlodipine Besilate', 1, '2022-02-15 06:01:13', '2022-02-15 06:01:13'),
(196, 'Bisoprolol Fumarate + Hydrochlorothiazide', 1, '2022-02-15 06:01:51', '2022-02-15 06:01:51'),
(197, 'Bisoprolol Hemifumarate', 1, '2022-02-15 06:02:22', '2022-02-15 06:02:22'),
(198, 'Bivalirudin', 1, '2022-02-15 06:02:45', '2022-02-15 06:02:45'),
(199, 'Bleomycin Sulfate', 1, '2022-02-15 06:03:06', '2022-02-15 06:03:06'),
(200, 'Bortezomib', 1, '2022-02-15 06:03:22', '2022-02-15 06:03:22'),
(201, 'Bosentan Monohydrate', 1, '2022-02-15 06:03:55', '2022-02-15 06:03:55'),
(202, 'Brexpiprazole', 1, '2022-02-15 06:04:17', '2022-02-15 06:04:17'),
(203, 'Brigatinib', 1, '2022-02-15 06:04:37', '2022-02-15 06:04:37'),
(204, 'Brimonidine Tartrate (0.025%)', 1, '2022-02-15 06:05:16', '2022-02-15 06:05:16'),
(205, 'Brimonidine Tartrate (0.15%)', 1, '2022-02-15 06:05:29', '2022-02-15 06:05:29'),
(206, 'Brimonidine Tartrate (0.2%)', 1, '2022-02-15 06:05:45', '2022-02-15 06:05:45'),
(207, 'Brimonidine Tartrate + Timolol Maleate', 1, '2022-02-15 06:06:13', '2022-02-15 06:06:13'),
(208, 'Brinzolamide', 1, '2022-02-15 06:06:54', '2022-02-15 06:06:54'),
(209, 'Brinzolamide + Brimonidine Tartrate', 1, '2022-02-15 06:07:27', '2022-02-15 06:07:27'),
(210, 'Brinzolamide + Timolol', 1, '2022-02-15 06:07:44', '2022-02-15 06:07:44'),
(211, 'Brivaracetam', 1, '2022-02-15 06:08:02', '2022-02-15 06:08:02'),
(212, 'Bromazepam', 1, '2022-02-15 06:08:19', '2022-02-15 06:08:19'),
(213, 'Bromelain + Trypsin', 1, '2022-02-15 06:08:47', '2022-02-15 06:08:47'),
(214, 'Bromfenac Sodium', 1, '2022-02-15 06:09:06', '2022-02-15 06:09:06'),
(215, 'Bromhexin Hydrochloride', 1, '2022-02-15 06:09:30', '2022-02-15 06:09:30'),
(216, 'Bromocriptine Mesylate', 1, '2022-02-15 06:09:56', '2022-02-15 06:09:56'),
(217, 'Budesonide (Inhaler)', 1, '2022-02-15 06:10:21', '2022-02-15 06:10:21'),
(218, 'Budesonide (Nasal Spray)', 1, '2022-02-15 06:10:56', '2022-02-15 06:10:56'),
(219, 'Budesonide (Nebuliser Suspension)', 1, '2022-02-15 06:11:34', '2022-02-15 06:11:34'),
(220, 'Budesonide (Tablet)', 1, '2022-02-15 06:11:54', '2022-02-15 06:11:54'),
(221, 'Budesonide + Formoterol Fumarate', 1, '2022-02-15 06:12:34', '2022-02-15 06:12:34'),
(222, 'Bumetanide', 1, '2022-02-15 06:12:53', '2022-02-15 06:12:53'),
(223, 'Bupivacaine Hydrochloride', 1, '2022-02-15 06:13:15', '2022-02-15 06:13:15'),
(224, 'Bupivacaine Hydrochloride + Dextrose', 1, '2022-02-15 06:13:32', '2022-02-15 06:13:32'),
(225, 'Bupropion Hydrochloride', 1, '2022-02-15 06:14:00', '2022-02-15 06:14:00'),
(226, 'Busulfan', 1, '2022-02-15 06:14:15', '2022-02-15 06:14:15'),
(227, 'Butamirate Citrate', 1, '2022-02-15 06:14:34', '2022-02-15 06:14:34'),
(228, 'butenafine Hydrochloride', 1, '2022-02-15 06:15:29', '2022-02-15 06:15:29'),
(229, 'Butoconazole Nitrate', 1, '2022-02-15 06:15:53', '2022-02-15 06:15:53'),
(230, 'Cabazitaxel', 1, '2022-02-18 18:39:20', '2022-02-18 18:39:20'),
(231, 'Carbergoline', 1, '2022-02-18 18:39:41', '2022-02-18 18:39:41'),
(232, 'Carbozantinib', 1, '2022-02-18 18:40:23', '2022-02-18 18:40:23'),
(233, 'Calamine + Zinc Oxide + Glycerine', 1, '2022-02-18 18:40:43', '2022-02-18 18:40:43'),
(234, 'Calcipotriol Monohydrate', 1, '2022-02-18 18:41:19', '2022-02-18 18:41:19'),
(235, 'Calcitriol', 1, '2022-02-18 18:41:34', '2022-02-18 18:41:34'),
(236, 'Calcitriol + Calcium Citrate', 1, '2022-02-18 18:41:57', '2022-02-18 18:41:57'),
(237, 'Calcium + Vitamin D3 + Vitamin C + Vitamin E + Multimineral', 1, '2022-02-18 18:42:12', '2022-02-18 18:42:12'),
(238, 'Calcium Acetate', 1, '2022-02-18 18:42:31', '2022-02-18 18:42:31'),
(239, 'Calcium Carbonate', 1, '2022-02-18 18:42:45', '2022-02-18 18:42:45'),
(240, 'Calcium Carbonate [Algae Source] + Vitamin D3', 1, '2022-02-18 18:43:30', '2022-02-18 18:43:30'),
(241, 'Calcium Carbonate [Coral Source] + Vitamin D3', 1, '2022-02-18 18:43:59', '2022-02-18 18:43:59'),
(242, 'Calcium Carbonate [Eggshell Source] + Vitamin D3', 1, '2022-02-18 18:44:20', '2022-02-18 18:44:20'),
(243, 'Calcium Carbonate [Elemental Source] + Vitamin D3', 1, '2022-02-18 18:44:49', '2022-02-18 18:44:49'),
(244, 'Calcium Carbonate + Vitamin D3 + Multimineral', 1, '2022-02-18 18:45:10', '2022-02-18 18:45:10'),
(245, 'Calcium Debesilate', 1, '2022-02-18 18:45:39', '2022-02-18 18:45:39'),
(246, 'Calcium Dobesilate + Lidocaine + Dexamethasone', 1, '2022-02-18 18:45:55', '2022-02-18 18:45:55'),
(247, 'Calcium Folinate (Folinic Acid)', 1, '2022-02-18 18:46:38', '2022-02-18 18:46:38'),
(248, 'Calcium Gluconate', 1, '2022-02-18 18:46:55', '2022-02-18 18:46:55'),
(249, 'Calcium Lactate', 1, '2022-02-18 18:47:38', '2022-02-18 18:47:38'),
(250, 'Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C', 1, '2022-02-18 18:47:47', '2022-02-18 18:47:47'),
(251, 'Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3', 1, '2022-02-18 18:48:04', '2022-02-18 18:48:04'),
(252, 'Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3', 1, '2022-02-18 18:48:21', '2022-02-18 18:48:21'),
(253, 'Calcium Orotate', 1, '2022-02-18 18:48:41', '2022-02-18 18:48:41'),
(254, 'Calcium Pantothenate', 1, '2022-02-18 18:49:03', '2022-02-18 18:49:03'),
(255, 'Calcium Polystyrene Sulfonate', 1, '2022-02-18 18:49:24', '2022-02-18 18:49:24'),
(256, 'Camphor + Menthol + Oil Clove + Oil Eucalyptus + Oil Turpentine', 1, '2022-02-18 18:50:44', '2022-02-18 18:50:44'),
(257, 'Canagliflozin Hemihydrate', 1, '2022-02-18 18:51:04', '2022-02-18 18:51:04'),
(258, 'Candesartan Cilexetil', 1, '2022-02-18 18:51:27', '2022-02-18 18:51:27'),
(259, 'Candesartan Cilexetil + Hydrochlorothiazide', 1, '2022-02-18 18:52:00', '2022-02-18 18:52:00'),
(260, 'Capecitabine', 1, '2022-02-18 18:52:24', '2022-02-18 18:52:24'),
(261, 'Caprylic + Capric Triglyceride', 1, '2022-02-18 18:54:15', '2022-02-18 18:54:15'),
(262, 'Capsaicin', 1, '2022-02-18 18:54:34', '2022-02-18 18:54:34'),
(263, 'Captopril', 1, '2022-02-18 19:01:15', '2022-02-18 19:01:15'),
(264, 'Carbamazepine', 1, '2022-02-18 19:01:30', '2022-02-18 19:01:30'),
(265, 'Carbetocin', 1, '2022-02-18 19:01:48', '2022-02-18 19:01:48'),
(266, 'Carbimazole', 1, '2022-02-18 19:02:15', '2022-02-18 19:02:15'),
(267, 'Carbocisteine', 1, '2022-02-18 19:02:41', '2022-02-18 19:02:41'),
(268, 'Carbonyl Iron + Folic Acid', 1, '2022-02-18 19:03:07', '2022-02-18 19:03:07'),
(269, 'Carbonyl Iron + Folic Acid + Zinc Sulfate', 1, '2022-02-18 19:05:42', '2022-02-18 19:05:42'),
(270, 'Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C', 1, '2022-02-18 19:11:38', '2022-02-18 19:11:38'),
(271, 'Carboplatin', 1, '2022-02-18 19:12:16', '2022-02-18 19:12:16'),
(272, 'Carboprost Tromethamine', 1, '2022-02-18 19:12:42', '2022-02-18 19:12:42'),
(273, 'Carboxymethylcellulose Sodium', 1, '2022-02-18 19:13:08', '2022-02-18 19:13:08'),
(274, 'Carboxymethylcellulose Sodium + Glycerin', 1, '2022-02-18 19:13:32', '2022-02-18 19:13:32'),
(275, 'Carboxymethylcellulose Sodium + Hypromellose', 1, '2022-02-18 19:13:54', '2022-02-18 19:13:54'),
(276, 'Carisoprodol', 1, '2022-02-18 19:14:20', '2022-02-18 19:14:20'),
(277, 'Carmellose Sodium', 1, '2022-02-18 19:14:38', '2022-02-18 19:14:38'),
(278, 'Carvedilol', 1, '2022-02-18 19:14:52', '2022-02-18 19:14:52'),
(279, 'Casirivimab + Imdevimab', 1, '2022-02-18 19:15:22', '2022-02-18 19:15:22'),
(280, 'Cefaclor Monohydrate', 1, '2022-02-18 19:15:51', '2022-02-18 19:15:51'),
(281, 'Cefadroxil Monohydrate', 1, '2022-02-18 19:20:44', '2022-02-18 19:20:44'),
(282, 'Cefazolin Sodium', 1, '2022-02-18 19:21:01', '2022-02-18 19:21:01'),
(283, 'Cefdinir', 1, '2022-02-18 19:21:17', '2022-02-18 19:21:17'),
(284, 'Cefditoren', 1, '2022-02-18 19:21:32', '2022-02-18 19:21:32'),
(285, 'Cefepime Hydrochloride', 1, '2022-02-18 19:21:55', '2022-02-18 19:21:55'),
(286, 'Cefixime Trihydrate', 1, '2022-02-18 19:22:11', '2022-02-18 19:22:11'),
(287, 'Cefoprezone Sodium', 1, '2022-02-18 19:22:33', '2022-02-18 19:22:33'),
(288, 'Cefotaxime', 1, '2022-02-18 19:22:50', '2022-02-18 19:22:50'),
(289, 'Cefoxitin', 1, '2022-02-18 19:23:10', '2022-02-18 19:23:10'),
(290, 'Cefpirome Sulfate', 1, '2022-02-18 19:23:37', '2022-02-18 19:23:37'),
(291, 'Cefpodoxime Proxetil', 1, '2022-02-18 19:23:57', '2022-02-18 19:23:57'),
(292, 'Cefpodoxime Proxetil + Clavulanic Acid', 1, '2022-02-18 19:24:24', '2022-02-18 19:24:24'),
(293, 'Cefprozil', 1, '2022-02-18 19:24:41', '2022-02-18 19:24:41'),
(294, 'Ceftazidime + Avibactam', 1, '2022-02-18 19:25:51', '2022-02-18 19:25:51'),
(295, 'Ceftazidime Pentahydrate', 1, '2022-02-18 19:28:39', '2022-02-18 19:28:39'),
(296, 'Ceftibuten Dihydrate', 1, '2022-02-18 19:29:01', '2022-02-18 19:29:01'),
(297, 'Ceftriaxone Sodium', 1, '2022-02-18 19:29:21', '2022-02-18 19:29:21'),
(298, 'Cefuroxime Axetil', 1, '2022-02-18 19:29:39', '2022-02-18 19:29:39'),
(299, 'Cefuroxime Axetil + Clavulanic Acid', 1, '2022-02-18 19:30:08', '2022-02-18 19:30:08'),
(300, 'Cececoxib', 1, '2022-02-18 19:30:26', '2022-02-18 19:30:26'),
(301, 'Celiprolol Hydrochloride', 1, '2022-02-18 19:30:46', '2022-02-18 19:30:46'),
(302, 'Cephalexin', 1, '2022-02-18 19:30:59', '2022-02-18 19:30:59'),
(303, 'Cephradine', 1, '2022-02-18 19:31:14', '2022-02-18 19:31:14'),
(304, 'Ceftinib', 1, '2022-02-18 19:31:30', '2022-02-18 19:31:30'),
(305, 'Cetalkonium Chloride + Choline Salicylate', 1, '2022-02-18 19:32:07', '2022-02-18 19:32:07'),
(306, 'Cetrizine Hydrochloride', 1, '2022-02-18 20:22:12', '2022-02-18 20:22:12'),
(307, 'Cetrizine Hydrochloride (Ophthalmic)', 1, '2022-02-18 20:22:41', '2022-02-18 20:22:41'),
(308, 'Cetrorelix Acetate', 1, '2022-02-18 20:23:05', '2022-02-18 20:23:05'),
(309, 'Cetuximab', 1, '2022-02-18 20:23:19', '2022-02-18 20:23:19'),
(310, 'Chlorambucil', 1, '2022-02-18 20:23:42', '2022-02-18 20:23:42'),
(311, 'Chloramphenicol (Ophthalmic)', 1, '2022-02-18 20:24:09', '2022-02-18 20:24:09'),
(312, 'Chloramphenicol (Oral)', 1, '2022-02-18 20:24:29', '2022-02-18 20:24:29'),
(313, 'Chloramphenicol + Lidocaine Hydrochloride', 1, '2022-02-18 20:25:05', '2022-02-18 20:25:05'),
(314, 'Chlorhexidine Gluconate [0.2%]', 1, '2022-02-18 20:25:39', '2022-02-18 20:25:39'),
(315, 'Chlorhexidine Gluconate [1%]', 1, '2022-02-18 20:25:57', '2022-02-18 20:25:57'),
(316, 'Chlorhexidine Gluconate [4%]', 1, '2022-02-18 20:26:13', '2022-02-18 20:26:13'),
(317, 'Chlorhexidine Gluconate [7.1%]', 1, '2022-02-18 20:26:26', '2022-02-18 20:26:26'),
(318, 'Chlorhexidine Gluconate + Cetrimide', 1, '2022-02-18 20:26:55', '2022-02-18 20:26:55'),
(319, 'Chlorhexidine Gluconate + Isopropyl Alcohol', 1, '2022-02-18 20:27:21', '2022-02-18 20:27:21'),
(320, 'Chlorhexidine Hydrochloride + Cetrimide', 1, '2022-02-18 20:27:51', '2022-02-18 20:27:51'),
(321, 'Chlorhexidine Hydrochloride + Nystatin', 1, '2022-02-18 20:28:20', '2022-02-18 20:28:20'),
(322, 'Chloroquine Phosphate', 1, '2022-02-18 20:28:41', '2022-02-18 20:28:41'),
(323, 'Chloroxylenol', 1, '2022-02-18 20:29:05', '2022-02-18 20:29:05'),
(324, 'Chloroxylenol + Triclosan', 1, '2022-02-18 20:29:46', '2022-02-18 20:29:46'),
(325, 'Chlorpheniramine Maleate', 1, '2022-02-18 20:30:13', '2022-02-18 20:30:13'),
(326, 'Chlorpromazine Hydrochloride', 1, '2022-02-18 20:30:38', '2022-02-18 20:30:38'),
(327, 'Chlorthalidone', 1, '2022-02-18 20:30:55', '2022-02-18 20:30:55'),
(328, 'Cholera Saline', 1, '2022-02-18 20:31:11', '2022-02-18 20:31:11'),
(329, 'Choriogonadotropin Alpha', 1, '2022-02-18 20:31:37', '2022-02-18 20:31:37'),
(330, 'Ciclesonide (Inhalation Aerosol)', 1, '2022-02-18 20:32:12', '2022-02-18 20:32:12'),
(331, 'Ciclesonide (Nasal Spray)', 1, '2022-02-18 20:39:55', '2022-02-18 20:39:55'),
(332, 'Ciclopirox Olamine (Cream)', 1, '2022-02-18 20:40:16', '2022-02-18 20:40:16'),
(333, 'Ciclopirox Olamine (Shampoo)', 1, '2022-02-18 20:40:54', '2022-02-18 20:40:54'),
(334, 'Cilnidipine', 1, '2022-02-18 20:41:20', '2022-02-18 20:41:20'),
(335, 'Cilostazol', 1, '2022-02-18 20:41:40', '2022-02-18 20:41:40'),
(336, 'Cinacalcet', 1, '2022-02-18 20:42:01', '2022-02-18 20:42:01'),
(337, 'Cinchocaine + Hydrocortisone + Framycetin + Esculin', 1, '2022-02-18 20:42:19', '2022-02-18 20:42:19'),
(338, 'Cinchocaine + Hydrocortisone + Neomycin + Esculin', 1, '2022-02-18 20:42:34', '2022-02-18 20:42:34'),
(339, 'Cinchocaine Hydrochloride', 1, '2022-02-18 20:43:06', '2022-02-18 20:43:06'),
(340, 'Cinnarizine', 1, '2022-02-18 20:43:19', '2022-02-18 20:43:19'),
(341, 'Cinnarizine + Dimenhydrinate', 1, '2022-02-18 20:43:45', '2022-02-18 20:43:45'),
(342, 'Ciprofibrate', 1, '2022-02-18 20:44:02', '2022-02-18 20:44:02'),
(343, 'Ciprofloxacin', 1, '2022-02-18 20:44:23', '2022-02-18 20:44:23'),
(344, 'Ciprofloxacin (Ophthalmic)', 1, '2022-02-18 20:44:48', '2022-02-18 20:44:48'),
(345, 'Ciprofloxacin + Dexamethasone', 1, '2022-02-18 20:45:15', '2022-02-18 20:45:15'),
(346, 'Ciprofloxacin + Hydrocortisone Acetate', 1, '2022-02-18 20:45:41', '2022-02-18 20:45:41'),
(347, 'Cisplatin', 1, '2022-02-18 20:45:53', '2022-02-18 20:45:53'),
(348, 'Citalopram Hydrobromide', 1, '2022-02-18 20:46:19', '2022-02-18 20:46:19'),
(349, 'Citicoline Sodium', 1, '2022-02-18 20:46:51', '2022-02-18 20:46:51'),
(350, 'Citric Acid Monohydrate', 1, '2022-02-18 20:47:13', '2022-02-18 20:47:13'),
(351, 'Clarithromycin', 1, '2022-02-18 20:47:54', '2022-02-18 20:47:54'),
(352, 'Clascoterone', 1, '2022-02-18 20:48:18', '2022-02-18 20:48:18'),
(353, 'Clindamycin', 1, '2022-02-18 20:48:50', '2022-02-18 20:48:50'),
(354, 'Clindamycin  (Lotion)', 1, '2022-02-18 20:49:15', '2022-02-18 20:49:15'),
(355, 'Clindamycin  (Vaginal Cream)', 1, '2022-02-18 20:54:52', '2022-02-18 20:54:52'),
(356, 'Clindamycin  + Benzoyl Peroxide', 1, '2022-02-18 20:55:19', '2022-02-18 20:55:19'),
(357, 'Clindamycin  Phosphate + Tretinoin', 1, '2022-02-18 20:56:26', '2022-02-18 20:56:26'),
(358, 'Clinoquinol + Flumetasone Privalate', 1, '2022-02-18 20:58:45', '2022-02-18 20:58:45'),
(359, 'Clobazam', 1, '2022-02-18 20:58:58', '2022-02-18 20:58:58'),
(360, 'Clobetasol Propionate (Scalp Preparation)', 1, '2022-02-18 20:59:16', '2022-02-18 20:59:16'),
(361, 'Clobetasol Propionate (Topical Preparation)', 1, '2022-02-18 20:59:39', '2022-02-18 20:59:39'),
(362, 'Clobetasol Propionate + Neomycin Sulphate + Nystatin', 1, '2022-02-18 21:00:39', '2022-02-18 21:00:39'),
(363, 'Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafine', 1, '2022-02-18 21:01:11', '2022-02-18 21:01:11'),
(364, 'Clobetasol Propionate + Salicylic Acid', 1, '2022-02-18 21:01:28', '2022-02-18 21:01:28'),
(365, 'Clobetasone Butyrate', 1, '2022-02-18 21:02:01', '2022-02-18 21:02:01'),
(366, 'Clomiphene Citrate', 1, '2022-02-18 21:02:23', '2022-02-18 21:02:23'),
(367, 'Clomipramine Hydrochloride', 1, '2022-02-18 21:03:12', '2022-02-18 21:03:12'),
(368, 'Clonazepam', 1, '2022-02-18 21:03:25', '2022-02-18 21:03:25'),
(369, 'Clonidine Hydrochloride', 1, '2022-02-18 21:03:54', '2022-02-18 21:03:54'),
(370, 'Clopidgrel + Aspirin', 1, '2022-02-18 21:04:12', '2022-02-18 21:04:12'),
(371, 'Clopidgrel Bisulphate', 1, '2022-02-18 21:04:58', '2022-02-18 21:04:58'),
(372, 'Clotrimazole (Ear Drop)', 1, '2022-02-18 21:12:11', '2022-02-18 21:12:11'),
(373, 'Clotrimazole (Eye Oinment)', 1, '2022-02-18 21:12:42', '2022-02-18 21:12:42'),
(374, 'Clotrimazole (Topical)', 1, '2022-02-18 21:13:48', '2022-02-18 21:13:48'),
(375, 'Clotrimazole (Vaginal Suppository)', 1, '2022-02-18 21:15:34', '2022-02-18 21:15:34'),
(376, 'Clotrimazole (Vaginal Tablet)', 1, '2022-02-18 21:16:03', '2022-02-18 21:16:03'),
(377, 'Clotrimazole + Hydrocortisone', 1, '2022-02-18 21:17:01', '2022-02-18 21:17:01'),
(378, 'Clove Oil', 1, '2022-02-18 21:17:16', '2022-02-18 21:17:16'),
(379, 'Cloxacillin Sodium', 1, '2022-02-18 21:17:48', '2022-02-18 21:17:48'),
(380, 'Clozapine', 1, '2022-02-18 21:18:02', '2022-02-18 21:18:02'),
(381, 'Coagulation Factor VIIa (Eptacog Alfa]', 1, '2022-02-18 21:20:27', '2022-02-18 21:20:27'),
(382, 'Coal Tar', 1, '2022-02-18 21:20:39', '2022-02-18 21:20:39'),
(383, 'Cyclophosphamide', 1, '2022-02-18 21:22:21', '2022-02-18 21:22:21'),
(384, 'Cyclosporine', 1, '2022-02-18 21:22:34', '2022-02-18 21:22:34'),
(385, 'Cyclosporine [Ophthalmic]', 1, '2022-02-18 21:26:25', '2022-02-18 21:26:25'),
(386, 'Cyproheptadine', 1, '2022-02-18 21:26:49', '2022-02-18 21:26:49'),
(387, 'Cyproterone Acetate + Ethinyl Estradiol', 1, '2022-02-18 21:27:30', '2022-02-18 21:27:30'),
(388, 'Cytarabine', 1, '2022-02-18 21:27:44', '2022-02-18 21:27:44'),
(389, 'D-Chiro-Inositol', 1, '2022-02-19 05:30:27', '2022-02-19 05:30:27'),
(390, 'Dabigatran Etexilate Mesylate', 1, '2022-02-19 05:30:57', '2022-02-19 05:30:57'),
(391, 'Dacarbazine', 1, '2022-02-19 05:31:20', '2022-02-19 05:31:20'),
(392, 'Daclatasvir + Sofosbuvir', 1, '2022-02-19 05:31:49', '2022-02-19 05:31:49'),
(393, 'Danazol', 1, '2022-02-19 05:32:01', '2022-02-19 05:32:01'),
(394, 'Dantrolene Sodium', 1, '2022-02-19 05:32:22', '2022-02-19 05:32:22'),
(395, 'Dapagliflozin Propanediol', 1, '2022-02-19 05:32:49', '2022-02-19 05:32:49'),
(396, 'Dapoxetine Hydrochloride', 1, '2022-02-19 05:39:50', '2022-02-19 05:39:50'),
(397, 'Dapsone (Oral Tab)', 1, '2022-02-19 05:40:30', '2022-02-19 05:40:30'),
(398, 'Dapsone (Topical Gel)', 1, '2022-02-19 05:41:02', '2022-02-19 05:41:02'),
(399, 'Darbepoetin Alfa', 1, '2022-02-19 05:41:25', '2022-02-19 05:41:25'),
(400, 'Darifenacin', 1, '2022-02-19 05:41:44', '2022-02-19 05:41:44'),
(401, 'Dasatinib', 1, '2022-02-19 05:42:06', '2022-02-19 05:42:06'),
(402, 'Daunorubicin', 1, '2022-02-19 05:42:23', '2022-02-19 05:42:23'),
(403, 'Deferasirox', 1, '2022-02-19 05:42:38', '2022-02-19 05:42:38'),
(404, 'Deferiprone', 1, '2022-02-19 05:43:11', '2022-02-19 05:43:11'),
(405, 'Deferoxamine Mesylate', 1, '2022-02-19 05:43:30', '2022-02-19 05:43:30'),
(406, 'Deflazacort', 1, '2022-02-19 05:43:56', '2022-02-19 05:43:56'),
(407, 'Degarelix Acetate', 1, '2022-02-19 05:44:22', '2022-02-19 05:44:22'),
(408, 'Dehydroepiandrosterone', 1, '2022-02-19 05:44:51', '2022-02-19 05:44:51'),
(409, 'Delafloxacin', 1, '2022-02-19 05:45:07', '2022-02-19 05:45:07'),
(410, 'Denosumab', 1, '2022-02-19 05:45:26', '2022-02-19 05:45:26'),
(411, 'Dequalinium Chloride', 1, '2022-02-19 05:45:51', '2022-02-19 05:45:51'),
(412, 'Desloratadine', 1, '2022-02-19 05:46:10', '2022-02-19 05:46:10'),
(413, 'Desmopressin Acetate', 1, '2022-02-19 05:46:29', '2022-02-19 05:46:29'),
(414, 'Desogestrel', 1, '2022-02-19 05:46:48', '2022-02-19 05:46:48'),
(415, 'Desonide', 1, '2022-02-19 05:47:02', '2022-02-19 05:47:02'),
(416, 'Desoximetasone', 1, '2022-02-19 05:47:23', '2022-02-19 05:47:23'),
(417, 'Desvenlafaxine', 1, '2022-02-19 05:47:45', '2022-02-19 05:47:45'),
(418, 'Dexamethasone (Ophthalmic)', 1, '2022-02-19 05:48:07', '2022-02-19 05:48:07'),
(419, 'Dexamethasone + Chloramphenicol', 1, '2022-02-19 05:48:31', '2022-02-19 05:48:31'),
(420, 'Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate', 1, '2022-02-19 05:48:50', '2022-02-19 05:48:50'),
(421, 'Dexamethasone + Tobramycin', 1, '2022-02-19 05:49:17', '2022-02-19 05:49:17'),
(422, 'Dexibuprofen', 1, '2022-02-19 05:49:34', '2022-02-19 05:49:34'),
(423, 'Dexketoprofen', 1, '2022-02-19 05:49:53', '2022-02-19 05:49:53'),
(424, 'Dexlansoprazole', 1, '2022-02-19 05:50:08', '2022-02-19 05:50:08'),
(425, 'Dexmedetomidine Hydrochloride', 1, '2022-02-19 05:50:32', '2022-02-19 05:50:32'),
(426, 'Dexpanthenol', 1, '2022-02-19 05:50:57', '2022-02-19 05:50:57'),
(427, 'Dextran + Dextrose', 1, '2022-02-19 05:51:19', '2022-02-19 05:51:19'),
(428, 'Dextran + Hypromellose', 1, '2022-02-19 05:51:41', '2022-02-19 05:51:41'),
(429, 'Dextran + Sodium Chloride', 1, '2022-02-19 05:52:00', '2022-02-19 05:52:00'),
(430, 'Dextromethorphan + Phenylephrine + Triprolidine', 1, '2022-02-19 05:52:16', '2022-02-19 05:52:16'),
(431, 'Dextromethorphan + Pseudoephedrine + Triprolidine', 1, '2022-02-19 05:52:58', '2022-02-19 05:52:58'),
(432, 'Dextromethorphan Hydrobromide', 1, '2022-02-19 05:53:28', '2022-02-19 05:53:28'),
(433, 'Dextromethorphan Hydrobromide + Guaifenesin', 1, '2022-02-19 05:53:55', '2022-02-19 05:53:55'),
(434, 'Dextrose', 1, '2022-02-19 05:54:11', '2022-02-19 05:54:11'),
(435, 'Dextrose + Hartmann\'s Solution', 1, '2022-02-19 05:54:36', '2022-02-19 05:54:36'),
(436, 'Diabasic Sodium Phosphate + Monobasic Sodium Phosphate', 1, '2022-02-19 05:55:08', '2022-02-19 05:55:08'),
(437, 'Diazepam', 1, '2022-02-19 06:18:40', '2022-02-19 06:18:40'),
(438, 'Diazepam', 1, '2022-02-19 06:18:40', '2022-02-19 06:18:40'),
(439, 'Diazoxide', 1, '2022-02-19 06:19:11', '2022-02-19 06:19:11'),
(440, 'Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil', 1, '2022-02-19 06:19:26', '2022-02-19 06:19:26'),
(441, 'Diclofenac Potassium', 1, '2022-02-19 06:19:50', '2022-02-19 06:19:50'),
(442, 'Diclofenac Sodium', 1, '2022-02-19 06:20:07', '2022-02-19 06:20:07'),
(443, 'Diclofenac Sodium (Ophthalmic)', 1, '2022-02-19 06:20:25', '2022-02-19 06:20:25'),
(444, 'Diclofenac Sodium + Lidocaine Hydrochloride', 1, '2022-02-19 06:20:51', '2022-02-19 06:20:51'),
(445, 'Diclofenac Sodium + Methyl Salicylate + Linseed Oil + Menthol', 1, '2022-02-19 06:21:07', '2022-02-19 06:21:07'),
(446, 'Diclofenac Sodium + Misoprostol', 1, '2022-02-19 06:21:41', '2022-02-19 06:21:41'),
(447, 'Dicycloverine Hydrochloride', 1, '2022-02-19 06:22:16', '2022-02-19 06:22:16'),
(448, 'Dienogest', 1, '2022-02-19 06:22:32', '2022-02-19 06:22:32'),
(449, 'Dienogest + Estradiol Valerate', 1, '2022-02-19 06:22:59', '2022-02-19 06:22:59'),
(450, 'Diethylcarbamazine Citrate', 1, '2022-02-19 06:23:24', '2022-02-19 06:23:24'),
(451, 'Diflorasone Diacetate', 1, '2022-02-19 06:23:52', '2022-02-19 06:23:52'),
(452, 'Difluprednate', 1, '2022-02-19 06:24:50', '2022-02-19 06:24:50'),
(453, 'Digoxin', 1, '2022-02-19 06:25:06', '2022-02-19 06:25:06'),
(454, 'Diloxanide Furoate', 1, '2022-02-19 06:25:29', '2022-02-19 06:25:29'),
(455, 'Diltiazem Hydrochloride (FC Tablet)', 1, '2022-02-19 06:26:02', '2022-02-19 06:26:02'),
(456, 'Diltiazem Hydrochloride (SR Tablet)', 1, '2022-02-19 06:26:18', '2022-02-19 06:26:18'),
(457, 'Diphenhydramine + Dextromethorphan + Levomenthol', 1, '2022-02-19 06:26:33', '2022-02-19 06:26:33'),
(458, 'Diphenhydramine +  Levomenthol', 1, '2022-02-19 06:27:10', '2022-02-19 06:27:10'),
(459, 'Diphenhydramine Hydrochloride', 1, '2022-02-19 06:27:32', '2022-02-19 06:27:32'),
(460, 'Diphenhydramine Hydrochloride + Zinc Acetate', 1, '2022-02-19 06:27:56', '2022-02-19 06:27:56'),
(461, 'Diphtheria + Pertussis + Tetanus (DPT)', 1, '2022-02-19 06:28:44', '2022-02-19 06:28:44'),
(462, 'Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Influenzae Vaccine', 1, '2022-02-19 06:28:57', '2022-02-19 06:28:57'),
(463, 'Diphtheria, Tetanus, Pertussis, Poliomyelitis Vaccine', 1, '2022-02-19 06:29:18', '2022-02-19 06:29:18'),
(464, 'Dipyridamole', 1, '2022-02-19 06:29:41', '2022-02-19 06:29:41'),
(465, 'Disopyramide Phosphate', 1, '2022-02-19 06:30:04', '2022-02-19 06:30:04'),
(466, 'Dithranol + Boric Acid + Salicylic Acid', 1, '2022-02-19 06:30:38', '2022-02-19 06:30:38'),
(467, 'Dobutamine', 1, '2022-02-19 06:30:59', '2022-02-19 06:30:59'),
(468, 'Docetaxel Trihydrate', 1, '2022-02-19 06:31:16', '2022-02-19 06:31:16'),
(469, 'Docosanol', 1, '2022-02-19 06:31:30', '2022-02-19 06:31:30'),
(470, 'Docusate Sodium (Ear Drop)', 1, '2022-02-19 06:31:55', '2022-02-19 06:31:55'),
(471, 'Docusate Sodium (Oral)', 1, '2022-02-19 06:32:12', '2022-02-19 06:32:12'),
(472, 'Domperidone Maleate', 1, '2022-02-19 06:32:31', '2022-02-19 06:32:31'),
(473, 'Donepezil Hydrochloride', 1, '2022-02-19 06:33:05', '2022-02-19 06:33:05'),
(474, 'Dopamine Hydrochloride', 1, '2022-02-19 06:33:23', '2022-02-19 06:33:23'),
(475, 'Doripenem', 1, '2022-02-19 06:33:40', '2022-02-19 06:33:40'),
(476, 'Dorzolamide + Timolol', 1, '2022-02-19 06:34:00', '2022-02-19 06:34:00'),
(477, 'Doxepin (Oral)', 1, '2022-02-19 06:34:18', '2022-02-19 06:34:18'),
(478, 'Doxepin (Topical)', 1, '2022-02-19 06:34:40', '2022-02-19 06:34:40'),
(479, 'Doxophylline', 1, '2022-02-19 06:34:58', '2022-02-19 06:34:58'),
(480, 'Doxorubicin Hydrochloride', 1, '2022-02-19 06:35:21', '2022-02-19 06:35:21'),
(481, 'Doxycycline Hydrochloride', 1, '2022-02-19 06:36:05', '2022-02-19 06:36:05'),
(482, 'Doxylamine Succinate', 1, '2022-02-19 06:36:26', '2022-02-19 06:36:26'),
(483, 'Drospirenone', 1, '2022-02-19 06:36:55', '2022-02-19 06:36:55'),
(484, 'Drotaverine', 1, '2022-02-19 06:37:25', '2022-02-19 06:37:25'),
(485, 'Dulaglutide', 1, '2022-02-19 06:37:44', '2022-02-19 06:37:44'),
(486, 'Duloxetine Hydrochloride', 1, '2022-02-19 06:38:38', '2022-02-19 06:38:38'),
(487, 'Dutasteride', 1, '2022-02-19 06:38:56', '2022-02-19 06:38:56'),
(488, 'Dydrogesterone', 1, '2022-02-19 06:39:14', '2022-02-19 06:39:14'),
(489, 'Ebastine', 1, '2022-02-20 01:21:03', '2022-02-20 01:21:03'),
(490, 'Econazole Nitrate', 1, '2022-02-20 01:21:23', '2022-02-20 01:21:23'),
(491, 'Econazole Nitrate + Triamcinolone Acetonide', 1, '2022-02-20 01:23:44', '2022-02-20 01:23:44'),
(492, 'Efavirenz', 1, '2022-02-20 01:24:04', '2022-02-20 01:24:04'),
(493, 'Eflornithine Hydrochloride', 1, '2022-02-20 01:24:32', '2022-02-20 01:24:32'),
(494, 'Elagolix', 1, '2022-02-20 01:24:46', '2022-02-20 01:24:46'),
(495, 'Eltrombopag Olamine', 1, '2022-02-20 01:25:15', '2022-02-20 01:25:15'),
(496, 'Eluxadoline', 1, '2022-02-20 01:25:40', '2022-02-20 01:25:40'),
(497, 'Emollient (Cepalin+Allantoin)', 1, '2022-02-20 01:26:12', '2022-02-20 01:26:12'),
(498, 'Empagliflozin', 1, '2022-02-20 01:26:31', '2022-02-20 01:26:31'),
(499, 'Empagliflozin + Metformin Hydrochloride', 1, '2022-02-20 01:29:51', '2022-02-20 01:29:51'),
(500, 'Enalapril Maleate', 1, '2022-02-20 01:30:13', '2022-02-20 01:30:13'),
(501, 'Encephalitis Vaccine', 1, '2022-02-20 01:30:32', '2022-02-20 01:30:32'),
(502, 'Enoxaparin Sodium', 1, '2022-02-20 01:30:48', '2022-02-20 01:30:48'),
(503, 'Entacapone', 1, '2022-02-20 01:31:05', '2022-02-20 01:31:05'),
(504, 'Entecavir', 1, '2022-02-20 01:31:30', '2022-02-20 01:31:30'),
(505, 'Epalrestat', 1, '2022-02-20 01:31:53', '2022-02-20 01:31:53'),
(506, 'Eperisone Hydrochloride', 1, '2022-02-20 01:32:19', '2022-02-20 01:32:19'),
(507, 'Ephedrine Hydrochloride', 1, '2022-02-20 01:32:45', '2022-02-20 01:32:45'),
(508, 'Epinastine Hyrochloride', 1, '2022-02-20 01:33:09', '2022-02-20 01:33:09'),
(509, 'Epirubicin Hydrochloride', 1, '2022-02-20 01:33:37', '2022-02-20 01:33:37'),
(510, 'Eplerenone', 1, '2022-02-20 01:33:59', '2022-02-20 01:33:59'),
(511, 'Epoetin Beta', 1, '2022-02-20 01:34:16', '2022-02-20 01:34:16'),
(512, 'Eptifibatide', 1, '2022-02-20 01:34:37', '2022-02-20 01:34:37'),
(513, 'Erdosteine', 1, '2022-02-20 01:34:58', '2022-02-20 01:34:58'),
(514, 'Ergotamine Tartrate + Caffeine', 1, '2022-02-20 01:35:28', '2022-02-20 01:35:28'),
(515, 'Eribulin Mesylate', 1, '2022-02-20 01:36:08', '2022-02-20 01:36:08'),
(516, 'Erlotinib', 1, '2022-02-21 23:17:16', '2022-02-21 23:17:16'),
(517, 'Ertapenem', 1, '2022-02-21 23:17:33', '2022-02-21 23:17:33'),
(518, 'Erythromycin (Lotion)', 1, '2022-02-21 23:17:57', '2022-02-21 23:17:57'),
(519, 'Erythromycin (Oral)', 1, '2022-02-21 23:18:19', '2022-02-21 23:18:19'),
(520, 'Erythropoietin', 1, '2022-02-21 23:18:55', '2022-02-21 23:18:55'),
(521, 'Erythropoietin Alfa', 1, '2022-02-21 23:19:08', '2022-02-21 23:19:08'),
(522, 'Escitalopram Oxalate', 1, '2022-02-21 23:19:29', '2022-02-21 23:19:29'),
(523, 'Eslicarbazepine Acetate', 1, '2022-02-21 23:19:52', '2022-02-21 23:19:52'),
(524, 'Esmolol Hyrochloride', 1, '2022-02-21 23:20:16', '2022-02-21 23:20:16'),
(525, 'Esomeprazole', 1, '2022-02-21 23:20:37', '2022-02-21 23:20:37'),
(526, 'Esomeprazole (MUPS Tablet)', 1, '2022-02-21 23:21:00', '2022-02-21 23:21:00'),
(527, 'Esomeprazole + Amoxicillin + Clarithromycin', 1, '2022-02-21 23:21:34', '2022-02-21 23:21:34'),
(528, 'Estradiol', 1, '2022-02-21 23:21:51', '2022-02-21 23:21:51'),
(529, 'Estradiol Valerate', 1, '2022-02-21 23:22:11', '2022-02-21 23:22:11'),
(530, 'Estradiol (Oral)', 1, '2022-02-21 23:22:27', '2022-02-21 23:22:27'),
(531, 'Estradiol (Vaginal)', 1, '2022-02-21 23:22:49', '2022-02-21 23:22:49'),
(532, 'Eszopiclone', 1, '2022-02-21 23:23:17', '2022-02-21 23:23:17'),
(533, 'Etanercept', 1, '2022-02-21 23:23:40', '2022-02-21 23:23:40'),
(534, 'Ethambutol', 1, '2022-02-21 23:23:54', '2022-02-21 23:23:54'),
(535, 'Ethanol + Isopropyl Alcohol', 1, '2022-02-21 23:24:17', '2022-02-21 23:24:17'),
(536, 'Ethinyl Estradiol + Desogestrel (0.02 mg)', 1, '2022-02-21 23:24:57', '2022-02-21 23:24:57'),
(537, 'Ethinyl Estradiol + Desogestrel (0.03 mg)', 1, '2022-02-21 23:25:16', '2022-02-21 23:25:16'),
(538, 'Ethinyl Estradiol + Desogestrel + Ferrous Fumarate', 1, '2022-02-21 23:25:53', '2022-02-21 23:25:53'),
(539, 'Ethinyl Estradiol + Drospirenone (21 Tablet)', 1, '2022-02-21 23:26:39', '2022-02-21 23:26:39'),
(540, 'Ethinyl Estradiol + Drospirenone (24 Tablet)', 1, '2022-02-21 23:26:54', '2022-02-21 23:26:54'),
(541, 'Ethinyl Estradiol + Drospirenone (HRT)', 1, '2022-02-21 23:27:36', '2022-02-21 23:27:36'),
(542, 'Ethinyl Estradiol + Drospirenone + Levomefolate', 1, '2022-02-21 23:28:26', '2022-02-21 23:28:26'),
(543, 'Ethinyl Estradiol + Gestodene', 1, '2022-02-21 23:29:22', '2022-02-21 23:29:22'),
(544, 'Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate', 1, '2022-02-21 23:30:18', '2022-02-21 23:30:18'),
(545, 'Ethinyl Estradiol + Lynestrenol (0.0375 mg)', 1, '2022-02-21 23:30:58', '2022-02-21 23:30:58'),
(546, 'Ethinyl Estradiol + Lynestrenol (0.05 mg)', 1, '2022-02-21 23:33:47', '2022-02-21 23:33:47'),
(547, 'Ethosuximide', 1, '2022-02-21 23:34:08', '2022-02-21 23:34:08'),
(548, 'Ethyl Alcohol + Hydrogen Peroxide + Glycerol', 1, '2022-02-21 23:34:53', '2022-02-21 23:34:53'),
(549, 'Ethyl Butylacetylaminopropionate', 1, '2022-02-21 23:35:33', '2022-02-21 23:35:33'),
(550, 'Etodolac', 1, '2022-02-21 23:35:47', '2022-02-21 23:35:47'),
(551, 'Etoposide', 1, '2022-02-21 23:36:24', '2022-02-21 23:36:24'),
(552, 'Eucalyptol + Menthol + Methyl Salicylate + Thymol + Sodium Fluoride', 1, '2022-02-21 23:37:23', '2022-02-21 23:37:23'),
(553, 'Eucalyptol + Methanol + Thymol', 1, '2022-02-21 23:37:51', '2022-02-21 23:37:51'),
(554, 'Everolimus', 1, '2022-02-21 23:38:11', '2022-02-21 23:38:11'),
(555, 'Ezetimibe', 1, '2022-02-21 23:38:29', '2022-02-21 23:38:29'),
(556, 'Famciclovir', 1, '2022-02-21 23:40:55', '2022-02-21 23:40:55'),
(557, 'Famotidine', 1, '2022-02-22 01:45:21', '2022-02-22 01:45:21'),
(558, 'Favipiravir', 1, '2022-02-22 01:47:29', '2022-02-22 01:47:29'),
(559, 'Febuxostat', 1, '2022-02-22 01:49:01', '2022-02-22 01:49:01'),
(560, 'Fenofibrate', 1, '2022-02-22 01:53:56', '2022-02-22 01:53:56'),
(561, 'Fentanyl Citrate', 1, '2022-02-22 01:58:19', '2022-02-22 01:58:19'),
(562, 'Fenticonazole Nitrate [Vaginal Cream]', 1, '2022-02-22 02:10:02', '2022-02-22 02:10:02'),
(563, 'Fenticonazole Nitrate [Vaginal Tablet]', 1, '2022-02-22 02:25:44', '2022-02-22 02:25:44'),
(564, 'Ferric Carboxymaltose', 1, '2022-02-22 02:39:25', '2022-02-22 02:39:25'),
(565, 'Ferric Citrate', 1, '2022-02-22 02:41:27', '2022-02-22 02:41:27'),
(566, 'Ferric Derisomaltose', 1, '2022-02-22 02:43:17', '2022-02-22 02:43:17'),
(567, 'Ferric Pyrophosphate Citrate', 1, '2022-02-22 02:53:59', '2022-02-22 02:53:59'),
(568, 'Ferrous Ascorbate', 1, '2022-02-22 02:56:12', '2022-02-22 02:56:12'),
(569, 'Ferrous Ascorbate + Folic Acid + Zinc Sulfate', 1, '2022-02-22 02:58:22', '2022-02-22 02:58:22'),
(570, 'Ferrous Fumarate', 1, '2022-02-22 03:02:48', '2022-02-22 03:02:48'),
(571, 'Ferrous Fumarate + Folic acid', 1, '2022-02-22 03:05:10', '2022-02-22 03:05:10'),
(572, 'Ferrous Gluconate', 1, '2022-02-22 03:06:48', '2022-02-22 03:06:48'),
(573, 'Ferrous Sulfate', 1, '2022-02-22 03:18:45', '2022-02-22 03:18:45'),
(574, 'Ferrous Sulfate + Folic Acid', 1, '2022-02-22 03:23:47', '2022-02-22 03:23:47'),
(575, 'Ferrous Sulfate + Folic Acid + Zinc Sulfate', 1, '2022-02-22 03:35:08', '2022-02-22 03:35:08'),
(576, 'Fexofenadine + Pseudoephedrine', 1, '2022-02-26 02:07:49', '2022-02-26 02:07:49'),
(577, 'Fexofenadine Hydrochloride', 1, '2022-02-26 02:09:17', '2022-02-26 02:09:17'),
(578, 'Filgrastim', 1, '2022-02-26 02:12:04', '2022-02-26 02:12:04'),
(579, 'Finasteride (Androgenic Alopecia)', 1, '2022-02-26 02:13:41', '2022-02-26 02:13:41'),
(580, 'Finasteride (B.P.H.)', 1, '2022-02-26 02:15:33', '2022-02-26 02:15:33'),
(581, 'Flavoxate Hydrochloride', 1, '2022-02-26 02:17:14', '2022-02-26 02:17:14'),
(582, 'Flucloxacillin Sodium', 1, '2022-02-26 02:20:05', '2022-02-26 02:20:05'),
(583, 'Fluconazole', 1, '2022-02-26 02:21:36', '2022-02-26 02:21:36'),
(584, 'Fluconazole (Ophthalmic)', 1, '2022-02-26 02:23:05', '2022-02-26 02:23:05'),
(585, 'Fludarabine Phosphate', 1, '2022-02-26 02:24:37', '2022-02-26 02:24:37'),
(586, 'Fludrocortisone Acetate', 1, '2022-02-26 02:26:50', '2022-02-26 02:26:50'),
(587, 'Flunarizine', 1, '2022-02-26 02:28:27', '2022-02-26 02:28:27'),
(588, 'Fluocinolone Acetonide', 1, '2022-02-26 02:29:53', '2022-02-26 02:29:53'),
(589, 'Fluocinolone Acetonide + Clioquinol', 1, '2022-02-26 02:32:01', '2022-02-26 02:32:01'),
(590, 'Fluocinolone Acetonide + Hydroquinone + Tretinoin', 1, '2022-02-26 02:36:13', '2022-02-26 02:36:13'),
(591, 'Fluocinolone Acetonide + Neomycin Sulfate', 1, '2022-02-26 02:38:44', '2022-02-26 02:38:44'),
(592, 'Fluorescein Sodium', 1, '2022-02-26 02:54:16', '2022-02-26 02:54:16'),
(593, 'Fluormetholone + Neomycin Sulphate', 1, '2022-02-26 02:56:27', '2022-02-26 02:56:27'),
(594, 'Fluorometholone + Gentamicin', 1, '2022-02-26 02:58:11', '2022-02-26 02:58:11'),
(595, 'Fluorometholone + Tetrahydrozoline', 1, '2022-02-26 02:59:47', '2022-02-26 02:59:47'),
(596, 'Fluorometholone Acetate', 1, '2022-02-26 03:13:12', '2022-02-26 03:13:12'),
(597, 'Fluorouracil', 1, '2022-02-26 03:35:26', '2022-02-26 03:35:26'),
(598, 'Fluoxetine Hydrochloride', 1, '2022-02-26 03:37:12', '2022-02-26 03:37:12'),
(599, 'Flupentixol', 1, '2022-02-26 03:38:55', '2022-02-26 03:38:55'),
(600, 'Flupentixol + Melitracen', 1, '2022-02-26 03:40:38', '2022-02-26 03:40:38'),
(601, 'Fluphenazine + Nortriptyline', 1, '2022-02-26 03:42:08', '2022-02-26 03:42:08'),
(602, 'Fluphenazine Decanoate', 1, '2022-02-26 03:44:34', '2022-02-26 03:44:34'),
(603, 'Flurazepam', 1, '2022-02-26 03:47:14', '2022-02-26 03:47:14'),
(604, 'Flurbiprofen', 1, '2022-02-26 03:49:08', '2022-02-26 03:49:08'),
(605, 'Flutamide', 1, '2022-02-26 03:50:41', '2022-02-26 03:50:41'),
(606, 'Fluticasone Furoate', 1, '2022-02-26 04:10:50', '2022-02-26 04:10:50'),
(607, 'Fluticasone Propionate (Inhaler)', 1, '2022-02-26 04:13:13', '2022-02-26 04:13:13'),
(608, 'Fluticasone Propionate (Nasal Spray)', 1, '2022-02-26 04:15:17', '2022-02-26 04:15:17'),
(609, 'Fluticasone Propionate (Nebulizer Suspension)', 1, '2022-02-26 04:17:10', '2022-02-26 04:17:10'),
(610, 'Fluticasone Propionate (Topical)', 1, '2022-02-26 04:18:53', '2022-02-26 04:18:53'),
(611, 'Fluticasone Propionate + Formoterol Fumarate', 1, '2022-02-26 04:21:11', '2022-02-26 04:21:11'),
(612, 'Fluvastatin', 1, '2022-02-26 05:18:09', '2022-02-26 05:18:09'),
(613, 'Fluvoxamine Maleate', 1, '2022-02-26 05:20:08', '2022-02-26 05:20:08'),
(614, 'Folic Acid', 1, '2022-02-26 05:28:49', '2022-02-26 05:28:49'),
(615, 'Folic Acid + Zinc Sulfate Monohydrate', 1, '2022-02-26 05:31:08', '2022-02-26 05:31:08'),
(616, 'Follicle Stimulating Hormone (Urofollitropin)', 1, '2022-02-26 05:34:06', '2022-02-26 05:34:06'),
(617, 'Follitropin Alfa', 1, '2022-02-26 05:35:41', '2022-02-26 05:35:41'),
(618, 'Follitropin Alfa + Lutropin Alfa', 1, '2022-02-26 05:37:17', '2022-02-26 05:37:17'),
(619, 'Follitropin Beta', 1, '2022-02-26 05:38:47', '2022-02-26 05:38:47'),
(620, 'Fondaparinux Sodium', 1, '2022-02-26 05:40:14', '2022-02-26 05:40:14'),
(621, 'Formoterol Fumarate', 1, '2022-02-26 05:41:52', '2022-02-26 05:41:52'),
(622, 'Formoterol Fumarate + Glycopyrrolate + Budesonide', 1, '2022-02-26 05:44:53', '2022-02-26 05:44:53'),
(623, 'Fosfomycin Trometamol', 1, '2022-02-26 05:46:24', '2022-02-26 05:46:24'),
(624, 'Fructose', 1, '2022-02-26 05:47:41', '2022-02-26 05:47:41'),
(625, 'Fucidic Acid + Betamethasone', 1, '2022-02-26 05:49:17', '2022-02-26 05:49:17'),
(626, 'Furosemide', 1, '2022-02-26 05:51:03', '2022-02-26 05:51:03'),
(627, 'Furosemide + Spironolactone', 1, '2022-02-26 05:52:52', '2022-02-26 05:52:52'),
(628, 'Fusidic Acid (Ophthalmic)', 1, '2022-02-26 05:54:18', '2022-02-26 05:54:18'),
(629, 'Fusidic acid + Betamethasone', 1, '2022-02-26 05:56:12', '2022-02-26 05:56:12'),
(630, 'Fusidic acid + Hydrocortisone', 1, '2022-02-26 05:57:38', '2022-02-26 05:57:38'),
(631, 'Gabapentin', 1, '2022-02-26 05:58:11', '2022-02-26 05:58:11'),
(632, 'Gadodiamide', 1, '2022-02-26 05:58:27', '2022-02-26 05:58:27'),
(633, 'Gadoversetamide', 1, '2022-02-26 05:58:44', '2022-02-26 05:58:44'),
(634, 'Galantamine', 1, '2022-02-26 05:59:03', '2022-02-26 05:59:03'),
(635, 'Ganciclovir (Ophthalmic)', 1, '2022-02-26 05:59:30', '2022-02-26 05:59:30');
INSERT INTO `generics` (`id`, `generic_name`, `category_id`, `created_at`, `updated_at`) VALUES
(636, 'Gatifloxacin (Ophthalmic)', 1, '2022-02-26 05:59:51', '2022-02-26 05:59:51'),
(637, 'Gatifloxacin (Oral)', 1, '2022-02-26 06:00:11', '2022-02-26 06:00:11'),
(638, 'Gatifloxacin + Dexamethasone', 1, '2022-02-26 06:00:33', '2022-02-26 06:00:33'),
(639, 'Geftinib', 1, '2022-02-26 06:00:50', '2022-02-26 06:00:50'),
(640, 'Gemcitabine', 1, '2022-02-26 06:01:05', '2022-02-26 06:01:05'),
(641, 'Gemfibrozil', 1, '2022-02-26 06:01:22', '2022-02-26 06:01:22'),
(642, 'Gemifloxacin', 1, '2022-02-26 06:01:37', '2022-02-26 06:01:37'),
(643, 'Gentamicin + Hydrocortisone Acetate', 1, '2022-02-26 06:02:09', '2022-02-26 06:02:09'),
(644, 'Gentamicin Sulfate (Injection)', 1, '2022-02-26 06:02:42', '2022-02-26 06:02:42'),
(645, 'Gentamicin Sulfate (Ophthalmic)', 1, '2022-02-26 06:03:04', '2022-02-26 06:03:04'),
(646, 'Gentamicin Sulfate (Topical)', 1, '2022-02-26 06:03:22', '2022-02-26 06:03:22'),
(647, 'Gentian Violet', 1, '2022-02-26 06:03:37', '2022-02-26 06:03:37'),
(648, 'Glecaprevir + Pibrentasvir', 1, '2022-02-26 06:04:04', '2022-02-26 06:04:04'),
(649, 'Glibenclamide', 1, '2022-02-26 06:04:24', '2022-02-26 06:04:24'),
(650, 'Gliclazide', 1, '2022-02-26 06:04:37', '2022-02-26 06:04:37'),
(651, 'Glimepiride', 1, '2022-02-26 06:05:07', '2022-02-26 06:05:07'),
(652, 'Glimepiride + Metformin', 1, '2022-02-26 06:05:30', '2022-02-26 06:05:30'),
(653, 'Glipizide', 1, '2022-02-26 06:05:46', '2022-02-26 06:05:46'),
(654, 'Glipizide + Metformin Hydrochloride', 1, '2022-02-26 06:06:20', '2022-02-26 06:06:20'),
(655, 'Glucosamine Hydrochloride', 1, '2022-02-26 06:06:46', '2022-02-26 06:06:46'),
(656, 'Glucosamine Sulfate + Chondroitin', 1, '2022-02-26 06:07:24', '2022-02-26 06:07:24'),
(657, 'Glucosamine Sulfate + Chondroitin + Camphor + Peppermint Oil', 1, '2022-02-26 06:07:47', '2022-02-26 06:07:47'),
(658, 'Glucosamine Sulfate + Diacerein', 1, '2022-02-26 06:08:19', '2022-02-26 06:08:19'),
(659, 'Glucose 11% + Vitamin 18 Novum + Intralipid 20%', 1, '2022-02-26 06:08:58', '2022-02-26 06:08:58'),
(660, 'Glucose 19% + Vitamin 18 Novum + Intralipid 20%', 1, '2022-02-26 06:09:24', '2022-02-26 06:09:24'),
(661, 'Glycerin', 1, '2022-02-26 06:09:40', '2022-02-26 06:09:40'),
(662, 'Glycerin + Hypromellose + Polyethylene glycol + Tetrahydrozoline + Zinc Sulfate', 1, '2022-02-26 06:09:51', '2022-02-26 06:09:51'),
(663, 'Glycerol', 1, '2022-02-26 06:10:10', '2022-02-26 06:10:10'),
(664, 'Glycerol + Hypromellose + Polyethylene Glycol 400', 1, '2022-02-26 06:10:39', '2022-02-26 06:10:39'),
(665, 'Glycerol + Liquid Sugar', 1, '2022-02-26 06:11:03', '2022-02-26 06:11:03'),
(666, 'Glycine', 1, '2022-02-26 06:11:59', '2022-02-26 06:13:05'),
(667, 'Glycopyrronium Bromide (Inhalation Capsule)', 1, '2022-02-26 06:13:30', '2022-02-26 06:13:30'),
(668, 'Glycopyrronium Bromide (Injection)', 1, '2022-02-26 06:13:52', '2022-02-26 06:13:52'),
(669, 'Glycopyrronium Bromide (Oral solution)', 1, '2022-02-26 06:14:12', '2022-02-26 06:14:12'),
(670, 'Glycopyrronium Bromide (Respirator Solution)', 1, '2022-02-26 06:14:27', '2022-02-26 06:14:27'),
(671, 'Glycopyrronium Bromide + Formoterol Fumarate', 1, '2022-02-26 06:14:48', '2022-02-26 06:14:48'),
(672, 'Golimumab', 1, '2022-02-26 06:15:05', '2022-02-26 06:15:05'),
(673, 'Gramacidin + Neomycin + Polymixin B', 1, '2022-02-26 06:15:37', '2022-02-26 06:15:37'),
(674, 'Granisetron', 1, '2022-02-26 06:15:52', '2022-02-26 06:15:52'),
(675, 'Griseofulvin (Microsize)', 1, '2022-02-26 06:16:20', '2022-02-26 06:16:20'),
(676, 'Guaifenesin + Dextromethorphan + Menthol', 1, '2022-02-26 06:16:57', '2022-02-26 06:16:57'),
(677, 'Guaifenesin + Levomenthol + Diphenhydramine', 1, '2022-02-26 06:17:44', '2022-02-26 06:17:44'),
(678, 'Haemophilus Influenzae Type B Vaccine (Conjugated)', 1, '2022-02-26 06:20:42', '2022-02-26 06:20:42'),
(679, 'Halazone', 1, '2022-02-26 06:22:45', '2022-02-26 06:22:45'),
(680, 'Halcinonide', 1, '2022-02-26 06:23:04', '2022-02-26 06:23:04'),
(681, 'Halobetasol Propionate', 1, '2022-02-26 06:23:27', '2022-02-26 06:23:27'),
(682, 'Halobetasol Propionate + Tazarotene', 1, '2022-02-26 06:23:50', '2022-02-26 06:23:50'),
(683, 'Haloperidol', 1, '2022-02-26 06:24:10', '2022-02-26 06:24:10'),
(684, 'Halothane', 1, '2022-02-26 06:24:23', '2022-02-26 06:24:23'),
(685, 'Hartmann\'s Solution', 1, '2022-02-26 06:24:42', '2022-02-26 06:24:42'),
(686, 'Heparin Sodium', 1, '2022-02-26 06:24:59', '2022-02-26 06:24:59'),
(687, 'Hepatitis A Vaccine', 1, '2022-02-26 06:25:18', '2022-02-26 06:25:18'),
(688, 'Hepatitis B Immune Globulin', 1, '2022-02-26 06:25:45', '2022-02-26 06:25:45'),
(689, 'Hepatitis B Vaccine [rDNA]', 1, '2022-02-26 06:26:15', '2022-02-26 06:26:15'),
(690, 'Homatropine Hydrobromide', 1, '2022-02-26 06:26:39', '2022-02-26 06:26:39'),
(691, 'Human Anti-D Immunoglobulins', 1, '2022-02-26 06:27:02', '2022-02-26 06:27:02'),
(692, 'Human Chorionic Gonadotrophin', 1, '2022-02-26 06:27:34', '2022-02-26 06:27:34'),
(693, 'Human Immunoglobulin-G [IgG]', 1, '2022-02-26 06:28:20', '2022-02-26 06:28:20'),
(694, 'Human Menopausal Gonadotrophin', 1, '2022-02-26 06:28:48', '2022-02-26 06:28:48'),
(695, 'Human Milk Based Amino Acid', 1, '2022-02-26 06:29:06', '2022-02-26 06:29:06'),
(696, 'Human Papillomavirus Bivalent [types 16 and 18]', 1, '2022-02-26 06:29:49', '2022-02-26 06:29:49'),
(697, 'Human Papillomavirus Quadrivalent [types 6, 11, 16 and 18]', 1, '2022-02-26 06:30:41', '2022-02-26 06:30:41'),
(698, 'Human Tetanus Immunoglobulin', 1, '2022-02-26 06:31:04', '2022-02-26 06:31:04'),
(699, 'Hydrochlorothiazide', 1, '2022-02-26 06:31:31', '2022-02-26 06:31:31'),
(700, 'Hydrochlorothiazide + Triamterene', 1, '2022-02-26 06:31:58', '2022-02-26 06:31:58'),
(701, 'Hydrocortisone', 1, '2022-02-26 06:32:16', '2022-02-26 06:32:16'),
(702, 'Hydrocortisone  + Lidocaine', 1, '2022-02-26 06:32:44', '2022-02-26 06:32:44'),
(703, 'Hydrocortisone + Neomycin Sulphate + Polymixin B', 1, '2022-02-26 06:33:23', '2022-02-26 06:33:23'),
(704, 'Hydrocortisone Acetate', 1, '2022-02-26 06:33:41', '2022-02-26 06:33:41'),
(705, 'Hydrocortisone Acetate + Benzyl Benzoate + Bismuth Subgallate + Bismuth Oxide + Balsam Peru + Zinc Oxide', 1, '2022-02-26 06:33:54', '2022-02-26 06:33:54'),
(706, 'Hydrocortisone Acetate + Neomycin Sulphate', 1, '2022-02-26 06:34:11', '2022-02-26 06:34:11'),
(707, 'Hydrocortisone + Butyrate', 1, '2022-02-26 06:34:46', '2022-02-26 06:34:46'),
(708, 'Hydrogen Peroxide', 1, '2022-02-26 06:36:10', '2022-02-26 06:36:10'),
(709, 'Hydroquinone', 1, '2022-02-26 06:36:33', '2022-02-26 06:36:33'),
(710, 'Hydroquinone + Octyldimethyl + Dioxybenzone + Oxybenzone', 1, '2022-02-26 06:36:45', '2022-02-26 06:36:45'),
(711, 'Hydroxocobalamin', 1, '2022-02-26 06:37:05', '2022-02-26 06:37:05'),
(712, 'Hydroxychloroquine Sulphate', 1, '2022-02-26 06:37:25', '2022-02-26 06:37:25'),
(713, 'Hydroxyethyl Cellulose + Glycerin', 1, '2022-02-26 06:37:44', '2022-02-26 06:37:44'),
(714, 'Hydroxyethyl Starch + Sodium Chloride', 1, '2022-02-26 06:38:03', '2022-02-26 06:38:03'),
(715, 'Hydroxyprogesterone Caproate', 1, '2022-02-26 06:38:18', '2022-02-26 06:38:18'),
(716, 'Hydroxypropyl Methylcellulose', 1, '2022-02-26 06:38:32', '2022-02-26 06:38:32'),
(717, 'Hydroxyurea', 1, '2022-02-26 06:38:45', '2022-02-26 06:38:45'),
(718, 'Hydroxyzine Hydrochloride', 1, '2022-02-26 06:39:05', '2022-02-26 06:39:05'),
(719, 'Hylan G-F 20', 1, '2022-02-26 06:39:23', '2022-02-26 06:39:23'),
(720, 'Hyoscine Butylbromide', 1, '2022-02-26 06:39:37', '2022-02-26 06:39:37'),
(721, 'Hyoscine Hydrobromide', 1, '2022-02-26 06:39:50', '2022-02-26 06:39:50'),
(722, 'Hypromellose (Ophthalmic Gel)', 1, '2022-02-26 06:40:10', '2022-02-26 06:40:10'),
(723, 'Hypromellose (Ophthalmic Solution)', 1, '2022-02-26 06:40:28', '2022-02-26 06:40:28'),
(724, 'Hypromellose + Carbomer', 1, '2022-02-26 06:40:47', '2022-02-26 06:40:47'),
(725, 'Ibandronic Acid', 1, '2022-02-27 19:02:04', '2022-02-27 19:02:04'),
(726, 'Ibandronic Acid & Calcium Orotate', 1, '2022-02-27 19:03:14', '2022-02-27 19:03:14'),
(727, 'Ibandronic Acid + Calcium Carbonate + Vitamin D3', 1, '2022-02-27 19:03:59', '2022-02-27 19:03:59'),
(728, 'Ibrutinib', 1, '2022-02-27 19:06:40', '2022-02-27 19:06:40'),
(729, 'Ibuprofen', 1, '2022-02-27 19:07:02', '2022-02-27 19:07:02'),
(730, 'Idoxuridine', 1, '2022-02-27 19:07:35', '2022-02-27 19:07:35'),
(731, 'Ifosfamide', 1, '2022-02-27 19:07:55', '2022-02-27 19:07:55'),
(732, 'Iloperidone', 1, '2022-02-27 19:08:19', '2022-02-27 19:08:19'),
(733, 'Imatinib Mesylate', 1, '2022-02-27 19:08:40', '2022-02-27 19:08:40'),
(734, 'Imipenem + Cilastatin', 1, '2022-02-27 19:09:04', '2022-02-27 19:09:04'),
(735, 'Imipramine Hydrochloride', 1, '2022-02-27 19:49:09', '2022-02-27 19:49:09'),
(736, 'Imiquimod', 1, '2022-02-27 19:49:28', '2022-02-27 19:49:28'),
(737, 'Inactivated Hepatitis A Vaccine', 1, '2022-02-27 19:49:53', '2022-02-27 19:49:53'),
(738, 'Inactivated Influenza Vaccine', 1, '2022-02-27 19:50:31', '2022-02-27 19:50:31'),
(739, 'Inactivated Polio Vaccine', 1, '2022-02-27 19:50:56', '2022-02-27 19:50:56'),
(740, 'Indacaterol + Glycopyrronium', 1, '2022-02-27 19:51:33', '2022-02-27 19:51:33'),
(741, 'Indacarerol Maleate', 1, '2022-02-27 19:51:55', '2022-02-27 19:51:55'),
(742, 'Indapamide', 1, '2022-02-27 19:52:11', '2022-02-27 19:52:11'),
(743, 'Indapamide + Amlodipine', 1, '2022-02-27 19:52:35', '2022-02-27 19:52:35'),
(744, 'Indapamide + Perindopril Arginine', 1, '2022-02-27 19:53:03', '2022-02-27 19:53:03'),
(745, 'Indomethacin (Oral)', 1, '2022-02-27 19:59:37', '2022-02-27 19:59:37'),
(746, 'Indomethacin (Rectal)', 1, '2022-02-27 19:59:51', '2022-02-27 19:59:51'),
(747, 'Infliximab', 1, '2022-02-27 20:00:15', '2022-02-27 20:00:15'),
(748, 'Inositol Nicotinate', 1, '2022-03-02 01:35:32', '2022-03-02 01:35:32'),
(749, 'Insulin Aspart', 1, '2022-03-02 01:49:24', '2022-03-02 01:49:24'),
(750, 'Insulin Degludec', 1, '2022-03-06 16:13:59', '2022-03-06 16:13:59'),
(751, 'Insulin Degludec + Insulin Aspart Premixed', 1, '2022-03-06 16:20:34', '2022-03-06 16:20:34'),
(752, 'Insulin Detemir', 1, '2022-03-06 16:24:37', '2022-03-06 16:24:37'),
(753, 'Insulin Glargine [rDNA]', 1, '2022-03-06 16:28:40', '2022-03-06 16:28:40'),
(754, 'Insulin Glulisine', 1, '2022-03-06 16:32:19', '2022-03-06 16:32:19'),
(755, 'Insulin Human [Fast-Acting]', 1, '2022-03-06 16:48:25', '2022-03-06 16:48:25'),
(756, 'Insulin Human [Long-Acting]', 1, '2022-03-07 05:21:06', '2022-03-07 05:21:06'),
(757, 'Insulin Human [rDNA] + Isophane Insulin Human', 1, '2022-03-07 05:24:50', '2022-03-07 05:24:50'),
(758, 'Insulin Lispro', 1, '2022-03-07 05:27:43', '2022-03-07 05:27:43'),
(759, 'Insulin Lispro Protamine + Insulin Lispro', 1, '2022-03-07 05:38:00', '2022-03-07 05:38:00'),
(760, 'Interferon Alfa-2a [Recombinant]', 1, '2022-03-07 05:41:33', '2022-03-07 05:41:33'),
(761, 'Intravenous Fat Emulsion', 1, '2022-03-07 05:44:22', '2022-03-07 05:44:22'),
(762, 'Iodixanol', 1, '2022-03-07 05:48:48', '2022-03-07 05:48:48'),
(763, 'Iohexol', 1, '2022-03-07 05:56:30', '2022-03-07 05:56:30'),
(764, 'Iopamidol', 1, '2022-03-07 05:59:15', '2022-03-07 05:59:15'),
(765, 'Ipratropium Bromide (Inhaler)', 1, '2022-03-07 06:23:39', '2022-03-07 06:23:39'),
(766, 'Ipratropium Bromide (Nasal Spray)', 1, '2022-03-07 06:25:51', '2022-03-07 06:25:51'),
(767, 'Ipratropium Bromide (Nebuliser Solution)', 1, '2022-03-07 06:27:51', '2022-03-07 06:27:51'),
(768, 'Irbesartan', 1, '2022-03-07 06:30:25', '2022-03-07 06:30:25'),
(769, 'Irbesartan + Hydrochlorothiazide', 1, '2022-03-07 06:32:48', '2022-03-07 06:32:48'),
(770, 'Irinotecan Hydrochloride', 1, '2022-03-07 06:35:13', '2022-03-07 06:35:13'),
(771, 'Iron + Folic Acid + Vitamin A + Vitamin C + Zinc', 1, '2022-03-07 06:40:20', '2022-03-07 06:40:20'),
(772, 'Iron + Folic acid + Vitamin B complex + Vitamin C', 1, '2022-03-07 06:42:52', '2022-03-07 06:42:52'),
(773, 'Iron + Folic Acid + Vitamin B Complex + Vitamine C + Zinc Sulfate', 1, '2022-03-07 06:46:03', '2022-03-07 06:46:03'),
(774, 'Iron Hydroxide Polymaltose + Folic acid + Zinc Sulfate Monohydrate', 1, '2022-03-07 06:47:44', '2022-03-07 06:47:44'),
(775, 'Iron Polymaltose Complex', 1, '2022-03-07 19:13:43', '2022-03-07 19:13:43'),
(776, 'Iron Polymaltose Complex + Folic Acid + Zinc + Vitamin B-Complex', 1, '2022-03-07 19:16:06', '2022-03-07 19:16:06'),
(777, 'Iron Polymaltose Complex + Folic Acid + Zinc Sulfate', 1, '2022-03-07 19:18:15', '2022-03-07 19:18:15'),
(778, 'Iron Polymaltose Complex + Vitamin B Complex + Zinc', 1, '2022-03-07 19:20:37', '2022-03-07 19:20:37'),
(779, 'Iron Sucrose Injection [Elemental Iron]', 1, '2022-03-07 19:23:19', '2022-03-07 19:23:19'),
(780, 'Irrigating Solution', 1, '2022-03-07 19:26:03', '2022-03-07 19:26:03'),
(781, 'Isoflurane', 1, '2022-03-07 20:01:17', '2022-03-07 20:01:17'),
(782, 'Isoniazid', 1, '2022-03-07 20:04:54', '2022-03-07 20:04:54'),
(783, 'Isopropamide + Trifluoperazine', 1, '2022-03-07 20:07:00', '2022-03-07 20:07:00'),
(784, 'Isopropyl alcohol', 1, '2022-03-07 20:12:45', '2022-03-07 20:12:45'),
(785, 'Isopropyl Alcohol + Hydrogen Peroxide + Glycerol', 1, '2022-03-07 20:15:33', '2022-03-07 20:15:33'),
(786, 'Isosorbide Mononitrate', 1, '2022-03-07 20:18:04', '2022-03-07 20:18:04'),
(787, 'Isotretinoin (Oral)', 1, '2022-03-07 20:21:21', '2022-03-07 20:21:21'),
(788, 'Isotretinoin (Topical)', 1, '2022-03-07 21:07:26', '2022-03-07 21:07:26'),
(789, 'Ispaghula Husk + Ispaghula Seed + Tinnevelly Senna Pods', 1, '2022-03-07 21:08:38', '2022-03-07 21:08:38'),
(790, 'Isradipine', 1, '2022-03-07 21:11:28', '2022-03-07 21:11:28'),
(791, 'Itraconazole', 1, '2022-03-07 21:13:52', '2022-03-07 21:13:52'),
(792, 'Ivabradine', 1, '2022-03-07 21:16:12', '2022-03-07 21:16:12'),
(793, 'Ivermectin (Tablet)', 1, '2022-03-07 21:18:52', '2022-03-07 21:18:52'),
(794, 'Ivermectin (Topical)', 1, '2022-03-07 21:20:55', '2022-03-07 21:20:55'),
(795, 'Kanamycin', 1, '2022-03-07 21:22:59', '2022-03-07 21:22:59'),
(796, 'Ketamine', 1, '2022-03-07 21:25:35', '2022-03-07 21:25:35'),
(797, 'Ketoconazole (Cream)', 1, '2022-03-07 21:27:40', '2022-03-07 21:27:40'),
(798, 'Ketoconazole (Shampoo)', 1, '2022-03-07 21:29:49', '2022-03-07 21:29:49'),
(799, 'Ketoconazole (Tablet)', 1, '2022-03-07 21:32:03', '2022-03-07 21:32:03'),
(800, 'Ketoprofen (oral & injection)', 1, '2022-03-07 21:34:43', '2022-03-07 21:34:43'),
(801, 'Ketoprofen (Topical)', 1, '2022-03-07 21:37:11', '2022-03-07 21:37:11'),
(802, 'Ketorolac Tromethamine', 1, '2022-03-07 21:39:10', '2022-03-07 21:39:10'),
(803, 'Ketorolac Tromethamine (Ophthalmic)', 1, '2022-03-07 21:41:11', '2022-03-07 21:41:11'),
(804, 'Ketotifen Fumarate (Ophthalmic)', 1, '2022-03-07 21:43:50', '2022-03-07 21:43:50'),
(805, 'Ketotifen Fumarate (Oral)', 1, '2022-03-07 21:45:55', '2022-03-07 21:45:55'),
(806, 'L-arginie + Proanthocyanidin + Folic Acid + Zinc', 1, '2022-03-07 22:03:10', '2022-03-07 22:03:10'),
(807, 'L-Lysine Hydrochloride', 1, '2022-03-07 22:05:15', '2022-03-07 22:05:15'),
(808, 'L-Ornithine L-Aspartate', 1, '2022-03-07 22:07:08', '2022-03-07 22:07:08'),
(809, 'L-Ornithine L-Aspartate + Pancreatin', 1, '2022-03-07 22:09:12', '2022-03-07 22:09:12'),
(810, 'Labetalol Hydrochloride (Injection)', 1, '2022-03-07 22:13:37', '2022-03-07 22:13:37'),
(811, 'Labetalol Hydrochloride (Tablet)', 1, '2022-03-07 22:16:31', '2022-03-07 22:16:31'),
(812, 'Lacidipine', 1, '2022-03-07 22:20:24', '2022-03-07 22:20:24'),
(813, 'Lacosamide', 1, '2022-03-07 22:23:12', '2022-03-07 22:23:12'),
(814, 'Lactase', 1, '2022-03-07 22:27:39', '2022-03-07 22:27:39'),
(815, 'Lactic acid + Citric acid + Potassium bitartrate', 1, '2022-03-07 22:29:43', '2022-03-07 22:29:43'),
(816, 'Lactic acid + Sodium PCA', 1, '2022-03-07 22:32:01', '2022-03-07 22:32:01'),
(817, 'Lactitol Monohydrate', 1, '2022-03-07 22:34:00', '2022-03-07 22:34:00'),
(818, 'Lactobacillus Rhamnosus GG', 1, '2022-03-07 22:35:56', '2022-03-07 22:35:56'),
(819, 'Lactulose', 1, '2022-03-07 22:38:22', '2022-03-07 22:38:22'),
(820, 'Lamivudine [For Chronic Hepatitis B]', 1, '2022-03-07 22:40:44', '2022-03-07 22:40:44'),
(821, 'Lamivudine [For HIV Infection]', 1, '2022-03-07 22:43:30', '2022-03-07 22:43:30'),
(822, 'Lamivudine + Zidovudine', 1, '2022-03-07 22:45:46', '2022-03-07 22:45:46'),
(823, 'Lamivudine + Zidovudine + Nevirapine', 1, '2022-03-07 22:47:56', '2022-03-07 22:47:56'),
(824, 'Lamotrigine', 1, '2022-03-07 22:50:43', '2022-03-07 22:50:43'),
(825, 'Lansoprazole', 1, '2022-03-07 22:52:34', '2022-03-07 22:52:34'),
(826, 'Lansoprazole + Amoxicillin + Clarithromycin', 1, '2022-03-08 05:44:18', '2022-03-08 05:44:18'),
(827, 'Lanthanum Carbonate', 1, '2022-03-08 05:47:50', '2022-03-08 05:47:50'),
(828, 'Lapatinib', 1, '2022-03-08 05:50:41', '2022-03-08 05:50:41'),
(829, 'Larotrectinib', 1, '2022-03-08 05:53:29', '2022-03-08 05:53:29'),
(830, 'Latanoprost', 1, '2022-03-08 05:55:51', '2022-03-08 05:55:51'),
(831, 'Latanoprost + Timolol', 1, '2022-03-08 05:57:59', '2022-03-08 05:57:59'),
(832, 'Ledipasvir + Sofosbuvir', 1, '2022-03-08 06:00:31', '2022-03-08 06:00:31'),
(833, 'Leflunomide', 1, '2022-03-08 06:02:36', '2022-03-08 06:02:36'),
(834, 'Lenalidomide', 1, '2022-03-08 06:05:55', '2022-03-08 06:05:55'),
(835, 'Lenograstim', 1, '2022-03-08 06:08:01', '2022-03-08 06:08:01'),
(836, 'Lenvatinib Mesylate', 1, '2022-03-08 06:10:56', '2022-03-08 06:10:56'),
(837, 'Lercanidipine Hydrochloride', 1, '2022-03-08 06:12:55', '2022-03-08 06:12:55'),
(838, 'Letrozole', 1, '2022-03-08 06:15:20', '2022-03-08 06:15:20'),
(839, 'Leuprorelin Acetate', 1, '2022-03-08 06:17:31', '2022-03-08 06:17:31'),
(840, 'Levamisole', 1, '2022-03-08 06:20:53', '2022-03-08 06:20:53'),
(841, 'Levetiracetam', 1, '2022-03-08 06:25:03', '2022-03-08 06:25:03'),
(842, 'Levobunolol', 1, '2022-03-08 06:27:20', '2022-03-08 06:27:20'),
(843, 'Levobupivacaine Hydrochloride', 1, '2022-03-08 06:29:37', '2022-03-08 06:29:37'),
(844, 'Levocarnitine', 1, '2022-03-08 06:32:35', '2022-03-08 06:32:35'),
(845, 'Levocetirizine Dihydrochloride', 1, '2022-03-08 06:34:31', '2022-03-08 06:34:31'),
(846, 'Levodopa + Benserazide', 1, '2022-03-08 06:53:02', '2022-03-08 06:53:02'),
(847, 'Levodopa + Carbidopa (CR tablet)', 1, '2022-03-08 06:56:10', '2022-03-08 06:56:10'),
(848, 'Levodopa + Carbidopa (FC tablet)', 1, '2022-03-08 06:58:22', '2022-03-08 06:58:22'),
(849, 'Levodopa + Carbidopa + Entacapone', 1, '2022-03-08 07:01:03', '2022-03-08 07:01:03'),
(850, 'Levofloxacin (Ophthalmic)', 1, '2022-03-08 07:02:58', '2022-03-08 07:02:58'),
(851, 'Levofloxacin Hemihydrate', 1, '2022-03-08 07:05:44', '2022-03-08 07:05:44'),
(852, 'Levomenthol + Thymol + Terpineol + Chlorobutanol', 1, '2022-03-08 07:06:17', '2022-03-08 07:06:17'),
(853, 'Levomilnacipran Hydrochloride', 1, '2022-03-08 07:08:37', '2022-03-08 07:08:37'),
(854, 'Levonorgestrel', 1, '2022-03-08 07:11:15', '2022-03-08 07:11:15'),
(855, 'Levosalbutamol', 1, '2022-03-08 07:13:38', '2022-03-08 07:13:38'),
(856, 'Levosalbutamol (Oral)', 1, '2022-03-09 01:02:42', '2022-03-09 01:02:42'),
(857, 'Levothyroxine Sodium', 1, '2022-03-09 01:06:08', '2022-03-09 01:06:08'),
(858, 'Lidocaine + Adrenaline', 1, '2022-03-09 01:08:52', '2022-03-09 01:08:52'),
(859, 'Lidocaine + Epinephrine', 1, '2022-03-09 01:12:07', '2022-03-09 01:12:07'),
(860, 'Lidocaine + Prilocaine', 1, '2022-03-09 01:15:09', '2022-03-09 01:15:09'),
(861, 'Lidocaine Hydrochloride (Injection)', 1, '2022-03-09 01:19:31', '2022-03-09 01:19:31'),
(862, 'Lidocaine Hydrochloride (Jelly)', 1, '2022-03-09 01:22:15', '2022-03-09 01:22:15'),
(863, 'Lidocaine Hydrochloride (Spray)', 1, '2022-03-09 01:25:37', '2022-03-09 01:25:37'),
(864, 'Lifitegrast', 1, '2022-03-09 01:29:15', '2022-03-09 01:29:15'),
(865, 'Light Liquid Paraffin + White Soft Paraffin + Glycerine', 1, '2022-03-09 01:46:24', '2022-03-09 01:46:24'),
(866, 'Linagliptin', 1, '2022-03-09 01:49:55', '2022-03-09 01:49:55'),
(867, 'Linagliptin + Metformin Hydrochloride', 1, '2022-03-09 01:53:14', '2022-03-09 01:53:14'),
(868, 'Linezolid', 1, '2022-03-09 01:56:21', '2022-03-09 01:56:21'),
(869, 'Liposome + Perilla + Sodium Hyaluronate', 1, '2022-03-09 01:57:58', '2022-03-09 01:57:58'),
(870, 'Liraglutide', 1, '2022-03-09 02:00:48', '2022-03-09 02:00:48'),
(871, 'Lisinopril', 1, '2022-03-09 02:04:00', '2022-03-09 02:04:00'),
(872, 'Lithium Carbonate', 1, '2022-03-09 02:06:33', '2022-03-09 02:06:33'),
(873, 'Lomefloxacin (Ophthalmic)', 1, '2022-03-09 02:09:03', '2022-03-09 02:09:03'),
(874, 'Lomefloxacin (Oral)', 1, '2022-03-09 02:11:21', '2022-03-09 02:11:21'),
(875, 'Loperamide Hydrochloride', 1, '2022-03-09 02:13:50', '2022-03-09 02:13:50'),
(876, 'Lopinavir + Ritonavir', 1, '2022-03-09 02:33:33', '2022-03-09 02:33:33'),
(877, 'Loratadine', 1, '2022-03-09 02:36:03', '2022-03-09 02:36:03'),
(878, 'Loratadine + Pseudoephedrine', 1, '2022-03-09 02:38:35', '2022-03-09 02:38:35'),
(879, 'Lorazepam', 1, '2022-03-09 02:40:43', '2022-03-09 02:40:43'),
(880, 'Losartan Potassium', 1, '2022-03-09 02:43:10', '2022-03-09 02:43:10'),
(881, 'Losartan Potassium + Hydrochlorothiazide', 1, '2022-03-09 02:46:09', '2022-03-09 02:46:09'),
(882, 'Loteprednol Etabonate (Ophthalmic Gel)', 1, '2022-03-09 02:48:16', '2022-03-09 02:48:16'),
(883, 'Loteprednol Etabonate (Ophthalmic Suspension)', 1, '2022-03-09 02:50:30', '2022-03-09 02:50:30'),
(884, 'Loteprednol Etabonate + Gatifloxacin', 1, '2022-03-09 02:53:20', '2022-03-09 02:53:20'),
(885, 'Loteprednol Etabonate + Tobramycin', 1, '2022-03-09 02:55:47', '2022-03-09 02:55:47'),
(886, 'Lubiprostone', 1, '2022-03-09 02:58:28', '2022-03-09 02:58:28'),
(887, 'Luliconazole', 1, '2022-03-09 03:00:35', '2022-03-09 03:00:35'),
(888, 'Lurasidone Hydrochloride', 1, '2022-03-09 03:02:51', '2022-03-09 03:02:51'),
(889, 'Lymecycline', 1, '2022-03-09 03:05:02', '2022-03-09 03:05:02'),
(890, 'Lynestrenol', 1, '2022-03-09 03:07:08', '2022-03-09 03:07:08'),
(891, 'Lyophilized Bacterial Lysate', 1, '2022-03-09 03:09:25', '2022-03-09 03:09:25'),
(892, 'Macrogol [Polypropylene glycol] + Electrolytes', 1, '2022-03-09 04:00:31', '2022-03-09 04:00:31'),
(893, 'Magaldrate', 1, '2022-03-09 04:02:15', '2022-03-09 04:02:15'),
(894, 'Magaldrate + Simethicone', 1, '2022-03-09 04:04:23', '2022-03-09 04:04:23'),
(895, 'Magnesium Hydroxide', 1, '2022-03-09 04:06:25', '2022-03-09 04:06:25'),
(896, 'Magnesium Hydroxide + Liquid Paraffin', 1, '2022-03-09 04:08:48', '2022-03-09 04:08:48'),
(897, 'Magnesium Oxide', 1, '2022-03-09 04:10:46', '2022-03-09 04:10:46'),
(898, 'Magnesium Sulfate', 1, '2022-03-09 04:12:55', '2022-03-09 04:12:55'),
(899, 'Magnesium Sulfate Heptahydrate', 1, '2022-03-09 04:15:12', '2022-03-09 04:15:12'),
(900, 'Mannitol', 1, '2022-03-09 04:16:47', '2022-03-09 04:16:47'),
(901, 'Maprotiline Hydrochloride', 1, '2022-03-09 04:19:07', '2022-03-09 04:19:07'),
(902, 'Measles and Rubella', 1, '2022-03-09 04:20:56', '2022-03-09 04:20:56'),
(903, 'Mebendazole', 1, '2022-03-09 04:23:05', '2022-03-09 04:23:05'),
(904, 'Mebeverine Hydrochloride', 1, '2022-03-09 04:25:21', '2022-03-09 04:25:21'),
(905, 'Mebhydrolin Napadisylate', 1, '2022-03-09 04:27:12', '2022-03-09 04:27:12'),
(906, 'Meclizine + Pyridoxine', 1, '2022-03-09 04:29:02', '2022-03-09 04:29:02'),
(907, 'Meclizine Hydrochloride', 1, '2022-03-09 04:30:58', '2022-03-09 04:30:58'),
(908, 'Mecobalamin', 1, '2022-03-09 04:33:09', '2022-03-09 04:33:09'),
(909, 'Medroxyprogesterone Acetate (Injection)', 1, '2022-03-09 04:35:07', '2022-03-09 04:35:07'),
(910, 'Medroxyprogesterone Acetate (Tablet)', 1, '2022-03-09 04:37:50', '2022-03-09 04:37:50'),
(911, 'Mefenamic acid', 1, '2022-03-09 04:40:01', '2022-03-09 04:40:01'),
(912, 'Mefloquine', 1, '2022-03-09 05:55:57', '2022-03-09 05:55:57'),
(913, 'Megestrol Acetate (Oral Suspension)', 1, '2022-03-09 05:58:05', '2022-03-09 05:58:05'),
(914, 'Megestrol Acetate (Tablet)', 1, '2022-03-09 06:00:14', '2022-03-09 06:00:14'),
(915, 'Melatonin', 1, '2022-03-09 06:02:26', '2022-03-09 06:02:26'),
(916, 'Meloxicam', 1, '2022-03-09 06:04:23', '2022-03-09 06:04:23'),
(917, 'Memantine + Donepezil', 1, '2022-03-09 06:06:32', '2022-03-09 06:06:32'),
(918, 'Memantine Hydrochloride', 1, '2022-03-09 06:08:25', '2022-03-09 06:08:25'),
(919, 'Menaquinone-7', 1, '2022-03-09 06:10:09', '2022-03-09 06:10:09'),
(920, 'Meningococcal Conjugate Vaccine', 1, '2022-03-09 06:12:20', '2022-03-09 06:12:20'),
(921, 'Meningococcal Polysaccharide Vaccine', 1, '2022-03-09 06:14:23', '2022-03-09 06:14:23'),
(922, 'Menthol + Pramoxine Hydrochloride', 1, '2022-03-09 06:16:19', '2022-03-09 06:16:19'),
(923, 'Menthol + Thymol + Eucalyptol + Methyl Salicylate', 1, '2022-03-09 06:18:04', '2022-03-09 06:18:04'),
(924, 'Mepyramine Maleate', 1, '2022-03-09 06:19:13', '2022-03-09 06:19:13'),
(925, 'Mercaptopurine', 1, '2022-03-09 06:21:34', '2022-03-09 06:21:34'),
(926, 'Meropenem Trihydrate', 1, '2022-03-09 06:24:17', '2022-03-09 06:24:17'),
(927, 'Mesalazine [5-aminosalicylic acid]', 1, '2022-03-09 06:26:24', '2022-03-09 06:26:24'),
(928, 'Mesna', 1, '2022-03-09 06:28:07', '2022-03-09 06:28:07'),
(929, 'Metamizol', 1, '2022-03-09 06:32:04', '2022-03-09 06:32:04'),
(930, 'Metformin Hydrochloride', 1, '2022-03-09 06:34:33', '2022-03-09 06:34:33'),
(931, 'Methenamine Hippurate', 1, '2022-03-09 06:36:22', '2022-03-09 06:36:22'),
(932, 'Methimazole', 1, '2022-03-09 06:46:29', '2022-03-09 06:46:29'),
(933, 'Methocarbamol', 1, '2022-03-09 06:48:42', '2022-03-09 06:48:42'),
(934, 'Methotrexate', 1, '2022-03-09 06:50:43', '2022-03-09 06:50:43'),
(935, 'Methoxsalen', 1, '2022-03-09 06:52:54', '2022-03-09 06:52:54'),
(936, 'Methoxy Polyethylene Glycol-Epoetin Beta', 1, '2022-03-09 06:55:35', '2022-03-09 06:55:35'),
(937, 'Methyl Salicylate + Menthol', 1, '2022-03-09 06:58:43', '2022-03-09 06:58:43'),
(938, 'Methyl Salicylate + Menthol + Camphor', 1, '2022-03-09 07:00:38', '2022-03-09 07:00:38'),
(939, 'Methyldopa', 1, '2022-03-09 07:02:56', '2022-03-09 07:02:56'),
(940, 'Methylergonovine Maleate', 1, '2022-03-09 07:05:04', '2022-03-09 07:05:04'),
(941, 'Methylphenidate Hydrochloride', 1, '2022-03-09 07:09:57', '2022-03-09 07:09:57'),
(942, 'Methylprednisolone', 1, '2022-03-09 07:12:16', '2022-03-09 07:12:16'),
(943, 'Methylprednisolone Acetate', 1, '2022-03-09 07:13:55', '2022-03-09 07:13:55'),
(944, 'Methylprednisolone Sodium Succcinate', 1, '2022-03-09 07:16:28', '2022-03-09 07:16:28'),
(945, 'Metoclopramide Hydrochloride', 1, '2022-03-09 07:18:47', '2022-03-09 07:18:47'),
(946, 'Metolazone', 1, '2022-03-09 07:20:42', '2022-03-09 07:20:42'),
(947, 'Metoprolol Tartrate', 1, '2022-03-09 07:23:05', '2022-03-09 07:23:05'),
(948, 'Metronidazole', 1, '2022-03-09 07:25:23', '2022-03-09 07:25:23'),
(949, 'Metronidazole + Miconazole Nitrate', 1, '2022-03-09 07:27:21', '2022-03-09 07:27:21'),
(950, 'Metronidazole + Neomycin Sulphate + Polymyxin B + Nystatin', 1, '2022-03-09 07:29:25', '2022-03-09 07:29:25'),
(951, 'Miconazole Nitrate (Oral Gel)', 1, '2022-03-09 07:31:37', '2022-03-09 07:31:37'),
(952, 'Miconazole Nitrate (Topical)', 1, '2022-03-10 16:31:16', '2022-03-10 16:31:16'),
(953, 'Miconazole Nitrate + Hydrocortisone', 1, '2022-03-10 16:33:18', '2022-03-10 16:33:18'),
(954, 'Micronised Diosmin + Hesperidin', 1, '2022-03-10 16:35:36', '2022-03-10 16:35:36'),
(955, 'Midazolam', 1, '2022-03-10 16:37:39', '2022-03-10 16:37:39'),
(956, 'Mifepristone', 1, '2022-03-10 16:40:19', '2022-03-10 16:40:19'),
(957, 'Mifepristone + Misoprostol', 1, '2022-03-10 16:42:35', '2022-03-10 16:42:35'),
(958, 'Miglitol', 1, '2022-03-10 16:45:13', '2022-03-10 16:45:13'),
(959, 'Milnacipran Hydrochloride', 1, '2022-03-10 16:47:50', '2022-03-10 16:47:50'),
(960, 'Miltefosine', 1, '2022-03-10 16:49:45', '2022-03-10 16:49:45'),
(961, 'Minocycline Hydrochloride', 1, '2022-03-10 16:56:15', '2022-03-10 16:56:15'),
(962, 'Minoxidil', 1, '2022-03-10 16:58:41', '2022-03-10 16:58:41'),
(963, 'Mirabegron', 1, '2022-03-10 17:01:04', '2022-03-10 17:01:04'),
(964, 'Mirtazapine', 1, '2022-03-10 17:04:09', '2022-03-10 17:04:09'),
(965, 'Misoprostol', 1, '2022-03-10 17:06:30', '2022-03-10 17:06:30'),
(966, 'Mitomycin C', 1, '2022-03-10 17:08:19', '2022-03-10 17:08:19'),
(967, 'Mizolastine is indicated for the symptomatic relief of the following conditions: Seasonal allergic rhinoconjunctivitis (hay fever) Perennial allergic rhinoconjunctivitis Urticaria', 1, '2022-03-10 17:10:16', '2022-03-10 17:10:16'),
(968, 'Molnupiravir', 1, '2022-03-10 17:12:14', '2022-03-10 17:12:14'),
(969, 'Mometasone Furoate (Inhalation Capsule)', 1, '2022-03-10 17:14:11', '2022-03-10 17:14:11'),
(970, 'Mometasone Furoate (Nasal Spray)', 1, '2022-03-10 17:16:39', '2022-03-10 17:16:39'),
(971, 'Mometasone Furoate (Topical)', 1, '2022-03-10 17:18:31', '2022-03-10 17:18:31'),
(972, 'Mometasone Furoate + Formoterol Fumarate', 1, '2022-03-10 17:21:20', '2022-03-10 17:21:20'),
(973, 'Monobasic sodium phosphate + Dibasic sodium phosphate', 1, '2022-03-10 17:23:13', '2022-03-10 17:23:13'),
(974, 'Monosemicarbazone Adrenochrome', 1, '2022-03-10 17:25:19', '2022-03-10 17:25:19'),
(975, 'Monosulfiram', 1, '2022-03-10 17:27:39', '2022-03-10 17:27:39'),
(976, 'Montelukast Sodium', 1, '2022-03-10 17:30:07', '2022-03-10 17:30:07'),
(977, 'Morphine Sulfate', 1, '2022-03-10 17:32:28', '2022-03-10 17:32:28'),
(978, 'Moxifloxacin Hydrochloride (Injection)', 1, '2022-03-10 17:34:38', '2022-03-10 17:34:38'),
(979, 'Moxifloxacin Hydrochloride (Ophthalmic)', 1, '2022-03-10 17:36:28', '2022-03-10 17:36:28'),
(980, 'Moxifloxacin Hydrochloride (Tablet)', 1, '2022-03-10 17:38:29', '2022-03-10 17:38:29'),
(981, 'Moxifloxacin Hydrochloride + Dexamethasone', 1, '2022-03-10 17:41:50', '2022-03-10 17:41:50'),
(982, 'Moxifloxacin Hydrochloride + Xanthan Gum', 1, '2022-03-10 17:44:12', '2022-03-10 17:44:12'),
(983, 'Moxonidine', 1, '2022-03-10 17:46:24', '2022-03-10 17:46:24'),
(984, 'Multivitamin [Adult preparation]', 1, '2022-03-10 17:48:14', '2022-03-10 17:48:14'),
(985, 'Multivitamin [Injection]', 1, '2022-03-10 17:50:53', '2022-03-10 17:50:53'),
(986, 'Multivitamin [Pediatric preparation]', 1, '2022-03-10 17:52:19', '2022-03-10 17:52:19'),
(987, 'Multivitamin & 5% Dextrose', 1, '2022-03-10 17:54:28', '2022-03-10 17:54:28'),
(988, 'Multivitamin & Cod Liver Oil', 1, '2022-03-10 17:56:40', '2022-03-10 17:56:40'),
(989, 'Multivitamin & Multimineral', 1, '2022-03-10 17:58:30', '2022-03-10 17:58:30'),
(990, 'Multivitamin & Multimineral [A-Z for infanrs & childrens]', 1, '2022-03-10 18:00:17', '2022-03-10 18:00:17'),
(991, 'Multivitamin & Multimineral [A-Z gold preparation]', 1, '2022-03-10 18:02:06', '2022-03-10 18:02:06'),
(992, 'Multivitamin & Multimineral [A-Z junior infusion preparation]', 1, '2022-03-10 18:04:21', '2022-03-10 18:04:21'),
(993, 'Multivitamin & Multimineral [A-Z juniors syrup preparation]', 1, '2022-03-10 18:06:50', '2022-03-10 18:06:50'),
(994, 'Multivitamin & Multimineral [A-Z silver preparation]', 1, '2022-03-10 18:09:05', '2022-03-10 18:09:05'),
(995, 'Multivitamin & Multimineral [A-Z syrup preparation]', 1, '2022-03-10 18:15:46', '2022-03-10 18:15:46'),
(996, 'Multivitamin & Multimineral [A-Z teen boys preparation]', 1, '2022-03-10 18:18:14', '2022-03-10 18:18:14'),
(997, 'Multivitamin & Multimineral [A-Z teen girls preparation]', 1, '2022-03-10 18:20:33', '2022-03-10 18:20:33'),
(998, 'Multivitamin & Multimineral [For nursing mother]', 1, '2022-03-10 18:22:21', '2022-03-10 18:22:21'),
(999, 'Multivitamin & Multimineral Essentials [For nursing mother]', 1, '2022-03-10 18:24:11', '2022-03-10 18:24:11'),
(1000, 'Multivitamin & Normal Saline', 1, '2022-03-10 18:26:14', '2022-03-10 18:26:14'),
(1001, 'Multivitamin with L-Lysine', 1, '2022-03-10 18:28:07', '2022-03-10 18:28:07'),
(1002, 'Multivitamins & Multiminerals [A-Z prenatal preparation]', 1, '2022-03-10 18:30:04', '2022-03-10 18:30:04'),
(1003, 'Mupirocin', 1, '2022-03-10 18:32:25', '2022-03-10 18:32:25'),
(1004, 'Mycophenolate Mofetil', 1, '2022-03-10 18:34:57', '2022-03-10 18:34:57'),
(1005, 'Mycophenolic acid', 1, '2022-03-10 18:36:48', '2022-03-10 18:36:48'),
(1006, 'Allylestrenol', 1, '2022-03-10 20:12:52', '2022-03-10 20:12:52'),
(1007, 'Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel]', 1, '2022-03-10 20:31:59', '2022-03-10 20:31:59'),
(1008, 'Nabumetone', 1, '2022-03-10 20:34:15', '2022-03-10 20:34:15'),
(1009, 'Naftidrofuryl Oxalate', 1, '2022-03-10 20:36:03', '2022-03-10 20:36:03'),
(1010, 'Naftifine Hydrochloride', 1, '2022-03-10 20:37:51', '2022-03-10 20:37:51'),
(1011, 'Nalbuphine', 1, '2022-03-10 20:40:05', '2022-03-10 20:40:05'),
(1012, 'Nalidixic Acid', 1, '2022-03-10 20:42:02', '2022-03-10 20:42:02'),
(1013, 'Naloxone Hydrochloride', 1, '2022-03-10 20:44:17', '2022-03-10 20:44:17'),
(1014, 'Naltrexone', 1, '2022-03-10 20:46:23', '2022-03-10 20:46:23'),
(1015, 'Nandrolone Decanoate', 1, '2022-03-10 20:48:32', '2022-03-10 20:48:32'),
(1016, 'Nandrolone Phenylpropionate', 1, '2022-03-10 20:50:42', '2022-03-10 20:50:42'),
(1017, 'Naphazoline + Pheniramine', 1, '2022-03-10 20:52:44', '2022-03-10 20:52:44'),
(1018, 'Naphazoline + Zinc Sulfate', 1, '2022-03-10 20:54:30', '2022-03-10 20:54:30'),
(1019, 'Naproxen Sodium', 1, '2022-03-10 20:56:09', '2022-03-10 20:56:09'),
(1020, 'Naproxen Sodium + Esomeprazole Magnesium', 1, '2022-03-10 20:58:26', '2022-03-10 20:58:26'),
(1021, 'Natamycin', 1, '2022-03-10 21:01:01', '2022-03-10 21:01:01'),
(1022, 'Nateglinide', 1, '2022-03-10 21:03:16', '2022-03-10 21:03:16'),
(1023, 'Nebivolol + Hydrochlorothiazide', 1, '2022-03-10 21:05:27', '2022-03-10 21:05:27'),
(1024, 'Nebivolol Hydrochloride', 1, '2022-03-10 21:08:16', '2022-03-10 21:08:16'),
(1025, 'Nedocromil Sodium', 1, '2022-03-10 21:10:54', '2022-03-10 21:10:54'),
(1026, 'Nefopam Hydrochloride', 1, '2022-03-10 21:12:46', '2022-03-10 21:12:46'),
(1027, 'Nelfinavir', 1, '2022-03-10 21:23:22', '2022-03-10 21:23:22'),
(1028, 'Neomycin Sulfate + Bacitracin Zinc', 1, '2022-03-10 21:25:58', '2022-03-10 21:25:58'),
(1029, 'Neomycin Sulfate + Bacitracin Zinc + Polymyxin B Sulfate', 1, '2022-03-10 21:28:17', '2022-03-10 21:28:17'),
(1030, 'Neomycin Sulfate + Bacitracin Zinc + Polymyxin B Sulfate (Ophthalmic)', 1, '2022-03-10 21:31:36', '2022-03-10 21:31:36'),
(1031, 'Neomycin Sulphate + Polymyxin B Sulphate + Pramoxine', 1, '2022-03-10 21:42:34', '2022-03-10 21:42:34'),
(1032, 'Neostigmine Methyl Sulphate', 1, '2022-03-10 21:45:01', '2022-03-10 21:45:01'),
(1033, 'Nepafenac', 1, '2022-03-10 21:47:09', '2022-03-10 21:47:09'),
(1034, 'Neratinib', 1, '2022-03-10 21:49:18', '2022-03-10 21:49:18'),
(1035, 'Netarsudil + Latanoprost', 1, '2022-03-10 21:51:03', '2022-03-10 21:51:03'),
(1036, 'Netarsudil Dimesylate', 1, '2022-03-10 21:52:46', '2022-03-10 21:52:46'),
(1037, 'Nevirapine', 1, '2022-03-10 21:55:01', '2022-03-10 21:55:01'),
(1038, 'Nicorandil', 1, '2022-03-10 21:57:09', '2022-03-10 21:57:09'),
(1039, 'Nicotinic Acid [Niacin]', 1, '2022-03-10 21:58:55', '2022-03-10 21:58:55'),
(1040, 'Nifedipine', 1, '2022-03-10 22:00:44', '2022-03-10 22:00:44'),
(1041, 'Nikethamide', 1, '2022-03-10 22:02:39', '2022-03-10 22:02:39'),
(1042, 'Nilotinib', 1, '2022-03-10 22:04:46', '2022-03-10 22:04:46'),
(1043, 'Nimesulide', 1, '2022-03-10 22:06:33', '2022-03-10 22:06:33'),
(1044, 'Nimodipine', 1, '2022-03-10 22:08:24', '2022-03-10 22:08:24'),
(1045, 'Nintedanib', 1, '2022-03-10 22:11:14', '2022-03-10 22:11:14'),
(1046, 'Niraparib', 1, '2022-03-10 22:13:25', '2022-03-10 22:13:25'),
(1047, 'Abacavir + Lamivudine + Zidovudine', 1, '2022-03-11 01:14:16', '2022-03-11 01:14:16'),
(1048, 'Nirmatrelvir + Ritonavir', 1, '2022-03-11 03:37:39', '2022-03-11 03:37:39'),
(1049, 'Nitazoxanide', 1, '2022-03-11 03:39:52', '2022-03-11 03:39:52'),
(1050, 'Nitrazepam', 1, '2022-03-11 03:42:06', '2022-03-11 03:42:06'),
(1051, 'Nitrofurantoin', 1, '2022-03-11 03:44:16', '2022-03-11 03:44:16'),
(1052, 'Nitrofurantoin + Nitrofurantoin Microcrystals', 1, '2022-03-11 03:46:30', '2022-03-11 03:46:30'),
(1053, 'Nitrofurazone', 1, '2022-03-11 03:48:02', '2022-03-11 03:48:02'),
(1054, 'Nitroglycerin (IV Infusion)', 1, '2022-03-11 03:50:29', '2022-03-11 03:50:29'),
(1055, 'Nitroglycerin (Ointment)', 1, '2022-03-11 03:52:24', '2022-03-11 03:52:24'),
(1056, 'Nitroglycerin (Oral preparation)', 1, '2022-03-11 03:54:07', '2022-03-11 03:54:07'),
(1057, 'Nitroglycerin (Sublingual Spray)', 1, '2022-03-11 03:55:57', '2022-03-11 03:55:57'),
(1058, 'Nitroglycerin (Sublingual Tablet)', 1, '2022-03-11 03:57:40', '2022-03-11 03:57:40'),
(1059, 'Nitrous Oxide', 1, '2022-03-11 03:59:14', '2022-03-11 03:59:14'),
(1060, 'Nivolumab', 1, '2022-03-11 04:01:16', '2022-03-11 04:01:16'),
(1061, 'Nizatidine', 1, '2022-03-11 04:03:16', '2022-03-11 04:03:16'),
(1062, 'Norepinephrine', 1, '2022-03-11 04:05:20', '2022-03-11 04:05:20'),
(1063, 'Norethisterone Acetate', 1, '2022-03-11 04:07:12', '2022-03-11 04:07:12'),
(1064, 'Norgestrel', 1, '2022-03-11 04:10:04', '2022-03-11 04:10:04'),
(1065, 'Norgestrel + Ethinyl Estradiol + Ferrous Fumarate', 1, '2022-03-11 04:11:50', '2022-03-11 04:11:50'),
(1066, 'Nortriptyline', 1, '2022-03-11 04:13:45', '2022-03-11 04:13:45'),
(1067, 'Nystatin (Oral)', 1, '2022-03-11 04:15:37', '2022-03-11 04:15:37'),
(1068, 'Nystatin (Topical)', 1, '2022-03-11 04:17:31', '2022-03-11 04:17:31'),
(1069, 'Obeticholic Acid', 1, '2022-03-11 04:44:09', '2022-03-11 04:44:09'),
(1070, 'Obinutuzumab', 1, '2022-03-11 04:46:19', '2022-03-11 04:46:19'),
(1071, 'Octreotide Acetate', 1, '2022-03-11 04:48:20', '2022-03-11 04:48:20'),
(1072, 'Ofloxacin (Ophthalmic)', 1, '2022-03-11 04:49:49', '2022-03-11 04:49:49'),
(1073, 'Ofloxacin (Oral & Injection)', 1, '2022-03-11 04:52:34', '2022-03-11 04:52:34'),
(1074, 'Ofloxacin + Clotrimazole + Beclomethasone + Lidocaine', 1, '2022-03-11 04:54:14', '2022-03-11 04:54:14'),
(1075, 'Olanzapine', 1, '2022-03-11 04:56:27', '2022-03-11 04:56:27'),
(1076, 'Olaparib', 1, '2022-03-11 04:58:18', '2022-03-11 04:58:18'),
(1077, 'Olmesartan Medoxomil', 1, '2022-03-11 05:00:20', '2022-03-11 05:00:20'),
(1078, 'Olmesartan Medoxomil + Hydrochlorothiazide', 1, '2022-03-11 05:02:37', '2022-03-11 05:02:37'),
(1079, 'Olopatadine Hydrochloride (Nasal Spray)', 1, '2022-03-11 05:04:30', '2022-03-11 05:04:30'),
(1080, 'Olopatadine Hydrochloride (Ophthalmic)', 1, '2022-03-11 05:06:29', '2022-03-11 05:06:29'),
(1081, 'Omalizumab', 1, '2022-03-11 05:08:32', '2022-03-11 05:08:32'),
(1082, 'Omega-3 Acid Ethyl Esters [Salmon Fish Oil]', 1, '2022-03-11 05:10:12', '2022-03-11 05:10:12'),
(1083, 'Omeprazole', 1, '2022-03-11 05:12:09', '2022-03-11 05:12:09'),
(1084, 'Omeprazole (MUPS tablet)', 1, '2022-03-11 05:14:04', '2022-03-11 05:14:04'),
(1085, 'Ondansetron', 1, '2022-03-11 05:16:25', '2022-03-11 05:16:25'),
(1086, 'Ondansetron (Oral solution)', 1, '2022-03-11 05:18:31', '2022-03-11 05:18:31'),
(1087, 'Oral Cholera Vaccine', 1, '2022-03-11 05:20:10', '2022-03-11 05:20:10'),
(1088, 'Oral Polio Vaccine', 1, '2022-03-11 05:21:57', '2022-03-11 05:21:57'),
(1089, 'Oral Rehydration Salt [Flavored]', 1, '2022-03-11 05:47:45', '2022-03-11 05:47:45'),
(1090, 'Oral Rehydration Salt [Powder]', 1, '2022-03-11 05:49:12', '2022-03-11 05:49:12'),
(1091, 'Oral Rehydration Salt [Rice Based]', 1, '2022-03-11 05:50:47', '2022-03-11 05:50:47'),
(1092, 'Orlistat', 1, '2022-03-11 05:53:15', '2022-03-11 05:53:15'),
(1093, 'Ornidazole', 1, '2022-03-11 05:55:11', '2022-03-11 05:55:11'),
(1094, 'Oseltamivir', 1, '2022-03-11 05:57:13', '2022-03-11 05:57:13'),
(1095, 'Osimertinib', 1, '2022-03-11 05:58:50', '2022-03-11 05:58:50'),
(1096, 'Ospemifene', 1, '2022-03-11 06:00:35', '2022-03-11 06:00:35'),
(1097, 'Oxaliplatin', 1, '2022-03-11 06:02:40', '2022-03-11 06:02:40'),
(1098, 'Oxaprozin', 1, '2022-03-11 06:04:56', '2022-03-11 06:04:56'),
(1099, 'Oxazepam', 1, '2022-03-11 06:06:49', '2022-03-11 06:06:49'),
(1100, 'OxcarbazepiOxcarbazepinene', 1, '2022-03-11 06:14:23', '2022-03-11 06:14:23'),
(1101, 'Oxiconazole Nitrate', 1, '2022-03-11 06:16:30', '2022-03-11 06:16:30'),
(1102, 'Oxybuprocaine Hydrochloride', 1, '2022-03-11 06:17:52', '2022-03-11 06:17:52'),
(1103, 'Oxybutynin Chloride', 1, '2022-03-11 06:19:40', '2022-03-11 06:19:40'),
(1104, 'Oxygen', 1, '2022-03-11 06:20:48', '2022-03-11 06:20:48'),
(1105, 'Oxymetazoline Hydrochloride (Cream)', 1, '2022-03-11 06:22:26', '2022-03-11 06:22:26'),
(1106, 'Oxymetazoline Hydrochloride (Nasal Preparation)', 1, '2022-03-11 06:24:41', '2022-03-11 06:24:41'),
(1107, 'Oxymorphone Hydrochloride', 1, '2022-03-11 06:26:51', '2022-03-11 06:26:51'),
(1108, 'Oxyphencyclimine Hydrochloride', 1, '2022-03-11 06:29:19', '2022-03-11 06:29:19'),
(1109, 'Oxyphenonium Bromide', 1, '2022-03-11 06:32:19', '2022-03-11 06:32:19'),
(1110, 'Oxytetracycline', 1, '2022-03-11 06:35:20', '2022-03-11 06:35:20'),
(1111, 'Oxytetracycline + Polymixin B Sulphate', 1, '2022-03-11 06:36:54', '2022-03-11 06:36:54'),
(1112, 'Oxytocin', 1, '2022-03-11 06:38:59', '2022-03-11 06:38:59'),
(1113, 'Ozenoxacin', 1, '2022-03-11 06:40:50', '2022-03-11 06:40:50'),
(1114, 'Zafirlukast', 1, '2022-03-12 00:17:15', '2022-03-12 00:17:15'),
(1115, 'Zaleplon', 1, '2022-03-12 00:19:03', '2022-03-12 00:19:03'),
(1116, 'Zidovudine', 1, '2022-03-12 00:21:23', '2022-03-12 00:21:23'),
(1117, 'Zinc Orotate', 1, '2022-03-12 00:23:08', '2022-03-12 00:23:08'),
(1118, 'Zinc Oxide', 1, '2022-03-12 00:27:44', '2022-03-12 00:27:44'),
(1119, 'Zinc Oxide [Microfine]', 1, '2022-03-12 00:29:32', '2022-03-12 00:29:32'),
(1120, 'Zinc oxide + Benzyl alcohol + Benzyl benzoate + Benzyl cinnamate + Lanolin', 1, '2022-03-12 00:31:15', '2022-03-12 00:31:15'),
(1121, 'Zinc oxide + Ethylhexyl Methoxycinnamate + 4-Methylbenzylidene Camphor + Butyl Methoxydibenzoylmethane', 1, '2022-03-12 00:33:50', '2022-03-12 00:33:50'),
(1122, 'Zinc Oxide + Virgin Castor Oil', 1, '2022-03-12 00:35:59', '2022-03-12 00:35:59'),
(1123, 'Zinc oxide, Octinoxate, Enzacamene and Avobenzone', 1, '2022-03-12 00:38:18', '2022-03-12 00:38:18'),
(1124, 'Zinc Sulfate Monohydrate', 1, '2022-03-12 00:40:44', '2022-03-12 00:40:44'),
(1125, 'Ziprasidone', 1, '2022-03-12 00:44:01', '2022-03-12 00:44:01'),
(1126, 'Zoledronic Acid [For hypercalcemia]', 1, '2022-03-12 00:46:21', '2022-03-12 00:46:21'),
(1127, 'Zoledronic Acid [For osteoporosis]', 1, '2022-03-12 00:48:38', '2022-03-12 00:48:38'),
(1128, 'Zolmitriptan', 1, '2022-03-12 00:50:31', '2022-03-12 00:50:31'),
(1129, 'Zolpidem Tartrate', 1, '2022-03-12 00:56:51', '2022-03-12 00:56:51'),
(1130, 'Zonisamide', 1, '2022-03-12 00:58:58', '2022-03-12 00:58:58'),
(1131, 'Zopiclone', 1, '2022-03-12 01:01:54', '2022-03-12 01:01:54'),
(1132, 'Zuclopenthixol', 1, '2022-03-12 01:04:36', '2022-03-12 01:04:36'),
(1133, 'Yellow Fever Vaccine', 1, '2022-03-12 01:07:57', '2022-03-12 01:07:57'),
(1134, 'Xylometazoline Hydrochloride', 1, '2022-03-12 01:26:38', '2022-03-12 01:26:38'),
(1135, 'Warfarin Sodium', 1, '2022-03-12 01:29:24', '2022-03-12 01:29:24'),
(1136, 'Water for injection', 1, '2022-03-12 01:30:27', '2022-03-12 01:30:27'),
(1137, 'White Soft Paraffin + Liquid Paraffin', 1, '2022-03-12 01:32:10', '2022-03-12 01:32:10'),
(1138, 'White soft paraffin + Liquid paraffin + Wool alcohol', 1, '2022-03-12 01:33:45', '2022-03-12 01:33:45'),
(1139, 'Ulipristal Acetate [For emergency contraception]', 1, '2022-03-12 01:36:25', '2022-03-12 01:36:25'),
(1140, 'Ulipristal Acetate [For uterine fibroids]', 1, '2022-03-12 01:38:19', '2022-03-12 01:38:19'),
(1141, 'Upadacitinib', 1, '2022-03-12 01:40:36', '2022-03-12 01:40:36'),
(1142, 'Urea (10%)', 1, '2022-03-12 01:42:14', '2022-03-12 01:42:14'),
(1143, 'Urea (25%)', 1, '2022-03-12 01:44:05', '2022-03-12 01:44:05'),
(1144, 'Urokinase', 1, '2022-03-12 01:45:43', '2022-03-12 01:45:43'),
(1145, 'Ursodeoxycholic Acid', 1, '2022-03-12 01:47:31', '2022-03-12 01:47:31'),
(1146, 'Quetiapine Fumarate', 1, '2022-03-12 01:51:06', '2022-03-12 01:51:06'),
(1147, 'Quinine Sulfate', 1, '2022-03-12 01:54:27', '2022-03-12 01:54:27'),
(1148, 'Rabeprazole + Amoxicillin + Clarithromycin', 1, '2022-03-12 04:31:17', '2022-03-12 04:31:17'),
(1149, 'Rabeprazole Sodium', 1, '2022-03-12 04:33:40', '2022-03-12 04:33:40'),
(1150, 'Rabies Immunoglobulin', 1, '2022-03-12 04:35:21', '2022-03-12 04:35:21'),
(1151, 'Rabies Vaccine', 1, '2022-03-12 04:59:08', '2022-03-12 04:59:08'),
(1152, 'Racecadotril', 1, '2022-03-12 05:00:51', '2022-03-12 05:00:51'),
(1153, 'Racepinephrine', 1, '2022-03-12 05:02:35', '2022-03-12 05:02:35'),
(1154, 'Raloxifene Hydrochloride', 1, '2022-03-12 05:04:37', '2022-03-12 05:04:37'),
(1155, 'Ramelteon', 1, '2022-03-12 05:06:29', '2022-03-12 05:06:29'),
(1156, 'Ramipril', 1, '2022-03-12 05:08:45', '2022-03-12 05:08:45'),
(1157, 'Ramipril + Hydrochlorothiazide', 1, '2022-03-12 05:39:06', '2022-03-12 05:39:06'),
(1158, 'Ramucirumab', 1, '2022-03-12 05:40:58', '2022-03-12 05:40:58'),
(1159, 'Ranibizumab', 1, '2022-03-12 05:42:42', '2022-03-12 05:42:42'),
(1160, 'Ranitidine Hydrochloride', 1, '2022-03-12 05:44:42', '2022-03-12 05:44:42'),
(1161, 'Ranolazine', 1, '2022-03-12 05:47:25', '2022-03-12 05:47:25'),
(1162, 'Rasagiline', 1, '2022-03-12 05:49:21', '2022-03-12 05:49:21'),
(1163, 'Recombinant Follicle Stimulating Hormone (rFSH)', 1, '2022-03-12 05:51:28', '2022-03-12 05:51:28'),
(1164, 'Red Clover [Trifolium Pratense]', 1, '2022-03-12 05:52:56', '2022-03-12 05:52:56'),
(1165, 'Regorafenib', 1, '2022-03-12 05:54:53', '2022-03-12 05:54:53'),
(1166, 'Remdesivir', 1, '2022-03-12 05:56:35', '2022-03-12 05:56:35'),
(1167, 'Repaglinide', 1, '2022-03-12 05:58:22', '2022-03-12 05:58:22'),
(1168, 'Paclitaxel', 1, '2022-03-14 04:17:50', '2022-03-14 04:17:50'),
(1169, 'Padimate O + Avobenzone + Oxybenzone + Titanium dioxide', 1, '2022-03-14 04:19:35', '2022-03-14 04:19:35'),
(1170, 'Palbociclib', 1, '2022-03-14 04:21:08', '2022-03-14 04:21:08'),
(1171, 'Paliperidone', 1, '2022-03-14 04:25:24', '2022-03-14 04:25:24'),
(1172, 'Paliperidone Palmitate', 1, '2022-03-14 04:27:48', '2022-03-14 04:27:48'),
(1173, 'Palonosetron', 1, '2022-03-14 04:29:53', '2022-03-14 04:29:53'),
(1174, 'Pancreatin', 1, '2022-03-14 04:33:12', '2022-03-14 04:33:12'),
(1175, 'Pancuronium Bromide', 1, '2022-03-14 04:35:08', '2022-03-14 04:35:08'),
(1176, 'Pantoprazole Sodium Sesquihydrate', 1, '2022-03-14 04:36:49', '2022-03-14 04:36:49'),
(1177, 'Paracetamol', 1, '2022-03-14 04:38:48', '2022-03-14 04:38:48'),
(1178, 'Paracetamol (IV Infusion)', 1, '2022-03-14 04:40:44', '2022-03-14 04:40:44'),
(1179, 'Paracetamol + Caffeine', 1, '2022-03-14 04:42:26', '2022-03-14 04:42:26'),
(1180, 'Paracetamol + Methionine', 1, '2022-03-14 04:44:08', '2022-03-14 04:44:08'),
(1181, 'Paracetamol + Tramadol Hydrochloride', 1, '2022-03-14 04:45:53', '2022-03-14 04:45:53'),
(1182, 'Parecoxib', 1, '2022-03-14 04:47:55', '2022-03-14 04:47:55'),
(1183, 'Paricalcitol', 1, '2022-03-14 04:49:31', '2022-03-14 04:49:31'),
(1184, 'Paroxetine Hydrochloride', 1, '2022-03-14 04:51:40', '2022-03-14 04:51:40'),
(1185, 'Pazopanib Hydrochloride', 1, '2022-03-14 04:53:29', '2022-03-14 04:53:29'),
(1186, 'Pefloxacin Mesylate Dihydrate', 1, '2022-03-14 04:55:04', '2022-03-14 04:55:04'),
(1187, 'Pegfilgrastim [Pegylated Filgrastim]', 1, '2022-03-14 04:56:55', '2022-03-14 04:56:55'),
(1188, 'Propylthiouracil', 1, '2022-03-14 04:59:05', '2022-03-14 04:59:05'),
(1189, 'Protamine Crystallised Insulin Aspart', 1, '2022-03-14 05:00:54', '2022-03-14 05:00:54'),
(1190, 'Protamine Sulfate', 1, '2022-03-14 05:02:40', '2022-03-14 05:02:40'),
(1191, 'Protein, Fat, Carbohydrate, Vitamin & Mineral', 1, '2022-03-14 05:03:58', '2022-03-14 05:03:58'),
(1192, 'Prucalopride Succinate', 1, '2022-03-14 05:05:58', '2022-03-14 05:05:58'),
(1193, 'Pseudoephedrine + Guaiphenasine + Triprolidine', 1, '2022-03-14 05:07:55', '2022-03-14 05:07:55'),
(1194, 'Pseudoephedrine Hydrochloride', 1, '2022-03-14 05:10:09', '2022-03-14 05:10:09'),
(1195, 'Psyllium Husk', 1, '2022-03-14 05:12:08', '2022-03-14 05:12:08'),
(1196, 'Pyrantel Pamoate', 1, '2022-03-14 05:13:40', '2022-03-14 05:13:40'),
(1197, 'Pyrazinamide', 1, '2022-03-14 05:15:59', '2022-03-14 05:15:59'),
(1198, 'Pyridostigmine Bromide', 1, '2022-03-14 05:18:19', '2022-03-14 05:18:19'),
(1199, 'Pyridoxine Hydrochloride', 1, '2022-03-14 05:20:29', '2022-03-14 05:20:29'),
(1200, 'Pyridoxine Hydrochloride + Doxylamine Succinate', 1, '2022-03-14 05:22:19', '2022-03-14 05:22:19'),
(1201, 'Pyrimethamine', 1, '2022-03-14 05:24:02', '2022-03-14 05:24:02'),
(1202, 'Peginterferon alfa-2a [Pegylated Interferon alfa-2a]', 1, '2022-03-15 04:13:11', '2022-03-15 04:13:11'),
(1203, 'Pegylated Erythropoietin', 1, '2022-03-15 04:16:01', '2022-03-15 04:16:01'),
(1204, 'Pembrolizumab', 1, '2022-03-15 04:17:50', '2022-03-15 04:17:50'),
(1205, 'Pemetrexed', 1, '2022-03-15 04:19:44', '2022-03-15 04:19:44'),
(1206, 'Pemirolast Potassium', 1, '2022-03-15 04:21:09', '2022-03-15 04:21:09'),
(1207, 'Pentazocine Hydrochloride', 1, '2022-03-15 04:22:42', '2022-03-15 04:22:42'),
(1208, 'Pentosan Polysulfate Sodium', 1, '2022-03-15 04:25:24', '2022-03-15 04:25:24'),
(1209, 'Pentoxifylline', 1, '2022-03-15 04:27:18', '2022-03-15 04:27:18'),
(1210, 'Perampanel', 1, '2022-03-15 04:28:51', '2022-03-15 04:28:51'),
(1211, 'Perindopril Arginine', 1, '2022-03-15 04:30:18', '2022-03-15 04:30:18'),
(1212, 'Perindopril Arginine + Amlodipine', 1, '2022-03-15 04:31:53', '2022-03-15 04:31:53'),
(1213, 'Peritoneal Dialysis solutions', 1, '2022-03-15 04:33:18', '2022-03-15 04:33:18'),
(1214, 'Permethrin', 1, '2022-03-15 04:35:04', '2022-03-15 04:35:04'),
(1215, 'Permethrin + Crotamiton', 1, '2022-03-15 04:37:01', '2022-03-15 04:37:01'),
(1216, 'Pertuzumab', 1, '2022-03-15 04:38:39', '2022-03-15 04:38:39'),
(1217, 'Pethidine Hydrochloride', 1, '2022-03-15 04:40:50', '2022-03-15 04:40:50'),
(1218, 'Pheniramine Maleate', 1, '2022-03-15 04:42:31', '2022-03-15 04:42:31'),
(1219, 'Phenobarbital', 1, '2022-03-15 04:44:10', '2022-03-15 04:44:10'),
(1220, 'Phenoxymethyl Penicillin [Penicillin V]', 1, '2022-03-15 04:46:08', '2022-03-15 04:46:08'),
(1221, 'Phenytoin Sodium', 1, '2022-03-15 04:48:11', '2022-03-15 04:48:11'),
(1222, 'Phospholipids', 1, '2022-03-15 05:09:28', '2022-03-15 05:09:28'),
(1223, 'Phytomenadione (Injection)', 1, '2022-03-15 05:10:58', '2022-03-15 05:10:58'),
(1224, 'Phytomenadione (Oral)', 1, '2022-03-15 05:12:36', '2022-03-15 05:12:36'),
(1225, 'Pilocarpine Hydrochloride (Ophthalmic)', 1, '2022-03-15 05:14:15', '2022-03-15 05:14:15'),
(1226, 'Pimavanserin', 1, '2022-03-15 05:37:47', '2022-03-15 05:37:47'),
(1227, 'Pimecrolimus', 1, '2022-03-15 05:39:28', '2022-03-15 05:39:28'),
(1228, 'Pioglitazone', 1, '2022-03-15 05:41:44', '2022-03-15 05:41:44'),
(1229, 'Pioglitazone + Glimepiride', 1, '2022-03-15 05:43:57', '2022-03-15 05:43:57'),
(1230, 'Pioglitazone + Metformin Hydrochloride', 1, '2022-03-15 05:46:04', '2022-03-15 05:46:04'),
(1231, 'Pipecuronium Bromide', 1, '2022-03-15 05:47:41', '2022-03-15 05:47:41'),
(1232, 'Piracetam', 1, '2022-03-15 05:58:29', '2022-03-15 05:58:29'),
(1233, 'Pirfenidone', 1, '2022-03-15 06:00:17', '2022-03-15 06:00:17'),
(1234, 'Pitavastatin Calcium', 1, '2022-03-15 06:05:34', '2022-03-15 06:05:34'),
(1235, 'Pivmecillinam', 1, '2022-03-15 06:08:05', '2022-03-15 06:08:05'),
(1236, 'Pizotifen', 1, '2022-03-15 06:09:46', '2022-03-15 06:09:46'),
(1237, 'Podophyllotoxin', 1, '2022-03-15 06:11:07', '2022-03-15 06:11:07');
INSERT INTO `generics` (`id`, `generic_name`, `category_id`, `created_at`, `updated_at`) VALUES
(1238, 'Polyethylene Glycol', 1, '2022-03-15 06:12:51', '2022-03-15 06:12:51'),
(1239, 'Polyethylene Glycol + Propylene Glycol', 1, '2022-03-16 03:50:32', '2022-03-16 03:50:32'),
(1240, 'Polyethylene Glycol 3350 + Electrolytes', 1, '2022-03-16 03:52:31', '2022-03-16 03:52:31'),
(1241, 'Polygeline + Electrolytes', 1, '2022-03-16 03:53:54', '2022-03-16 03:53:54'),
(1242, 'Polymyxin B Sulfate', 1, '2022-03-16 03:56:22', '2022-03-16 03:56:22'),
(1243, 'Polysaccharide Diphtheria Toxoid Conjugate Vaccine', 1, '2022-03-16 03:58:19', '2022-03-16 03:58:19'),
(1244, 'Polysaccharide Pneumococcal Vaccine', 1, '2022-03-16 04:00:23', '2022-03-16 04:00:23'),
(1245, 'Ponatinib Hydrochloride', 1, '2022-03-16 04:02:18', '2022-03-16 04:02:18'),
(1246, 'Posaconazole', 1, '2022-03-16 04:05:42', '2022-03-16 04:05:42'),
(1247, 'Potassium Chloride', 1, '2022-03-16 04:08:25', '2022-03-16 04:08:25'),
(1248, 'Potassium Citrate + Citric Acid', 1, '2022-03-16 04:10:35', '2022-03-16 04:10:35'),
(1249, 'Povidone Iodine', 1, '2022-03-16 04:12:39', '2022-03-16 04:12:39'),
(1250, 'Pralidoxime Chloride', 1, '2022-03-16 04:14:45', '2022-03-16 04:14:45'),
(1251, 'Pramipexole', 1, '2022-03-16 04:19:09', '2022-03-16 04:19:09'),
(1252, 'Pramoxine Hydrochloride + Calamine', 1, '2022-03-16 04:21:28', '2022-03-16 04:21:28'),
(1253, 'Prasugrel Hydrochloride', 1, '2022-03-16 04:23:40', '2022-03-16 04:23:40'),
(1254, 'Prazosin Hydrochloride', 1, '2022-03-16 04:26:18', '2022-03-16 04:26:18'),
(1255, 'Precipitated Sulpher + Salicylic Acid', 1, '2022-03-16 04:28:58', '2022-03-16 04:28:58'),
(1256, 'Prednisolone', 1, '2022-03-16 04:31:09', '2022-03-16 04:31:09'),
(1257, 'Prednisolone + Neomycin Sulphate + Polymixin B Sulphate', 1, '2022-03-16 04:33:21', '2022-03-16 04:33:21'),
(1258, 'Prednisolone Acetate', 1, '2022-03-16 04:37:47', '2022-03-16 04:37:47'),
(1259, 'Pregabalin', 1, '2022-03-16 04:39:41', '2022-03-16 04:39:41'),
(1260, 'Primaquine Phosphate', 1, '2022-03-16 04:42:38', '2022-03-16 04:42:38'),
(1261, 'Probiotic Combination [14 strains]', 1, '2022-03-16 04:45:12', '2022-03-16 04:45:12'),
(1262, 'Probiotic Combination [20 Billion]', 1, '2022-03-16 04:46:54', '2022-03-16 04:46:54'),
(1263, 'Probiotic Combination [9 Billion]', 1, '2022-03-16 04:48:13', '2022-03-16 04:48:13'),
(1264, 'Procaine Penicillin + Benzyl Penicillin', 1, '2022-03-16 04:49:55', '2022-03-16 04:49:55'),
(1265, 'Prochlorperazine Maleate', 1, '2022-03-16 04:51:44', '2022-03-16 04:51:44'),
(1266, 'Procyclidine Hydrochloride', 1, '2022-03-16 04:53:36', '2022-03-16 04:53:36'),
(1267, 'Progesterone (Capsule)', 1, '2022-03-16 04:55:16', '2022-03-16 04:55:16'),
(1268, 'Progesterone (Vaginal Gel)', 1, '2022-03-16 04:57:21', '2022-03-16 04:57:21'),
(1269, 'Progesterone (Vaginal Pessary)', 1, '2022-03-16 04:59:10', '2022-03-16 04:59:10'),
(1270, 'Promethazine Hydrochloride', 1, '2022-03-16 05:01:09', '2022-03-16 05:01:09'),
(1271, 'Promethazine Hydrochloride (Injection)', 1, '2022-03-16 05:03:22', '2022-03-16 05:03:22'),
(1272, 'Promethazine Theoclate', 1, '2022-03-16 05:05:32', '2022-03-16 05:05:32'),
(1273, 'Propafenone Hydrochloride', 1, '2022-03-16 05:07:17', '2022-03-16 05:07:17'),
(1274, 'Propantheline Bromide', 1, '2022-03-16 05:09:04', '2022-03-16 05:09:04'),
(1275, 'Proparacaine Hydrochloride', 1, '2022-03-16 05:10:43', '2022-03-16 05:10:43'),
(1276, 'Propofol', 1, '2022-03-16 05:13:00', '2022-03-16 05:13:00'),
(1277, 'Propranolol Hydrochloride', 1, '2022-03-16 05:14:40', '2022-03-16 05:14:40'),
(1278, 'Bendamustine', 1, '2022-03-17 04:41:46', '2022-03-17 04:41:46'),
(1279, 'Retapamulin', 1, '2022-03-17 23:52:49', '2022-03-17 23:52:49'),
(1280, 'Rhubarb Extract + Salicylic Acid', 1, '2022-03-18 00:54:21', '2022-03-18 00:54:21'),
(1281, 'Ribavirin', 1, '2022-03-18 03:48:00', '2022-03-18 03:48:00'),
(1282, 'Riboflavin', 1, '2022-03-18 03:49:50', '2022-03-18 03:49:50'),
(1283, 'Rifampicin', 1, '2022-03-18 03:51:57', '2022-03-18 03:51:57'),
(1284, 'Rifampicin + Isoniazid', 1, '2022-03-18 03:53:39', '2022-03-18 03:53:39'),
(1285, 'Rifampicin + Isoniazid + Pyrazinamide', 1, '2022-03-18 04:09:00', '2022-03-18 04:09:00'),
(1286, 'Rifampicin + Isoniazid + Pyrazinamide + Ethambutol', 1, '2022-03-18 04:12:10', '2022-03-18 04:12:10'),
(1287, 'Rifaximin', 1, '2022-03-18 04:14:54', '2022-03-18 04:14:54'),
(1288, 'Riluzole', 1, '2022-03-18 04:17:13', '2022-03-18 04:17:13'),
(1289, 'Rimexolone', 1, '2022-03-18 04:20:00', '2022-03-18 04:20:00'),
(1290, 'Ringer\'s Lactate Solution', 1, '2022-03-18 04:21:38', '2022-03-18 04:21:38'),
(1291, 'Risedronate Sodium', 1, '2022-03-18 04:23:38', '2022-03-18 04:23:38'),
(1292, 'Risperidone (Injection)', 1, '2022-03-18 04:25:45', '2022-03-18 04:25:45'),
(1293, 'Risperidone (Oral)', 1, '2022-03-18 04:34:17', '2022-03-18 04:34:17'),
(1294, 'Ritodrine Hydrochloride', 1, '2022-03-18 04:37:12', '2022-03-18 04:37:12'),
(1295, 'Rituximab', 1, '2022-03-18 04:38:55', '2022-03-18 04:38:55'),
(1296, 'Rivaroxaban', 1, '2022-03-18 04:43:39', '2022-03-18 04:43:39'),
(1297, 'Rivastigmine Tartrate', 1, '2022-03-18 04:46:43', '2022-03-18 04:46:43'),
(1298, 'Rizatriptan Benzoate', 1, '2022-03-18 04:49:32', '2022-03-18 04:49:32'),
(1299, 'Rocuronium Bromide', 1, '2022-03-18 04:52:20', '2022-03-18 04:52:20'),
(1300, 'Roflumilast', 1, '2022-03-18 04:54:04', '2022-03-18 04:54:04'),
(1301, 'Ropinirole', 1, '2022-03-18 04:59:18', '2022-03-18 04:59:18'),
(1302, 'Rosiglitazone', 1, '2022-03-18 05:01:06', '2022-03-18 05:01:06'),
(1303, 'Rosiglitazone + Metformin Hydrochloride', 1, '2022-03-18 05:02:54', '2022-03-18 05:02:54'),
(1304, 'Rosuvastatin', 1, '2022-03-18 05:04:49', '2022-03-18 05:04:49'),
(1305, 'Rotavirus Vaccine', 1, '2022-03-18 05:06:32', '2022-03-18 05:06:32'),
(1306, 'Roxatidine', 1, '2022-03-18 05:08:22', '2022-03-18 05:08:22'),
(1307, 'Roxithromycin', 1, '2022-03-18 05:09:50', '2022-03-18 05:09:50'),
(1308, 'Rupatadine Fumarate', 1, '2022-03-18 05:11:48', '2022-03-18 05:11:48'),
(1309, 'Ruxolitinib', 1, '2022-03-18 05:13:39', '2022-03-18 05:13:39'),
(1310, 'Valacyclovir', 1, '2022-03-18 19:36:56', '2022-03-18 19:36:56'),
(1311, 'Valganciclovir', 1, '2022-03-18 19:39:01', '2022-03-18 19:39:01'),
(1312, 'Valsartan', 1, '2022-03-18 19:49:36', '2022-03-18 19:49:36'),
(1313, 'Valsartan + Hydrochlorothiazide', 1, '2022-03-18 19:54:06', '2022-03-18 19:54:06'),
(1314, 'Vancomycin Hydrochloride', 1, '2022-03-18 20:03:53', '2022-03-18 20:03:53'),
(1315, 'Vardenafil', 1, '2022-03-18 20:05:35', '2022-03-18 20:05:35'),
(1316, 'Varenicline Varenicline TartrateTartrate', 1, '2022-03-18 20:09:26', '2022-03-18 20:09:26'),
(1317, 'Varicella Virus Vaccine', 1, '2022-03-18 20:11:24', '2022-03-18 20:11:24'),
(1318, 'Vecuronium Bromide', 1, '2022-03-18 20:13:55', '2022-03-18 20:13:55'),
(1319, 'Venlafaxine Hydrochloride', 1, '2022-03-18 20:15:49', '2022-03-18 20:15:49'),
(1320, 'Verapamil Hydrochloride', 1, '2022-03-18 20:17:59', '2022-03-18 20:17:59'),
(1321, 'Verteporfin', 1, '2022-03-18 20:19:48', '2022-03-18 20:19:48'),
(1322, 'Vilanterol + Umeclidinium + Fluticasone Furoate', 1, '2022-03-18 20:21:47', '2022-03-18 20:21:47'),
(1323, 'Vilanterol Trifenatate + Fluticasone Furoate', 1, '2022-03-18 20:24:02', '2022-03-18 20:24:02'),
(1324, 'Vildagliptin', 1, '2022-03-18 20:26:17', '2022-03-18 20:26:17'),
(1325, 'Vildagliptin + Metformin Hydrochloride', 1, '2022-03-18 20:27:56', '2022-03-18 20:27:56'),
(1326, 'Vinblastine Sulfate', 1, '2022-03-18 20:29:45', '2022-03-18 20:29:45'),
(1327, 'Vincristine Sulfate', 1, '2022-03-18 20:31:52', '2022-03-18 20:31:52'),
(1328, 'Vinorelbine Tartrate', 1, '2022-03-18 20:33:36', '2022-03-18 20:33:36'),
(1329, 'Vinpocetine', 1, '2022-03-18 20:35:11', '2022-03-18 20:35:11'),
(1330, 'Vitamin A', 1, '2022-03-18 20:37:20', '2022-03-18 20:37:20'),
(1331, 'Vitamin A, Vitamin B complex, Vitamin C , Vitamin D and Vitamin E', 1, '2022-03-18 20:39:06', '2022-03-18 20:39:06'),
(1332, 'Vitamin B complex', 1, '2022-03-18 20:40:37', '2022-03-18 20:40:37'),
(1333, 'Vitamin B complex + Vitamin C', 1, '2022-03-18 20:42:09', '2022-03-18 20:42:09'),
(1334, 'Vitamin B Complex + Zinc', 1, '2022-03-18 20:44:27', '2022-03-18 20:44:27'),
(1335, 'Vitamin B1, B2 & B6', 1, '2022-03-18 20:46:05', '2022-03-18 20:46:05'),
(1336, 'Vitamin B1, B6 & B12', 1, '2022-03-18 20:48:47', '2022-03-18 20:48:47'),
(1337, 'Vitamin B12 + Elemental Iron + Folic Acid', 1, '2022-03-18 20:50:41', '2022-03-18 20:50:41'),
(1338, 'Vitamin B6, B9 & B12', 1, '2022-03-18 20:52:22', '2022-03-18 20:52:22'),
(1339, 'Vitamin C [Ascorbic acid]', 1, '2022-03-18 20:53:52', '2022-03-18 20:53:52'),
(1340, 'Vitamin C + Vitamin D3 + Folic acid', 1, '2022-03-18 20:55:29', '2022-03-18 20:55:29'),
(1341, 'Vitamin C + Vitamin E', 1, '2022-03-18 20:57:10', '2022-03-18 20:57:10'),
(1342, 'Vitamin C, Vitamin E, Lutein, Copper & Zinc', 1, '2022-03-18 20:58:42', '2022-03-18 20:58:42'),
(1343, 'vitamins [C, E, B9 and B12] and minerals [Selenium, Copper and Zinc]', 1, '2022-03-18 21:02:11', '2022-03-18 21:02:11'),
(1344, 'Voglibose', 1, '2022-03-18 21:04:17', '2022-03-18 21:04:17'),
(1345, 'Voriconazole', 1, '2022-03-18 21:06:18', '2022-03-18 21:06:18'),
(1346, 'S-Amlodipine Besilate (Levamlodipine)', 1, '2022-03-18 23:26:40', '2022-03-18 23:26:40'),
(1347, 'Saccharin Sodium', 1, '2022-03-18 23:28:02', '2022-03-18 23:28:02'),
(1348, 'Sacubitril + Valsartan', 1, '2022-03-18 23:30:23', '2022-03-18 23:30:23'),
(1349, 'Salbutamol', 1, '2022-03-18 23:33:54', '2022-03-18 23:33:54'),
(1350, 'Salbutamol (Inhaler)', 1, '2022-03-19 01:48:07', '2022-03-19 01:48:07'),
(1351, 'Salbutamol + Ipratropium (Inhaler)', 1, '2022-03-19 01:50:09', '2022-03-19 01:50:09'),
(1352, 'Salbutamol + Ipratropium (Solution for inhalation)', 1, '2022-03-19 01:52:22', '2022-03-19 01:52:22'),
(1353, 'Salicylic Acid', 1, '2022-03-19 01:54:03', '2022-03-19 01:54:03'),
(1354, 'Salicylic Acid + Lactic Acid', 1, '2022-03-19 02:02:39', '2022-03-19 02:02:39'),
(1355, 'Salmeterol + Fluticasone Propionate', 1, '2022-03-19 02:04:41', '2022-03-19 02:04:41'),
(1356, 'Salmon Calcitonin', 1, '2022-03-19 05:00:42', '2022-03-19 05:00:42'),
(1357, 'Salsalate', 1, '2022-03-20 03:22:03', '2022-03-20 03:22:03'),
(1358, 'Salvia Officinalis', 1, '2022-03-20 03:23:12', '2022-03-20 03:23:12'),
(1359, 'Saquinavir Mesylate', 1, '2022-03-20 03:38:04', '2022-03-20 03:38:04'),
(1360, 'Saxagliptin', 1, '2022-03-20 03:40:10', '2022-03-20 03:40:10'),
(1361, 'Secnidazole', 1, '2022-03-20 03:41:42', '2022-03-20 03:41:42'),
(1362, 'Secukinumab', 1, '2022-03-20 03:43:26', '2022-03-20 03:43:26'),
(1363, 'Selegiline Hydrochloride', 1, '2022-03-20 03:44:59', '2022-03-20 03:44:59'),
(1364, 'Selexipag', 1, '2022-03-20 03:47:23', '2022-03-20 03:47:23'),
(1365, 'Semaglutide (Injection)', 1, '2022-03-20 03:49:49', '2022-03-20 03:49:49'),
(1366, 'Semaglutide (Tablet)', 1, '2022-03-20 03:51:38', '2022-03-20 03:51:38'),
(1367, 'Sennosides', 1, '2022-03-20 03:53:00', '2022-03-20 03:53:00'),
(1368, 'Sertaconazole Nitrate', 1, '2022-03-20 03:54:37', '2022-03-20 03:54:37'),
(1369, 'Sertraline Hydrochloride', 1, '2022-03-20 03:56:07', '2022-03-20 03:56:07'),
(1370, 'Sesame oil + Cactus extract + Beeswax', 1, '2022-03-20 04:27:59', '2022-03-20 04:27:59'),
(1371, 'Sevelamer Carbonate', 1, '2022-03-20 04:29:52', '2022-03-20 04:29:52'),
(1372, 'Sevelamer Hydrochloride', 1, '2022-03-20 04:31:22', '2022-03-20 04:31:22'),
(1373, 'Sevoflurane', 1, '2022-03-20 04:33:54', '2022-03-20 04:33:54'),
(1374, 'Sibutramine', 1, '2022-03-20 04:35:23', '2022-03-20 04:35:23'),
(1375, 'Sildenafil Citrate', 1, '2022-03-20 04:36:51', '2022-03-20 04:36:51'),
(1376, 'Silodosin', 1, '2022-03-20 04:38:38', '2022-03-20 04:38:38'),
(1377, 'Silver Sulfadiazine', 1, '2022-03-20 04:40:10', '2022-03-20 04:40:10'),
(1378, 'Simethicone', 1, '2022-03-20 04:41:36', '2022-03-20 04:41:36'),
(1379, 'Simvastatin', 1, '2022-03-20 04:43:11', '2022-03-20 04:43:11'),
(1380, 'Sitagliptin', 1, '2022-03-20 04:45:02', '2022-03-20 04:45:02'),
(1381, 'Sitagliptin + Metformin Hydrochloride', 1, '2022-03-20 04:46:52', '2022-03-20 04:46:52'),
(1382, 'Snake Venom Antiserum', 1, '2022-03-20 04:48:37', '2022-03-20 04:48:37'),
(1383, 'Sodium Alginate + Potassium Bicarbonate', 1, '2022-03-20 04:50:08', '2022-03-20 04:50:08'),
(1384, 'Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate', 1, '2022-03-20 04:51:52', '2022-03-20 04:51:52'),
(1385, 'Sodium Bicarbonate', 1, '2022-03-20 04:54:06', '2022-03-20 04:54:06'),
(1386, 'Sodium Chloride (Intravenous Solution)', 1, '2022-03-20 04:55:18', '2022-03-20 04:55:18'),
(1387, 'Sodium Chloride (Nasal preparation)', 1, '2022-03-20 04:56:58', '2022-03-20 04:56:58'),
(1388, 'Sodium Chloride (Ophthalmic Solution)', 1, '2022-03-20 04:58:32', '2022-03-20 04:58:32'),
(1389, 'Sodium Chloride (Tablet)', 1, '2022-03-20 05:00:39', '2022-03-20 05:00:39'),
(1390, 'Sodium Chloride + Dextrose', 1, '2022-03-20 05:02:04', '2022-03-20 05:02:04'),
(1391, 'Sodium Chloride + Potassium Chloride + Sodium Acetate', 1, '2022-03-20 05:02:52', '2022-03-20 05:02:52'),
(1392, 'Sodium Cromoglicate [2%]', 1, '2022-03-20 05:04:29', '2022-03-20 05:04:29'),
(1393, 'Sodium Cromoglicate [4%]', 1, '2022-03-20 05:06:12', '2022-03-20 05:06:12'),
(1394, 'Sodium Cromoglicate + Xylometazoline Hydrochloride', 1, '2022-03-20 05:07:51', '2022-03-20 05:07:51'),
(1395, 'Sodium Dichloroisocyanurate', 1, '2022-03-20 05:10:17', '2022-03-20 05:10:17'),
(1396, 'Sodium Dihydrogen Phosphate + Disodium Hydrogen Phosphate', 1, '2022-03-20 05:11:51', '2022-03-20 05:11:51'),
(1397, 'Sodium Fluoride (Mouthwash)', 1, '2022-03-20 05:13:21', '2022-03-20 05:13:21'),
(1398, 'Sodium Fusidate (Oral)', 1, '2022-03-20 05:14:43', '2022-03-20 05:14:43'),
(1399, 'Sodium Fusidate (Topical)', 1, '2022-03-20 05:16:02', '2022-03-20 05:16:02'),
(1400, 'Sodium Hyaluronate (Injection)', 1, '2022-03-20 05:17:24', '2022-03-20 05:17:24'),
(1401, 'Sodium Hyaluronate (Ophthalmic)', 1, '2022-03-20 05:18:32', '2022-03-20 05:18:32'),
(1402, 'Sodium Hyaluronate + Carboxymethylcellulose Sodium', 1, '2022-03-20 05:19:54', '2022-03-20 05:19:54'),
(1403, 'Sodium Hypochlorite', 1, '2022-03-20 05:21:09', '2022-03-20 05:21:09'),
(1404, 'Sodium Nitroprusside Dihydrate', 1, '2022-03-20 05:22:36', '2022-03-20 05:22:36'),
(1405, 'Sodium Picosulfate', 1, '2022-03-20 05:24:41', '2022-03-20 05:24:41'),
(1406, 'Sodium Picosulfate + Magnesium Oxide + Citric Acid', 1, '2022-03-20 05:26:22', '2022-03-20 05:26:22'),
(1407, 'Sodium Polystyrene Sulfonate', 1, '2022-03-20 05:28:05', '2022-03-20 05:28:05'),
(1408, 'Sodium Stibogluconate', 1, '2022-03-20 05:29:28', '2022-03-20 05:29:28'),
(1409, 'Sodium Succinate + Cytochrome C + Adenosine + Nicotinamide', 1, '2022-03-20 05:31:07', '2022-03-20 05:31:07'),
(1410, 'Sodium Thiosulfate', 1, '2022-03-20 05:32:35', '2022-03-20 05:32:35'),
(1411, 'Sodium Valproate', 1, '2022-03-20 05:34:07', '2022-03-20 05:34:07'),
(1412, 'Sofosbuvir', 1, '2022-03-20 05:35:45', '2022-03-20 05:35:45'),
(1413, 'Sofosbuvir + Velpatasvir', 1, '2022-03-20 05:37:54', '2022-03-20 05:37:54'),
(1414, 'Solifenacin Succinate', 1, '2022-03-20 05:39:50', '2022-03-20 05:39:50'),
(1415, 'Somatostatin', 1, '2022-03-20 05:41:26', '2022-03-20 05:41:26'),
(1416, 'Somatropin', 1, '2022-03-20 05:42:49', '2022-03-20 05:42:49'),
(1417, 'Sorafenib Tosylate', 1, '2022-03-20 05:44:25', '2022-03-20 05:44:25'),
(1418, 'Sotalol Hydrochloride', 1, '2022-03-20 05:45:56', '2022-03-20 05:45:56'),
(1419, 'Sparfloxacin', 1, '2022-03-20 05:47:35', '2022-03-20 05:47:35'),
(1420, 'Spectinomycin', 1, '2022-03-20 05:48:57', '2022-03-20 05:48:57'),
(1421, 'Spiramycin', 1, '2022-03-20 05:50:35', '2022-03-20 05:50:35'),
(1422, 'Spironolactone', 1, '2022-03-20 05:52:16', '2022-03-20 05:52:16'),
(1423, 'Streptokinase', 1, '2022-03-20 05:54:32', '2022-03-20 05:54:32'),
(1424, 'Streptomycin', 1, '2022-03-20 05:56:16', '2022-03-20 05:56:16'),
(1425, 'Strontium Ranelate', 1, '2022-03-21 03:30:34', '2022-03-21 03:30:34'),
(1426, 'Sucralfate', 1, '2022-03-21 03:32:30', '2022-03-21 03:32:30'),
(1427, 'Sucralose', 1, '2022-03-21 03:33:58', '2022-03-21 03:33:58'),
(1428, 'Sucralose + Acesulfame Potassium', 1, '2022-03-21 03:35:00', '2022-03-21 03:35:00'),
(1429, 'Sulconazole Nitrate', 1, '2022-03-21 03:36:24', '2022-03-21 03:36:24'),
(1430, 'Sulfacetamide sodium', 1, '2022-03-21 03:38:06', '2022-03-21 03:38:06'),
(1431, 'Sulfasalazine', 1, '2022-03-21 03:39:45', '2022-03-21 03:39:45'),
(1432, 'Sulfinpyrazone', 1, '2022-03-21 03:41:36', '2022-03-21 03:41:36'),
(1433, 'Sulindac', 1, '2022-03-21 03:48:01', '2022-03-21 03:48:01'),
(1434, 'Sulphadoxine + Pyrimethamine', 1, '2022-03-21 03:49:59', '2022-03-21 03:49:59'),
(1435, 'Sulphamethoxazole + Trimethoprim', 1, '2022-03-21 03:51:41', '2022-03-21 03:51:41'),
(1436, 'Sulphonated Surfactant', 1, '2022-03-21 03:53:18', '2022-03-21 03:53:18'),
(1437, 'Sumatriptan', 1, '2022-03-21 03:55:30', '2022-03-21 03:55:30'),
(1438, 'Sunitinib', 1, '2022-03-21 03:57:55', '2022-03-21 03:57:55'),
(1439, 'Super antioxidant vitamins & minerals', 1, '2022-03-21 03:59:29', '2022-03-21 03:59:29'),
(1440, 'Suvorexant', 1, '2022-03-21 04:01:28', '2022-03-21 04:01:28'),
(1441, 'Suxamethonium Chloride', 1, '2022-03-21 04:03:10', '2022-03-21 04:03:10'),
(1442, 'Tacrolimus (Oral)', 1, '2022-03-21 04:48:47', '2022-03-21 04:48:47'),
(1443, 'Tacrolimus (Topical)', 1, '2022-03-21 04:50:29', '2022-03-21 04:50:29'),
(1444, 'Tadalafil', 1, '2022-03-21 04:52:00', '2022-03-21 04:52:00'),
(1445, 'Tafluprost', 1, '2022-03-21 04:53:20', '2022-03-21 04:53:20'),
(1446, 'Tamoxifen Citrate', 1, '2022-03-21 04:56:50', '2022-03-21 04:56:50'),
(1447, 'Tamsulosin Hydrochloride', 1, '2022-03-21 04:58:25', '2022-03-21 04:58:25'),
(1448, 'Tamsulosin Hydrochloride + Dutasteride', 1, '2022-03-21 05:00:48', '2022-03-21 05:00:48'),
(1449, 'Tapentadol Hydrochloride', 1, '2022-03-21 05:02:33', '2022-03-21 05:02:33'),
(1450, 'Tazarotene', 1, '2022-03-21 05:04:19', '2022-03-21 05:04:19'),
(1451, 'Tea tree oil + Echinacea + Geothermal water', 1, '2022-03-21 05:05:22', '2022-03-21 05:05:22'),
(1452, 'Tea tree oil + Geothermal water (eye)', 1, '2022-03-21 05:07:45', '2022-03-21 05:07:45'),
(1453, 'Tea tree oil + Geothermal water (hair & body)', 1, '2022-03-21 05:09:08', '2022-03-21 05:09:08'),
(1454, 'Tea Tree Oil + Geothermal Water + Vitamin E', 1, '2022-03-21 05:11:11', '2022-03-21 05:11:11'),
(1455, 'Tedizolid Phosphate', 1, '2022-03-21 05:13:17', '2022-03-21 05:13:17'),
(1456, 'Tegaserod', 1, '2022-03-21 05:16:22', '2022-03-21 05:16:22'),
(1457, 'Teicoplanin', 1, '2022-03-21 05:18:12', '2022-03-21 05:18:12'),
(1458, 'Telbivudine', 1, '2022-03-21 05:19:51', '2022-03-21 05:19:51'),
(1459, 'Telmisartan', 1, '2022-03-21 05:21:43', '2022-03-21 05:21:43'),
(1460, 'Telmisartan + Hydrochlorothiazide', 1, '2022-03-21 05:23:35', '2022-03-21 05:23:35'),
(1461, 'Temazepam', 1, '2022-03-21 05:25:02', '2022-03-21 05:25:02'),
(1462, 'Temozolomide', 1, '2022-03-21 05:32:24', '2022-03-21 05:32:24'),
(1463, 'Tenecteplase', 1, '2022-03-21 05:34:19', '2022-03-21 05:34:19'),
(1464, 'Tenofovir Alafenamide', 1, '2022-03-21 05:36:04', '2022-03-21 05:36:04'),
(1465, 'Tenofovir Disoproxil Fumarate', 1, '2022-03-21 05:37:43', '2022-03-21 05:37:43'),
(1466, 'Tenoxicam', 1, '2022-03-21 05:39:55', '2022-03-21 05:39:55'),
(1467, 'Terazosin Hydrochloride', 1, '2022-03-21 05:41:35', '2022-03-21 05:41:35'),
(1468, 'Terbinafine Hydrochloride', 1, '2022-03-21 05:43:23', '2022-03-21 05:43:23'),
(1469, 'Terbutaline Sulfate', 1, '2022-03-21 05:45:04', '2022-03-21 05:45:04'),
(1470, 'Terconazole', 1, '2022-03-21 05:46:49', '2022-03-21 05:46:49'),
(1471, 'Terfenadine', 1, '2022-03-21 05:48:17', '2022-03-21 05:48:17'),
(1472, 'Teriparatide', 1, '2022-03-21 05:50:24', '2022-03-21 05:50:24'),
(1473, 'Terlipressin Acetate', 1, '2022-03-21 05:53:15', '2022-03-21 05:53:15'),
(1474, 'Testosterone Decanoate', 1, '2022-03-21 05:55:11', '2022-03-21 05:55:11'),
(1475, 'Testosterone Undecanoate', 1, '2022-03-21 05:57:15', '2022-03-21 05:57:15'),
(1476, 'Tetanus Antitoxin [Equine]', 1, '2022-03-21 05:59:14', '2022-03-21 05:59:14'),
(1477, 'Tetrabenazine', 1, '2022-03-21 06:01:08', '2022-03-21 06:01:08'),
(1478, 'Tetracycline Hydrochloride (Ophthalmic)', 1, '2022-03-21 06:03:00', '2022-03-21 06:03:00'),
(1479, 'Tetracycline Hydrochloride (Oral)', 1, '2022-03-21 06:04:52', '2022-03-21 06:04:52'),
(1480, 'Tetracycline Hydrochloride (Topical)', 1, '2022-03-21 06:06:34', '2022-03-21 06:06:34'),
(1481, 'Thalidomide', 1, '2022-03-21 06:08:14', '2022-03-21 06:08:14'),
(1482, 'Theophylline', 1, '2022-03-21 06:15:16', '2022-03-21 06:15:16'),
(1483, 'Thiamine Hydrochloride', 1, '2022-03-21 06:16:38', '2022-03-21 06:16:38'),
(1484, 'Thiopental Sodium', 1, '2022-03-21 20:07:46', '2022-03-21 20:07:46'),
(1485, 'Thioridazine', 1, '2022-03-21 20:09:38', '2022-03-21 20:09:38'),
(1486, 'Thiotepa', 1, '2022-03-21 20:11:42', '2022-03-21 20:11:42'),
(1487, 'Thymus Vulgaris Extracts', 1, '2022-03-21 20:13:31', '2022-03-21 20:13:31'),
(1488, 'Tibolone', 1, '2022-03-21 20:15:09', '2022-03-21 20:15:09'),
(1489, 'Ticagrelor', 1, '2022-03-21 20:17:02', '2022-03-21 20:17:02'),
(1490, 'Ticlopidine Hydrochloride', 1, '2022-03-21 20:21:18', '2022-03-21 20:21:18'),
(1491, 'Tiemonium Methylsulphate', 1, '2022-03-21 20:23:22', '2022-03-21 20:23:22'),
(1492, 'Tigecycline', 1, '2022-03-21 20:25:06', '2022-03-21 20:25:06'),
(1493, 'Timolol Maleate', 1, '2022-03-21 20:26:46', '2022-03-21 20:26:46'),
(1494, 'Tinidazole', 1, '2022-03-21 20:28:34', '2022-03-21 20:28:34'),
(1495, 'Tioconazole', 1, '2022-03-21 20:30:05', '2022-03-21 20:30:05'),
(1496, 'Tiotropium (Dry Powder Inhaler)', 1, '2022-03-21 20:31:43', '2022-03-21 20:31:43'),
(1497, 'Titanium dioxide + Butyl methoxydibenzoyl methane + Padimate + Oxybenzone', 1, '2022-03-21 20:33:20', '2022-03-21 20:33:20'),
(1498, 'Tizanidine Hydrochloride', 1, '2022-03-21 20:40:12', '2022-03-21 20:40:12'),
(1499, 'Tobramycin (Nebuliser Solution)', 1, '2022-03-21 20:42:05', '2022-03-21 20:42:05'),
(1500, 'Tobramycin (Ophthalmic)', 1, '2022-03-21 20:43:59', '2022-03-21 20:43:59'),
(1501, 'Tocilizumab', 1, '2022-03-21 20:46:05', '2022-03-21 20:46:05'),
(1502, 'Tofacitinib', 1, '2022-03-21 23:33:13', '2022-03-21 23:33:13'),
(1503, 'Tolfenamic acid', 1, '2022-03-21 23:34:42', '2022-03-21 23:34:42'),
(1504, 'Tolnaftate', 1, '2022-03-21 23:36:14', '2022-03-21 23:36:14'),
(1505, 'Tolperisone + Lidocaine', 1, '2022-03-21 23:37:44', '2022-03-21 23:37:44'),
(1506, 'Tolperisone Hydrochloride', 1, '2022-03-21 23:42:29', '2022-03-21 23:42:29'),
(1507, 'Tolterodine Tartrate', 1, '2022-03-21 23:44:15', '2022-03-21 23:44:15'),
(1508, 'Tolvaptan', 1, '2022-03-21 23:46:25', '2022-03-21 23:46:25'),
(1509, 'Topiramate', 1, '2022-03-21 23:48:30', '2022-03-21 23:48:30'),
(1510, 'Topotecan', 1, '2022-03-21 23:50:52', '2022-03-21 23:50:52'),
(1511, 'Torasemide', 1, '2022-03-21 23:52:35', '2022-03-21 23:52:35'),
(1512, 'Torsemide', 1, '2022-03-21 23:54:05', '2022-03-21 23:54:05'),
(1513, 'Tramadol Hydrochloride', 1, '2022-03-21 23:55:44', '2022-03-21 23:55:44'),
(1514, 'Tranexamic Acid', 1, '2022-03-21 23:57:30', '2022-03-21 23:57:30'),
(1515, 'Trastuzumab', 1, '2022-03-21 23:59:39', '2022-03-21 23:59:39'),
(1516, 'Trastuzumab Emtansine', 1, '2022-03-22 00:01:35', '2022-03-22 00:01:35'),
(1517, 'Travoprost', 1, '2022-03-22 00:03:58', '2022-03-22 00:03:58'),
(1518, 'Travoprost + Timolol Maleate', 1, '2022-03-22 00:06:20', '2022-03-22 00:06:20'),
(1519, 'Trelagliptin Succinate', 1, '2022-03-22 00:08:46', '2022-03-22 00:08:46'),
(1520, 'Tretinoin (Oral)', 1, '2022-03-22 00:10:56', '2022-03-22 00:10:56'),
(1521, 'Tretinoin (Topical)', 1, '2022-03-22 00:13:54', '2022-03-22 00:13:54'),
(1522, 'Triamcinolone + Neomycin + Nystatin + Gramicidin', 1, '2022-03-22 00:17:10', '2022-03-22 00:17:10'),
(1523, 'Triamcinolone Acetonide (Injection)', 1, '2022-03-22 00:19:19', '2022-03-22 00:19:19'),
(1524, 'Triamcinolone Acetonide (Nasal Spray)', 1, '2022-03-22 00:21:18', '2022-03-22 00:21:18'),
(1525, 'Triamcinolone Acetonide (Topical)', 1, '2022-03-22 00:22:52', '2022-03-22 00:22:52'),
(1526, 'Trifarotene', 1, '2022-03-22 00:24:25', '2022-03-22 00:24:25'),
(1527, 'Trifluoperazine', 1, '2022-03-22 00:26:09', '2022-03-22 00:26:09'),
(1528, 'Trifluridine', 1, '2022-03-22 00:27:41', '2022-03-22 00:27:41'),
(1529, 'Trihexyphenidyl Hydrochloride', 1, '2022-03-22 00:29:27', '2022-03-22 00:29:27'),
(1530, 'Trimebutine Maleate', 1, '2022-03-22 00:31:13', '2022-03-22 00:31:13'),
(1531, 'Trimetazidine Dihydrochloride', 1, '2022-03-22 00:32:31', '2022-03-22 00:32:31'),
(1532, 'Trimipramine', 1, '2022-03-22 00:34:05', '2022-03-22 00:34:05'),
(1533, 'Tropicamide', 1, '2022-03-22 00:35:32', '2022-03-22 00:35:32'),
(1534, 'Tropicamide + Phenylephrine + Lidocaine', 1, '2022-03-22 00:36:40', '2022-03-22 00:36:40'),
(1535, 'Tropicamide + Phenylephrine Hydrochloride', 1, '2022-03-22 00:38:16', '2022-03-22 00:38:16'),
(1536, 'Trospium Chloride', 1, '2022-03-22 00:40:01', '2022-03-22 00:40:01'),
(1537, 'Trypan Blue', 1, '2022-03-22 00:41:41', '2022-03-22 00:41:41'),
(1538, 'TTO Thermal Toothpaste', 1, '2022-03-22 00:42:43', '2022-03-22 00:42:43'),
(1539, 'Tulobuterol Hydrochloride', 1, '2022-03-22 00:44:21', '2022-03-22 00:44:21'),
(1540, 'Typhoid Polysaccharide Vaccine', 1, '2022-03-22 00:45:35', '2022-03-22 00:45:35'),
(1541, 'Abemaciclib', 1, '2022-04-03 01:34:23', '2022-04-03 01:34:23'),
(1542, 'Acalabrutinib', 1, '2022-04-03 01:50:47', '2022-04-03 01:50:47'),
(1543, 'Acarbose', 1, '2022-04-03 01:52:56', '2022-04-03 01:52:56'),
(1545, 'Acidic component (HCO3 Hemodialysis Solution)', 1, '2022-04-15 08:19:27', '2022-04-15 08:19:27'),
(1546, '23 herb formula to increase breast milk', 2, '2022-04-24 04:47:44', '2022-04-24 04:47:44'),
(1547, 'Abhayarista', 2, '2022-04-24 04:49:32', '2022-04-24 04:49:32'),
(1548, 'Acacia + Dates + Asparagus + Edible Pine', 2, '2022-04-24 04:50:37', '2022-04-24 04:50:37'),
(1549, 'Almond + Coconut + Edible Pine + Salep', 2, '2022-04-24 04:51:35', '2022-04-24 04:51:35'),
(1550, 'Aloe + Black Pepper + Henbane', 2, '2022-04-24 04:52:38', '2022-04-24 04:52:38'),
(1551, 'Aloe indica+ Hyoscyamus niger + Piper nigrum', 2, '2022-04-24 04:58:34', '2022-04-24 04:58:34'),
(1552, 'Amalaki Rasayana', 2, '2022-04-24 04:59:44', '2022-04-24 04:59:44'),
(1553, 'Ambar Momiyaee', 2, '2022-04-24 05:00:51', '2022-04-24 05:00:51'),
(1554, 'Ambergris + Salep + Galangal', 2, '2022-04-24 05:02:29', '2022-04-24 05:02:29'),
(1555, 'Andrographis paniculata', 2, '2022-04-24 05:04:47', '2022-04-24 05:04:47'),
(1556, 'Aniseed + Indian dill + Black cardamom + Peppermint', 2, '2022-04-24 05:06:04', '2022-04-24 05:06:04'),
(1557, 'Amitriptyline Hydrochloride', 1, '2022-05-09 19:44:22', '2022-05-09 19:44:22'),
(1558, 'Amlodipine Besilate + Olmesartan Medoxomil', 1, '2022-05-10 21:35:09', '2022-05-10 21:35:09'),
(1559, 'Atorvastatin + Ezetimibe', 1, '2022-06-02 01:25:57', '2022-06-02 01:25:57'),
(1560, 'Vaccine', 1, '2022-06-04 04:17:20', '2022-06-04 04:17:20'),
(1561, 'Baricitinib', 1, '2022-06-07 00:08:16', '2022-06-07 00:08:16'),
(1562, 'Curran Franks', 1, '2022-06-08 17:48:10', '2022-06-08 17:48:10'),
(1563, 'Curran Franks2', 1, '2022-06-08 17:49:22', '2022-06-08 17:49:22');

-- --------------------------------------------------------

--
-- Table structure for table `generic_categories`
--

CREATE TABLE `generic_categories` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `category_name` varchar(255) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `generic_categories`
--

INSERT INTO `generic_categories` (`id`, `category_name`, `created_at`, `updated_at`) VALUES
(1, 'Allopathic', NULL, NULL),
(2, 'Herbal', NULL, NULL),
(3, 'Veterinary', NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `generic_combinations`
--

CREATE TABLE `generic_combinations` (
  `parent_id` bigint(20) UNSIGNED NOT NULL,
  `generic_id` bigint(20) UNSIGNED NOT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1 COLLATE=latin1_swedish_ci;

--
-- Dumping data for table `generic_combinations`
--

INSERT INTO `generic_combinations` (`parent_id`, `generic_id`) VALUES
(1, 26),
(1, 23),
(1, 21),
(1563, 23),
(1563, 27),
(1563, 30),
(1563, 31),
(1563, 40),
(1563, 41),
(1563, 42),
(1563, 43),
(1563, 48),
(1563, 52),
(1563, 57),
(1563, 58),
(1563, 59),
(1563, 61),
(1563, 62),
(1563, 68),
(1563, 70),
(1563, 71),
(1563, 76),
(1563, 80),
(1563, 85),
(1563, 94),
(1563, 104),
(1563, 108),
(1563, 112),
(1563, 113),
(1563, 115),
(1563, 117),
(1563, 118),
(1563, 135),
(1563, 139),
(1563, 140),
(1563, 141),
(1563, 145),
(1563, 152),
(1563, 160),
(1563, 161),
(1563, 163),
(1563, 164),
(1563, 168),
(1563, 170),
(1563, 177),
(1563, 178),
(1563, 184),
(1563, 185),
(1563, 198),
(1563, 205),
(1563, 212),
(1563, 215),
(1563, 217),
(1563, 222),
(1563, 228),
(1563, 230),
(1563, 235),
(1563, 252),
(1563, 253),
(1563, 254),
(1563, 255),
(1563, 256),
(1563, 257),
(1563, 258),
(1563, 261),
(1563, 265),
(1563, 266),
(1563, 269),
(1563, 272),
(1563, 276),
(1563, 279),
(1563, 282),
(1563, 294),
(1563, 298),
(1563, 300),
(1563, 302),
(1563, 311),
(1563, 319),
(1563, 320),
(1563, 326),
(1563, 327),
(1563, 335),
(1563, 338),
(1563, 343),
(1563, 344),
(1563, 351),
(1563, 353),
(1563, 358),
(1563, 361),
(1563, 365),
(1563, 366),
(1563, 367),
(1563, 369),
(1563, 378),
(1563, 382),
(1563, 385),
(1563, 400),
(1563, 406),
(1563, 407),
(1563, 410),
(1563, 414),
(1563, 419),
(1563, 422),
(1563, 423),
(1563, 426),
(1563, 431),
(1563, 435),
(1563, 447),
(1563, 449),
(1563, 450),
(1563, 460),
(1563, 461),
(1563, 466),
(1563, 468),
(1563, 474),
(1563, 477),
(1563, 482),
(1563, 485),
(1563, 498),
(1563, 499),
(1563, 500),
(1563, 511),
(1563, 515),
(1563, 516),
(1563, 518),
(1563, 520),
(1563, 522),
(1563, 523),
(1563, 527),
(1563, 537),
(1563, 538),
(1563, 542),
(1563, 546),
(1563, 547),
(1563, 551),
(1563, 552),
(1563, 553),
(1563, 559),
(1563, 566),
(1563, 576),
(1563, 577),
(1563, 584),
(1563, 591),
(1563, 592),
(1563, 595),
(1563, 596),
(1563, 601),
(1563, 609),
(1563, 615),
(1563, 617),
(1563, 629),
(1563, 632),
(1563, 636),
(1563, 639),
(1563, 640),
(1563, 641),
(1563, 644),
(1563, 645),
(1563, 647),
(1563, 648),
(1563, 657),
(1563, 665),
(1563, 668),
(1563, 671),
(1563, 674),
(1563, 676),
(1563, 679),
(1563, 680),
(1563, 683),
(1563, 689),
(1563, 692),
(1563, 693),
(1563, 696),
(1563, 702),
(1563, 703),
(1563, 706),
(1563, 707),
(1563, 712),
(1563, 735),
(1563, 740),
(1563, 741),
(1563, 746),
(1563, 749),
(1563, 755),
(1563, 756),
(1563, 758),
(1563, 762),
(1563, 765),
(1563, 773),
(1563, 775),
(1563, 776),
(1563, 780),
(1563, 784),
(1563, 787),
(1563, 788),
(1563, 790),
(1563, 793),
(1563, 795),
(1563, 797),
(1563, 802),
(1563, 808),
(1563, 824),
(1563, 828),
(1563, 830),
(1563, 832),
(1563, 833),
(1563, 837),
(1563, 849),
(1563, 852),
(1563, 853),
(1563, 857),
(1563, 862),
(1563, 863),
(1563, 864),
(1563, 865),
(1563, 868),
(1563, 874),
(1563, 882),
(1563, 883),
(1563, 884),
(1563, 885),
(1563, 896),
(1563, 903),
(1563, 906),
(1563, 910),
(1563, 915),
(1563, 941),
(1563, 946),
(1563, 949),
(1563, 952),
(1563, 955),
(1563, 965),
(1563, 977),
(1563, 980),
(1563, 983),
(1563, 984),
(1563, 989),
(1563, 994),
(1563, 997),
(1563, 999),
(1563, 1001),
(1563, 1002),
(1563, 1005),
(1563, 1007),
(1563, 1010),
(1563, 1011),
(1563, 1012),
(1563, 1014),
(1563, 1018),
(1563, 1025),
(1563, 1028),
(1563, 1029),
(1563, 1030),
(1563, 1031),
(1563, 1043),
(1563, 1048),
(1563, 1051),
(1563, 1052),
(1563, 1054),
(1563, 1061),
(1563, 1062),
(1563, 1066),
(1563, 1072),
(1563, 1073),
(1563, 1083),
(1563, 1086),
(1563, 1091),
(1563, 1093),
(1563, 1096),
(1563, 1107),
(1563, 1109),
(1563, 1111),
(1563, 1112),
(1563, 1113),
(1563, 1117),
(1563, 1129),
(1563, 1133),
(1563, 1134),
(1563, 1138),
(1563, 1141),
(1563, 1146),
(1563, 1150),
(1563, 1154),
(1563, 1163),
(1563, 1165),
(1563, 1182),
(1563, 1188),
(1563, 1191),
(1563, 1192),
(1563, 1196),
(1563, 1197),
(1563, 1199),
(1563, 1200),
(1563, 1201),
(1563, 1208),
(1563, 1209),
(1563, 1212),
(1563, 1214),
(1563, 1216),
(1563, 1217),
(1563, 1222),
(1563, 1223),
(1563, 1227),
(1563, 1234),
(1563, 1236),
(1563, 1244),
(1563, 1247),
(1563, 1255),
(1563, 1257),
(1563, 1260),
(1563, 1264),
(1563, 1265),
(1563, 1271),
(1563, 1274),
(1563, 1277),
(1563, 1279),
(1563, 1281),
(1563, 1282),
(1563, 1290),
(1563, 1292),
(1563, 1297),
(1563, 1299),
(1563, 1303),
(1563, 1306),
(1563, 1307),
(1563, 1311),
(1563, 1318),
(1563, 1319),
(1563, 1326),
(1563, 1329),
(1563, 1335),
(1563, 1337),
(1563, 1341),
(1563, 1342),
(1563, 1344),
(1563, 1346),
(1563, 1363),
(1563, 1365),
(1563, 1382),
(1563, 1390),
(1563, 1391),
(1563, 1399),
(1563, 1400),
(1563, 1406),
(1563, 1412),
(1563, 1413),
(1563, 1416),
(1563, 1418),
(1563, 1424),
(1563, 1426),
(1563, 1440),
(1563, 1450),
(1563, 1460),
(1563, 1463),
(1563, 1465),
(1563, 1468),
(1563, 1477),
(1563, 1478),
(1563, 1481),
(1563, 1483),
(1563, 1489),
(1563, 1499),
(1563, 1500),
(1563, 1502),
(1563, 1509),
(1563, 1513),
(1563, 1514),
(1563, 1517),
(1563, 1518),
(1563, 1519),
(1563, 1520),
(1563, 1539),
(1563, 1540),
(1563, 1541),
(1563, 1542),
(1563, 1543),
(1563, 1546),
(1563, 1547),
(1563, 1550),
(1563, 1552),
(1563, 1558),
(1563, 1559),
(21, 52),
(21, 48),
(21, 43),
(21, 41),
(169, 61),
(169, 62),
(169, 63),
(169, 77),
(27, 27),
(27, 28),
(27, 29),
(27, 30),
(27, 31),
(27, 34),
(930, 499),
(930, 652),
(930, 654),
(930, 867),
(930, 1303),
(930, 1325),
(930, 1381),
(39, 41),
(39, 40),
(39, 39),
(39, 38),
(39, 37),
(21, 58),
(40, 37),
(40, 38),
(40, 39),
(40, 40),
(71, 69),
(71, 70),
(71, 71),
(71, 72),
(91, 91),
(91, 92),
(91, 93),
(91, 94),
(91, 95),
(91, 96);

-- --------------------------------------------------------

--
-- Table structure for table `generic_companies`
--

CREATE TABLE `generic_companies` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `company_id` int(11) NOT NULL,
  `generic_id` int(11) NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

-- --------------------------------------------------------

--
-- Table structure for table `generic_details`
--

CREATE TABLE `generic_details` (
  `id` bigint(20) UNSIGNED NOT NULL,
  `generic_id` int(11) NOT NULL,
  `indications` longtext DEFAULT NULL,
  `pharmacology` longtext DEFAULT NULL,
  `dosage_and_administration` longtext DEFAULT NULL,
  `interaction` longtext DEFAULT NULL,
  `contraindications` longtext DEFAULT NULL,
  `side_effects` longtext DEFAULT NULL,
  `pregnancy_and_lactation` longtext DEFAULT NULL,
  `precautions_and_warnings` longtext DEFAULT NULL,
  `overdose_effects` longtext DEFAULT NULL,
  `therapeutic_class` longtext DEFAULT NULL,
  `storage_conditions` longtext DEFAULT NULL,
  `use_in_special_populations` longtext DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

--
-- Dumping data for table `generic_details`
--

INSERT INTO `generic_details` (`id`, `generic_id`, `indications`, `pharmacology`, `dosage_and_administration`, `interaction`, `contraindications`, `side_effects`, `pregnancy_and_lactation`, `precautions_and_warnings`, `overdose_effects`, `therapeutic_class`, `storage_conditions`, `use_in_special_populations`, `created_at`, `updated_at`) VALUES
(21, 21, '<p>Lidocaine Injection is indicated-</p>\r\n\r\n<ul>\r\n	<li>As a local anaesthetic for use in infiltration blockade and intravenous regional analgesia.</li>\r\n	<li>For the prevention and treatment of ventricular tachyarrhythmias</li>\r\n</ul>\r\n\r\n<p>Lidocaine Injection is a sterile, non-pyrogenic, aqueous solution which contains Lidocaine Hydrochloride. It is a local anaesthetic of the amide type and has a fast onset and an intermediate duration of action. The onset of action ranges from 5 minutes for infiltration anaesthesia to 20 minutes for regional anaesthesia. The duration of action is approximately one hour. Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anaesthetic action.</p>', '<p>Lidocaine acts mainly by inhibiting sodium influx through sodium specific ion channels in the neuronal cell membrane, in particular the so called voltage-gated sodium channels. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Lidocaine binds more readily to sodium channels in activated state, thus onset of neuronal blockade is faster in neurons that are rapidly firing. This is referred to as state dependent blockade.</p>', '<p>The dosage is adjusted according to the response of the patient and site of administration.<br />\r\n<br />\r\n<strong>Adult</strong>: For healthy adults, the maximum individual dose should not exceed 4.5mg/kg of body weight and in general it is recommended that the maximum total dose does not exceed 300 mg. Recommended doses given in the below serve only as a guide to the amount of anaesthetic required for most routine procedures.<br />\r\n<br />\r\nInfiltration-</p>\r\n\r\n<ul>\r\n	<li>Percutaneous: Total dose 5-300 mg</li>\r\n	<li>Intravenous regional: Total dose 50-300 mg</li>\r\n</ul>\r\n\r\n<p>Peripheral Nerve Blocks-</p>\r\n\r\n<ul>\r\n	<li>Brachial: Total dose 225-300 mg</li>\r\n	<li>Dental: Total dose 20-100 mg</li>\r\n	<li>Intercostal: Total dose 30 mg</li>\r\n	<li>Paravertebral: Total dose 30-50 mg</li>\r\n</ul>\r\n\r\n<p>Pudenal (each side):&nbsp;</p>\r\n\r\n<ul>\r\n	<li>Paracervical Obstetrical analgesia: Total dose 100 mg</li>\r\n</ul>\r\n\r\n<p>Sympathetic Nerve Blocks</p>\r\n\r\n<ul>\r\n	<li>Cervical: Total dose 50 mg</li>\r\n	<li>Lumbar: Total dose 50-100 mg</li>\r\n</ul>\r\n\r\n<p>Central Neural Blocks</p>\r\n\r\n<ul>\r\n	<li>Epidural: Total dose 200-300 mg [Dose determined by number of dermatomes to be anesthetized (2-3 mL/dermatome) periodically.]</li>\r\n	<li>Thoracic: Total dose 200-300 mg</li>\r\n</ul>\r\n\r\n<p>Lumbar</p>\r\n\r\n<ul>\r\n	<li>Analgesia: Total dose 250-300 mg</li>\r\n	<li>Anesthesia: Total dose 200-300 mg</li>\r\n</ul>\r\n\r\n<p>Caudal</p>\r\n\r\n<ul>\r\n	<li>Obstetrical analgesia: Total dose 200-300 mg</li>\r\n	<li>Surgical anesthesia: Total dose 225-300 mg<strong>.</strong></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong>Administration : </strong>Antiarrhythmic treatment: An intravenous dose of 1 mg.kg-1&nbsp;may be given over 2 min and repeated after 5 min, but giving an infusion of 2-4 mg.min-1&nbsp;to produce a plasma level of 2-4 mg. l-1&nbsp;is a more satisfactory technique. To avoid a long delay in achieving a steady state, a loading dose of approximately 1 mg.kg-1&nbsp;is usually given intravenously over 2 min at the outset.</p>', '<p>Cimetidine can impair the metabolism of lidocaine absorbed into the circulation. Elimination will be delayed and the risk of adverse reactions increased. Significant increases in plasma lidocaine concentrations have occurred during concomitant therapy with beta blockers such as propranolol, metoprolol or nadolol. It prolongs the duration of action of suxamethonium.</p>', '<p>Known hypersensitivity to anaesthetics of the amide type.</p>', '<p>In common with other local anaesthetics, adverse reactions to lidocaine are rare and are usually the result of excessively high blood concentrations due to inadvertent intravascular injection, excessive dosage, rapid absorption or occasionally to hypersensitivity, idiosyncracy or diminished tolerance on the part of the patient. In such circumstances systemic effects occur involving the central nervous system and/or the cardiovascular system. CNS reactions are excitatory and/or depressant and may be characterized by nervousness, dizziness, blurred vision and tremors, followed by drowsiness, convulsions, unconsciousness and possibly respiratory arrest. Cardiovascular reactions are hypotension, myocardial depression, bradycardia and possibly cardiac arrest. Allergic reactions are extremely rare. They may be characterized by cutaneous lesions, urticaria, oedema or anaphylactoid reactions.</p>', '<p>Although there is no evidence from animal studies of harm to the foetus, as with all drugs, it should not be given during early pregnancy unless the benefits are considered to outweigh the risks. Caution should be exercised when it is administered to a nursing woman.</p>', '<p>Lidocaine for infiltration and nerve block should be employed only by clinicians who are well versed in diagnosis and management of dose-related toxicity. The safety and effectiveness of lidocaine depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Standard text books should be consulted for specific techniques and precautions for various regional anaesthetic procedures. Resuscitative equipment, oxygen and other resuscitative drugs should be available for immediate use.<br />\r\n<br />\r\nIt should be used cautiously in patients with epilepsy, impaired cardiac conduction, bradycardia, impaired respiratory function and in patients with impaired hepatic function, if the dose or site of administration is likely to result in high blood levels. The effect of local anaesthetics may be reduced if an injection is made into an inflamed or infected area. Repeated doses of lidocaine may cause significant increases in blood levels with each repeated dose because of slow accumulation of the drug or its metabolites. Tolerance to elevated blood levels varies with the status of the patient. Careful and constant monitoring of cardiovascular and respiratory vital signs and the patient&#39;s state of consciousness should be accomplished after each local anaesthetic injection.</p>', '<p>Overdose Effects</p>', '<p>Local &amp; Surface anesthesia</p>', '<p>Lidocaine Injection is indicated-</p>\r\n\r\n<ul>\r\n	<li>As a local anaesthetic for use in infiltration blockade and intravenous regional analgesia.</li>\r\n	<li>For the prevention and treatment of ventricular tachyarrhythmias</li>\r\n</ul>\r\n\r\n<p>Lidocaine Injection is a sterile, non-pyrogenic, aqueous solution which contains Lidocaine Hydrochloride. It is a local anaesthetic of the amide type and has a fast onset and an intermediate duration of action. The onset of action ranges from 5 minutes for infiltration anaesthesia to 20 minutes for regional anaesthesia. The duration of action is approximately one hour. Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anaesthetic action.</p>', '<p>Dosages in children should be reduced, commensurate with age, body-weight and physical condition. Elderly patients may be more sensitive to systemic effects and may require dose reductions.</p>', '2022-01-29 04:30:45', '2022-06-08 18:02:03'),
(22, 22, '<p>Indications</p>', '<p>Pharmacology</p>', '<p>Dosage &amp; Administration</p>', '<p>Interaction</p>', '<p>Contraindications</p>', '<p>Side Effects</p>', '<p>Pregnancy &amp; Lactation</p>', '<p>Precautions &amp; Warnings</p>', '<p>Overdose Effects</p>', '<p>Therapeutic Class</p>', '<p>Storage Conditions</p>', '<p>Use In Special Populations</p>', '2022-01-29 04:34:00', '2022-01-29 04:34:00'),
(23, 23, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2022-02-01 06:31:59', '2022-02-01 06:31:59'),
(26, 26, '<p>This drug&nbsp;is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.</p>', '<p>Lidocaine is a local anaesthetic which decreases permeability of sodium ions, blocking induction and conduction of nerve impulses. Combination with epinephrine restricts systemic spread of lidocaine, vascular absorption and its duration of local anaesthetic effect.</p>', '<p>Dosage depends on several factors such as route, type and extent of surgical procedure, duration of anaesthesia and patient&#39;s condition and age.<br />\r\n<strong>Adult</strong>: Max dose of lidocaine given with epinephrine: 7 mg/kg and not &gt;500 mg.<br />\r\n<strong>Child</strong>: 3 mth-12 yr: Max dose 3 mg/kg. Ideal body weight should be used in children with high body weight.</p>', '<p>Halogenated inhalation anaesthetics; alpha or beta blocking agents; methyldopa, guanethidine; drugs with vasoconstrictor and pressor effects; antihypertensives; adrenergic neuron blockers; potassium-depleting drugs; cardiac glycosides; ephedra, yohimbe. TCAs may induce hypertension and arrhythmia.</p>', '<p>Tachycardia, hypertension, cerebral arteriosclerosis, ischaemic heart disease, IV admin, anaesthetise digits or appendages, myasthenia gravis.</p>', '<p><strong>More common side effects</strong>:&nbsp;Minor redness, burning, irritation, or numbness at the application site; lightheadedness; nausea.<br />\r\n<br />\r\n<strong>Severe side effects</strong>:&nbsp;Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; dizziness; fainting; fast, slow, or irregular heartbeat; loss of consciousness; mental or mood changes; nervousness; paleness; redness or warmth of skin; ringing in the ears or hearing changes; seizures; sensation of heat or cold; shortness of breath; swelling or blistering of skin; tremors or twitching; vision changes or double vision; vomiting.</p>', '<p>Pregnancy Category C+B. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using epinephrine/lidocaine iontophoretic patch while you are pregnant. Epinephrine/lidocaine iontophoretic patch is found in breast milk. If you are or will be breast-feeding while you use epinephrine/lidocaine iontophoretic patch, check with your doctor. Discuss any possible risks to your baby.</p>', '<p>Epilepsy, impaired cardiac conduction, CHE DM, closed angle glaucoma, impaired liver function (if site of admin is likely to result in high blood levels), severe renal dysfunction. Local anaesthetic effect may be reduced if injected into an inflamed or infected area. Cerebrovascular insufficiency, hyperthyroidism. Neonates, elderly, patients in poor general condition (optimise patient&#39;s condition before major block), pregnancy.</p>', NULL, '<p>Local &amp; Surface anesthesia</p>', '<p>Store at room temperature, between 20℃ to 25℃. Store away from heat and light. Keep the child-resistant envelope sealed at all times when not in use. Keep out of the reach of children and away from pets.</p>', NULL, '2022-02-10 02:31:48', '2022-02-10 02:31:48'),
(27, 27, '<p>Aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, toothache, trauma and lumbago.</p>', '<p>Aceclofenac is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.</p>', '<p><strong>Extended release tablet</strong>: The recommended dose in adults is one 200 mg Aceclofenac tablet daily or as prescribed by the physician.<br />\r\n<strong>Film coated tablet</strong>: The recommended dose in adults is 100 mg, twice daily.</p>', '<p>No significant drug interactions has not been observed but close monitoring of patients is required when it is used with:</p>\r\n\r\n<ul>\r\n	<li><strong>Lithium and Digoxin</strong>: may increase plasma concentration of lithium and digoxin.</li>\r\n	<li><strong>Diuretics</strong>: may interact the activity of diuretics.</li>\r\n	<li><strong>Anticoagulants</strong>: may enhance the activity of anticoagulant.</li>\r\n	<li><strong>Methotrexate</strong>: may increase the plasma level of methotrexate.</li>\r\n</ul>', '<p>Aceclofenac is contraindicated in patients with known hypersensitivity to it or in whom aspirin or NSAIDs precipitate attacks of asthma.</p>', '<p>Aceclofenac is a non-steroidal drug with anti-inflammatory and analgesic properties. It is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandin. After oral administration, it is rapidly and completely absorbed an unchanged drug.</p>', '<p>The use of Aceclofenac should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.</p>\r\n\r\n<p>s</p>', '<p>Caution should be exercised to patients with active or suspected peptic ulcer or gastro-intestinal bleeding moderate to severe hepatic impairment and cardiac or renal impairment. Caution should also be exercised in patients suffering from dizziness or urticaria.</p>', NULL, '<p>Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)</p>', '<p>Aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, toothache, trauma and lumbago.</p>', '<p>There are no clinical data on the use of Aceclofenac in children.</p>', '2022-02-10 21:57:38', '2022-06-09 18:00:20'),
(28, 28, '<p>Abiraterone Acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with</p>\r\n\r\n<ul>\r\n	<li>Metastatic castration-resistant prostate cancer (CRPC)</li>\r\n	<li>Metastatic high-risk castration-sensitive prostate cancer (CSPC)</li>\r\n</ul>', '<p>Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 in a selective and irreversible manner via covalent binding mechanism. CYP17A1 is an enzyme that catalyzes the biosynthesis of androgen and is highly expressed in testicular, adrenal, and prostatic tumor tissue. More specifically, abiraterone inhibits the conversion of 17-hydroxyprognenolone to dehydroepiandrosterone (DHEA) by the enzyme CYP17A1 to decrease serum levels of testosterone and other androgens.</p>', '<p><strong>Metastatic castration-resistant prostate cancer</strong>: Abiraterone 1,000 mg orally once daily with prednisone 5 mg orally twice daily.<br />\r\n<br />\r\n<strong>Metastatic castration-sensitive prostate cancer</strong>: Abiraterone 1,000 mg orally once daily with prednisone 5 mg orally once daily.<br />\r\n<br />\r\nPatients receiving Abiraterone should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Abiraterone must be taken on an empty stomach with water at least 1 hour before or 2 hours after a meal. Do not crush or chew tablets.<br />\r\n<br />\r\nDose Modification:</p>\r\n\r\n<ul>\r\n	<li>For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the Abiraterone starting dose to 250 mg once daily.</li>\r\n	<li>For patients who develop hepatotoxicity during treatment, hold Abiraterone until recovery. Retreatment may be initiated at a reduced dose. Abiraterone should be discontinued if patients develop severe hepatotoxicity.</li>\r\n</ul>', '<p><strong>CYP3A4 Inducers</strong>: Avoid concomitant strong CYP3A4 inducers during Abiraterone treatment. If a strong CYP3A4 inducer must be co-administered, increase the Abiraterone dosing frequency.<br />\r\n<br />\r\n<strong>CYP2D6 Substrates</strong>: Avoid co-administration of Abiraterone with CYP2D6 substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate.</p>', '<p>Hypersensitivity to the Abiraterone acetate or to any of the excipients of Abiraterone.</p>', '<p>The most common adverse reactions are fatigue, arthralgia, hypertension, nausea, edema, hypokalemia, hot flush, diarrhea, vomiting, upper respiratory infection, cough, and headache.</p>', '<p>The safety and efficacy of Abiraterone have not been established in females. Based on findings from animal studies and the mechanism of action, Abiraterone can cause fetal harm and potential loss of pregnancy. There are no human data on the use of Abiraterone in pregnant women. The safety and efficacy of Abiraterone have not been established in females. There is no information available on the presence of abiraterone acetate in human milk, or on the effects on the breastfed child or milk production.</p>', '<p><strong>Mineralocorticoid excess</strong>: Closely monitor patients with cardiovascular disease. Control hypertension and correct hypokalemia before treatment. Monitor blood pressure, serum potassium and symptoms of fluid retention at least monthly.<br />\r\n<br />\r\n<strong>Adrenocortical insufficiency</strong>: Monitor for symptoms and signs of adrenocortical insufficiency. Increased dosage of corticosteroids may be indicated before, during and after stressful situations.<br />\r\n<br />\r\n<strong>Hepatotoxicity</strong>: Can be severe and fatal. Monitor liver function and modify, interrupt, or discontinue Abiraterone dosing as recommended.<br />\r\n<br />\r\n<strong>Increased fractures and mortality in combination with radium Ra 223 dichloride</strong>: Use of Abiraterone plus prednisone/prednisolone in combination with radium Ra 223 dichloride is not recommended.<br />\r\n<br />\r\n<strong>Embryo-Fetal Toxicity</strong>: Abiraterone can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception.</p>', '<p>Human experience of overdose with Abiraterone is limited. There is no specific antidote. In the event of an overdose, stop Abiraterone, undertake general supportive measures, including monitoring for arrhythmias and cardiac failure and assess liver function.</p>', '<p>Cytotoxic Chemotherapy</p>', '<p>Abiraterone Acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with</p>\r\n\r\n<ul>\r\n	<li>Metastatic castration-resistant prostate cancer (CRPC)</li>\r\n	<li>Metastatic high-risk castration-sensitive prostate cancer (CSPC)</li>\r\n</ul>', NULL, '2022-02-11 05:16:05', '2022-02-20 02:25:27'),
(29, 29, '<p>Acemetacin is indicated in</p>\r\n\r\n<ul>\r\n	<li>Pain &amp; inflammation associated with musculoskeletal &amp; joint disorders. Such as: Rheumatoid arthritis, Osteoarthritis, Low back pain.</li>\r\n	<li>Pain after an operation.</li>\r\n</ul>', '<p>Acemetacin is a non-steroidal anti-inflammatory drug. It is also known as an NSAID. It works by blocking a substance in the body called cyclooxygenase (also known as COX) which is involved in the production of certain irritant chemicals in response to injury or rheumatic disease. By blocking the action of COX, Acemetacin reduces the symptoms of pain and inflammation.</p>', '<p>The recommended starting dose is 120mg/day in divided doses, increasing to 180mg/day in divided doses, depending on patient response. For the treatment of elderly patients, adjustment of dosage is not normally required. However, NSAIDs should be used with particular care in older patients who may be more prone to adverse reactions. Acemetacin should be taken with food, milk or an antacid to reduce the possibility of gastro-intestinal disturbance.</p>', '<p>Acemetacin reduces the antihypertensive effect of b-blockers. Increase risk of convulsion when used with quinolone. Concurrent use with aspirin, NSAIDs or corticosteroids may increase risk of GI bleeding. Increased risk of methotrexate toxicity when used together.</p>', '<p>Acemetacin is contraindicated to known hypersensitivity to Acemetacin or Indomethacin; peptic ulcer; safety in children is not established.</p>', '<p>Common side effects include anorexia, nausea, vomiting, diarrhoea and constipation, peptic ulceration, headache, dizziness &amp; vertigo. Rarely confusion, depressed mood, oedema, chest pain, blood urea elevation are found.</p>', '<p>The safety of this medicine in human pregnancy and lactation has not been established. Some animal reproduction studies showed some toxic/ teratogenic effects on fetus. Therefore, use of this drug during pregnancy and lactation period is not recommended.</p>', '<p>Caution should be taken in elderly people, history of disorders affecting the stomach or intestines, inflammatory bowel disease such as Crohn&#39;s disease or ulcerative colitis, kidney disease, liver disease, heart failure.</p>', NULL, '<p>Non-steroidal Anti-inflammatory Drugs (NSAIDs)</p>', '<p>Acemetacin is indicated in</p>\r\n\r\n<ul>\r\n	<li>Pain &amp; inflammation associated with musculoskeletal &amp; joint disorders. Such as: Rheumatoid arthritis, Osteoarthritis, Low back pain.</li>\r\n	<li>Pain after an operation.</li>\r\n</ul>', NULL, '2022-02-11 05:18:28', '2022-03-24 22:31:59'),
(30, 30, '<p>This solution is used for haemodialysis.</p>\r\n\r\n<p><strong>Composition</strong></p>\r\n\r\n<p>Calcium Chloride Dihydrate 0.5 %<br />\r\nMagnessium Chloride 0.4 %<br />\r\nPotassium Chloride 0.5 %<br />\r\nSodium Acetate 18.1 %<br />\r\nSodium Chloride 19.8 %</p>', '<p><strong>Calcium chloride</strong>&nbsp;is used to prevent or treat negative calcium balance. It also regulates action potential excitation threshold to facilitate nerve and muscle performance.<br />\r\n<br />\r\n<strong>Potassium chloride</strong>&nbsp;is a major cation of the intracellular fluid. It plays an active role in the conduction of nerve impulses in the heart, brain and skeletal muscle; contraction of cardiac skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism and gastric secretion.<br />\r\n<br />\r\n<strong>Magnessium Chloride</strong>&nbsp;acts as cofactor in numerous enzymatic reactions involving protein synthesis and carbohydrate metabolism; depresses CNS, blocks peripheral neuromuscular transmission, produces anticonvulsant effects.<br />\r\n<br />\r\n<strong>Sodium chloride</strong>&nbsp;is the major extracellular cation. It is important in electrolyte and fluid balance, osmotic pressure control and water distribution as it restores sodium ions. It is used as a source of electrolytes and water for hydration, treatment of metabolic acidosis, priming solution in haemodialysis and treatment of hyperosmolar diabetes. It is also used as diluents for infusion of compatible drug additives.</p>', '<p>Recommended dose: 5 liters concentrate per dialysis or as required.</p>', '<p>There are no known drug interactions and none well documented.</p>', '<p>Known hypersensitivity to any of the ingredients of this preparation.</p>', '<p>Fluid and electrolyte imbalance, hypovolemia, hypotension or muscle cramping may occur.</p>', '<p>Pregnancy Category-not Classified. FDA has not yet classified the drug into a specified pregnancy category.</p>', '<p>It is used for haemodialysis purposes only.</p>', NULL, '<p>Haemodialysis solutions</p>', NULL, NULL, '2022-02-11 05:21:39', '2022-02-11 05:21:39'),
(31, 31, '<p>Acetazolamide is indicated in open angle glaucoma, secondary glaucoma and as an adjuvant in the treatment of edema and epilepsy.</p>', '<p>Acetazolamide is a carbonic anhydrase inhibitor. This enzyme catalyzes the reversible reaction involving the hydration of carbon-di-oxide and the dehydration of carbonic acid. In the eye, this inhibitory action of Acetazolamide decreases the secretion of aqueous humor and results in a drop in intraocular pressure, a reaction considered desirable in case of glaucoma. Inhibition of carbonic anhydrase in the central nervous system appears to retard abnormal paroxysmal and excessive discharge from central nervous system neurons. So, Acetazolamide is also used as an adjuvant in the treatment of epilepsy.</p>', '<p><strong>Adults</strong>&nbsp;: Initially 250 mg (1 tablet) 4 times daily. Dose should be adjusted later with individual need.<br />\r\n<br />\r\n<strong>Children</strong>&nbsp;: &frac12; to 2 tablets in divided doses.<br />\r\n<br />\r\n<strong>In intraocular pressure</strong>: 1 tablet 6 hourly. In acute condition, dose should be started with 2 tablets followed by 1 tablet 6 hourly or as directed by the physician</p>', '<p>Acetazolamide is contraindicated in cases of marked kidney and liver diseases or dysfunction, in situations in which sodium and or potassium blood serum levels decreased. Acetazolamide is also contraindicated in patients with chronic noncongestive angle closure glaucoma.</p>', NULL, '<p>Common side effects are headache, drowsiness, dizziness, fatigue, anorexia, polyurea, insomnia, gastrointestinal upset.</p>', '<p>There are no adequate and well controlled studies in pregnant women and neonates. So, Acetazolamide should be used with care in those physiological conditions.</p>', NULL, NULL, '<p>Carbonic anhydrase inhibitor</p>', '<p>Acetazolamide is indicated in open angle glaucoma, secondary glaucoma and as an adjuvant in the treatment of edema and epilepsy.</p>', NULL, '2022-02-11 05:24:05', '2022-02-20 02:26:19'),
(32, 32, '<p>Atorvastatin is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in following diseases when response to diet and other non-pharmacological measures is inadequate.</p>\r\n\r\n<ul>\r\n	<li>To reduce total cholesterol and LDL cholesterol in patients with heterozygous and homozygous familial hypercholesterolaemia.</li>\r\n	<li>To reduce elevated cholesterol and triglycerides in patient with mixed dyslipidemia (Fredrickson Type Ia and Ib).</li>\r\n	<li>For the treatment of patients with elevated serum triglyceride levels in hypertriglyceridaemia (Fredrickson Type IV).</li>\r\n	<li>For the treatment of patients with dysbetalipoproteinaemia (Fredrickson Type III).</li>\r\n	<li>To reduce cardiac ischaemic events in patients with asymptomatic or mild to moderate symptomatic coronary artery disease with elevated LDL-cholesterol level.</li>\r\n	<li>To reduce total and LDL-cholesterol concentrations patients with hypercholesterolemia associated with or exacerbated by diabetes mellitus or renal transplantation.</li>\r\n</ul>', '<p>Atorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.</p>', '<p>Primary hypercholesterolaemia and combined hyperlipidaemia-</p>\r\n\r\n<ul>\r\n	<li><strong>Adults</strong>: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily.</li>\r\n	<li><strong>Child (10-18 years)</strong>: Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily.</li>\r\n</ul>\r\n\r\n<p>Familial hypercholesterolaemia-</p>\r\n\r\n<ul>\r\n	<li><strong>Adults</strong>: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia).</li>\r\n	<li><strong>Child (10-18 years)</strong>: Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily.</li>\r\n</ul>\r\n\r\n<p>Prevention of cardiovascular events-</p>\r\n\r\n<ul>\r\n	<li><strong>Adults</strong>: Initially 10 mg once daily adjusted according to response.</li>\r\n</ul>', '<p>The risk of myopathy during treatment with Atorvastatin is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives or hypoglycemic agents. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.</p>', '<p>Atorvastatin should not be used in patient with hypersensitivity to any component of this medication. Atorvastatin is contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. It is also contraindicated in patient with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors.</p>', '<p>Atorvastatin is generally well-tolerated. The most frequent side effects related to Atorvastatin are constipation, flatulence, dyspepsia, abdominal pain. Other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia.</p>', '<p><strong>Pregnancy</strong>: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnant<br />\r\n<br />\r\n<strong>Lactation</strong>: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.</p>', '<p>Liver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.</p>', '<p>Specific treatment is not available for atorvastatin overdose. The patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.</p>', '<p>Anti-anginal &amp; Anti-ischaemic Drugs, Statins</p>', '<p>Keep in a dry place away from light and heat. Keep out of the reach of children.</p>', '<p><strong>Hepatic impairment</strong>: Atorvastatin should be used with caution in patients with hepatic impairment.<br />\r\n<br />\r\n<strong>Pediatric use</strong>: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. Atorvastatin is not indicated in the treatment of patients below the age of 10 years.</p>', '2022-02-12 00:40:11', '2022-02-12 00:40:11'),
(33, 33, '<p><strong>Atenolol is indicated-</strong></p>\r\n\r\n<ul>\r\n	<li>In the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.</li>\r\n	<li>For the long-term management of patients with angina pectoris.</li>\r\n	<li>In the management of hemodynamically stable patients with defnite or suspected acute myocardial infarction to reduce cardiovascular mortality.</li>\r\n</ul>', '<p>The synthesis of atenolol resulted from attempts to produce a &beta;-adrenoceptor antagonist that would competitively block &beta;1 (cardiac) receptors but have no effect on &beta;2-receptors. It is classified as a &beta;1 selective (cardioselective) &beta;-adrenergic receptor antagonist with no membranestability activity and no partial agonist activity. It is markedly the most hydrophilic of the currently available &beta;- blockers and thus penetrates the lipid of cell membranes poorly</p>', '<p><strong>Hypertension</strong>: The initial dose of Atenolol is 50 mg given as one tablet a day either alone or added to diuretic therapy. The full effect of this dose will usually be seen within one to two weeks. If an optimal response is not achieved, the dosage should be increased to Atenolol 100 mg given as one tablet a day. Increasing the dosage beyond 100 mg a day is unlikely to produce any further benefit.<br />\r\n<br />\r\n<strong>Angina Pectoris</strong>: The initial dose of Atenolol is 50 mg given as one tablet a day. If an optimal response is not achieved within one week, the dosage should be increased to Atenolol 100 mg given as one tablet a day. Some patients may require a dosage of 200 mg once a day for optimal effect. Twenty-four hour control with once daily dosing is achieved by giving doses larger than necessary to achieve an immediate maximum effect. The maximum early effect on exercise tolerance occurs with doses of 50 to 100 mg, but at these doses the effect at 24 hours is attenuated, averaging about 50% to 75% of that observed with once a day oral doses of 200 mg.<br />\r\n<br />\r\n<strong>Acute Myocardial Infarction</strong>: In patients with definite or suspected acute myocardial infarction, treatment with Atenolol I.V. Injection should be initiated as soon as possible after the patient&#39;s arrival in the hospital and after eligibility is established. Treatment should begin with the intravenous administration of 5 mg Atenolol over 5 minutes followed by another 5 mg intravenous injection 10 minutes later. In patients who tolerate the full intravenous dose (10 mg), Atenolol Tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. Thereafter, Atenolol can be given orally either 100 mg once daily or 50 mg twice a day for a further 6-9 days or until discharge from the hospital. If bradycardia or hypotension requiring treatment or any other untoward effects occur, Atenolol should be discontinued.</p>', '<ul>\r\n	<li>Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with Atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.</li>\r\n	<li>Calcium channel blockers may also have an additive effect when given with Atenolol.</li>\r\n	<li>Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers.</li>\r\n	<li>Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers.</li>\r\n	<li>Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.</li>\r\n	<li>Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.</li>\r\n	<li>While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.</li>\r\n	<li>Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.</li>\r\n</ul>', '<p>Atenolol is contraindicated in-</p>\r\n\r\n<ul>\r\n	<li>Sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure.</li>\r\n	<li>Those patients with a history of hypersensitivity to the atenolol or any of the drug product&rsquo;s components.</li>\r\n</ul>', '<p>In a series of investigations in the treatment of acute myocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker. In addition, a variety of adverse efects has been reported with other beta-adrenergic blocking agents, and may be considered potential adverse efects of Atenolol.</p>\r\n\r\n<ul>\r\n	<li><strong>Hematologic</strong>: Agranulocytosis.</li>\r\n	<li><strong>Allergic</strong>: Fever, combined with aching and sore throat, laryngospasm, and respiratory distress.</li>\r\n	<li><strong>Central Nervous System</strong>: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short term memory loss; emotional lability with slightly clouded sensorium; and, decreased performance on neuropsychometrics.</li>\r\n	<li><strong>Gastrointestinal</strong>: Mesenteric arterial thrombosis, ischemic colitis.</li>\r\n	<li><strong>Miscellaneous</strong>: There have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenergic blocking drugs. Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy.</li>\r\n	<li><strong>Other</strong>: Erythematous rash</li>\r\n</ul>', '<p>Pregnancy Category D. Caution should be exercised when Atenolol is administered to a nursing woman. Clinically significant bradycardia has been reported in breast-fed infants. Premature infants, or infants with impaired renal function, may be more likely to develop adverse effects.</p>', '<p><strong>General: </strong>Patients already on a beta blocker must be evaluated carefully before Atenolol is administered. Initial and subsequent Atenolol dosages can be adjusted downward depending on clinical observations including pulse and blood pressure. Atenolol may aggravate peripheral arterial circulatory disorders.<br />\r\n<br />\r\n<strong>Impaired Renal Function:</strong> The drug should be used with caution in patients with impaired renal function.<br />\r\n<br />\r\n<strong>Geriatric Use:</strong></p>\r\n\r\n<ul>\r\n	<li>Hypertension and Angina Pectoris: Due to Coronary Atherosclerosis: Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</li>\r\n	<li>Acute Myocardial Infarction: Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Evaluation of patients with hypertension or myocardial infarction should always include assessment of renal function.</li>\r\n</ul>', '<p>Overdosage with Atenolol has been reported with patients surviving acute doses as high as 5 g. One death was reported in a man who may have taken as much as 10 g acutely. The predominant symptoms reported following Atenolol overdose are lethargy, disorder of respiratory drive, wheezing, sinus pause and bradycardia. Additionally, common efects associated with overdosage of any beta-adrenergic blocking agent and which might also be expected in Atenolol overdose are congestive heart failure, hypotension, bronchospasm and/or hypoglycemia. Treatment of overdose should be directed to the removal of any unabsorbed drug by induced emesis, gastric lavage, or administration of activated charcoal. Atenolol can be removed from the general circulation by hemodialysis. Based on the severity of symptoms, management may require intensive support care and facilities for applying cardiac and respiratory support.</p>', '<p>Beta-adrenoceptor blocking drugs, Beta-blockers</p>', '<p>Do not use later than the date of expiry. Keep all medicines out of the reach of children. To be dispensed only on the prescription of a registered physician.</p>', '<p>Elderly Patients or Patients with Renal Impairment: Atenolol is excreted by the kidneys; consequently dosage should be adjusted in cases of severe impairment of renal function. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, refecting greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The following maximum oral dosages are recommended for elderly, renal impaired patients and for patients with renal impairment due to other causes:</p>\r\n\r\n<ul>\r\n	<li>Creatinine clearance 15-35 ml/min/1.73 m2: Maximum dosage 50 mg daily</li>\r\n	<li>Creatinine clearance &lt;15 mL/min/1.73 m2: Maximum dosage 25 mg daily</li>\r\n</ul>\r\n\r\n<p>Some renal impaired or elderly patients being treated for hypertension may require a lower starting dose of Atenolol: 25 mg given as one tablet a day. Patients on hemodialysis should be given 25 mg or 50 mg after each dialysis; this should be done under hospital supervision as marked falls in blood pressure can occur.</p>', '2022-02-12 00:43:46', '2022-02-12 00:43:46'),
(34, 34, '<p>Acetylcysteine is indicated as an adjuvant treatment in certain clinical condition characterized by the presence of thick and viscous mucoid or mucopurulent secretions such as: Chronic bronchopulmonary diseases (chronic obstructive pulmonary disease, emphysema with bronchitis, chronic asthmatic bronchitis, bronchiectasis); Acute bronchopulmonary diseases (asthma with bronchial mucus plugging, bronchitis, bronchopneumonia, tracheobronchitis, bronchiolitis, pulmonary complications of cystic fibrosis, pulmonary complications associated with surgery).</p>', '<p>Acetylcysteine is a mucolytic agent that reduces the viscosity of secretions probably by the splitting of disulphide bonds in mucoproteins. Moreover it gives antisecretory effect. These results in clearing of respiratory ducts and facilitate breathing. Acetylcysteine also has anti-oxidant properties by reacting with free radicals and also by serving as a precursor to glutathione, which is an important intra and extra-cellular antioxidant. By providing anti-oxidant action, it neutralizes exogenous and endogenous oxidants, which in fact act as pathogens in respiratory inflammations.</p>', '<p><strong>Effervescent tablet or Dispersible tablet</strong>: Adults and children above 6 years: One effervescent tablet of Acetylcysteine 600 mg a day (preferably in the evening). The duration of treatment should be 5 to 10 days in the acute treatment, whereas it may be continued in the chronic states for several months, according to the advice of the physician. Dissolve the tablets in a glass containing a small quantity of water, mixing it, if necessary, with a spoon. A palatable solution is thus obtained, which can be drunk directly from the glass.<br />\r\n<br />\r\n<strong>Effervescent Granules</strong>:</p>\r\n\r\n<ul>\r\n	<li>Adults and children above 6 years: 1 sachet Acetylcysteine 200 mg or 2 sachets Acetylcysteine 100 mg, 2-3 times a day.</li>\r\n	<li>Children (2-6 years of age): 1 sachet Acetylcysteine 100 mg from 2 to 4 times a day, according to the age.</li>\r\n</ul>\r\n\r\n<p>The duration of treatment should be 5 to 10 days in the acute treatment, whereas it may be continued in the chronic states for several months, according to the advice of the physician.<br />\r\n<br />\r\nDissolve the contents of the sachets in a glass containing a small quantity of water; mixing it, if necessary, with a spoon. A palatable solution is thus obtained, which can be drunk directly from the glass.<br />\r\n<br />\r\n<strong>Nebuliser Solution</strong>: The 20% solution may be diluted to a lesser concentration with either Sodium Chloride for injection, Sodium Chloride for inhalation, sterile water for injection, or sterile water for inhalation.</p>\r\n\r\n<ul>\r\n	<li>Adult: 5-10 ml of 10% or 20% solution by Nebuliser every 6-8 hr PRN.</li>\r\n	<li>Children: 1-11 months: 1-2 ml of 20% or 2-4 ml of 10% solution by Nebuliser every 6-8 hr PRN.</li>\r\n	<li>12 months-11 years: 3-5 ml of 20% or 6-10 ml of 10% solution by Nebuliser every 6-8 hr PRN.</li>\r\n	<li>Below 12 years: 5-10 ml of 10/20% solution by Nebuliser every 6-8 hr PRN.</li>\r\n</ul>\r\n\r\n<p><strong>** Diagnostic Bronchograms</strong>: 1-2 ml of 20% or 2-4 ml of 10% solution 2-3 times by Nebulisation or by instillation intratracheally prior to procedure.<br />\r\n<br />\r\n<strong>** Nebulisation tent or croupette</strong>: This form of administration requires very large volumes of the solution, occasionally as much as 300 ml during a single treatment period. If a tent or croupette must be used, the recommended dose is the volume of acetylcysteine (using 20%) that will maintain a very heavy mist in the tent or croupette for the desired period. Administration for intermittent or continuous prolonged periods, including overnight, may be desirable.<br />\r\n<br />\r\n<strong>** Direct Instillation</strong>: When used by direct instillation, 1-2 ml of a 20% solution may be given as often as every hour. When used for the routine nursing care of patients with tracheostomy, 1-2 ml of a 20% solution may be given every 1-4 hours by instillation into the tracheostomy.</p>', '<p>The thiol group of Acetylcysteine can reduce the efficacy of certain antibiotics such as ampicillin, tetracycline, macrolides, cephalosporins, aminoglycosides and amphotericin. Concomitant use of Acetylcysteine and amoxicillin will increase the level of the antibiotic in tissues. It is, therefore, advisable to use the two medicines 2 hours apart from each other. Acetylcysteine can increase the inhibitory effect of thrombocyte aggregation and vasodialation by nitroglycerine.</p>', '<p>Known hypersensitivity to Acetylcysteine. Acetylcysteine contains aspartame, thus it is contraindicated in patients suffering from phenylketonuria.</p>', '<p>Like all medicines, Acetylcysteine can cause side effects, although not everybody gets them. In very rare cases, severe immune reactions may occur such as anaphylactic shock and severe skin reaction. In rare cases the oral administration can be followed by shortness of breath, upset stomach and bronchospasm. The most frequent side effects are headache, increased heart rate, stomatitis, pruritus, urticaria, nausea, vomiting, abdominal pain, fever, decrease in the blood pressure, diarrhoea and noises in the ears.</p>', '<p>In case of pregnancy &amp; lactation the medicine should be taken consulting physician or pharmacist.</p>', '<p>Patients suffering from bronchial asthma must be strictly controlled during the therapy; should bronchospasm occur, the treatment must immediately be suspended. Caution should be taken in patients suffering from or with a history of peptic ulcer. As Viscotin contains sodium (156.9mg per dose) this has to be taken into consideration by patients on a controlled sodium diet. The possible presence of a sulphureous odor does not indicate an alteration of the product but is a characteristic of the active ingredient contained in this preparation. It is preferable not to mix other drugs with the Viscotin solution.</p>', '<p>Overdose of Acetylcysteine may cause nausea, vomiting or diarrhoea.</p>', '<p>Antidote preparations, Cough expectorants &amp; mucolytics</p>', '<p>Store in a cool and dry place, protected from light.</p>', NULL, '2022-02-14 04:06:34', '2022-02-14 04:06:34');
INSERT INTO `generic_details` (`id`, `generic_id`, `indications`, `pharmacology`, `dosage_and_administration`, `interaction`, `contraindications`, `side_effects`, `pregnancy_and_lactation`, `precautions_and_warnings`, `overdose_effects`, `therapeutic_class`, `storage_conditions`, `use_in_special_populations`, `created_at`, `updated_at`) VALUES
(35, 35, '<p>Acitretin is indicated in severe extensive psoriasis which is resistant to other forms of therapy, palmo-plantar pustular psoriasis, severe congenital ichthyosis, severe Darier&rsquo;s disease (keratosis follicularis).</p>', '<p>Acitretin is a retinoid, an aromatic analogue of vitamin A. The mechanism of action of acitretin is unknown, however, evidence exists for a wide range of actions at various cellular and subcellular levels. These include regulation of RNA/DNA synthesis, modulation of factors which influence epidermal proliferation, modification of glycoprotein synthesis and modulation of the immune response. Whatever the exact mechanism of action, the most prominent effect of acitretin is a modulation of cellular differentiation in the epidermis which re-establishes a more normal pattern of cell growth.</p>', '<p><strong>Adult and elderly</strong>: Initial daily dose should be 25 mg or 30 mg for 2 to 4 weeks. After this initial treatment period the involved areas of the skin should show a marked response and/or side-effects should be apparent. In general, a daily dosage of 25-50 mg taken for a further 6 to 8 weeks to achieve optimal therapeutic results. However, it may be necessary in some cases to increase the dose up to a maximum of 75 mg/day.<br />\r\n<br />\r\nIn patients with Darier&rsquo;s disease a starting dose of 10 mg may be appropriate. The dose should be increased cautiously as isomorphic reactions may occur. Patients with severe congenital ichthyosis and severe Darier&rsquo;s disease may require therapy beyond 3 months. The lowest effective dosage, not exceeding 50mg/day, should be given. Continuous use beyond 6 months is contra-indicated as only limited clinical data are available on patients treated beyond this length of time.<br />\r\n<br />\r\n<strong>Children</strong>: The daily dosage is about 0.5mg/kg. Higher doses (up to 1mg/kg daily) may be necessary in some cases for limited periods, but only up to a maximum of 35 mg/day.</p>', '<p>Existing data suggests that concurrent intake of acitretin with ethanol led to the formation of etretinate. Concomitant administration of methotrexate, tetracyclines or vitamin A and other retinoids with acitretin is contraindicated. In concurrent treatment with phenytoin, it must be remembered that Acitretin partially reduces the protein binding of phenytoin. Low dose progesterone-only products (minipills) may be an inadequate method of contraception during acitretin therapy, Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.</p>', '<p>Acitretin is highly teratogenic and must not be used by women who are pregnant. The same applies to women of childbearing potential unless strict contraception is practiced 4 weeks before, during and for 2 years after treatment. The use of Acitretin is contra-indicated in women who are breast feeding.Acitretin is contraindicated in patients with severe hepatic or renal impairment and in patients with chronic abnormally elevated blood lipid values. Concomitant administration of Acitretin with other retinoids or Vitamin A is contra-indicated due to the risk of hypervitaminosis A. Acitretin is contra-indicated in cases of hypersensitivity to the preparation (acitretin or excipients) or to other retinoids. Patients with rare glucose-galactosemalabsorption should not take this medicine.</p>', '<p>Adverse effects are seen in most patients receiving acitretin. Most of the clinical side-effects of Acitretin are dose-related and are usually well-tolerated at the recommended dosages. However, the toxic dose of Acitretin is close to the therapeutic dose and most patients experience some side-effects during theinitial period whilst dosage is being adjusted. The skin and mucous membranes are most commonly affected. An initial worsening of psoriasis symptoms issometimes seen at the beginning of the treatment period.</p>', '<p>Acitretin is contraindicated in pregnant women or nursing mother. It is highly teratogenic. Its use is contraindicated in women who might become pregnant during or within 2 years of the cessation of treatment.</p>', '<p>The risk of giving birth to a deformed child is exceptionally high if Acitretin is taken before or during pregnancy, no matter for how long or at what dosage. Women of childbearing potential must not receive blood from patients being treated with acitretin. Donation of blood by a patient being treated with acitretin is prohibited during and for two years after completion of treatment with acitretin. The effects of UV light are enhanced by retinoid therapy; therefore patients should avoid excessive exposure to sunlight. Hepatic function should be checked before starting treatment with Acitretin, every 1-2 weeks for the first 2 months after commencement and then every 3 months during treatment. Serum cholesterol and serum triglycerides (fasting values) must be monitored before starting treatment, one month after the commencement and then every 3 months during treatment, especially in high-risk patients and during long-term treatment. Retinoids can alter glucose tolerance, blood sugar levels should therefore be checked. Patients should be warned of the possibility of alopecia. Decreased night vision has been reported with acitretin therapy. Patients with severe headache, nausea, vomiting, and visual disturbances should discontinue acitretin immediately.</p>', '<p>Manifestations of acute Vitamin A toxicity include severe headache, vertigo, nausea or vomiting, drowsiness, irritability and pruritus. Signs and symptoms of accidental or deliberate overdosage with Acitretin would probably be similar. Specific treatment is unnecessary because of the low acute toxicity of the preparation.</p>', '<p>Oral Retinoid preparations</p>', '<p>Store in a cool &amp; dry place, protected from light. Do not store above 25&deg;C.</p>', NULL, '2022-02-14 06:20:27', '2022-03-07 06:13:16'),
(36, 36, '<p>Diarrhoea &amp; poisoning due to foods, heavy meals &amp; drugs. Flatulence due to diet &amp; other factors.</p>\r\n\r\n<p>Activated charcoal, also known as activated carbon, is a medication used to treat poisonings that occurred by mouth. To be effective it must be used within a short time of the poisoning occurring, typically an hour. It does not work for poisonings by cyanide, corrosive agents, iron, lithium, alcohols, or malathion. It may be taken by mouth or given by a nasogastric tube. Other uses include inside hemoperfusion machines.</p>\r\n\r\n<p>&nbsp;</p>', '<p>Active charcoal binds the poison and prevents its absorption by the gastrointestinal tract. In cases of suspected poisoning, medical personnel administer activated carbon on the scene or at a hospital&#39;s emergency department. In rare situations, it may also be used in a hemoperfusion system to remove toxins from the blood stream of poisoned patients. Activated carbon has become the treatment of choice for many poisonings, and other decontamination methods such as ipecac-induced emesis or stomach pumping are now used rarely. It interrupts the enterohepatic and enteroenteric circulation of some drugs/toxins and their metabolites.</p>', '<p>Diarrhoea:</p>\r\n\r\n<ul>\r\n	<li><strong>Adult</strong>: 2-4 tab tds-qds.</li>\r\n	<li><strong>Children</strong>: &frac12; adult dose.</li>\r\n</ul>\r\n\r\n<p>Poisoning:</p>\r\n\r\n<ul>\r\n	<li><strong>Adult:</strong>&nbsp;2-4 tab/kg body weight</li>\r\n	<li><strong>children</strong>: 3-4 tab/kg body weight</li>\r\n</ul>\r\n\r\n<p>Flatulence:</p>\r\n\r\n<ul>\r\n	<li><strong>Adult</strong>: Disintegrate 1-2 tab. Repeat every 2 hr.</li>\r\n</ul>', '<p>Ultracarbon should not be administered together with other drugs because their efficacy can be reduced.</p>', '<p>Febrile diarrhoea. Medicinal charcoal should not be taken in the case of intoxication with corrosive substances (strong acids and alkalis) as this would complicate diagnostic measures eg, oesophagoscopy and gastroscopy.</p>', '<p>As most undesirable effects are based on post-marketing spontaneous reporting, precise frequency estimation is not possible. No adverse reactions to Ultracarbon are known to occur if taken in the recommended dosage to treat the diarrhoea. After very high doses as those taken in intoxications, constipation and intestinal obstruction (mechanical ileus) may occur in individual cases; this can be prevented by administering saline laxatives (eg, sodium sulfate). As medicinal charcoal is excreted in unchanged form, the stools turn black (discoloured faeces) after intake of Ultracarbon tablets.</p>', '<p>No data found</p>', '<p>Several poisons and drugs require different or additional measures. Medicinal charcoal is not effective in intoxications with organic and inorganic salts as well as solvents eg, for instance, lithium, thallium, cyanide, iron salts, methanol, ethanol and ethylene glycol. Different measures are in these cases indicated to eliminate the poison (eg, gastric lavage).&nbsp;<br />\r\n<br />\r\nIn many intoxications, a specific antidote must be administered additionally to medicinal charcoal (eg, acetylcysteine in paracetamol poisoning).<br />\r\n<br />\r\nTo avoid aspiration in unconscious patients, a physician should administer the suspension of Ultracarbon tablets in water by gastric tube.<br />\r\n<br />\r\nIn patients undergoing multiple dose, activated charcoal therapy after intoxication, gastrointestinal sounds should be monitored frequently to assess peristaltic action.<br />\r\n<br />\r\nUltracarbon should not be used in cases of poisoning with pesticides.</p>', '<p>Activated charcoal is well tolerated and due to its lack of toxicity, overdose requiring treatment is unlikely. Should symptoms of overdose like constipation and intestinal obstruction (mechanical ileus) occur, a saline laxative may be administered to enhance the elimination of Ultracarbon tablets.</p>', '<p>Anti-diarrhoeal, Antidote preparations</p>', '<p>Do not store above 30&deg;C.</p>', NULL, '2022-02-14 06:20:58', '2022-02-20 02:38:23'),
(37, 37, '<p>Acyclovir intravenous infusion is indicated for the treatment of-</p>\r\n\r\n<ul>\r\n	<li>Acute clinical manifestations of Herpes simplex virus in immunocompromised patients</li>\r\n	<li>Severe primary or non-primary genital herpes in immune competent patients</li>\r\n	<li>Varicella zoster virus infection in immunocompromised patients</li>\r\n	<li>Herpes zoster (shingles) in immune competent patients who show very severe acute local or systemic manifestations of the disease</li>\r\n	<li>Herpes simplex encephalitis</li>\r\n</ul>', '<p>Acyclovir exerts its antiviral e&shy;ects on Herpes simplex virus and Varicella zoster virus by interfering with DNA synthesis and inhibiting viral replication. In cells infected with Herpes virus, the antiviral activity of Acyclovir appears to depend principally on the intracellular conversion of the drug to Acyclovir Triphosphate. Acyclovir is converted to Acyclovir Monophosphate principally via virus coded thymidine kinase, the monophosphate is phosphorylated to diphosphate via cellular guanylate kinase and then via other cellular enzymes to the Triphosphate, which is the pharmacologically active form of the drug.</p>', '<ul>\r\n	<li>Herpes simplex infection: For normal or immunocompromised immune status: 5 mg/kg every 8 hours</li>\r\n	<li>Very severe Herpes zoster infection (shingles): For normal immune status: 5 mg/kg every 8 hours</li>\r\n	<li>Varicella zoster infection: For immunocompromised immune status: 10 mg/kg every 8 hours</li>\r\n	<li>Herpes simplex encephalitis: For normal or immunocompromised immune status: 10 mg/kg every 8 hours</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>Each dose should be administered by slow intravenous infusion over a one-hour period.</p>\r\n\r\n<p>It is recommended that Acyclovir IV Injection for Intravenous Infusion should be administered for five to seven days in the treatment of most infections and for at least ten days in the treatment of Herpes simplex encephalitis.<br />\r\n<br />\r\nAcyclovir IV Injection after reconstitution may be injected directly into a vein over one hour by a controlled-rate infusion pump or be further diluted for administration by infusion. For intravenous infusion each vial of Acyclovir IV Injection should be reconstituted and then, wholly or in part according to the dosage required, added to and mixed with at least 50 mL-100 ml infusion solution. A maximum of 250 mg &amp; 500 mg of Acyclovir may be added to 50 ml &amp; 100 ml infusion solution respectively. After addition of Acyclovir IV Injection to an infusion solution the mixture should be shaken to ensure thorough mixing. Acyclovir IV Injection when diluted in accordance with the above schedule will give an Acyclovir concentration not greater than 0.5% w/v.<br />\r\n<br />\r\nAcyclovir IV Injection is known to be compatible with the following infusion fluids and stable for up to 12 hours at room temperature (below 25&deg;C) when diluted to a concentration not greater than 0.5% w/v Acyclovir.</p>\r\n\r\n<ul>\r\n	<li>Sodium Chloride Intravenous Infusion BP (0.45% and 0.9% w/v)</li>\r\n	<li>Sodium Chloride (0.18% w/v) and Glucose (4% w/v) Intravenous Infusion</li>\r\n	<li>Sodium Chloride (0.45% w/v) and Glucose (2.5% w/v) Intravenous Infusion</li>\r\n	<li>Compound Sodium Lactate Intravenous Infusion BP (Hartmann&#39;s Solution)</li>\r\n</ul>\r\n\r\n<p>Acyclovir IV Injection for Intravenous Infusion contains no preservative. Reconstitution and dilution should therefore be carried out immediately before use and any unused solution should be discarded. The solution should not be refrigerated.</p>', '<p>Co-administration of probenecid with Acyclovir has been shown to increase the mean Acyclovir half-life and the area under the concentration time curve. Urinary excretion and renal clearance correspondingly reduced. In patients over 60 years of age concurrent use of diuretics increases plasma levels of Acyclovir very significantly.</p>', '<p>Acyclovir IV Injection is contraindicated in patients known to be hypersensitive to Acyclovir or Valacyclovir.</p>', '<p>Some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. Local inflammatory reactions may occur if Acyclovir IV Infusion is inadvertently infused into extracellular tissues.</p>', '<p>Pregnancy category B. There have been no adequate and well controlled studies concerning the safety of Acyclovir in pregnant women. It should not be used during pregnancy unless the benefits to the patient clearly outweigh the potential risks to the fetus. Acyclovir should only be administered to nursing mothers if the benefits to the mother outweigh the potential risks to the baby. There is no experience of the effect of Acyclovir on human fertility.</p>', '<p>Acyclovir IV injection is intended for intravenous infusion only and should not be used through any other route. Reconstituted Acyclovir IV Infusion has a pH of approximately 11.0 and should not be administered by mouth. Acyclovir IV injection as infusion must be given over a period of at least one hour in order to avoid renal tubular damage. It should not be administered as a bolus injection. Acyclovir IV infusion must be accompanied by adequate hydration. Since maximum urine concentration occurs within the first few hours following infusion, particular attention should be given to establish sufficient urine ‑ow during that period. Concomitant use of other nephrotoxic drugs, pre-existing renal disease and dehydration increase the risk of further renal impairment by Acyclovir. As Acyclovir has been associated with reversible encephalopathic changes, it should be used with caution in patients with neurological abnormalities, significant hypoxia or serious renal, hepatic or electrolyte abnormalities.</p>', '<p>Overdosage of intravenous Acyclovir has resulted in elevations of serum creatinine, blood urea nitrogen and subsequent renal failure. Neurological effects including confusion, hallucinations, agitation, seizures and coma have been described in association with over dosage. Adequate hydration is essential to reduce the possibility of crystal formation in the urine. Hemodialysis significantly enhances the removal of Acyclovir from the blood and may, therefore, be considered an option in the management of overdose of Acyclovir.</p>', '<p>Herpes simplex &amp; Varicella-zoster virus infections</p>', '<p>Store at 15&deg;C to 25&deg;C. Protected from light and moisture. Keep the medicine out of the reach of children.</p>', '<p><strong>Pediatric use</strong>: The dose of Acyclovir IV injection in children aged 1-12 years should be calculated on the basis of body surface area. Children in this age group with Herpes simplex infections (except Herpes simplex encephalitis) or Varicella zoster infections should be given Acyclovir IV Infusion in doses of 250 mg/m2&nbsp;(equivalent to 5 mg/kg in adults). Immunocompromised children in this age group with Varicella zoster virus infection or with Herpes simplex encephalitis should be given Acyclovir IV Infusion in doses of 500 mg/m2&nbsp;(equivalent to 10 mg/kg in adults). Children with impaired renal function require an appropriately modified dose, according to the degree of impairment.<br />\r\n&nbsp;<br />\r\n<strong>Geriatric use</strong>: No data are available on this age group. However, as creatinine clearance is often low in the elderly, special attention should be given to dosage reduction.<br />\r\n<br />\r\n<strong>In patients with renal impairment</strong>:&nbsp;Acyclovir should be administered with caution since the drug is excreted through the kidneys. The following modifications in dosage are suggested:</p>\r\n\r\n<ul>\r\n	<li>CrCl: 25-50 ml/min: 5 or 10 mg/kg every 12 hours</li>\r\n	<li>CrCl: 10-25 ml/min: 5 or 10 mg/kg every 24 hours</li>\r\n	<li>CrCl: 0-10 ml/min: 2.5 or 5 mg/kg every 24 hours and after dialysis.</li>\r\n</ul>', '2022-02-14 06:21:49', '2022-02-20 02:43:42'),
(38, 38, '<p>Acyclovir is indicated for the treatment of Herpes simplex keratitis.</p>', '<p>Acyclovir is an antiviral agent which is highly active in vitro against Herpes simplex (HSV) types I and II and Varicella zoster viruses, but its toxicity to mammalian cells is low. Acyclovir is phosphorylated to the active compound Acyclovir triphosphate after entry into herpes infected cell. The &shy;first step in this process requires the presence of the viral-coded thymidine kinase. Acyclovir triphosphate acts as an inhibitor of and substrate for the herpes specifi&shy;ed DNA polymerase preventing further viral DNA synthesis without affecting normal cellular processes.</p>', '<p>The dosage for all age groups is the same. A 10 mm ribbon of the ointment should be placed inside the lower conjunctival sac &shy;five times a day at approximately four hourly intervals. Treatment should continue for at least 3 days after healing</p>', '<p>No clinically signi&shy;ficant interactions have been identi&shy;fied.</p>', '<p>Acyclovir is contraindicated in patients known to be hypersensitive to Acyclovir or Valacyclovir</p>', '<p>Very common: Superfi&shy;cial punctate keratopathy. This did not necessitate an early termination of therapy and healed without apparent sequelae. Common: Transient mild stinging of the eye occurring immediately following application, conjunctivitis. Rare: Blepharitis.</p>', '<p>Pregnancy category B. There are no adequate and well-controlled studies of Acyclovir in pregnant women. It is not known whether topically applied Acyclovir is excreted in breast milk.</p>', '<p>The recommended dosage, frequency of applications, and length of treatment should not be exceeded.</p>', '<p>No adverse effects would be expected if the entire contents of the tube containing 90 mg Acyclovir were ingested orally.</p>', '<p>Ophthalmic Anti-viral Products</p>', '<p>Acyclovir is indicated for the treatment of Herpes simplex keratitis.</p>', NULL, '2022-02-14 06:22:15', '2022-02-20 02:50:11'),
(39, 39, '<p>Aciclovir is indicated for-</p>\r\n\r\n<ul>\r\n	<li>The treatment of viral infections due to Herpes simplex virus (type I &amp; II) and Varicella zoster virus (herpes zoster &amp; chicken pox).</li>\r\n	<li>The treatment of Herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes and herpes labialis.</li>\r\n	<li>The prophylaxis of Herpes simplex infections in immunocompromised patients</li>\r\n</ul>', '<p>Aciclovir is a synthetic purine derivative. Aciclovir exerts its antiviral effect on Herpes simplex virus (HSV) and Varicella-zoster virus by interfering with DNA synthesis and inhibiting viral replication. In cells infected with herpes virus, the antiviral activity of Aciclovir appears to depend principally on the intracellular conversion of the drug to Aciclovir Triphosphate. Aciclovir is converted to Aciclovir Monophosphate principally via virus coded thymidine kinase; the monophosphate is phosphorylated to the diphosphate via cellular guanylate kinase and then via another cellular enzyme to the triphosphate, which is the pharmacologically active form of the drug. 15-30% of an oral dose of the drug is absorbed from Gl tract. Peak plasma concentrations usually occur within 1.5-2 hours after oral administration. It is widely distributed into body tissues and fluids including the brain, saliva, lungs, liver, muscle, spleen, uterus, vaginal mucosa and secretions, CSF, and herpetic vesicular fluid. Aciclovir is excreted through the kidney by the glomerular filtration &amp; tubular secretion.</p>', '<p>Treatment of initial herpes simplex: 200 mg 5 times daily usually for 5 days.<br />\r\n<br />\r\nFor immunocompromised patients:</p>\r\n\r\n<ul>\r\n	<li><strong>Adult</strong>: 400 mg 5 times daily for 5 days (longer if new lesions appear during treatment or if healing is incomplete; increase dose to 800 mg 5 times daily for genital herpes in immunocompromised) or as directed by the registered physician.</li>\r\n	<li><strong>Children under 2 years</strong>: Half of the adult dose.</li>\r\n	<li><strong>Children over 2 years</strong>: Adult dose.</li>\r\n</ul>\r\n\r\n<p>Prevention of recurrence of herpes simplex:</p>\r\n\r\n<ul>\r\n	<li><strong>Adult</strong>: 200 mg 4 times daily or 400 mg twice daily possibly reduced to 200 mg 2 or 3 times daily and interrupted every 6-12 months.</li>\r\n	<li><strong>Children under 2 years</strong>: Half of the adult dose.</li>\r\n	<li><strong>Children over 2 years</strong>: Adult dose.</li>\r\n</ul>\r\n\r\n<p>Prophylactic treatment of herpes simplex in the immunocompromised patients:</p>\r\n\r\n<ul>\r\n	<li><strong>Adult</strong>: 200 to 400 mg 4 times daily.</li>\r\n	<li><strong>Children under 2 years</strong>: Half of the adult dose.</li>\r\n	<li><strong>Children over 2 years</strong>: Adult dose.</li>\r\n</ul>\r\n\r\n<p>Treatment of vericella (chicken pox):</p>\r\n\r\n<ul>\r\n	<li><strong>Adult and children over 40 kg</strong>: 800 mg 4 times daily for 5 days.</li>\r\n	<li><strong>Children below 40 kg</strong>: 20 mg/kg (maximum 800 mg) per dose orally 4 times daily (80 mg/kg/day) for 5 days.</li>\r\n	<li><strong>Children 1 month-2 years</strong>: 200 mg 4 times daily for 5 days.</li>\r\n	<li><strong>Children 2-5 years</strong>:400 mg 4 times daily for 5 days.</li>\r\n	<li><strong>Children 6-12 years</strong>:800 mg 4 times daily for 5 days.</li>\r\n</ul>\r\n\r\n<p>Treatment of herpes zoster (Shingles): 800 mg 5 times daily for 7 days.<br />\r\n<br />\r\nTreatment of initial rectal (Proctitis) herpes infections: An oral Aciclovir dosage of 400 mg 5 times daily for 10 days or until clinical resolution occurs has been recommended.<br />\r\n<br />\r\nRenal Impairment: For patients with severe renal impairment, a reduction of the doses is recommended.</p>', '<p>Probenecid reduces Aciclovir excretion and so increases plasma concentration and risk of toxicity.</p>', '<p>Aciclovir is contraindicated in patients known to be hypersensitive to Aciclovir.</p>', '<p>Rash, gastrointestinal disturbance, rise in bilirubin and liver-related enzymes, increase in blood urea and creatinine, decrease in hematological indices, headache, neurological reaction, fatigue.</p>', '<p>Pregnancy category B. Aciclovir should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Caution should be exercised when it is administered to a nursing mother.</p>', '<p>Aciclovir should be administered with caution in patients with renal impairment and doses should be adjusted according to creatinine clearance. Monitor neutrophil count at least twice weekly in neonates.</p>', NULL, '<p>Herpes simplex &amp; Varicella-zoster virus infections</p>', '<p>Aciclovir is indicated for-</p>\r\n\r\n<ul>\r\n	<li>The treatment of viral infections due to Herpes simplex virus (type I &amp; II) and Varicella zoster virus (herpes zoster &amp; chicken pox).</li>\r\n	<li>The treatment of Herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes and herpes labialis.</li>\r\n	<li>The prophylaxis of Herpes simplex infections in immunocompromised patients</li>\r\n</ul>', NULL, '2022-02-14 06:22:41', '2022-06-12 04:10:27'),
(40, 40, '<p>Acyclovir&nbsp;cream is a herpes simplex virus (HSV) nucleoside analogue DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.</p>', '<p>Acyclovir is an antiviral drug active against herpes simplex virus. Acyclovir is a synthetic purine nucleoside analogue with cell culture and in vivo inhibitory activity against HSV types 1 (HSV-1) and 2 (HSV-2). The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In cell culture, acyclovir triphosphate stops replication of herpes viral DNA. This inhibition is accomplished in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase.</p>', '<p>Acyclovir&nbsp;cream should be applied five times per day for four days. Therapy should be initiated as early as possible following the onset of signs or symptoms of herpes labialis i.e., during the prodrome or when lesions appear. For adolescents 12 years of age and older, the dosage is the same as in adults.</p>', '<p>Clinical experience has identified no interactions resulting from topical or systemic administration of other drugs concomitantly with Acyclovir&nbsp;cream. Due to minimal systemic absorption of Acyclovir&nbsp;cream, systemic drug interactions are unlikely.</p>', '<p>Acyclovir&nbsp;cream is contraindicated in patients with known hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.</p>', '<p>The most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each adverse reaction occurred in less than 1% of patients receiving Acyclovir&nbsp;cream and placebo. Three patients on Acyclovir&nbsp;cream and one patient on placebo discontinued treatment due to an adverse event.</p>', '<p>Pregnancy Category B. There are no adequate and well-controlled studies of acyclovir cream in pregnant women. Acyclovir cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether topically applied acyclovir is excreted in breast milk. Systemic exposure following topical administration is minimal.</p>', '<p>Acyclovir&nbsp;cream should only be applied on the affected external aspects of the lips and face in patients with herpes labialis. Because no data are available, application to human mucous membranes is not recommended. Acyclovir&nbsp;cream is intended for cutaneous use only and should not be used in the eye or inside the mouth or nose. Cream has a potential for irritation and contact. The effect of Acyclovir&nbsp;cream has not been established in immunocompromised patients.</p>', NULL, '<p>Topical Antiviral preparations</p>', '<p>Acyclovir&nbsp;cream is a herpes simplex virus (HSV) nucleoside analogue DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.</p>', '<p><strong>Pediatric Use</strong>: An open-label, uncontrolled trial with Acyclovir cream 5% was conducted in 113 patients aged 12 to 17 years with recurrent herpes labialis. In this trial, therapy was applied using the same dosing regimen as in adults and subjects were followed for adverse events. The safety profile was similar to that observed in adults. Safety and effectiveness in pediatric patients less than 12 years of age have not been established.<br />\r\n<br />\r\n<strong>Geriatric Use</strong>: Clinical studies of acyclovir cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Systemic absorption of acyclovir after topical administration is minimal.</p>', '2022-02-14 06:25:46', '2022-07-02 05:27:49'),
(41, 41, '<p>Acyclovir &amp; Hydrocortisone Cream is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older).</p>', '<p>Acyclovir is a synthetic purine nucleoside analogue with inhibitory activity against Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) in cell culture and in vivo. The inhibitory activity of Acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV. This viral enzyme converts Acyclovir into Acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In cell culture, Acyclovir Triphosphate stops replication of herpes viral DNA. This inhibition is accomplished in 3 ways:</p>\r\n\r\n<ul>\r\n	<li>Competitive inhibition of viral DNA polymerase</li>\r\n	<li>Incorporation into and termination of the growing viral DNA chain</li>\r\n	<li>Inactivation of the viral DNA polymerase</li>\r\n</ul>\r\n\r\n<p>Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. It is used topically for its anti-inflammatory effects which suppress the clinical manifestations of the disease in a wide range of disorders where inflammation is a prominent feature.</p>', '<p>The cream should be topically applied 5 times per day for 5 days. Therapy should be initiated as early as possible after the first signs and symptoms.</p>', NULL, '<p>There is no known contraindication.</p>', '<p>The following most common adverse reactions (&lt;1%) were local skin reactions like drying or flaking of the skin; burning or tingling, erythema; pigmentation changes, application site reactions including signs and symptoms of inflammation.</p>', '<p>Pregnancy Category B. There are no adequate and well-controlled studies of systemic Acyclovir in pregnant women. No studies have been performed in pregnant women. Systemic exposure of Acyclovir and Hydrocortisone following topical administration of this cream is minimal. It is not known whether topically applied Acyclovir or Hydrocortisone is excreted in breast milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman.</p>', '<p>Acyclovir and Hydrocortisone should not be used in the eye, inside the mouth or nose, or on the genitals. Patients should seek medical advice when a cold sore fails to heal within 2 weeks.</p>', NULL, '<p>Hydrocortisone &amp; Combined preparations</p>', '<p>Keep below 30&deg;C temperature, away from light &amp; moisture. Keep out of the reach of children.</p>', '<p>Safety and effectiveness in pediatric subjects less than 6 years of age have not been established.</p>', '2022-02-14 06:26:35', '2022-03-09 15:17:42'),
(42, 42, '<p>Adalimumab is a tumor necrosis factor (TNF) blocker indicated for treatment of:</p>\r\n\r\n<ul>\r\n	<li><strong>Rheumatoid Arthritis (RA)</strong>: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA</li>\r\n	<li><strong>Juvenile Idiopathic Arthritis (JIA)</strong>: Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older</li>\r\n	<li><strong>Psoriatic Arthritis (PsA)</strong>: Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA</li>\r\n	<li><strong>Ankylosing Spondylitis (AS)</strong>: Reducing signs and symptoms in adult patients with active AS</li>\r\n	<li><strong>Adult Crohn&rsquo;s Disease (CD)</strong>: Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn&rsquo;s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab</li>\r\n	<li><strong>Pediatric Crohn&rsquo;s Disease</strong>: Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn&rsquo;s disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate</li>\r\n	<li><strong>Ulcerative Colitis (UC)</strong>: Inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of Adalimumab has not been established in patients who have lost response to or were intolerant to TNF blockers</li>\r\n	<li><strong>Plaque Psoriasis (Ps)</strong>: The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate</li>\r\n	<li><strong>Hidradenitis Suppurative (HS)</strong>: The treatment of moderate to severe hidradenitis suppurativa</li>\r\n</ul>', '<p>Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of patients with Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis plaques. In Plaque Psoriasis, treatment with Adalimumab may reduce the epidermal thickness and infiltration of inflammatory cells.</p>', '<p><strong>Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis</strong>: 40 mg every other week Some patients with RA not receiving methotrexate may benefit from increasing the frequency to 40 mg every week.<br />\r\n<br />\r\nJuvenile Idiopathic Arthritis:</p>\r\n\r\n<ul>\r\n	<li><strong>10 kg to &lt;15 kg</strong>: 10 mg every other week</li>\r\n	<li><strong>15 kg to &lt; 30 kg</strong>: 20 mg every other week</li>\r\n	<li><strong>&ge; 30 kg</strong>: 40 mg every other week</li>\r\n</ul>\r\n\r\n<p>Adult Crohn&#39;s Disease and Ulcerative Colitis:</p>\r\n\r\n<ul>\r\n	<li><strong>Initial dose (Day 1)</strong>: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days).</li>\r\n	<li><strong>Second dose two weeks later (Day 15)</strong>: 80 mg.</li>\r\n	<li><strong>Two weeks later (Day 29)</strong>: Maintenance dose of 40 mg every other week.</li>\r\n	<li><strong>For patients with Ulcerative Colitis only</strong>: Adalimumab should only be continued in patients who have shown evidence of clinical remission by eight weeks (Day 57) of therapy.</li>\r\n</ul>\r\n\r\n<p>Pediatric Crohn&rsquo;s Disease:</p>\r\n\r\n<ul>\r\n	<li><strong>17 kg to &lt; 40 kg</strong>: Initial dose (Day 1): 80 mg (two 40 mg injections in one day) , Second dose two weeks later (Day 15): 40 mg , Two weeks later (Day 29): Maintenance dose of 20 mg every other week.</li>\r\n	<li><strong>&ge; 40 kg</strong>: Initial dose (Day 1): 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) , Second dose two weeks later (Day 15): 80 mg (two 40 mg injections in one day) , Two weeks later (Day 29): Maintenance dose of 40 mg every other week.</li>\r\n</ul>\r\n\r\n<p>Plaque Psoriasis:</p>\r\n\r\n<ul>\r\n	<li>80 mg initial dose, followed by 40 mg every other week starting one week after initial dose.</li>\r\n	<li><strong>Hidradenitis Suppurativa</strong>: Initial dose (Day 1): 160 mg (given as four 40 mg injection on Day 1 or as two 40 mg injections per day on Days 1 and 2, Second dose two weeks later (Day 15): 80 mg (two 40 mg injections in one day), Third (Day 29) and subsequent doses: 40 mg every week.</li>\r\n</ul>\r\n\r\n<p><strong>Administration : Administered by subcutaneous injection.</strong></p>', '<p>Abatacept: Increased risk of serious infection<br />\r\nAnakinra: Increased risk of serious infection<br />\r\nLive vaccines: Adalimumab use should be avoided</p>', '<p>Adalimumab should not be administered to patients with known hypersensitivity to&nbsp;Adalimumab or any of its components.</p>', '<p>The most common adverse reaction with Adalimumab was injection site reactions (erythema and/or itching, hemorrhage, pain or swelling). The most common adverse reactions leading to discontinuation of Adalimumab in rheumatoid arthritis were clinical flare reaction, rash and pneumonia.</p>\r\n\r\n<ul>\r\n	<li>Other adverse reactions of Adalimumab includes- Gastrointestinal disorders: Diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, pancreatitis.</li>\r\n	<li>General disorders and administration site conditions: Pyrexia.</li>\r\n	<li>Hepato-biliary disorders: Liver failure, hepatitis.</li>\r\n	<li>Immune system disorders: Sarcoidosis.</li>\r\n	<li>Neoplasms benign, malignant and unspecified (including cysts and polyps): Merkel Cell Carcinoma (neuroendocrine carcinoma of the skin).&nbsp;</li>\r\n	<li>Nervous system disorders: Demyelinating disorders (e.g., optic neuritis, Guillain-Barr&eacute; syndrome).</li>\r\n	<li>Cerebrovascular accident Respiratory disorders: Interstitial lung disease, including pulmonary fibrosis.</li>\r\n	<li>Pulmonary embolism Skin reactions: Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all sub-types including pustular and palmoplantar), alopecia.</li>\r\n	<li>Vascular disorders: Systemic vasculitis, deep vein thrombosis.</li>\r\n</ul>', '<p>Pregnancy Category B. Adequate and well controlled studies with Adalimumab have not been conducted in pregnant women. Adalimumab is an IgG1 monoclonal antibody and IgG1 is actively transferred across the placenta during the third trimester of pregnancy. Limited data from published literature indicate that Adalimumab is present in low levels in human milk and is not likely to be absorbed by a breastfed infant. However, no data is available on the absorption of Adalimumab from breast milk in newborn or preterm infants. Caution should be exercised when Adalimumab is administered to a nursing woman.</p>', '<ul>\r\n	<li><strong>Serious infections</strong>: Adalimumab should not be started during an active infection. If an infection develops, should be carefully monitored and if infection becomes serious Adalimumab should be stopped.</li>\r\n	<li><strong>Invasive fungal infections</strong>: For patients who develop a systemic illness on Adalimumab, empiric antifungal therapy should be considered for those who reside or travel to regions where mycoses are endemic</li>\r\n	<li><strong>Malignancies</strong>: Incidence of malignancies was greater in Adalimumab-treated patients than in controls</li>\r\n	<li><strong>Anaphylaxis or serious allergic reactions</strong>&nbsp;may occur Hepatitis B virus reactivation: HBV carriers should be monitored during and several months after therapy. If reactivation occurs, Adalimumab should be stopped and antiviral therapy should be started</li>\r\n	<li><strong>Demyelinating disease</strong>: Exacerbation or new onset, may occur Cytopenias, pancytopenia: Patients should be advised to seek immediate medical attention if symptoms develop, and should be considered stopping Adalimumab</li>\r\n	<li><strong>Heart failure</strong>: Worsening or new onset, may occur</li>\r\n	<li><strong>Lupus-like syndrome</strong>: Adalimumab should be stopped if syndrome develops</li>\r\n</ul>', '<p>The maximum tolerated dose of Adalimumab has not been established in humans. Multiple doses up to 10 mg/kg have been administered to patients in clinical trials without evidence of dose-limiting toxicities. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately.</p>', '<p>Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressant</p>', '<p>Do not use beyond the expiration date on the container. Adalimumab must be refrigerated at 2-8&deg; C. Do not freeze. Protect the pre-filled syringe from exposure to light. Store in original carton until time of administration.</p>', '<p><strong>Pediatric Use</strong>: Safety and efficacy of Adalimumab in pediatric patients for uses other than polyarticular juvenile idiopathic arthritis (JIA) and pediatric Crohn&rsquo;s disease have not been established.<br />\r\n<br />\r\n<strong>Geriatric Use</strong>: A total of 519 patients 65 years of age and older, including 107 patients 75 years and older, received Adalimumab in clinical studies. No overall difference in effectiveness was observed between these subjects and younger subjects. The frequency of serious infection and malignancy among Adalimumab treated subjects over age 65 was higher than for those under age 65. Because there is a higher incidence of infections and malignancies in the elderly population in general, caution should be used when treating the elderly.</p>', '2022-02-14 06:26:56', '2022-03-09 15:26:07'),
(43, 43, '<p>Adapalene cream or gel is indicated for topical treatment of acne vulgaris.</p>', '<p>Adapalene acts on retinoid receptors that are commonly found in the skin of face, back and chest. Biochemical and pharmacological studies have demonstrated that Adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes, all of that represent important features in the pathology of acne vulgaris. Adapalene binds with specific retinoic acid nuclear receptors that normalize the differentiation of follicular epithelial cells resulting in decreased microcomedone formation. Absorption of Adapalene through human skin is low.</p>', '<p><strong>Adapalene 0.1%</strong>: It should be applied to the affected areas of skin, once daily at night-time.<br />\r\n<strong>Adapalene 0.3%</strong>: It should be applied to the entire face and any other affected areas of the skin, once daily in the evening.<br />\r\n<br />\r\n<strong>Children below 12 years of age</strong>: Safety and effectiveness in children below 12 years of age have not been established.</p>\r\n\r\n<p><strong>Administration:</strong></p>\r\n\r\n<p>A thin film of gel or cream should be applied to the skin areas where lesions present, using enough to cover the entire affected areas lightly.</p>', '<p>Concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, products with high concentrations of alcohol, astringents, spices or lime) should be approached with caution. Exercise particular caution in using preparations containing sulfur, resorcinol or salicylic acid in combination with Adapalene. If any of these preparations have been used, it is advisable not to start therapy with Adapalene until the effects of such preparations in skin have subsided. If combined use of both medications is important, it is better to use in two different times.</p>', '<p>Adapalene should not be administered to individuals who are hypersensitive to Adapalene or any of its components.</p>', '<p>Erythema, scaling, dryness, pruritus, burning sensation, skin irritation, stinging unburn, acne flares, etc. are commonly seen during the first month of therapy but usually lessen with continued use of the medication.</p>', '<p>Use Adapalene during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in breast milk. Exercise caution when administering Adapalene to a nursing mother.</p>', '<p>Adapalene should not be applied to cuts, abrasions, eczematous or sunburned skin.</p>', NULL, '<p>Topical retinoid and related preparations</p>', '<p>Store in a cool (below 25&deg;C) and dry place protected from light and moisture. Keep out of the reach of children. Keep the tube tightly closed after use.</p>', NULL, '2022-02-14 06:27:22', '2022-03-10 02:05:07'),
(44, 44, '<p>Adapalene &amp; Benzoyl peroxide gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.</p>', '<p>Adapalene &amp; Benzoyl peroxide gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that Adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. Adapalene binds with specific retinoic acid nuclear receptors that normalize the differentiation of follicular epithelial cells resulting in decreased microcomedone formation. Benzoyl peroxide is an oxidizing agent with bacteriocidal and keratolytic effects.</p>', '<p>Apply a thin film of Adapalene &amp; Benzoyl peroxide gel to affected areas of the face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek). Avoid the eyes, lips and mucous membranes. Adapalene &amp; Benzoyl peroxide is not for oral, ophthalmic, or intravaginal use.<br />\r\n<br />\r\n<strong>Pediatric use</strong>: The safety and effectiveness of Adapalene and Benzoyl peroxide gel in pediatric patients under the age of 12 years have not been established.</p>', '<p>Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. No formal drug-drug interaction studies were conducted.</p>', '<p>Should not be administered to individuals who are hypersensitive to any of its component.</p>', '<p>Should not be administered to individuals who are hypersensitive to any of its component.</p>', '<p>There are no well-controlled trials in pregnant women treated with Adapalene and Benzoyl peroxide. Animal reproduction studies have not been conducted with the combination gel or Benzoyl peroxide. Furthermore, such studies are not always predictive of human response; therefore, this preparation should be used during pregnancy only if the potential benefit justifies the risk to the fetus. It is not known whether Adapalene or Benzoyl peroxide is excreted in human milk following use. Caution should be exercised when administered to a nursing woman.</p>', '<p>Avoid exposure to sunlight and sunlamps. Wear sunscreen when sun exposure cannot be avoided.</p>', NULL, '<p>Topical retinoid and related preparations</p>', '<p>Topical retinoid and related preparations</p>', NULL, '2022-02-14 06:27:45', '2022-03-10 02:14:43');
INSERT INTO `generic_details` (`id`, `generic_id`, `indications`, `pharmacology`, `dosage_and_administration`, `interaction`, `contraindications`, `side_effects`, `pregnancy_and_lactation`, `precautions_and_warnings`, `overdose_effects`, `therapeutic_class`, `storage_conditions`, `use_in_special_populations`, `created_at`, `updated_at`) VALUES
(45, 45, '<p>Adefovir Dipivoxil is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.</p>', '<p>Adefovir dipivoxil is a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). Adefovir is phosphorylated to the active metabolite, adefovir diphosphate, by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The approximate oral bioavailability of adefovir from a 10 mg single dose is 59%. In vitro binding of adefovir to human plasma or human serum proteins is 4%. Adefovir is excreted through renal route by a combination of glomerular filtration and active tubular secretion.</p>', '<p>The recommended dose of Adefovir in chronic hepatitis B patients with adequate renal function is 10 mg, once daily, taken orally, without regard to food.</p>', '<p>The pharmacokinetics of adefovir was unchanged when adefovir dipivoxil was coadministered with lamivudine, trimethoprim/ sulfamethoxazole and acetaminophen. When adefovir dipivoxil was co-administered with ibuprofen (800 mg three times daily), increases in adefovir Cmax (33%), AUC (23%) and urinary recovery were observed due to higher oral bioavailability of adefovir.</p>', '<p>Adefovir dipivoxil is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product.</p>', '<p>The most common side effects of adefovir dipivoxil are weakness, headache, stomach pain and nausea. Severe acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis B therapy, including therapy with adefovir dipivoxil. In patients at risk of or having underlying renal dysfunction, chronic administration of adefovir dipivoxil may result in nephrotoxicity. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals.</p>', '<p>Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Adefovir dipivoxil should be used during pregnancy only if clearly needed and after careful consideration of the risks and benefits. It is not known whether adefovir is excreted in human milk. Mothers should be instructed not to breast-feed if they are taking adefovir dipivoxil.</p>', '<p>Patients who discontinued adefovir dipivoxil should be monitored at repeated intervals over a period of time for hepatic function. The patients at risk of or having underlying renal dysfunction should be monitored closely for renal function and may require dose adjustment.</p>', '<p>Doses of adefovir dipivoxil 500 mg daily for 2 weeks and 250 mg daily for 12 weeks have been associated with gastrointestinal side effects. If overdose occurs the patient must be monitored for evidence of toxicity and standard supportive treatment applied as necessary.</p>', '<p>Hepatic viral infections (Hepatitis B)</p>', '<p>Store at cool and dry place. Protect from light and moisture. Keep all the medicines out of the reach of children.</p>', '<p><strong>Pediatric use</strong>:&nbsp;Safety and effectiveness in pediatric patients have not been established.<br />\r\n<br />\r\n<strong>Geriatric use</strong>:&nbsp;In general, caution should be exercised when prescribing to elderly patients since they have greater frequency of decreased renal or cardiac function due to concomitant disease or other drug therapy.<br />\r\n<br />\r\n<strong>Dose Adjustment in Renal Impairment</strong>: the dosing interval of Adefovir should be adjusted in patients with baseline creatinine clearance &lt;50 ml/min using the following suggested guidelines:</p>\r\n\r\n<ul>\r\n	<li>CrCl &le; 50 ml/min: 10 mg</li>\r\n	<li>CrCl 20-49 ml/min:&nbsp;10 mg&nbsp;every&nbsp;48 hours</li>\r\n	<li>CrCl 10-19 ml/min:&nbsp;10 mg&nbsp;every 72 hours</li>\r\n	<li>Haemodialysis patients:&nbsp;10 mg&nbsp;every&nbsp;7 days&nbsp;following dialysis</li>\r\n</ul>', '2022-02-14 06:28:26', '2022-03-10 02:21:12'),
(46, 46, '<p>Intravenous Adenosine is indicated for the following: Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).</p>', '<p>This preparation is a sterile, nonpyrogenic solution for rapid bolus intravenous injection. Adenosine injection slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia.</p>', '<p><strong>Adult</strong>:</p>\r\n\r\n<ul>\r\n	<li>Initial dose: 6 mg given as rapid IV bolus (administered over 1-2 second period).</li>\r\n	<li>Repeat administration: If the first dose does not result in elimination of the supraventricular tachycardia within 1-2 minutes, 12 mg should be given as rapid intravenous bolus. This 12 mg dose may be repeated for second time if required.</li>\r\n</ul>\r\n\r\n<p><strong>Pediatric</strong>: The dosages used in neonates, infants, children and adolescents were equivalent to those administered to adults on a weight basis.</p>\r\n\r\n<ul>\r\n	<li>Body weight &lt; 50 kg: Initial dose - 0.05 to 0.1 mg/kg as a rapid IV bolus given either centrally or peripherally. A saline flush should follow.</li>\r\n	<li>Body weight &gt; 50 kg: The adult dose is recommended. Doses greater than 12 mg are not recommended for adult and pediatric patients.</li>\r\n</ul>\r\n\r\n<p>Repeat administration: If conversion of PSVT does not occur within 1-2 minutes, additional bolus injections of adenosine can be administered at incrementally higher doses, increasing the amount given by 0.05 to 0.1 mg/kg. A saline flush should follow. This process should continue until sinus rhythm is established or a maximum single dose of 0.3 mg/kg is used.</p>', '<p>Intravenous Adenosine injection has been effectively administered in the presence of other cardioactive drugs, such as Quinidine, beta- adrenergic blocking agents, Calcium channel blocking agents and angiotensin converting enzyme inhibitors without any change in the adverse reaction profile. Digoxin and Verapamil use may be rarely associated with ventricular fibrillation when combined with Adenosine. Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenosine should be used with caution in the presence of these agents. The use of Adenosine in patients receiving Digitalis may be rarely associated with ventricular fibrillation. The effects of Adenosine are antagonized by Methylxanthines, such as, Caffeine and Theophylline.</p>', '<p>Intravenous Adenosine is contraindicated in:</p>\r\n\r\n<ul>\r\n	<li>Second- or third-degree A-V block (except in patients with a functioning artificial pacemaker).</li>\r\n	<li>Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker).</li>\r\n	<li>Known hypersensitivity to Adenosine.</li>\r\n</ul>', '<p><strong>Cardiovascular</strong>: Facial flushing, headache, sweating, palpitations, chest pain, hypotension. Respiratory: Shortness of breath/dyspnea, chest pressure, hyperventilation, head pressure.<br />\r\n<br />\r\n<strong>Central Nervous System</strong>: Lightheadedness, dizziness, tingling in arms, numbness, apprehension, blurred vision, burning sensation, heaviness in arms, neck and back pain.<br />\r\n<br />\r\n<strong>Gastrointestinal</strong>: Nausea, metallic taste, tightness in throat, pressure in groin. In post-market clinical experience with Adenosine, cases of prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, hypotension, atrial fibrillation and bronchospasm, in association with Adenosine use, have been reported.</p>', '<p>US FDA pregnancy category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.</p>', NULL, '<p>The half-life of Adenosine is less than 10 seconds. Thus, adverse effects are generally rapidly self-limiting. Treatment of any prolonged adverse effects should be individualized and be directed toward the specific effect. Methylxanthines, such as, Caffeine and Theophylline, are competitive antagonists of Adenosine.</p>', '<p>Paroxysmal supraventricular tachycardia (PSVT)</p>', '<p>Store in cool dry place protected from light. Keep out of reach of children. Do not refrigerate as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear at the time of use.</p>', NULL, '2022-02-14 06:29:45', '2022-03-10 02:55:16'),
(47, 47, '<p>This syrup is indicated in-</p>\r\n\r\n<ul>\r\n	<li>Cough</li>\r\n	<li>Dry Cough</li>\r\n	<li>Bronchitis</li>\r\n	<li>Chronic lung infection</li>\r\n	<li>Rhinitis</li>\r\n	<li>Flu &amp; headache</li>\r\n</ul>', '<p>Adhatoda vasica Contains alkaloid vasicine which has expectorant qualities so it is useful for bronchitis and other chest conditions of upper respiratory tract. The soothing action of vasac helps irritation in the throat and the expectorant action helps loosen phlegm deposits in the airway and expels it out. Honey reduces mucus secretion and cough.</p>', '<p>Children: 1/2-1 teaspoonful 2-3 times daily.<br />\r\nAdult: 2-4 teaspoonful 2-3 times daily.<br />\r\nOr as directed by the registered physician.</p>', '<p>There is no data available.</p>', '<p>It is contraindicated in patients known to have hypersensitivity to the drug or any of its components.</p>', '<p>There is no data available.</p>', '<p>The safety of the Syrup in pregnancy &amp; lactation has not been established. Therefore, it should be used with caution during pregnancy &amp; lactation.</p>', '<p>There is no data available.</p>', NULL, NULL, '<p>Keep out of reach of children. Keep away from direct sunlight. Store in a cool and dry place.</p>', NULL, '2022-02-14 06:31:17', '2022-03-10 03:05:36'),
(48, 48, '<p>Adjunctive use in the management of cardiac arrest. It is used in cardiopulmonary resuscitation. Intracardiac puncture and intramyocardial injection of adrenaline may be effective when external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail. Adrenaline is a drug that leads to increased blood pressure, increased heart rate, increased air entry, increased blood glucose, stimulates cardiac activity and reduces allergic reactions by reducing inflammatory response caused by histamine. Due to these properties, it is used for the treatment of allergic and anaphylactic reactions. Adrenaline is the favored treatment for anaphylactic shock and should be administered immediately if a person begins exhibiting severe allergic reactions. Adrenaline is also used in life threatening asthma when failing ventilation and continued deterioration despite nebulizer therapy.</p>', '<p>The actions of epinephrine resemble the effects of stimulation of adrenergic nerves. It acts on both alpha and beta receptor sites of sympathetic effector cells. Its most prominent actions are on the beta receptors of the heart, vascular and other smooth muscle. When given by rapid intravenous injection, it produces a rapid rise in blood pressure, mainly systolic, by (1) direct stimulation of cardiac muscle which increases the strength of ventricular contraction, (2) increasing the heart rate and (3) constriction of the arterioles in the skin, mucosa and splanchnic areas of the circulation.<br />\r\n<br />\r\nWhen given by slow intravenous injection, epinephrine usually produces only a moderate rise in systolic and a fall in diastolic pressure. Although some increase in pulse pressure occurs, there is usually no great elevation in mean blood pressure. Accordingly, the compensatory reflex mechanisms that come into play with a pronounced increase in blood pressure do not antagonize the direct cardiac actions of epinephrine as much as with catecholamines that have a predominant action on alpha receptors.</p>', '<p>Cardiac arrest:</p>\r\n\r\n<ul>\r\n	<li><strong>Intravenous injection</strong>: 1 mg injection repeated every 2-3 minutes as necessary.</li>\r\n	<li><strong>Endotracheal</strong>: 2-3 mg via an endotracheal tube, repeated as necessary.</li>\r\n	<li><strong>Intracardiac</strong>: 0.1 to 1 mg, direct into the atrium of the heart.</li>\r\n	<li><strong>Intraspinal</strong>: Usual dose is 0.2 to 0.4 mg added to anesthetic spinal fluid mixture (to prolong anesthetic action by limiting absorption).</li>\r\n</ul>\r\n\r\n<p>Anaphylaxis, asthma or severe bronchospasm:</p>\r\n\r\n<ul>\r\n	<li><strong>Adult dose</strong>&nbsp;is 0.25 0.5 mg. It may be repeated at 5 minutes intervals until perfusion and respiratory status normalizes.</li>\r\n	<li><strong>In case of dose dilution</strong>: 1 mg of Adrenaline to be diluted in 9 ml Normal Saline.</li>\r\n</ul>\r\n\r\n<p><strong>Children</strong>: Initially 10 mcg/kg body weight, not to exceed 250 mcg. May be repeated every 3-5 minutes if necessary. Subsequent doses should be 100 mcg/kg.</p>', '<p>Use of Adrenaline with excessive doses of digitalis, mercurial diuretics or other drugs that sensitize the heart to arrhythmias is not recommended. The adverse effects of Adrenaline may be potentiated by tricyclic antidepressants; certain antihistamines; e.g, Diphenhydramine, Tripelennamine, Chlorpheniramine and L-thyroxine Sodium.</p>', '<p>Hypertension, arteriosclerosis, coronary disease and hyperthyroidism. Not to be given to patients taking monoamine oxidase inhibitors.</p>', '<p>Common side effects are anxiety, restlessness, dizziness, headache, palpitations, rapid pulse, tremors, weakness and coldness of the extremities may be reported even with small doses and especially when given in conjunction with local anaesthetics.</p>', '<p>Pregnancy Category C. It crosses the placenta and is excreted in breast milk. Adrenaline should only be used in pregnancy if the potential benefits outweigh the risks to the fetus. It is excreted in breast milk and therefore Adrenaline is not recommended for use during lactation because of the risk of adverse effects of infants.</p>', '<p>The solution should not be used if it is pinkish or darker than slightly yellow or if it contains a precipitate. Adrenaline is readily destroyed by alkalies and oxidizing agents. In the latter category are Oxygen, Chlorine, Iodine, Permanganates, Chromates, Nitrites and salts of easily reducible metals, especially Iron. Adrenaline should not be mixed with Sodium bicarbonate; the solution is oxidised to adrenochrome and then forms polymers. Administer slowly with caution to elderly patients and to patients with ischemic heart disease, hypertension, diabetes mellitus, hyperthyroidism or psychoneurosis. Use with extreme caution in patients with long-standing bronchial asthma and emphysema who have developed degenerative heart disease. Anginal pain may be induced when coronary insufficiency is present.</p>', '<p>Cardiac arrhythmia leading to ventricular fibrillation, severe hypertension leading to pulmonary edema and cerebral hemorrhage. Combined alpha and beta-adrenergic blocking agents such as Labetalol may counteract the effects of adrenaline, or a beta-blocking agent may be used to treat any supraventricular arrhythmias and Phentolamine to control the alpha-mediated effects on the peripheral circulation. Rapidly acting vasodilators such as nitrates and Sodium Nitroprusside may also be helpful. Immediate resuscitation support must be available.</p>', '<p>Anaphylaxis, Mydriatic and Cycloplegic agents, Other adrenoceptor stimulants, Respiratory stimulants: analeptics</p>', '<p>Store below 25&deg;C. Protect from light. Keep out of the reach of children.</p>', NULL, '2022-02-14 06:31:56', '2022-03-10 03:13:13'),
(49, 49, '<ul>\r\n	<li>For the active immunization of infants, children 7 years of age or older and adults against tetanus, wherever combined antigen preparations are not indicated.</li>\r\n	<li>For the prevention of neonatal tetanus in infants by immunizing women of childbearing age or infants bom of unvaccinated pregnant women.</li>\r\n	<li>Those who are liable to be exposed to tetanus infection and persons engaged in outdoor activities e.g. gardeners, agricultural, veterinary, athletes, industrial, sewage, road and outdoor workers, etc.</li>\r\n	<li>This vaccine is not to be used for the treatment of tetanus infection. If passive immunization is required, Tetanus Immunoglobulin (TIG) should be used.</li>\r\n</ul>', '<p>or. Adsorbed tetanus toxoid is prepared from tetanus toxin, produced by the growth of the bacterium Clostridium tetani in a peptone-based media. The toxin is converted to tetanus formol toxoid by treatment with formaldehyde solution. Formol tetanus toxoid is then purified, sterile, filtered and adsorbed to the aluminium phosphate.Thiomersal is added as preservative.</p>', '<p>Primary immunization for persons 7 years of age and older-</p>\r\n\r\n<p>A series of three doses of 0.5 ml each, of adsorbed tetanus vaccine should be given intramuscularly</p>\r\n\r\n<ul>\r\n	<li><strong>First dose</strong>: At appropriate date</li>\r\n	<li><strong>Second dose</strong>: 4 to 8 weeks after the first dose</li>\r\n	<li><strong>Third dose</strong>: 6 to 12 months after the second dose</li>\r\n</ul>\r\n\r\n<p>Children older than 7 years who did not complete primary immunization series (e.g., previously received only two doses of DTaP or DTP) need to receive only one dose of tetanus toxoid adsorbed vaccine to complete the primary series of tetanus. Interruption of the recommended schedule with a delay between doses does not interfere with the final immunity achieved with adsorbed tetanus vaccine. There is no need to start the series over again, regardless of the time elapsed between doses.<br />\r\n<br />\r\n<strong>Routine booster injections</strong>: To maintain adequate protection, a booster dose of 0.5 ml of adsorbed tetanus vaccine every 10 years thereafter is recommended.<br />\r\n&nbsp;</p>\r\n\r\n<p>Vaccination of injured persons-</p>\r\n\r\n<p>Clean and minor wound:</p>\r\n\r\n<ul>\r\n	<li>If primary immunization confirmed and receiving booster dose within previous 5 years, no need of additional vaccine.</li>\r\n	<li>If primary immunization confirmed and receiving booster dose more than previous 5 years, 1 dose of 0.5 ml required.</li>\r\n</ul>\r\n\r\n<p>All other dirty wounds (contaminated with feces, soil, and saliva):</p>\r\n\r\n<ul>\r\n	<li>If primary immunization confirmed and receiving booster dose within previous 5 years, 1 dose of 0.5 ml required.</li>\r\n	<li>If primary immunization confirmed and receiving booster dose more than previous 5 years, 1 dose of 0.5 ml along with tetanus immunoglobulin required.</li>\r\n</ul>\r\n\r\n<p>If a person has no previous vaccination or uncertain, the primary series of 3 doses of 0.5ml adsorbed tetanus vaccine should be given along with tetanus immunoglobulin with 1st dose.<br />\r\n&nbsp;</p>\r\n\r\n<p>Protection of neonatal tetanus-</p>\r\n\r\n<p>For prevention of neonatal tetanus, adsorbed tetanus vaccine is recommended for immunization of women of childbearing age.<br />\r\n<br />\r\n<strong>Women (15-49 Years)</strong>: For pregnant woman who have not had previous immunization, 2 doses of tetanus toxoid at four weeks interval preferably during the last two trimester or at least 2 weeks before delivery should be given during pregnancy so that protective antibody would be transferred to the infant in order to prevent neonatal tetanus, e.g. 1 dose of 0.5 ml at 6th month of pregnancy and 1 dose of 0.5 ml at 7th month of pregnancy. Pregnant woman who have completed the course of tetanus, next 10 years no need of additional dose during pregnancy. Thereafter a single booster dose would be sufficient to extend immunity.</p>\r\n\r\n<p><strong>Method of administration</strong>: Adsorbed Tetanus Vaccine is for intramuscular injection only. Do not inject intravenously. For adults and older children Adsorbed Tetanus Vaccine should be given intramuscularly in the deltoid muscle. For infants Adsorbed Tetanus Vaccine should be given intramuscularly in the anterolateral aspect of the upper thigh. It should not be injected into the gluteal areas as the immune response may be lower. The attending physician should determine final selection of the injection site and needle size, depending upon the patient&#39;s age and the size of the target muscle. The vaccine should be shaken well before use to obtain a homogenous turbid white suspension. Please do not shake vigorously.<br />\r\n<br />\r\n<strong>Preparation for administration:</strong></p>\r\n\r\n<ul>\r\n	<li>The vaccine should be shaken well before use to obtain a homogenous turbid white suspension. Please do not shake vigorously.</li>\r\n	<li>The vaccine should be inspected visually for particulate matter and discoloration prior to administration. If either of these conditions exist, the vaccine should not be administered.</li>\r\n	<li>The vaccine should be used as supplied; no dilution is necessary.</li>\r\n	<li>The full recommended dose of the vaccine should be used. Any vaccine remaining in a single-dose ampoule/vial should be discarded.</li>\r\n</ul>\r\n\r\n<p><strong>Co-administration</strong>: Adsorbed tetanus vaccine can be given at the same time with other vaccine as diphtheria, tetanus, pertussis (DTP), polio (OPV), measles, mumps and rubella (MMR), Haemophilus Influenzae type b (Hib) and Meningococcal vaccines at separate sites with separate syringes. It should not be mixed with other vaccines or medicinal products in the same syringe.</p>', '<p>Decreased immunologic response with concurrent immunosuppressants. Neutralisation of tetanus immune globulin and tetanus toxoid adsorbed if not given at different sites using different syringes.</p>', '<p>Hypersensitivity to any component of the vaccine, including thiomersal, is a contraindication. This vaccine is contraindicated in patients with previous hypersensitivity to any tetanus-containing vaccine. Tetanus toxoid vaccination should be defferred during the course of any febrile illness or acute infection. A minor febrile illness such as a mild upper respiratory infection should not preclude immunization.</p>', '<p>Adsorbed tetanus vaccine is generally well tolerated. Most recipients of tetanus vaccine experience some reactions upon vaccination. These are generally moderate and short in duration. They mainly consist of local reactions at the injection site (erythema, induration and tenderness). Systemic reactions (malaise and elevated temperature) are reported less commonly.</p>', '<p>For protection of neonatal tetanus, tetanus toxoid is recommended for immunization of women of childbearing age and especially pregnant women. Tetanus toxoid may be safely administered during pregnancy and should be given to the mother at first contact or as early as possible. It is not known if tetanus toxoid is excreted in human milk. It may be administered to nursing mothers only if clearly needed.</p>', '<p>Do not administer IV. Use subcutaneous route in bleeding disorders. Withhold vaccination in moderate or severe febrile illness. Pregnancy, lactation, history of Guillian-Barre syndrome.</p>', NULL, '<p>Vaccines, Anti-sera &amp; Immunoglobulin</p>', '<ul>\r\n	<li>For the active immunization of infants, children 7 years of age or older and adults against tetanus, wherever combined antigen preparations are not indicated.</li>\r\n	<li>For the prevention of neonatal tetanus in infants by immunizing women of childbearing age or infants bom of unvaccinated pregnant women.</li>\r\n	<li>Those who are liable to be exposed to tetanus infection and persons engaged in outdoor activities e.g. gardeners, agricultural, veterinary, athletes, industrial, sewage, road and outdoor workers, etc.</li>\r\n	<li>This vaccine is not to be used for the treatment of tetanus infection. If passive immunization is required, Tetanus Immunoglobulin (TIG) should be used.</li>\r\n</ul>', NULL, '2022-02-14 06:32:33', '2022-03-10 03:17:22'),
(50, 50, '<p><strong>EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer</strong>: Afatinib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.<br />\r\n<br />\r\n<strong>Limitation of Use</strong>: The safety and efficacy of Afatinib have not been established in patients whose tumors have resistant EGFR mutations.<br />\r\n<br />\r\n<strong>Previously Treated, Metastatic Squamous NSCLC</strong>: Afatinib is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.</p>', '<p>Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor, leading to receptor activation, sometimes in the absence of ligand binding, and can support cell proliferation in NSCLC. Non-resistant mutations are defined as those occurring in exons constituting the kinase domain of EGFR that lead to increased receptor activation and where efficacy is predicted by 1) clinically meaningful tumor shrinkage with the recommended dose of afatinib and/or 2) inhibition of cellular proliferation or EGFR tyrosine kinase phosphorylation at concentrations of afatinib sustainable at the recommended dosage according to validated methods. The most commonly found of these mutations are exon 21 L858R substitutions and exon 19 deletions.<br />\r\n<br />\r\nAfatinib demonstrated inhibition of autophosphorylation and/or in vitro proliferation of cell lines expressing wild type EGFR and in those expressing selected EGFR exon 19 deletion mutations, exon 21 L858R mutations, or other less common non-resistant mutations, at afatinib concentrations achieved in patients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.<br />\r\n<br />\r\nTreatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors either overexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.</p>', '<p><strong>Patient Selection for Non-Resistant EGFR Mutation-Positive Metastatic NSCLC</strong>: Select patients for first line treatment of metastatic NSCLC with Afatinib based on the presence of non-resistant EGFR mutations in tumor specimens.<br />\r\n<br />\r\n<strong>Recommended Dose</strong>: The recommended dose of Afatinib is 40 mg orally, once daily until disease progression or no longer tolerated by the patient.<br />\r\n<br />\r\n<strong>Renal impairment</strong>: 30 mg orally, once daily in patients with severe renal impairment.<br />\r\n<br />\r\nInstruct patients to take Afatinib at least 1 hour before or 2 hours after a meal.</p>', '<p>Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce Afatinib by 10 mg per day if not tolerated. Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase Afatinib by 10 mg per day as tolerated.</p>', NULL, '<p>Most common adverse reactions (&ge;20%) were diarrhea, rash/acneiform dermatitis, stomatitis, paronychia, dry skin, decreased appetite, nausea, vomiting, pruritus.</p>', '<p>Based on findings from animal studies and its mechanism of action, Afatinib can cause fetal harm when administered to a pregnant woman. There are no available data on the use of Afatinib in pregnant women. Administration of afatinib to pregnant rabbits during organogenesis at exposures approximately 0.2 times the exposure in humans at the recommended dose of 40 mg daily resulted in embryotoxicity and, in rabbits showing maternal toxicity, increased abortions at late gestational stages [see Data]. Advise a pregnant woman of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.<br />\r\n<br />\r\nThere are no data on the presence of afatinib in human milk or its effects on the breastfed infant or on milk production. Afatinib was present in the milk of lactating rats. Because of the potential for serious adverse reactions in nursing infants from Afatinib, advise a lactating woman not to breastfeed during treatment with Afatinib and for 2 weeks after the final dose.</p>', '<p><strong>Diarrhea</strong>: Diarrhea may result in dehydration and renal failure. Withhold afatinib for severe and prolonged diarrhea not responsive to anti-diarrheal agents.<br />\r\n<br />\r\n<strong>Bullous and exfoliative skin disorders</strong>: Severe bullous, blistering, and exfoliating lesions occurred in 0.2% of patients. Discontinue for life-threatening cutaneous reactions. Withhold afatinib for severe and prolonged cutaneous reactions.<br />\r\n<br />\r\n<strong>Interstitial lung disease (ILD)</strong>: Occurs in 1.6% of patients. Withhold afatinib for acute onset or worsening of pulmonary symptoms. Discontinue afatinib if ILD is diagnosed.<br />\r\n<br />\r\n<strong>Hepatic toxicity</strong>: Fatal hepatic impairment occurs in 0.2% of patients. Monitor with periodic liver testing. Withhold or discontinue afatinib for severe or worsening liver tests.<br />\r\n<br />\r\n<strong>Keratitis</strong>: Occurs in 0.7% of patients. Withhold afatinib for keratitis evaluation. Withhold or discontinue afatinib for confirmed ulcerative keratitis.<br />\r\n<br />\r\n<strong>Embryo-fetal toxicity</strong>: Can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to the fetus and to use effective contraception.</p>', NULL, '<p>Tyrosine Kinase Inhibitor</p>', '<p>Store at 25&deg;C; excursions permitted to 15&deg;-30&deg;C. Dispense medication in the original container to protect from exposure to high humidity and light.</p>', NULL, '2022-02-14 06:32:52', '2022-03-10 03:24:04'),
(51, 51, '<p>Aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.</p>', '<p>Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.</p>', '<p>4 mg/kg as an intravenous infusion over 1 hour every 2 weeks.&nbsp;Do not administer as an intravenous (IV) push or bolus.</p>\r\n\r\n<p><strong>Administration</strong></p>\r\n\r\n<p><strong>Preparation for Administration:&nbsp;</strong>Inspect vials visually prior to use. Aflibercept is a clear, colorless to pale yellow solution. Do not use vial if the solution is discolored or cloudy or if the solution contains particles. Do not re-enter the vial after the initial puncture. Discard any unused portion left in the vial. Withdraw the prescribed dose of Aflibercept and dilute in 0.9% sodium chloride solution, 5% dextrose solution for injection, to achieve a final concentration of 0.6&ndash;8 mg/mL.<br />\r\n<br />\r\nUse polyvinyl chloride (PVC) infusion bags containing bis (2-ethylhexyl) phthalate (DEHP) or polyolefin infusion bags. Store diluted Aflibercept at 2&deg;&ndash;8&deg;C for up to 24 hours, or at controlled room temperature 20&deg;&ndash;25&deg;C for up to 8 hours. Discard any unused portion left in the infusion bag.<br />\r\n<br />\r\n<strong>Administration:&nbsp;</strong>Administer the diluted Aflibercept solution as an intravenous infusion over 1 hour through a 0.2 micron polyethersulfone filter. Do not use filters made of polyvinylidene fluoride (PVDF) or nylon. Do not administer as an intravenous (IV) push or bolus. Do not combine Aflibercept with other drugs in the same infusion bag or intravenous line.</p>', '<p>No dedicated drug-drug interaction studies have been conducted for Aflibercept. No clinically important pharmacokinetic drug-drug interactions were found between ziv-aflibercept and irinotecan/SN-38 or 5-FU, based on cross-study comparisons and population pharmacokinetic analyses.</p>', NULL, '<p>Most common adverse reactions (all grades, &ge;20% incidence and at least 2% greater incidence for the Aflibercept/FOLFIRI regimen) were leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache</p>', '<p>Pregnancy category C. There are no adequate and well-controlled studies with Aflibercept in pregnant women. Aflibercept was embryotoxic and teratogenic in rabbits at exposure levels lower than human exposures at the recommended dose, with increased incidences of external, visceral, and skeletal fetal malformations.&nbsp;Aflibercept should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br />\r\n<br />\r\nIt is not known whether Aflibercept is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Aflibercept, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>', '<p>Adverse reactions, sometimes severe and life-threatening or fatal, have been seen in clinical trials with Aflibercept, including:</p>\r\n\r\n<ul>\r\n	<li>Fistula Formation: Discontinue Aflibercept if fistula occurs.</li>\r\n	<li>Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend Aflibercept if hypertension is not controlled. Discontinue Aflibercept if hypertensive crisis develops.</li>\r\n	<li>Arterial Thromboembolic Events (ATE) (e.g., transient ischemic attacks, cerebrovascular accident, angina pectoris): Discontinue Aflibercept if ATE develops.</li>\r\n	<li>Proteinuria: Monitor urine protein. Suspend Aflibercept when proteinuria &ge; 2 grams per 24 hours. Discontinue Aflibercept if nephrotic syndrome or thrombotic microangiopathy (TMA) develops.</li>\r\n	<li>Neutropenia and Neutropenic Complications: Delay administration of Aflibercept/FOLFIRI until neutrophil count is &ge; 1.5 &times; 109/L.</li>\r\n	<li>Diarrhea and Dehydration: Incidence of severe diarrhea and dehydration is increased. Monitor elderly patients more closely.</li>\r\n	<li>Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue Aflibercept.</li>\r\n</ul>', '<p>There have been no cases of overdose reported with Aflibercept. There is no information on the safety of Aflibercept given at doses exceeding 7 mg per kg every 2 weeks or 9 mg per kg every 3 weeks.</p>', '<p>Cytotoxic Chemotherapy</p>', '<p>Store Aflibercept vials in a refrigerator at 2 to 8&deg; C . Keep the vials in the original outer carton to protect from light.</p>', '<p><strong>Pediatric Use</strong>: The safety and effectiveness in pediatric patients have not been established. In a dose-escalation, safety, and tolerability study, 21 patients ages 2 to 21 years (median age 12.9) with solid tumors received Aflibercept at doses ranging from 2 to 3 mg/kg, IV, every two weeks. The pharmacokinetics of free ziv-aflibercept were evaluated in 8 of these patients (ages 5 to 17 years). The maximum tolerated dose in the study was 2.5 mg/kg, below the dose known to be safe and effective in adults with mCRC.<br />\r\n<br />\r\n<strong>Geriatric Use</strong>: Of the 611 patients with mCRC, patients treated with Aflibercept/FOLFIRI, 205 (34%) were 65 years or older, and 33 (5%) were 75 years or older. Elderly patients (&ge;65 years of age) experienced higher incidences (&ge;5%) of diarrhea, dizziness, asthenia, weight decrease, and dehydration when compared to younger patients. Monitor elderly patients more closely for diarrhea and dehydration<br />\r\n<br />\r\nThe effect of Aflibercept on overall survival was similar in patients &lt;65 years old and &ge;65 years old who received Aflibercept/FOLFIRI. No dose adjustment of Aflibercept is recommended for patients greater than or equal to 65 years of age.<br />\r\n<br />\r\n<strong>Hepatic Impairment:&nbsp;</strong>No dedicated clinical studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of ziv-aflibercept. Based on a population PK analysis with data from 1507 patients, ziv-aflibercept exposure in patients with mild and moderate hepatic impairment were similar to those in patients with normal hepatic function. There are no data available for patients with severe hepatic impairment.<br />\r\n<br />\r\n<strong>Renal Impairment</strong>: No dedicated clinical studies have been conducted to evaluate the effect of renal impairment on the pharmacokinetics of ziv-aflibercept. Based on a population PK analysis with data from 1507 patients, ziv-aflibercept exposure in patients with mild, moderate, and severe renal impairment were similar to those in patients with normal renal function [see&nbsp;Clinical Pharmacology.<br />\r\n<br />\r\n<strong>Females and Males of Reproductive Potential</strong>: Male and female reproductive function and fertility may be compromised during treatment with Aflibercept, as suggested by findings in monkeys [see&nbsp;Nonclinical Toxicology. These animal findings were reversible within 18 weeks after cessation of treatment. Females and males of reproductive potential should use highly effective contraception during and up to a minimum of 3 months after the last dose of treatment.</p>', '2022-02-14 06:33:22', '2022-03-10 03:31:40'),
(52, 52, '<p>Agomelatine is indicated for:</p>\r\n\r\n<ul>\r\n	<li>Major depressive disorder especially in non-responders and intolerant to SSRIs</li>\r\n	<li>Generalized anxiety disorder</li>\r\n	<li>Bipolar depression</li>\r\n	<li>Sleep disturbances</li>\r\n	<li>Seasonal affective disorder</li>\r\n	<li>Migraine and cluster headaches</li>\r\n</ul>', '<p>This compound binds to the melatoninergic receptors and the serotoninergic 5-HT2c receptor giving rise to the Melatonin Agonist and Selective Serotonin Antagonist (MASSA) concept. The melatoninergic receptors MT1 and MT2, are G protein coupled receptors and they act through decreasing cAMP and cGMP. Agomelatine strongly binds to and stimulates the activity of MT1 and MT2 receptors normalizing the disturbed circadian rhythms and disrupted sleep-wake cycles. Unlike the existing antidepressants, agomelatine does not inhibit the uptake of serotonin, norepinephrine or dopamine. It inhibits 5HT-2C receptor (G protein coupled receptor which increases IP3/DAG secondary messenger system) found abundantly in the SCN, frontal cortex, hippocampus and basal ganglia involved in the mood, motor and cognitive deficits associated with depressive states. 5HT-2C receptor antagonism increases norepinephrine and dopamine levels in the frontal cortex of the brain. This action of agomelatine produces antidepressant, antianxiety and also increases slow-wave sleep which is decreased in depression. It has been observed that it can increase neurogenesis in the hippocampus and may also have neuroprotective effects (by influencing glutamate release, glucocorticoid receptor gene expression and various neurotropic factors) which might also contribute to its antidepressant effects. A study has shown that agomelatine alleviates sleep disturbances after one week of therapy and by two weeks antidepressant effects manifest. The combined actions of agomelatine at MT1, MT2, and 5HT-2C receptors can improve the disturbed circadian rhythm and abnormal sleep pattern thus produce the antidepressant effect. These unique effects suggest that it might be effective for the treatment of seasonal affective disorder like anxiety and bipolar depression.</p>', '<p>The effective dose of agomelatine is 25 mg per day given once at bed time for two weeks and can be increased to 50 mg per day in patients with inadequate response. Night time dosing is recommended because agomelatine improves the quality of sleep without day time sedation.</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong>Administration</strong></p>\r\n\r\n<p>For oral administration with or without food. Most adult patients should take a dosage of 25 mg (one tablet) daily. It is usually taking prior to bed time. If no improvement is noticed after two weeks, the dosage can be increased to 50 mg (two tablets) daily.</p>', '<p>Potential interactions affecting agomelatine:&nbsp;Agomelatine is metabolised mainly by cytochrome P450 1A2 (CYP1A2) (90%) and by CYP2C9 (10%). Medicinal products that interact with these isoenzymes may decrease or increase the bioavailability of agomelatine. Fluvoxamine, a potent CYP1A2 and moderate CYP2C9 inhibitor markedly inhibits the metabolism of agomelatine resulting in a 60-fold (range 12-412) increase of agomelatine exposure. Consequently, co-administration of agomelatine with potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin) is contraindicated.</p>', '<p>It is contraindicated in patients with hepatic impairment and hypersensitivity to the active substances or any of the excipients.</p>', '<p>The commonly reported adverse effects in the clinical trials of agomelatine are headache, nausea and diarrhea.</p>', '<p>For agomelatine, no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see Toxicology: Preclinical Safety Data under Actions). Caution should be exercised when prescribing to pregnant women. It is not known whether Agomelatine is excreted into human milk. agomelatine or its metabolites are excreted in the milk of lactating rats. Potential effects of agomelatine on the breastfeeding infant have not been established. If treatment with agomelatine is considered necessary, breastfeeding should be discontinued.</p>', '<p>It is found to increase the level of liver enzymes and so monitoring of enzyme level is warranted before starting therapy and therefore every 6 weeks.</p>', '<p>There is limited experience with agomelatine overdose. During the clinical development, there were a few reports of agomelatine overdose, taken alone (up to 450 mg) or in combination (up to 525 mg) with other psychotropic medicinal products. Signs and symptoms of overdose were limited and included drowsiness and epigastralgia. No specific antidotes for agomelatine are known. Management of overdose should consist of treatment of clinical symptoms and routine monitoring. Medical follow-up in a specialised environment is recommended.</p>', '<p>Atypical anti-depressant drugs</p>', '<p>Store in a cool and dry place away from light. Keep out of the reach of children.</p>', '<p>Children under 18 years: Should be given only on medical advice.<br />\r\n<br />\r\nChildren and adolescents: Agomelatine is not recommended in the treatment of depression in patients .<br />\r\n<br />\r\nUse in the elderly: Efficacy has not been clearly demonstrated in the elderly (65 years). Only limited clinical data is available on the use of Agomelatine in elderly patients 65 years with major depressive episodes. Therefore, caution should be exercised when prescribing Agomelatine to these patients.</p>', '2022-02-14 06:33:42', '2022-03-10 03:38:41'),
(53, 53, '<p>Albendazole is indicated in single and mixed infestations of-</p>\r\n\r\n<ul>\r\n	<li>Hookworm (Ancylostoma, Necator)</li>\r\n	<li>Roundworm (Ascaris)</li>\r\n	<li>Threadworm (Enterobius)</li>\r\n	<li>Whipworm (Trichuris)</li>\r\n	<li>Strongyloides</li>\r\n	<li>Tapeworm</li>\r\n	<li>Opisthorchi</li>\r\n	<li>Hydatid.</li>\r\n</ul>', '<p>Albendazole is a broad spectrum anthelmintic. Albendazole exhibits vermicidal, ovicidal and larvicidal activities. The drug is thought to exert its anthelmintic effect by blocking glucose uptake in the susceptible helminths, thereby depleting the energy level until it becomes inadequate for survival. Immobilization is followed by the parasite. These events may be a consequence of the binding and subsequent inhibition of parasite tubulin polymerization by Albendazole and its metabolites, although the drug also binds to human tubulin. Albendazole is extensively metabolized, probably in the liver. Albendazole is poorly absorbed from the gastrointestinal tract but rapidly undergoes extensive first-pass metabolism. The principal metabolite albendazole sulphoxide has anthelmintic activity and a plasma half-life of about 8.5 hrs. It is excreted in the urine together with other metabolites.</p>', '<p><strong>Adults &amp; children over 2 years</strong>:</p>\r\n\r\n<ul>\r\n	<li>400 mg (1 tablet or 10 ml suspension) as a single dose in cases of Enterobius vermicularis, Trichuris trichiura, Ascaris lumbricoides, Ancylostoma duodenale and Necator americanus.</li>\r\n	<li>In cases of strongyloidiasis or taeniasis, 400 mg (1 tablet or 10 ml suspension) daily should be given for 3 consecutive days. If the patient is not cured on follow-up after three weeks, a second course of treatment is indicated.&nbsp;</li>\r\n</ul>\r\n\r\n<p><strong>Children of 1-2 years</strong>: Recommended dose is a single dose of 200 mg (5 ml suspension).<br />\r\n<br />\r\n<strong>Children under 1 year</strong>: Not recommended.<br />\r\n<br />\r\n<strong>In Hydatid disease (Echinococcosis)</strong>:</p>\r\n\r\n<ul>\r\n	<li>Albendazole is given by mouth with meals in a dose of 400 mg twice daily for 28 days for patients weighing over 60 kg.</li>\r\n	<li>A dose of 15 mg/kg body weight daily in two divided doses (to a maximum total daily dose of 800 mg) is used for patients weighing less than 60 kg.</li>\r\n	<li>For cystic echinococcosis, the 28 days course may be repeated after 14 days without treatment, to a total of 3 treatment cycles.</li>\r\n	<li>For alveolar echinococcosis, cycles of 28 days of treatment followed by 14 days without treatment, may need to continue for months or years.</li>\r\n	<li>In giardiasis, 400 mg (1 tablet or 10 ml suspension) once daily for five days is used.</li>\r\n</ul>', '<p>No interaction involving Albendazole, either pharmacodynamic or pharmacokinetic, has been reported.</p>', '<p><strong>Neonates</strong>: Albendazole is not normally used in neonates.<br />\r\n<br />\r\n<strong>Children</strong>: Reduction of the dose from 400 mg to 200 mg may be indicated in children weighing less than 10 kg but there are no grounds for a general reduction in dosage to children.<br />\r\n<br />\r\n<strong>Pregnant woman</strong>: Albendazole should not be given during pregnancy or women thought to be pregnant. No information is available on placental transfer.<br />\r\n<br />\r\n<strong>Concurrent disease</strong>: There is no evidence to suggest that dose should be altered in renal, hepatic or cardiac failure.</p>', '<p>Gastrointestinal disturbances, headache, dizziness, changes in liver enzymes, rarely reversible alopecia; rash, fever, blood disorders including leucopenia and pancytopenia reported; allergic shock if cyst leakage; convulsion and meningism in cerebral disease.</p>', '<p>US FDA Pregnancy category of Albendazole is C. So, Albendazole should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.</p>', '<p>Blood counts and liver function tests before treatment and twice during each cycle; breastfeeding; exclude pregnancy before starting treatment. Albendazole should only be used in the treatment of Echinococcosis if there is constant medical supervision with regular monitoring of serum-transaminase concentrations and of leucocyte and platelet counts</p>', NULL, '<p>Anthelmintic</p>', '<p>Keep in a dry place, away from light and heat. Keep out of the reach of children.</p>', NULL, '2022-02-14 06:33:56', '2022-03-10 03:45:10');
INSERT INTO `generic_details` (`id`, `generic_id`, `indications`, `pharmacology`, `dosage_and_administration`, `interaction`, `contraindications`, `side_effects`, `pregnancy_and_lactation`, `precautions_and_warnings`, `overdose_effects`, `therapeutic_class`, `storage_conditions`, `use_in_special_populations`, `created_at`, `updated_at`) VALUES
(54, 54, '<p><strong>Shock:</strong>&nbsp;Albumin&nbsp;is indicated in the emergency treatment of shock and in other similar conditions where the restoration of blood volume is urgent. If there has been considerable loss of&nbsp;red blood cells,&nbsp;transfusion&nbsp;with packed red blood cells is indicated.<br />\r\n<br />\r\n<strong>Burns:</strong>&nbsp;Albumin or Albumin in either normal saline or dextrose is indicated to prevent marked hemoconcentration and to maintain appropriate&nbsp;electrolyte&nbsp;balance.<br />\r\n<br />\r\n<strong>Hypoproteinemia with or without edema:</strong>&nbsp;Albumin is indicated in those clinical situations usually associated with a low concentration of&nbsp;plasma&nbsp;protein&nbsp;and a resulting decreased circulating blood volume. Although&nbsp;diuresis&nbsp;may occur soon after albumin administration has been instituted, best results are obtained if albumin is continued until the normal serum protein level is regained.</p>', '<p>The main function of albumin results from its contribution to plasma colloid oncotic pressure and transport function. Albumin stabilizes circulating blood volume and carries hormones, enzymes, medicines, and toxins. Other physiological functions include antioxidant properties, free radical scavenging, in addition to maintenance capillary membrane integrity. Exogenously administered albumin increases the oncotic pressure of the intravascular system, moving fluids from the interstitial space, thereby decreasing edema and increasing the circulating blood volume. The increase in volume reduces the concentration and viscosity of blood in patients with decreased circulating blood volume while maintaining cardiac output in shock. In dehydrated patients, negligible effects exist on circulating blood volume. In addition to the above albumin replaces protein in patients with hypoproteinemia until the cause of the deficiency can be determined.<br />\r\n<br />\r\nThis drug has thousands of endogenous and exogenous targets. Human albumin also binds and carries a plethora of hydrophobic molecules, such as endogenous (i.e., cholesterol, fatty acids, bilirubin, thyroxine) or exogenous substances (for example, drugs and toxins), transition metal ions, as well as gas (nitric oxide [NO]), with resulting implications for their solubilisation, transport, metabolism, and detoxification.</p>', '<p><strong>Human albumin 25%</strong>&nbsp;is for intravenous administration only. Human albumin may be diluted with 5% glucose or 0.9% sodium chloride. Concentration, dosage, and infusion-rate should be adjusted to the patient&rsquo;s individual requirements and indication.</p>\r\n\r\n<ul>\r\n	<li>Hypovolemia: Initial dose 25 g is suggested.</li>\r\n	<li>Hypoalbuminemia: 50-75 gm</li>\r\n	<li>Prevention of central volume fluid removed depletion after</li>\r\n	<li>paracentesis due to cirrhotic ascites: 6-8 gm for every 1000 mL of ascitic.</li>\r\n	<li>OHSS: 50 to 100 gm over 4 hours and repeated at 4-12 hour intervals as necessary. 10-50 gm; single infusion.</li>\r\n	<li>ARDS: 25 g over 30 minutes and repeated at 8 hours for 3 days if necessary.</li>\r\n	<li>Burns: Determined by direct observation of vital sign or measurement of either plasma oncotic pressure or protein content.</li>\r\n</ul>\r\n\r\n<p><strong>Human albumin 20%</strong>: Measures of adequacy of circulating volume and not plasma albumin levels should be used to determine the dose required. If human albumin is to be administered, haemodynamic performance should be monitored regularly; this may include:</p>\r\n\r\n<ul>\r\n	<li>arterial blood pressure and pulse rate</li>\r\n	<li>central venous pressure</li>\r\n	<li>pulmonary artery wedge pressure</li>\r\n	<li>urine output</li>\r\n	<li>electrolyte</li>\r\n	<li>haematocrit / haemoglobin</li>\r\n</ul>\r\n\r\n<p>The solution can be directly administered by the intravenous route, or it can be diluted in an isotonic solution (e.g. 0.9% sodium chloride). In plasma exchange the infusion rate should be adjusted to the rate of removal.<br />\r\n<br />\r\n<strong>Human albumin 5%</strong>&nbsp;may be given intravenously without further dilution. This concentration is approximately isotonic and iso-osmotic with citrated plasma. Albumin (Human) in this concentration provides additional fluid for plasma volume expansion. Therefore, when it is administered to patients with normal blood volume, the rate of infusion should be slow enough to prevent too rapid expansion of plasma volume.<br />\r\n<br />\r\nIn the treatment of shock in an adult patient an initial dose of 500 mL of the 5% albumin solution is given as rapidly as tolerated. If response within 30 minutes is inadequate, an additional 500 mL of 5% albumin solution may be given. The 50 mL dosage form would be appropriate for pediatric use, with a dose of 10-20 mL per kg of body weight infused intravenously at a rate up to 5-10 mL per minute. Therapy should be guided by the clinical response, blood pressure and an assessment of relative anemia. If more than 1000 mL are given, or if hemorrhage has occurred, the administration of packed red blood cells may be desirable.<br />\r\n<br />\r\nIn severe burns, immediate therapy should include large volumes of crystalloid with lesser amounts of 5% albumin solution to maintain an adequate plasma volume. After the first 24 hours, the ratio of albumin to crystalloid may be increased to establish and maintain a plasma albumin level of about 2.5 g/100 mL or a total serum protein level of about 5.2 g/100 mL. However, an optimal regimen for the use of colloids, electrolytes and water after severe burns has not been established.<br />\r\n<br />\r\nThe infusion of Albumin (Human) as a nutrient in the treatment of chronic hypoproteinemia is not recommended. In acute hypoproteinemia, 5% albumin may be used in replacing the protein lost in hypoproteinemic conditions. However, if edema is present or if large amounts of albumin are lost, Albumin (Human) 25% is preferred because of the greater amount of protein in the concentrated solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>\r\n\r\n<p>&nbsp;</p>', '<p>Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.</p>', '<p>Albumin (Human) may be contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.</p>', '<p>Allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. Should an adverse reaction occur, slow or stop the infusion for a period of time which may result in the disappearance of the symptoms. If administration has been stopped and the patient requires additional Albumin (Human), material from a different lot should be used. Albumin (Human), particularly if administered rapidly, may result in vascular overload with resultant pulmonary edema.</p>', '<p>Pregnancy&nbsp;Category C.&nbsp;Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.</p>', '<p>Hypertension or low cardiac reserve; additional fluids for dehydrated patients. Monitor for signs of cardiac overload in injured or postoperative patients. May carry risk of viral transmission. Volume admin and rate of infusion must always be individualised according to situation and response. Pregnancy, lactation.</p>', NULL, '<p>Plasma expanders</p>', '<p>Store below 30&deg;C. Do not freeze.</p>', '<p>No clinical studies using Albumin (Human) have been conducted in pediatric patients. Safety and effectiveness in pediatric patients have not been established. However, extensive experience in patients suggests that children respond to Albumin (Human) in the same manner as adults.</p>', '2022-02-14 06:34:15', '2022-03-10 03:56:32'),
(55, 55, '<p>Alcaftadine eye drops is indicated for the prevention of itching associated with allergic conjunctivitis. Alcaftadine ophthalmic solution is an H1 receptor antagonist, in a sterile ophthalmic solution for topical ophthalmic use.</p>', '<p>This eye drops is a sterile topical ophthalmic solution containing Alcaftadine. Alcaftadine is an histamine receptor antagonist and inhibitor of the release of histamine from mast cell. It is also a potent histamine H2 and H4 receptor antagonist that has demonstrated anti-inflammatory property. In doing so, antihistaminic effect provides relief from itching associated with early phase of ocular allergic response, whereas mast cell stabilization inhibits the release of mediators such as cytokines and lipid mediators that play a role in late-phase response of allergic conjunctivitis.</p>', '<p>Adults and children 2 years and over: Instill one drop in each eye once daily.</p>', NULL, '<p>Alcaftadine is contraindicated in patients with hypersensitivity to any component in the product.</p>', '<p>The most frequent ocular reactions are eye irritation, burning or/and stinging upon instillation, eye redness and eye pruritus, nasopharyngitis and headache.</p>', '<p>Pregnancy category B. There are however, no adequate and well controlled studies in pregnant women, thus this drug should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Caution should be exercised while administered to a nursing woman.</p>', '<p>To minimize eye injury and contamination of the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. This preparation should not be used to treat contact lens related irritation and should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation this preparation. Lenses may be reinserted after 10 minutes following administration. If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.</p>', NULL, '<p>Ophthalmic Anti-allergic preparations</p>', '<p>Store in a cool (15&deg;C - 25&deg;C) and dry place protected from light. Do not use after one month once the cap is opened.</p>', '<p><strong>Pediatric Use</strong>: Safety and effectiveness in pediatric patients below the age of 2 years have not been established.<br />\r\n<strong>Geriatric Use</strong>: No overall differences in safety or effectiveness were observed between elderly and younger subjects.</p>', '2022-02-14 06:34:34', '2022-03-10 04:02:02'),
(56, 56, '<p>Alectinib indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.</p>', '<p>Alectinib is a highly selective and potent ALK and RET tyrosine kinase inhibitor.In nonclinicalstudies, inhibition of ALK tyrosine kinase activity led to blockage of downstream signaling pathways including STAT 3 and PI3K/AKT and inducedtumor cell death (apoptosis).<br />\r\n<br />\r\nAlectinib demonstratedin vitroand in vivoactivity against mutant forms of the ALK enzyme, including mutations responsible forresistance to crizotinib.The major metabolite of alectinib (M4) has shown similar in vitropotency and activity.<br />\r\n<br />\r\nBased on nonclinicaldata, alectinib is not a substrate of p-glycoprotein (P-gp) or breast cancer resistance protein (BCRP), which are both efflux transporters in the blood brain barrier, and is therefore able to distribute into and be retained within the central nervous system. Alectinibinducedtumor regressionin nonclinicalmousexenograft models, including antitumor activity in the brain, and prolonged survival inintracranial tumor animal models.</p>', '<p>The recommended dose of Alectinib is 600 mg (four 150 mg capsules) given orally, twice daily (total daily dose of 1200 mg). Patients with underlying severe hepatic impairment should receive a dose of 450 mg given orally twice daily (total daily dose of 900 mg). Alectinib hard capsules should be taken with food, swallowed whole and must not be opened or dissolved.</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong>Administration</strong></p>\r\n\r\n<p>Duration of Treatment: It is recommended that patients are treated with Alectinib until disease progression or unmanageable toxicity.<br />\r\n<br />\r\nDose Modifications: Management of adverse events may require temporary interruption, dosereduction, or discontinuation of treatment with Alectinib. The dose of Alectinib should be reduced in steps of 150 mg twice daily based on tolerability. Alectinib treatment should be permanently discontinued if patients are unable to tolerate the 300 mg twice-daily dose.</p>', '<p>In vitro studies indicate that neither alectinib nor its major active metabolite (M4) inhibits CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant concentrations. Alectinib and M4 show weak time-dependent inhibition of CYP3A4. In vitro, alectinib exhibits a weak induction potential of CYP3A4 and CYP2B6 at clinical concentrations. Results from a clinical drug-drug interaction study in ALK-positive NSCLC patients demonstrated that multiple doses of alectinib had no influence on the exposure of midazolam, a sensitive CYP3A substrate. Therefore, no dose adjustment is required for co-administered CYP3A substrates. Although in vitro studies indicate that alectinib is an inhibitor of CYP2C8, physiologically based pharmacokinetic (PBPK) modeling supports that at clinically relevant concentrations alectinib does not have the potential to increase plasma concentrations of co-administered substrates of CYP2C8.</p>', '<p>Alectinib is contraindicated in patients with a known hypersensitivity to alectinib or any of the excipients.</p>', '<p>The most common adverse drug reactions were constipation, edema including peripheral, generalized, eyelid, periorbital; myalgia (31% including myalgia and musculoskeletal pain), nausea, increased bilirubin (21% including increased blood bilirubin, hyperbilirubinemia and increased bilirubin conjugated), anemia (20%, including anemia and hemoglobin decreased), and rash (20%, including rash, rash maculopapular, dermatitis acneiform, erythema, rash generalized, rash papular, rash pruritic and rash macular).</p>', '<p><strong>Pregnancy</strong>: Women of childbearing potential must be advised to avoid pregnancy while on Alectinib. No clinical studies of Alectinib in pregnant women have been performed. Based on its mechanism of action, Alectinib may cause fetal harm when administered to a pregnant woman. Female patients or women who are partners of male patients receiving Alectinib, who become pregnant while taking Alectinib or during the 3 months following the last dose of Alectinib must contact their doctor and should be advised of the potential harm to the fetus.<br />\r\n<br />\r\n<strong>Lactation</strong>: It is not known whether Alectinib is excreted in human breast milk. No studies have been conducted to assess the impact of Alectinib on milk production or its presence in breast milk. As many drugs are excreted in human milk and because of the potential harm to the infant, mothers should be advised against breastfeeding while receiving Alectinib.<br />\r\n<br />\r\n<strong>Contraception</strong>: Female patients of child-bearing potential, or women of child-bearing potential who are partners of male patients receiving Alectinib, must use highly effective contraceptive methods during treatment and for at least 3 months following the last dose of Alectinib</p>', '<p><strong>Interstitial lung disease (ILD)/pneumonitis</strong>: Cases of ILD/pneumonitishave been reported in clinical trials with Alectinib. Patients should be monitored for pulmonary symptoms indicative of pneumonitis. Alectinib should be immediately interrupted in patients diagnosed with ILD/pneumonitis and should be permanently discontinued if no other potential causes of ILD/pneumonitis have been identified<br />\r\n<br />\r\n<strong>Hepatotoxicity</strong>: Elevations in alanine amino transferase (ALT) and aspartate amino transferase (AST) greater than 5 times the upper limit of normal (ULN) as well as bilirubin elevations of more than 3 times the ULN occurred in patients in pivotal clinical trials with Alectinib. The majority of these events occurred during the first 3months of treatment. In the pivotal Alectinib clinical trials it was reported that three patients with Grade 3‒4 AST/ALT elevations had drug-induced liver injury. Concurrent elevations in ALT or AST greater than or equal to three times the ULN and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred in 1 patient treated in Alectinib clinical trials.</p>', NULL, '<p>Anti neoplastic preparations, Protein kinase inhibitor</p>', '<p>Keep below 30&deg;C temperature, away from light &amp; moisture. Keep out of the reach of children.</p>', '<p><strong>Pediatric use</strong>: The safety and efficacy of alectinib in children and adolescents (&lt;18 years) have not been studied.<br />\r\n<br />\r\n<strong>Geriatric use</strong>: No dose adjustment of alectinib is required in patients&ge;65 years of age.<br />\r\n<br />\r\n<strong>Renal impairment</strong>: No dose adjustment is required in patients with mild or moderate renal impairment. alectinib has not been studied in patients with severe renal impairment, however,since alectinib elimination via the kidney is negligible, no dose adjustment is required inpatients with severe renal impairment<br />\r\n<br />\r\n<strong>Hepatic impairment</strong>: No dose adjustment is required in patients with underlying mild or moderate hepatic impairment. Patients with underlying severe hepatic impairment should receive a dose of 450 mg given orally twice daily (total daily dose of 900 mg)</p>', '2022-02-14 06:34:52', '2022-03-10 04:09:25'),
(57, 57, '<p>Alendronic acid is indicated for the-</p>\r\n\r\n<ul>\r\n	<li>Treatment of Osteoporosis in Postmenopausal Women: Alendronic acid is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, Alendronic acid increases bone mass and reduces the incidence of fractures, including those of the hip and spine.</li>\r\n	<li>Prevention of Osteoporosis in Postmenopausal Women: Alendronic acid is indicated for the prevention of postmenopausal osteoporosis.</li>\r\n	<li>Treatment to Increase Bone Mass in Men with Osteoporosis: Alendronic acid is indicated for treatment to increase bone mass in men with osteoporosis.</li>\r\n	<li>Treatment of Glucocorticoid-Induced Osteoporosis: Alendronic acid is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density.</li>\r\n	<li>Treatment of Paget&#39;s Disease of Bone: Alendronic acid is indicated for the treatment of Paget&rsquo;s disease of bone in men and women. Treatment is indicated in patients with Paget&#39;s disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.</li>\r\n</ul>', '<p>Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone turnover.<br />\r\n<br />\r\nAnimal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [3H] alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined 6 and 49 days after [3H] alendronate administration in rats and mice, respectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover (i.e., the number of sites at which bone is remodeled). In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass.</p>', '<p><strong>Treatment of Osteoporosis in Postmenopausal Women</strong>: The recommended dosage is one 70 mg tablet once weekly or one bottle of 70 mg oral solution once weekly or one 10 mg tablet once daily.<br />\r\n<br />\r\n<strong>Prevention of Osteoporosis in Postmenopausal Women</strong>: The recommended dosage is one 35 mg tablet once weekly or one 5 mg tablet once daily.<br />\r\n<br />\r\n<strong>Treatment to Increase Bone Mass in Men with Osteoporosis</strong>: The recommended dosage is one 70 mg tablet once weekly or one bottle of 70 mg oral solution once weekly or one 10 mg tablet once daily.<br />\r\n<br />\r\n<strong>Treatment of Glucocorticoid-Induced Osteoporosis</strong>: The recommended dosage is one 5 mg tablet once daily, except for postmenopausal women not receiving estrogen, for whom the recommended dosage is one 10 mg tablet once daily.<br />\r\n<br />\r\n<strong>Treatment of Paget&#39;s Disease of Bone</strong>: The recommended treatment regimen is 40 mg once a day for six months.</p>', '<p>The incidence of upper gastrointestinal side effects are increased with the concomitant use of non-steroidal anti-inflammatory agents and aspirin. Absorption of Alendronate is reduced in the presence of antacids and calcium supplements.</p>', '<p>Alendronic acid is contraindicated in patients with the following conditions:&nbsp;</p>\r\n\r\n<ul>\r\n	<li>Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia.</li>\r\n	<li>Inability to stand or sit upright for at least 30 minutes.</li>\r\n	<li>Do not administer Alendronic acid oral solution to patients at increased risk of aspiration.</li>\r\n	<li>Hypocalcemia.</li>\r\n	<li>Hypersensitivity to any component of this product. Hypersensitivity reactions including urticaria and angioedema have been reported.</li>\r\n</ul>', '<p>The commonest symptomatic side effects are constipation, diarrhoea, oesophageal ulcer, flatulence, dysphagia, musculoskeletal pain, headache, rarely rash, erythema, transient decrease in serum calcium and phosphate, nausea, vomiting, peptic ulceration, hypersensitivity reactions including urticaria and angio-oedema.</p>', '<p>Alendronic acid should not be given to pregnant women or nursing mother.</p>', '<ul>\r\n	<li>Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new or worsening symptoms occur.</li>\r\n	<li>Hypocalcemia can worsen and must be corrected prior to use.</li>\r\n	<li>Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop.</li>\r\n	<li>Osteonecrosis of the Jaw has been reported.</li>\r\n	<li>Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out an incomplete femoral fracture.</li>\r\n</ul>', NULL, '<p>Bisphosphonate preparations</p>', '<p>Store in a well-closed container at room temperature, 15-30&deg;C</p>', '<p><strong>Pediatric Use</strong>: Alendronic acid is not indicated for use in pediatric patients.<br />\r\n<br />\r\n<strong>Renal Impairment</strong>: Alendronic acid is not recommended for patients with creatinine clearance less than 35 mL/min. No dosage adjustment is necessary in patients with creatinine clearance values between 35-60 mL/min.<br />\r\n<br />\r\n<strong>Hepatic Impairment</strong>: As there is evidence that alendronate is not metabolized or excreted in the bile, no studies were conducted in patients with hepatic impairment. No dosage adjustment is necessary.</p>', '2022-02-14 06:35:12', '2022-03-10 19:32:17'),
(58, 58, '<p>Alendronic Acid &amp; Vitamin D3 is indicated in:</p>\r\n\r\n<ul>\r\n	<li>Treatment of osteoporosis in postmenopausal women.</li>\r\n	<li>Treatment of osteoporosis in men.</li>\r\n	<li>Treatment of osteoporosis as it increases the bone mass and reduces the incidence of fractures, including those of the hip and spine.</li>\r\n</ul>', '<p>Alendronate Sodium is a bisphosphonate that acts as a specific inhibitor of osteoclast mediated bone resorption. Alendronate is effective when administered at least 30 minutes before breakfast. It transiently distributes to soft tissues following administration but is then rapidly distributed to bone or excreted in the urine. Protein binding in human plasma is approximately 78%. There is no evidence that Alendronate is metabolised in animals or humans. At the cellular level, Alendronate shows preferential localization to sites of bone resorption, specially under osteoclasts. It inhibits osteoclast activity. In addition, bone formation exceeds bone resorption, leading to progressive gains in bone mass. Vitamin D is required for normal bone formation. Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate. Insufficiency is associated with negative calcium balance, increased parathyroid hormone levels, bone loss, and increased risk of skeletal fracture.</p>', '<p>Treatment of Osteoporosis in Postmenopausal Women: The recommended dosage is-</p>\r\n\r\n<ul>\r\n	<li>70 mg alendronate and 2800 IU vitamin D3 or</li>\r\n	<li>70 mg alendronate and 5600 IU vitamin D3 tablet once weekly.</li>\r\n	<li>For most osteoporotic women, the appropriate dose is 70 mg alendronate and 5600 IU vitamin D3 once weekly.</li>\r\n</ul>\r\n\r\n<p>Treatment to Increase Bone Mass in Men with Osteoporosis: The recommended dosage is-</p>\r\n\r\n<ul>\r\n	<li>70 mg alendronate and 2800 IU vitamin D3 or</li>\r\n	<li>70 mg alendronate and 5600 IU D3 tablet once weekly.</li>\r\n	<li>For most osteoporotic men, the appropriate dose is 70 mg alendronate and 5600 IU vitamin D3 once weekly.</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong>Administration</strong></p>\r\n\r\n<p>To permit adequate absorption, Alendronate &amp; Colecalciferol must be taken at least 30 minutes before the first food, beverage or medication of the day with plain water only. Other beverages (including mineral water), food and some medications are likely to reduce the absorption of Alendronate. To facilitate delivery to the stomach and thus to reduce the potential for esophageal irritation, Alendronate &amp; Colecalciferol tablet should only be swallowed upon rising for the day with a full glass of water. Patients should not lie down for at least 30 minutes after taking Alendronate until after their first food of the day. Alendronate &amp; Colecalciferol should not be taken at bed time.</p>', '<p>Calcium supplement, antacids and some oral medications will interfere with absorption of Alendronate if taken at the same time. Intravenous ranitidine makes the bioavailability of oral Alendronate double. Incidence of upper gastro-intestinal adverse events associated with NSAID and aspirin appears to be greater with concomitant administration of Alendronate. Mineral oils, orlistat, and bile acid sequestrants (e.g., cholestyramine, colestipol) may impair the absorption of vitamin D. Anticonvulsants, cimetidine, and thiazides may increase the catabolism of vitamin D.</p>', '<ul>\r\n	<li>Abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia.</li>\r\n	<li>Inability to stand or sit upright for at least 30 minutes.</li>\r\n	<li>Hypersensitivity to any component of this product.</li>\r\n	<li>Hypocalcaemia.</li>\r\n</ul>', '<p>Usually mild and generally do not require discontinuation of therapy. Side effects include esophageal reactions, abdominal pain and distension, diarrhoea or constipation, flatulence, musculoskeletal pain, headache, rash, erythema and transient decreases in serum calcium and phosphate.</p>', '<p>Pregnancy category C. Overdoses of vitamin D have shown teratogenic effects in pregnant animals. Alendronic Acid &amp; Vitamin D3 (Colecalciferol) should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus. Cholecalciferol and some of its active metabolites pass into breast milk. It is not known whether alendronate is excreted in human milk. Caution should be exercised when administered to lactating women.</p>', '<p>Hypocalcaemia and other disturbances of mineral metabolism should be corrected before initiation of therapy. Alendronate can cause local irritation of the upper gastro-intestinal mucosa. Caution should be used when Alendronate is given to patients with active upper gastrointestinal problems such as dysphagia, esophageal disease, gastritis, duodenitis or ulcers. Patients should stop taking medicine and consult their physician if they develop esophageal diseases.</p>', '<p>Hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer, may result from oral overdosage. &nbsp;Signs and symptoms of vitamin D toxicity include hypercalcemia, hypercalciuria, anorexia, nausea, vomiting, polyuria, polydipsia, weakness, and lethargy.</p>', '<p>Combined preparations: Inhibiting bone resorption</p>', '<p>Store in a cool and dry place. Protect from light &amp; moisture. Keep out of the reach of children.</p>', '<p>Dosing in elderly and renal insufficiency: No dosage adjustment is necessary for the elderly or for patients with mild-to-moderate renal insufficiency (creatinine clearance 35 to 60 mL/min). Alendronic Acid + Vitamin D3 (Colecalciferol) is not recommended for patients with more severe renal insufficiency (creatinine clearance&lt;35 mL/min) due to lack of experience.</p>', '2022-02-14 06:35:38', '2022-03-10 19:39:17'),
(59, 59, '<p>Alfacalcidol is indicated in:</p>\r\n\r\n<ul>\r\n	<li>It is used to increase the amount of vitamin D in your body. This often increases calcium levels as well which can help in treatment of certain illnesses.</li>\r\n	<li>In general this drug is used to treat diseases where the amount of calcium and phosphate (which is controlled by the level of vitamin D) in your body needs changing.</li>\r\n	<li>Benefits of being on this drug can include control of the levels of calcium and phosphate in your body.</li>\r\n	<li>Treat and prevent bone conditions that are caused by kidney failure (osteodystrophy)</li>\r\n	<li>Treat illnesses and abnormalities affecting the parathyroid glands which make a substance called the parathyroid hormone.</li>\r\n	<li>Correct low levels of calcium in the blood of newborn babies (hypocalcaemia)</li>\r\n	<li>Treat the softening and deformity of the bones due to lack of calcium (rickets or osteomalacia)</li>\r\n</ul>', '<p>The first step involved in the activation of vitamin D3 is a 25-hydroxylation which is catalysed by the 25-hydroxylase in the liver and then by other enzymes. The mitochondrial sterol 27-hydroxylase catalyses the first reaction in the oxidation of the side chain of sterol intermediates. The active form of vitamin D3 (calcitriol) binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.</p>', '<p><strong>Adults</strong>: The usual starting dose is 1 microgram each day. People usually take between 1 and 3 micrograms each day. Most people take between 0.25 and 1 microgram each day once the blood test results show the medicine is working.<br />\r\n<br />\r\nIf you have very low levels of calcium in your blood, your doctor may prescribe between 3 and 5 microgram each day. Your doctor may prescribe another medicine called a calcium supplement to take as well as Alfacalcidol. This will help to keep the right amount of calcium level in your blood.<br />\r\n<br />\r\n<strong>Elderly</strong>: The usual starting dose is 0.5 microgram each day.<br />\r\n<br />\r\nChildren:</p>\r\n\r\n<ul>\r\n	<li><strong>Newborn and premature babies</strong>: The usual starting dose is 0.05 to 0.1 microgram per kilogram of body weight each day. If the level of calcium in their blood is very low, up to 2 micrograms per kilogram of body weight may be needed each day. A dose of 0.1 microgram per kilogram body weight each day is used to stop low blood calcium levels in premature babies.</li>\r\n	<li><strong>Children weighing less than 20 kilograms</strong>: The usual starting dose is 0.05 microgram per kilogram body weight each day.</li>\r\n	<li><strong>Children weighing more than 20 kilograms</strong>: The usual starting dose is 1 microgram each day.</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>Administration : Should be taken with food.</p>', '<p>Thiazides may increase the risk of hypercalcaemia. Some antiepileptics e.g. carbamazepine, phenobarbital, phenytoin and primidone may increase vitamin D requirements. Rifampicin, isoniazid and corticosteroids may reduce the efficacy of vitamin D.</p>', '<p>Hypercalcaemia, metastatic calcification, hyperphosphataemia (except when occurring with hypoparathyroidism), hypermagnesaemia.</p>', '<p>Anorexia, nausea, vomiting, diarrhoea, lassitude, polyuria, sweating, headache, thirst, vertigo, pruritus, rash, urticaria. Hypercalcaemia, hypercalciuria and ectopic calcification.<br />\r\n<br />\r\nIn case of renal impairment, hyperphosphataemia. In hypercalcaemic dialysis patients, possibility of calcium influx from the dialysate should be considered.</p>', '<p>FDA has not yet classified the drug into a specified pregnancy category.</p>', '<p>Pregnancy, lactation, renal impairment, infants, elderly. Monitor serum levels of calcium in patients with renal failure. Caution in hypercalciuria in those with history of renal calculi. Avoid in patients with hypersensitivity to inj. containing propylene glycol.</p>', NULL, '<p>Vitamin in bone formation, Vitamin-D preparations</p>', '<p>Keep below 30&deg;C temperature, away from light &amp; moisture. Keep out of the reach of children.</p>', NULL, '2022-02-14 06:35:57', '2022-03-10 19:45:01'),
(60, 60, '<p>Alfuzosin Hydrochloride is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia(BPH), lower urinary tract symptoms (LUTS) including urinary frequency, nocturia, incomplete emptying and urinary hesitancy associated with BPH.</p>', '<p>Alfuzosin Hydrochloride is a selective antagonist of post-synaptic a1 adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. Alfuzosin Hydrochloride relaxes the tone of the prostate smooth muscle, prostate capsule, bladder neck and proximal urethra. It competitively and selectively binds to the post synaptic a1-adrenergic receptors in the lower urinary tract. It also relaxes sympathetic nervous stimulation, reduces resting urethral pressure and inhibits urethral hypertonia-induced sympathetic nervous stimulation. As an uroselective agent, Alfuzosin Hydrochloride preferentially binds to prostatic a1 receptors, blockage of these receptors result in reduction of BPH symptoms, improvement of urine flow and decreased potential for hypertensive events.</p>', '<p><strong>Benign prostatic hyperplasia (BPH)</strong>: The recommended dose is 10 mg to be taken once daily after a meal.<br />\r\n<br />\r\n<strong>Acute urinary retention (AUR)</strong>: In patients 65 years and older, 10 mg&nbsp; daily after a meal to be taken from the first day of catheterisation. The treatment should be administered for 3-4 days, 2-3 days during catheterisation and 1 day after its removal. In this indication no benefit has been established in patients under 65 years of age or if treatment is extended beyond 4 days.</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong>Administration : </strong>Alfuzosin Hydrochloride tablet should be swallowed whole.</p>', '<p>Combinations contra-indicated: Alpha-1-receptor blockers. Combinations to be taken into account: Antihypertensive drugs, nitrates, potent CYP3A4 inhibitors such as ketoconazole, itraconazole and ritonavir. Repeated 200mg daily dosing of ketoconazole, for seven days resulted in a 2.1-fold increase in Cmax and a 2.5-fold increase in exposure of Alfuzosin Hydrochloride 10mg when administered as a single dose under fed conditions (high fat meal). Other parameters such as tmax and t1/2 were not modified. Cmax and AUC of Alfuzosin Hydrochloride 10mg, when administered as a single dose under fed conditions, increased 2.3- fold and 3.0- fold, respectively following 8-day repeated 400mg ketoconazole daily dosing. The administration of general anaesthetics to patients receiving Alfuzosin Hydrochloride could cause profound hypotension. It is recommended that the tablets be withdrawn 24 hours before surgery.<br />\r\n<br />\r\nOther forms of interaction:&nbsp;No pharmacodynamic or pharmacokinetic interaction has been observed in healthy volunteers between Alfuzosin Hydrochloride and the following drugs: warfarin, digoxin, hydrochlorothiazide and atenolol.</p>', '<p>As with all alpha-1-blockers in some subjects, in particular patients receiving antihypertensive medications or nitrates, postural hypotension with or without symptoms (dizziness, fatigue, sweating) may develop within a few hours following administration. In such cases, the patient should lie down until the symptoms have completely disappeared. These effects are transient, occur at the beginning of treatment and do not usually prevent the continuation of treatment. The patient should be warned of the possible occurrence of such events. As with all alpha1-receptor blockers, Alfuzosin Hydrochloride should be used with caution in patients with acute cardiac failure. Care should be taken when Alfuzosin Hydrochloride is administered to patients who have had a pronounced hypotensive response to another alpha-1-blocker. Treatment should be initiated gradually in patients with hypersensitivity to alpha-1-blockers. Alfuzosin Hydrochloride should be administered carefully to patients being treated with antihypertensives. Blood pressure should be monitored regularly, especially at the beginning of treatment. Patients with congenital QTc prolongation, with a known history of acquired QTc prolongation or who are taking drugs known to increase the QTc interval should be evaluated before and during the administration of Alfuzosin Hydrochloride. In coronary patients, the specific treatment for coronary insufficiency should be continued. If angina pectoris reappears or worsens Alfuzosin Hydrochloride should be discontinued.&nbsp; As there are no clinical safety data available in patients with severe renal impairment (creatinine clearance &lt; 30ml/min), Alfuzosin Hydrochloride 10mg prolonged released tablets should not be administered to this patient group. Patients should be warned that the tablet should be swallowed whole. Any other mode of administration, such as crunching, crushing, chewing, grinding or pounding to powder should be prohibited. These actions may lead to inappropriate release and absorption of the drug and therefore possible early adverse reactions. The &lsquo;Intraoperative Floppy Iris Syndrome&rsquo; (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with alpha-1-blockers. Although the risk of this event with Alfuzosin Hydrochloride appears very low, ophthalmic surgeons should be informed in advance of cataract surgery of current or past use of alpha-1-blockers, as IFIS may lead to increased procedural complications. The ophthalmologists should be prepared for possible modifications to their surgical technique. Alfuzosin Hydrochloride 10mg prolonged release tablets contain hydrogenated castor oil which may cause stomach upset and diarrhoea.</p>', '<p>Classification of expected frequencies: Very common (&lt;1/10), common (&lt;1/100 to &lt;1/10), uncommon (&lt;1/1,000 to &lt;1/100), rare (&lt;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Nervous system disorders: Common: faintness/dizziness, headache; Uncommon: syncope, vertigo, malaise, drowsiness. Eye disorders: Uncommon: vision abnormal; Not known: intraoperative floppy iris syndrome. Cardiac disorders: Uncommon: tachycardia, palpitations, hypotension (postural); Very rare: New onset, aggravation or recurrence of angina pectoris in patients with pre-existing coronary artery disease; Not known: atrial fibrillation. Vascular disorders: Uncommon: hypotension (postural), flushing. Blood and lymphatic system disorders: Not known: neutropenia, thrombocytopenia. Respiratory, thoracic and mediastinal disorders: Uncommon: rhinitis. Gastro-intestinal disorders: Common: nausea, abdominal pain; Uncommon: diarrhoea, dry mouth, vomiting; Not known: vomiting. Hepatobiliary disorders: Frequency unknown: hepatocellular injury, cholestatic liver disease. Skin and subcutaneous tissue disorders: Uncommon: rash, pruritus; Very rare: urticaria, angioedema. Reproductive system and breast disorders: Frequency unknown: priapism. General disorders and administration site conditions: Common: asthenia; Uncommon: flushes, oedema, chest pain.</p>', '<p>Due to the type of indication this is not applicable.</p>', '<p>The administration of general anesthetics to patients receiving Alfuzosin could cause profound hypotension. It is recommended that the tablets be withdrawn 24 hours before surgery. If symptoms of angina pectoris start or get worse, taking Alfuzosin should be stopped.</p>', '<p>In case of overdosage, the patient should be hospitalised, kept in the supine position, and conventional treatment of hypotension should take place. In case of significant hypotension, the appropriate corrective treatment may be a vasoconstrictor that acts directly on vascular muscle fibres.</p>', '<p>BPH/ Urinary retention/ Urinary incontinence</p>', '<p>Store in a cool and dry place, protected from light</p>', '<p>Paediatric Population: Efficacy of Alfuzosin Hydrochloride has not been demonstrated in children aged 2 to 16 years. Therefore Alfuzosin Hydrochloride is not indicated for use in the paediatric population.</p>', '2022-02-14 06:36:24', '2022-03-10 19:47:38'),
(61, 61, '<p>This gel is indicated for the following scar treatment:</p>\r\n\r\n<ul>\r\n	<li>hypertrophic and keloid scars</li>\r\n	<li>scar that occurs after surgery</li>\r\n	<li>scar that occurs after amputation, burns and trauma</li>\r\n	<li>scar due to traumatic tendon contracture</li>\r\n</ul>', '<p><strong>Extract of Allium cepa</strong>: It is derived from the membrane of Allium cepa (onion membrane). It shows antiphlogistic efects through inhibition of infammatory mediators&rsquo; secretion and anti-allergenic efect. Extract of Allium cepa inhibits growth of fbroblast of diferent origin, particularly kelloidal fbroblasts. It has also bactericidal efect. While these properties stimulate primary wound healing, it prevents non-physiological scar formation.<br />\r\n<br />\r\n<strong>Heparin</strong>: In case of local application, it shows inhibitory efect on fbroblast proliferation. While heparin increases tissue hydration, it reduces irritation resulted from induration and infammation.<br />\r\n<br />\r\n<strong>Allantoin</strong>: Allantoin stimulates cellular proliferation. It also supports the development of healthy cells. Allantoin is convenient substance for the treatment of scar through its properties of stimulating epithelization and providing elastic surface formation.<br />\r\n<br />\r\nClinical studies:</p>\r\n\r\n<ul>\r\n	<li><strong>Evaluation of the use of Extract of Allium cepa, Heparin &amp; Allantoin gel for the prevention of scar formation</strong>: Total 1,268 patients were evaluated and after 2 to 3 months of treatment with Extract of Allium cepa, Heparin &amp; Allantoin gel, a reduction of 31.5% in mean scar width and 47.8% reduction of mean scar height at the end of the observation period.</li>\r\n	<li><strong>Assessment of the use of Extract of Allium cepa, Allantoin, and Heparin in the early treatment of C-section scars</strong>: A total of 61 females, aged &ge;18 years, who had given birth by C-section were evaluated. After six weeks of treatment, the gel showed signifcant improvement of the color, stifness and irregularity of C-section scars.</li>\r\n</ul>', '<p>This gel should be applied 3-4 times a day to the affected area and massaged gently in order to achieve better penetration. Continue with a circular motion until the gel is completely absorbed. Treatment may take several weeks or months depending on the size of existing scars and contracture.<br />\r\n<br />\r\nThis gel is very safe and its tolerability has been proven in numerous clinical studies. Small children and even babies can be treated safely.</p>', '<p>There is no known and reported drug interaction.</p>', '<p>This gel should not be used in patients with known hypersensitivity to any of its ingredients.</p>', '<p>This gel is generally well tolerated even in long-term use. In rare cases, some local irritations are reported such as slight erythema and itching. These side effects do not require discontinuation of the treatment.</p>', '<p>There are no studies conducted during pregnancy and lactation periods. Therefore it should be used with caution.</p>', '<p>During treatment of fresh scars with this preparation, excess cold, UV lights and abrupt massage should be avoided. Avoid contact with eyes, the inside of the nose or mouth and other mucous membranes.</p>', NULL, NULL, '<p>Store in a cool and dry place, below 25&deg;C. Protect from direct sunlight and moisture. Do not freeze. Keep the medicine out of the reach of children.</p>', NULL, '2022-02-14 06:36:58', '2022-03-10 19:51:09');
INSERT INTO `generic_details` (`id`, `generic_id`, `indications`, `pharmacology`, `dosage_and_administration`, `interaction`, `contraindications`, `side_effects`, `pregnancy_and_lactation`, `precautions_and_warnings`, `overdose_effects`, `therapeutic_class`, `storage_conditions`, `use_in_special_populations`, `created_at`, `updated_at`) VALUES
(62, 62, '<p>Allopurinol is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis). Allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phospho ribosyltransferase. Allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.</p>', '<p>Allopurinol is a xanthine oxidase inhibitor which is administered orally. It acts on purine catabolism without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. Allopurinol is a structural analogue of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, the end product of purine metabolism. Allopurinol is approximately 90% absorbed from the GI tract. Peak plasma levels generally occur at 1.5 hours to 4.5 hours. It has a plasma half life of about 1 to 2 hours. Approximately 20% of the ingested Allopurinol is excreted in the faeces.</p>', '<p><strong>Adults</strong>: Allopurinol should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions.<br />\r\n<br />\r\n<strong>Children</strong>: Children under 15 years: 10 to 20 mg/kg body weight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.<br />\r\n<br />\r\n<strong>Elderly</strong>: In the absence of specific data, the lowest dosage which produces satisfactory urate reduction should be used.<br />\r\n<br />\r\n<strong>Dosage in renal impairment</strong>: In severe renal insufficiency, it may be advisable to use less than 100 mg per day or to use single doses of 100mg&nbsp;at longer intervals than one day.</p>', '<p>When 6-mercaptopurine or azathioprine is given concurrently with Allopurinol, only one-quarter of the usual dose of 6- mercaptopurine or azathioprine should be given because inhibition of xanthine oxidase will prolong their activity. Evidence suggests that the plasma half-life of vidarabine is increased in the presence of allopurinol. When the two products are used concomitantly extra vigilance is necessary, to recognise enhanced toxic effects. Theophylline levels should be monitored in patients starting or increasing allopurinol therapy. An increase in frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs. Reports suggest that the plasma concentration of ciclosporin may be increased during concomitant treatment with allopurinol.</p>', '<p>Allopurinol tablet is contra-indicated in patients with&nbsp;known hypersensitive to allopurinol.</p>', '<p>Rashes, gastro intestinal disorder&rsquo;s, rearly malaise, headache,&nbsp;vertigo, drowsiness, visual and test disturbances, hypertension, alopecia,&nbsp;hepatotoxicity, neuropathy, gynaeconastia and blood disorders.</p>', '<p>There is inadequate evidence of safety of&nbsp;Allopurinol in human pregnancy. Use in pregnancy only when there is no&nbsp;safer alternative and when the disease itself carries risk for the mother or&nbsp;unborn child. There are no data concerning the effects of allopurinol or its&nbsp;metabolites on the breast-feed baby.</p>', '<p>Allopurinol should be withdrawn immediately when a skin rash&nbsp;or other evidence of sensitivity occurs. Reduced doses should be used in&nbsp;patients with hepatic or renal impairment. Patients under treatment for&nbsp;hypertension or cardiac insufficiency may have some concomitant&nbsp;impairment of renal function and allopurinol should be used with care in this&nbsp;group.</p>', NULL, '<p>Drugs used in Gout</p>', '<p>Store in a cool and dry place, protected from light.</p>', '<p>Ingestion of up to 22.5 g allopurinol without adverse effect has been reported. Symptoms and signs including nausea, vomiting, diarrhoea and dizziness have been reported in a patient who ingested 20 gm allopurinol. Adequate hydration to maintain optimum diuresis facilitates excretion of allopurinol and its metabolites. If considered necessary haemodialysis may be used.</p>', '2022-02-14 06:37:25', '2022-03-10 20:02:42'),
(63, 63, '<p>This tablet is indicated for-</p>\r\n\r\n<ul>\r\n	<li>Reduction of neurological damage &amp; accelerates recovery after cerebral stroke</li>\r\n	<li>Minor age-related neurological disorders</li>\r\n	<li>Some visual disorders related to the circulation</li>\r\n	<li>Some disorders of the inner ear related to circulation (hearing loss, dizziness, buzzing sounds in the ear).</li>\r\n</ul>', '<p>Almitrine Bismesylate &amp; Raubasine combines raubasine, a vasodilator; and almitrine, a respiratory stimulant. Raubasine has a adrenolytic activity which is predominantly related to a post-synaptic blocking effect. Furthermore, under conditions of cerebral hypoxia, almitrine causes an increase in the partial pressure of oxygen in arterial blood (Pa02); almitrine causes an increase in the Pa02&nbsp;and an increase in the oxygen saturation in arterial blood (Sa02), without modifying ventilatory parameters.</p>', '<p>1 tablet once or twice daily (taken separately, several hours apart), without exceeding 2 tablets per day. Or, as directed by the registered physicians.</p>', '<p>Do not associate with MAO-l (monoamine oxidase inhibitor), Not to be used concurrently with other almitrine-containing preparations.</p>', '<p>This tablet is contraindicated in patients with hypersensitivity to any of the ingredients of it or severe hepatic impairment.</p>', '<p>Weight loss, nausea, sensations of heaviness or burning in the stomach, gastrointestinal disorders, diarrhoea or constipation, insomnia, drowsiness, agitation, anxiety, dizziness, palpitations.</p>', '<p>It is not recommended in pregnancy. It should be used with caution only when the expected benefit to the mother is greater than the possible risk to the fetus.</p>', '<p>Due to the presence of lactose, this drug should not be used in the case of galactosemia, of glucose and galactose malabsorption syndrome or of lactose deficiency (rare metabolic diseases). Do not exceed the recommended dose.</p>', NULL, '<p>Cerebral vasodilator &amp; Neurosensory oxygenator drugs</p>', '<p>Store at a cool and dry place, protected from light and moisture. Keep out of reach of children.</p>', NULL, '2022-02-14 06:37:58', '2022-03-15 04:35:10'),
(64, 64, '<p>Almotriptan is prescribed to treat the acute headache phase of migraine attacks with or without aura. Almotriptan is the only oral triptan approved in the USA for the treatment of migraine in adolescent from 12 to 17 years of age.</p>', '<p>Almotriptan is a selective and potent serotonin (5-hydroxytryptamine 1B/1D) agonist. Almotriptan binds to specific serotonin receptors on meningeal arteries inhibiting the release of vasoactive peptides and causing constriction of the arteries. It has a limited effect on arteries supplying blood to the brain and little effect on cardiac and pulmonary vessels.</p>', '<p><strong>Acute Treatment of Migraine Attacks</strong>: The recommended dose of Almotriptan in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. If the headache is relieved after the initial almotriptan malate dose but returns, the dose may be repeated after 2 hours. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.<br />\r\n<br />\r\n<strong>Hepatic Impairment</strong>: The recommended starting dose of almotriptan malate in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period<br />\r\n<br />\r\n<strong>Renal Impairment</strong>: The recommended starting dose of almotriptan malate in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period</p>', '<p>These drugs have been reported to cause prolonged vasospastic reactions. Cases of life-threatening serotonin syndrome have been reported during combined use of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs).</p>', '<p>As with other 5-HT1B/1D receptor agonists, almotriptan should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal&#39;s angina) or severe hypertension and uncontrolled mild or moderate hypertension. Concomitant administration with ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/1D agonists is contraindicated.</p>', '<p>Serious cardiac reactions, including myocardial infarction, have occurred following the use of almotriptan malate Tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD (Coronary Artery Disease).</p>', '<p>Pregnancy Category C. There is no data regarding excretion of almotriptan in human milk.</p>', '<p>Hypersensitivity to the active substance or to any of the excipients. Patients with severe hepatic impairment, with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA) Peripheral vascular disease.</p>', NULL, '<p>5-HT Agonists</p>', '<p>Keep below 30&deg; C temperature in a dry place. Protected from light. Do not freeze. Keep out of the reach of children.</p>', NULL, '2022-02-14 06:38:14', '2022-03-15 04:42:53'),
(65, 65, '<p>Alogliptin is indicated for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It can be used as monotherapy or in combination with other antidiabetic medications, including metformin, sulfonylureas, thiazolidinediones, or insulin.</p>', '<p>Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 diabetes, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is preserved. Alogliptin is a DPP-4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus. Alogliptin selectively binds to and inhibits DPP-4 but not DPP-8 or DPP-9 activity in vitro at concentrations approximating therapeutic exposures.</p>', '<p>The recommended dosage of alogliptin is 25 mg once daily with or without food.<br />\r\n<br />\r\nPatients with Renal Impairment:</p>\r\n\r\n<ul>\r\n	<li>No dose adjustment of Alogliptin is necessary for patients with mild renal impairment (creatinine clearance &ge;60 mL/min).</li>\r\n	<li>The dose of Alogliptin is 12.5 mg once daily for patients with moderate renal impairment (creatinine clearance &ge;30 to &lt;60 mL/min).</li>\r\n	<li>The dose of Alogliptin is 6.25 mg once daily for patients with severe renal impairment (creatinine clearance &ge;15 to &lt;30 mL/min) or with end-stage renal disease (ESRD) (creatinine clearance &lt;15 mL/min or requiring hemodialysis).</li>\r\n</ul>\r\n\r\n<p>Patients requiring hemodialysis can receive their dose of alogliptin without regard to the timing of the dialysis.</p>', '<p>Alogliptin is primarily renally excreted, and CYP-450&ndash;related metabolism is negligible. Alogliptin is not an inducer or inhibitor of CYP-450 enzymes.1 Clinically relevant interactions have not been observed with the CYP substrates or inhibitors tested or with renally excreted drugs.</p>', '<p>Alogliptin is contraindicated in patients with a history of serious hypersensitivity reactions, such as anaphylaxis, angioedema, or severe cutaneous adverse reactions, to alogliptin-containing products.</p>', '<p>The most common side effects of alogliptin are headaches, indigestion, diarrhoea and skin rashes. Adverse events include mild hypoglycemia based on clinical studies. Alogliptin may also cause joint pain that can be severe and disabling. In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of heart failure.</p>', '<p><strong>Use in Pregnancy:&nbsp;</strong>Alogliptin is in Pregnancy Category B. Abnormalities were not observed in animal models; however, placental transfer to the fetus was observed. Alogliptin should be used in pregnancy only if clearly needed.<br />\r\n<br />\r\n<strong>Use in Lactation:&nbsp;</strong>Alogliptin is secreted in the milk of lactating rats in a 2:1 ratio to plasma. It is not known whether it is excreted in human milk. Caution is advised if alogliptin is administered to a breastfeeding woman.</p>', '<p><strong>Pancreatitis:</strong>&nbsp;Acute pancreatitis has been reported in patients receiving alogliptin therapy. Patients should be monitored for signs and symptoms of pancreatitis, and therapy should be discontinued if pancreatitis is suspected. It is unknown whether patients with a history of pancreatitis have an increased risk of developing pancreatitis while receiving alogliptin.<br />\r\n<br />\r\n<strong>Hypersensitivity Reactions:</strong>&nbsp;Serious hypersensitivity reactions, including anaphylaxis, angioedema, and severe cutaneous reactions including Stevens-Johnson syndrome, have been observed in patients receiving alogliptin therapy. It is unknown whether patients with a history of angioedema with another DPP-4 inhibitor will be predisposed to angioedema with alogliptin.<br />\r\n<br />\r\n<strong>Heart Failure:&nbsp;</strong>Consider the risks and benefits of alogliptin prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy. Patients should be advised of the characteristic symptoms of heart failure and should be instructed to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of alogliptin.<br />\r\n<br />\r\nInsulin and insulin secretagogues, such as sulfonylureas, are known to cause hypoglycemia. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with angioedema.</p>', '<p>The highest doses of Alogliptin administered in clinical trials were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 diabetes (equivalent to 32 times and 16 times the maximum recommended clinical dose of 25 mg, respectively). No serious adverse events were observed at these doses. In the event of an overdose, it is reasonable to institute the necessary clinical monitoring and supportive therapy as dictated by the patient&#39;s clinical status. Per clinical judgment, it may be reasonable to initiate removal of unabsorbed material from the gastrointestinal tract. Alogliptin is minimally dialyzable; over a 3-hour hemodialysis session, approximately 7% of the drug was removed. Therefore, hemodialysis is unlikely to be beneficial in an overdose situation. It is not known if Alogliptin is dialyzable by peritoneal dialysis.</p>', '<p>Dipeptidyl Peptidase-4 (DPP-4) inhibitor</p>', '<p>Keep below 30&deg;C temperature, away from light &amp; moisture. Keep out of the reach of children.</p>', '<p><strong>Pediatric Use</strong>: Safety and effectiveness of Alogliptin in pediatric patients have not been established.<br />\r\n<br />\r\n<strong>Geriatric Use</strong>: Of the total number of patients (N=8507) in clinical safety and efficacy studies treated with Alogliptin, 2064 (24.3%) patients were 65 years and older and 341 (4%) patients were 75 years and older. No overall differences in safety or effectiveness were observed between patients 65 years and over and younger patients. While this clinical experience has not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out.<br />\r\n<br />\r\n<strong>Hepatic Impairment</strong>: No dose adjustments are required in patients with mild to moderate hepatic impairment (Child-Pugh Grade A and B) based on insignificant change in systemic exposures (e.g., AUC) compared to subjects with normal hepatic function in a pharmacokinetic study. Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh Grade C). Use caution when administering Alogliptin to patients with liver disease.</p>', '2022-02-14 06:38:36', '2022-03-15 04:49:41'),
(66, 66, '<p><strong>Alphanate, (antihemophilic factor/von Willebrand factor complex), is indicated for</strong>:</p>\r\n\r\n<ul>\r\n	<li>Control and prevention of bleeding episodes and&nbsp;perioperative&nbsp;management in adult and pediatric patients with&nbsp;Factor VIII(FVIII) deficiency due to&nbsp;hemophilia A.</li>\r\n	<li>Surgical and/or invasive procedures in adult and pediatric patients with&nbsp;von Willebrand Disease&nbsp;(VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery.</li>\r\n</ul>', '<p>Antihemophilic Factor/ Von Willebrand Factor Complex (Human) contains Antihemophilic Factor (FVIII) and von Willebrand Factor (VWF), constituents of normal plasma, which are required for clotting. The administration of Alphanate temporarily increases the plasma level of FVIII, thus minimizing the hazard of hemorrhage in patients with hemophilia A. FVIII is an essential cofactor in activation of factor X leading to formation of thrombin and fibrin. VWF promotes platelet aggregation and platelet adhesion on damaged vascular endothelium; it also serves as a stabilizing carrier protein for the procoagulant protein FVIII.</p>', '<p>Alphanate contains the labeled amount of Factor VIII expressed in International Units (IU) FVIII/vial and Willebrand.<br />\r\n<br />\r\n<strong>Factor</strong>: Ristocetin Cofactor activity in IU VWF:RCo/vial.<br />\r\n<br />\r\n<strong>Hemophilia A</strong>: Control and prevention of bleeding episodes</p>\r\n\r\n<ul>\r\n	<li>Dose (units) = body weight (kg) x desired FVIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL)</li>\r\n	<li>Frequency of intravenous injection of the reconstituted product is determined by the type of bleeding episode and the recommendation of the treating physician</li>\r\n</ul>\r\n\r\n<p><strong>Von Willebrand Disease</strong>: Surgical and/or invasive procedure in adult and pediatric patients except Type 3 undergoing major surgery</p>\r\n\r\n<ul>\r\n	<li><strong>Adults</strong>: Pre-operative dose of 60 IU VWF:RCo/kg body weight; subsequent doses of 40-60 IU VWF:RCo/kg/body weight at 8-12 hour intervals post-operative as clinically needed.</li>\r\n	<li><strong>Pediatric</strong>: Pre-operative dose of 75 IU VWF:RCo/kg/body weight; subsequent doses of 50-75 IU VWF:RCo/kg body weight at 8-12 hour intervals post-operative as clinically needed.</li>\r\n	<li>Dosage based on protocol used in the Alphanate prospective clinical trial according to judgment of the investigator.</li>\r\n</ul>\r\n\r\n<p><strong>Pediatric Use</strong>-</p>\r\n\r\n<ul>\r\n	<li><strong>Hemophilia A Indication</strong>: Clinical trials for safety and effectiveness in pediatric hemophilia A patients 16 years of age and younger have not been conducted.</li>\r\n	<li><strong>VWD Indication</strong>: The hemostatic efficacy of Alphanate has been studied in 20 pediatric subjects with VWD 18 years of age and under. Based on the data from a subset of these subjects, age had no effect on the pharmacokinetics of VWF:RCo. There were no clinically important differences between pediatric patients and adults.</li>\r\n</ul>\r\n\r\n<p><strong>Geriatric Use</strong>: No human or animal data. Use only if clearly needed.</p>\r\n\r\n<p><strong>Administration</strong></p>\r\n\r\n<p>Alphanate is for intravenous use only after reconstitution. Use plastic disposable syringes. Do not refrigerate after reconstitution. Reconstituted Alphanate may be stored at room temperature (not to exceed 30&deg; C) prior to administration, but administer intravenously within three hours.<br />\r\n<br />\r\nDiscard any unused contents into the appropriate safety container. Do not administer Alphanate at a rate exceeding 10 mL/minute.</p>', '<p>None known.</p>', '<p>Alphanate is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.</p>', '<p>The most frequent adverse events reported with Alphanate in &gt;5% of patients are respiratory distress, pruritus, rash, urticaria, face<br />\r\nedema, paresthesia, pain, fever, chills, joint pain and fatigue</p>', '<p><strong>Pregnancy</strong>: No human or animal data. Use only if clearly needed<br />\r\n<br />\r\n<strong>Labor and Delivery</strong>: No human or animal data. Use only if clearly needed<br />\r\n<br />\r\n<strong>Nursing Mothers</strong>: No human or animal data. Use only if clearly needed</p>', '<p>Risk of thromboembolic events &amp; infections. Pregnancy.</p>', NULL, '<p>Haemostatics</p>', NULL, '<p><strong>Pediatric Use</strong>: Clinical trials for safety and effectiveness in pediatric hemophilia A patients have not been conducted. The hemostatic efficacy of Alphanate has been studied in 20 pediatric subjects with VWD 18 years of age and under. Based on the data from a subset of these subjects, age had no effect on the pharmacokinetics of VWF:RCo<br />\r\n<br />\r\n<strong>Geriatric Use</strong>: No human or animal data. Use only if clearly needed</p>', '2022-02-14 06:38:57', '2022-03-15 04:55:52'),
(67, 67, '<p>Alprazolam is indicated in-</p>\r\n\r\n<ul>\r\n	<li>Anxiety disorder</li>\r\n	<li>Short term relief of anxiety</li>\r\n	<li>Anxiety associated with depression</li>\r\n	<li>Panic disorder, with or without agoraphobia.</li>\r\n</ul>', '<p>Alprazolam is a triazole analog of the 1,4-benzodiazepine class of drugs. It is an anxiolytic with hypnotic and anticonvulsive properties. Alprazolam is presumed to produce its effects via interacting with the Gamma Aminobutyric Acid (GABA)- benzodiazepine receptor complex. Like all benzodiazepines, it causes a dose-related CNS depressant activity varying from mild impairment of task performance to hypnosis.</p>', '<p>Treatment should be initiated with a dose of 0.25 to 0.5 mg three times daily. Depending on the response, dose may be increased at intervals of 3 to 4 days in increments of no more than 1 mg/day. The maximum dose should not exceed 4 mg/day. Occasional patients with panic disorder may need as much as 10 mg a day to achieve a successful response and in these cases periodic reassessment and consideration of dosage adjustment is required.<br />\r\n<br />\r\nDosage should be individualized for maximum beneficial effect with the lowest possible dose. If side-effects occur at starting dose, dose may be lowered. When discontinuing therapy, dosage should be reduced gradually by no more than 0.5 mg every three days.<br />\r\n<br />\r\nIn elderly patients or in patients with advanced liver disease, the usual starting dose is 0.25 mg, two or three times daily and may be gradually increased if needed and tolerated.<br />\r\n<br />\r\nAlprazolam 1 mg should be administered once daily, preferably in the morning by patients who are on multiple dosage regimens of Alprazolam 0.25/0.5 mg. The tablets should be taken intact, they should not be chewed, crushed, or broken.</p>', '<p>The CNS-depressant action of Alprazolam may be aggravated by concomitant use of other psychotropic drugs, anticonvulsants, antihistaminics, alcohol and oral ontraceptives.</p>', NULL, '<p>Side effects, if occur, are generally observed at the beginning of therapy and usually disappear upon continued medication. The most frequent side effects are drowsiness and light-headedness. The other side effects, that may occur include depression, headache, confusion, dry mouth, constipation, etc.</p>', '<p>Alprazolam has been categorized in pregnancy category D; that means, it should be avoided in pregnancy. Like other benzodiazepines, Alprazolam is assumed to be excreted in breast milk. Therefore, nursing should not be undertaken by mothers who must use Alprazolam.</p>', '<p>Because Alprazolam may produce psychological and physical dependence, the increment of dose or abrupt discontinuation of Alprazolam therapy should not be done without the physician&#39;s advice. The duration of therapy must be determined by the physicians. Alprazolam should be administered with caution to patients with hepatic or renal disease, chronic pulmonary insufficiency, or sleep apnea.</p>', '<p>Manifestations of Alprazolam overdosage include somnolence, confusion, impaired coordination, diminished reflexes, and coma. In such cases of overdosage general supportive measures should be employed along with immediate gastric lavage.</p>', '<p>Benzodiazepine sedatives</p>', '<p>Keep below 30&deg;C temperature, away from light &amp; moisture. Keep out of the reach of children.</p>', '<p>The safety and effectiveness of Alprazolam in individuals below 18 years of age have not been established.</p>', '2022-02-14 06:39:14', '2022-03-15 05:05:38'),
(68, 68, '<p><strong>Acute Ischemic Stroke</strong>: Alteplase is indicated for the treatment of acute ischemic stroke. Exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment. Initiate treatment as soon as possible but within 3 hours after symptom onset.<br />\r\n<br />\r\n<strong>Acute Myocardial Infarction</strong>: Alteplase is indicated for use in acute myocardial infarction (AMI) for the reduction of mortality and the reduction of the incidence of heart failure.<br />\r\n<br />\r\n<strong>Pulmonary Embolism</strong>: Alteplase is indicated for the lysis of acute massive pulmonary embolism, defined as:</p>\r\n\r\n<ul>\r\n	<li>Acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments.</li>\r\n	<li>Acute pulmonary emboli accompanied by unstable hemodynamics, e.g., failure to maintain blood pressure without supportive measures.</li>\r\n</ul>', '<p>Alteplase is a serine protease responsible for fibrin-enhanced conversion of plasminogen to plasmin. It produces limited conversion of plasminogen in the absence of fibrin. When introduced into the systemic circulation at pharmacologic concentration, alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. This initiates local fibrinolysis with limited systemic proteolysis.<br />\r\n<br />\r\n<strong>Pharmacodynamics</strong>: Following administration of 100 mg Alteplase, there is a decrease (16%-36%) in circulating fibrinogen. In a controlled trial, 8 of 73 patients (11%) receiving Alteplase (1.25 mg/kg body weight over 3 hours) experienced a decrease in fibrinogen to below 100 mg/dL.<br />\r\n<br />\r\n<strong>Pharmacokinetics</strong>: Alteplase in acute myocardial infarction (AMI) patients is rapidly cleared from the plasma with an initial half-life of less than 5 minutes. There is no difference in the dominant initial plasma half-life between the 3-hour and accelerated regimens for AMI. The plasma clearance of alteplase is 380-570 mL/min, primarily mediated by the liver. The initial volume of distribution approximates plasma volume.</p>', '<p><strong>Acute Ischemic Stroke</strong>: Administer Alteplase as soon as possible but within 3 hours after onset of symptoms. The recommended dose is 0.9 mg/kg (not to exceed 90 mg total dose), with 10% of the total dose administered as an initial intravenous bolus over 1 minute and the remainder infused over 60 minutes. During and following Alteplase administration for the treatment of acute ischemic stroke, frequently monitor and control blood pressure. In patients without recent use of oral anticoagulants or heparin, Alteplase treatment can be initiated prior to the availability of coagulation study results. Discontinue Alteplase if the pretreatment International Normalized Ratio (INR) is greater than 1.7 or the activated partial thromboplastin time (aPTT) is elevated.<br />\r\n<br />\r\n<strong>Acute Myocardial Infarction</strong>: Administer Alteplase as soon as possible after the onset of symptoms. The recommended total doses for acute myocardial infarction (AMI) is based on patient weight, not to exceed 100 mg, regardless of the selected administration regimen (accelerated or 3 hour). There are two Alteplase dose regimens (accelerated and 3-hour) for use in the management of AMI; there are no controlled studies to compare clinical outcomes with these regimens<br />\r\n<br />\r\n<strong>Pulmonary Embolism (PE)</strong>: The recommended dose is 100 mg administered by IV infusion over 2 hours. Institute parenteral anticoagulation near the end of or immediately following the Alteplase infusion when the partial thromboplastin time or thrombin time returns to twice normal or less.</p>\r\n\r\n<p><strong>Administration</strong></p>\r\n\r\n<p>Following bolus dose, if indicated:</p>\r\n\r\n<ul>\r\n	<li><strong>50 mg vials</strong>: administer using either a polyvinyl chloride bag or glass vial and infusion set.</li>\r\n	<li><strong>100 mg vials</strong>: remove from the vial any quantity of drug in excess of that specified for patient treatment. Insert the spike end of an infusion set through the same puncture site created by the transfer device in the stopper of the vial of reconstituted Alteplase. Peel the clear plastic hanger from the vial label. Hang the Alteplase vial from the resulting loop.</li>\r\n</ul>\r\n\r\n<p>Alteplase is for intravenous administration only. Extravasation of Alteplase infusion can cause ecchymosis or inflammation. If extravasation occurs, terminate the infusion at that IV site and apply local therapy. Do not add any other medication to infusion solutions containing Alteplase.</p>', '<p>The interaction of Alteplase with other cardioactive or cerebroactive drugs has not been studied. Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Alteplase therapy. In the post-marketing setting, there have been reports of orolingual angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors.</p>', '<p><strong>Acute Ischemic Stroke</strong>: Do not administer Alteplase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit [see Warnings and Precautions (5.1)]:</p>\r\n\r\n<ul>\r\n	<li>Current intracranial hemorrhage</li>\r\n	<li>Subarachnoid hemorrhage</li>\r\n	<li>Active internal bleeding</li>\r\n	<li>Recent (within 3 months) intracranial or intraspinal surgery or serious head trauma</li>\r\n	<li>Presence of intracranial conditions that may increase the risk of bleeding (e.g., some neoplasms, arteriovenous malformations, or aneurysms)</li>\r\n	<li>Bleeding diathesis</li>\r\n	<li>Current severe uncontrolled hypertension.</li>\r\n</ul>\r\n\r\n<p><strong>Acute Myocardial Infarction or Pulmonary Embolism</strong>: Do not administer Alteplase for treatment of AMI or PE in the following situations in which the risk of bleeding is greater than the potential benefit:</p>\r\n\r\n<ul>\r\n	<li>Active internal bleeding</li>\r\n	<li>History of recent stroke</li>\r\n	<li>Recent (within 3 months) intracranial or intraspinal surgery or serious head trauma</li>\r\n	<li>Presence of intracranial conditions that may increase the risk of bleeding (e.g. some neoplasms, arteriovenous malformations, or aneurysms)</li>\r\n	<li>Bleeding diathesis</li>\r\n	<li>Current severe uncontrolled hypertension.</li>\r\n</ul>', '<p>The following adverse reactions are:</p>\r\n\r\n<ul>\r\n	<li>Bleeding&nbsp;</li>\r\n	<li>Orolingual Angioedema&nbsp;</li>\r\n	<li>Cholesterol Embolization</li>\r\n	<li>Reembolization of Deep Venous Thrombi during Treatment for Acute Massive Pulmonary</li>\r\n	<li>Embolism.</li>\r\n</ul>', '<p>Pregnancy Category C. Alteplase is embryocidal in rabbits when intravenously administered in doses of approximately two times (3 mg/kg) the human dose for AMI. No maternal or fetal toxicity was evident at 0.65 times (1 mg/kg) the human dose in pregnant rats and rabbits dosed during the period of organogenesis. There are no adequate and well-controlled studies in pregnant women. It is not known whether Alteplase is excreted in human milk. Many drugs are excreted in human milk.</p>', '<ul>\r\n	<li>Increases the risk of bleeding. Avoid intramuscular injections. Monitor for bleeding. If serious bleeding occurs, discontinue Alteplase.</li>\r\n	<li>Monitor patients during and for several hours after infusion for orolingual angioedema. If angioedema develops, discontinue Alteplase.</li>\r\n	<li>Cholesterol embolism has been reported rarely in patients treated with thrombolytic agents.</li>\r\n	<li>Consider the risk of reembolization from the lysis of underlying deep venous thrombi in patients with pulmonary embolism.</li>\r\n</ul>', NULL, '<p>Anti-platelet drugs, Fibrinolytics (Thrombolytics)</p>', '<p>Store lyophilized Alteplase at controlled room temperature not to exceed 30&deg;C, or under refrigeration (2-8&deg;C). Protect the lyophilized material during extended storage from excessive exposure to light. If stored between 2-30&deg;C, Alteplase may be used within 8 hours following reconstitution. Discard any unused solution after administration is complete. Do not use beyond the expiration date stamped on the vial.</p>', '<p>Pediatric Use: Safety and effectiveness of Alteplase in pediatric patients have not been established.<br />\r\n<br />\r\nGeriatric Use:</p>\r\n\r\n<ul>\r\n	<li><strong>Acute Ischemic Stroke</strong>: In exploratory, multivariate analyses of Studies 1 and 2, age greater than 77 years was one of several interrelated baseline characteristics associated with an increased risk of intracranial hemorrhage. Efficacy results suggest a reduced but still favorable clinical outcome for Alteplase-treated elderly.</li>\r\n	<li><strong>Acute Myocardial Infarction</strong>: In a large trial of accelerated-infusion Alteplase that enrolled 41,021 patients with AMI to one of four thrombolytic regimens [see Clinical Studies (14.2)], patients over 75 years of age, a predefined subgroup, comprised 12% of enrolment. In these patients, the incidence of stroke was 4.0% for the Alteplase accelerated infusion group, 2.8% for streptokinase IV [SK (IV)], and 3.2% for streptokinase SQ [SK (SQ)]. The incidence of combined 30-day mortality or nonfatal stroke was 20.6% for accelerated infusion of Alteplase, 21.5% for SK (IV), and 22.0% for SK (SQ).</li>\r\n</ul>', '2022-02-14 06:39:30', '2022-03-15 05:13:18'),
(69, 69, '<p>This spray is indicated for the tratment of Hyperhidrosis.</p>', NULL, '<p>Initially apply this spray in the morning &amp; evening after drying the affected areas carefully. The frequency of application may be reduced to twice a week or less after improving the condition.</p>', NULL, '<p>Contraindicated in any other ingredient of this preparations.</p>', NULL, NULL, NULL, NULL, '<p>Miscellaneous topical agents</p>', '<p>Keep below 30&deg;C temperature, away from light &amp; moisture. Keep out of the reach of children.</p>', NULL, '2022-02-14 06:40:11', '2022-03-15 05:17:35'),
(70, 70, '<p>Aluminium Chloride Hexahydrate is indicated for the treatment of excessive perspiration of the underarms, hands, feet and scalp.</p>', '<p>Aluminium Chloride Hexahydrate acts locally in the stratum corneum and terminal duct to relieve hyperhidrosis. Aluminium salts cause an obstruction of the ducts of sweat glands at the skin surface. It seems that the metal (Aluminium) ions precipitate with mucopolysaccharides, damaging epithelial cells along with the duct lumen and forms a plug (gel) that blocks sweat output.</p>', '<p><strong>Step 1</strong>: Apply Aluminium Chloride Hexahydrate topical solution at night after drying the affected areas carefully.<br />\r\n<br />\r\n<strong>Step 2</strong>: Wash off in the morning. Do not re-apply the product during the day.<br />\r\n<br />\r\n<strong>Step 3</strong>: Initially the product may be applied every night until sweating stops during the day. The frequency of application may be reduced to twice a week or less, if excess sweating is stopped during the day.</p>', '<p>There are no known drug interactions for Aluminium Chloride Hexahydrate topical solution.</p>', '<p>Aluminium Chloride Hexahydrate is contraindicated in patients with known hypersensitivity to any of its components.</p>', '<p>Aluminium Chloride Hexahydrate is normally well tolerated and adverse effects are only mild and short-lasting. But sometimes irritation of the skin like- stinging, burning, redness, swelling, tingling or itching of treated skin areas may occur. These irritations may be alleviated by use of a weak corticosteroid cream.</p>', '<p>There are no restrictions on the use of this medication during pregnancy and lactation.</p>', '<p>For external use only. Do not apply this medication to broken, irritated or recently shaved skin. Avoid contact with eyes, mouth, nose and lips. Avoid direct contact with clothing and polished metal or jewellery surfaces. Keep out of reach of children.</p>', NULL, '<p>Miscellaneous topical agents</p>', '<p>Store in a cool &amp; dry place, protected from light. Keep out of reach of children. Keep away from naked flame. Store upright.</p>', NULL, '2022-02-14 06:40:46', '2022-03-15 05:25:52'),
(71, 71, '<p>Aluminium Hydroxide and Magnesium Hydroxide is indicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach &amp; dyspepsia.</p>', '<p>This drug is well-balanced combination of essential non-systemic antacids which excel in efficacy and palatability. These are dependable antacid preparations without acid rebound, constipating or cathertic effects. Both the preparations provide symptomatic relief of hyperacidity associated with heartburn, acid ingestion or sour stomach.<br />\r\n<br />\r\nAluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation.</p>', '<p><strong>Tablet</strong>: Two tablets 1-3 hours after meal and at bed time or as directed by the physician.<br />\r\n<br />\r\n<strong>Suspension</strong>: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician.</p>', '<p>This drug inhibits the absorption of following drugs: Azithromycin, cefpodoxime, ciprofloxacin, isoniazid, rifampicin, norfloxacin, ofloxacin, pivampicillin, tetracyclines, Gabapentin and phenytoin, Itraconazole, ketoconazole, Chloroquine, hydroxychloroquine and Phenothiazines.</p>', '<p>This is contraindicated in hypophosphataemia. It is also contraindicated in alkalosis and hypermagnesaemia where abdominal distention may be due to partial or complete intestinal obstruction.</p>', '<p>Long term use of any antacid results in alkaluria, which may predispose to nephrolithiasis by forming precipitation of calcium phosphate.</p>', '<p>It is advised to avoid antacid preparations in the first trimester of pregnancy.</p>', '<p>Antacids reduce the absorption of tetracycline when given concomitantly. These should not be used concomitantly</p>', NULL, '<p>Antacids</p>', '<p>Aluminium Hydroxide and Magnesium Hydroxide is indicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach &amp; dyspepsia.</p>', NULL, '2022-02-14 06:41:35', '2022-07-02 05:33:05'),
(72, 72, '<p>Aluminium Oxide &amp; Magnesium Trisilicate is indicated in Heartburn, Indigestion, Gastric Hyperacidity, Peptic ulcer disease, Gastroesophageal reflux disorder (GERD)</p>', '<p><strong>Aluminum hydroxide&nbsp;</strong>neutralizes stomach hydrocloride to form AICI3&nbsp;salt plus water; increases gastric pH.<br />\r\n<br />\r\n<strong>Magnesium Trisilicate</strong>&nbsp;neutralizes gastric acidity by increasing gastric pH</p>', '<p>Take 2-4 teaspoonful after meals and at bedtime as needed (up to 4 times a day)</p>', '<p><strong>Aluminium Hydroxide</strong>: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.<br />\r\n<br />\r\n<strong>Magnesium Trisilicate</strong>: None well documented.</p>', '<p>Hypophosphataemia</p>', '<p>Diarrhoea, constipation, nausea, vomiting.</p>', '<p>Pregnancy Category- Not Classified. FDA has not yet classified the drug into a specified pregnancy category.</p>', '<p>Renal dysfunction, low phosphate diet, prolonged use.</p>', NULL, '<p>Antacid with laxative action, Antacids</p>', NULL, NULL, '2022-02-14 06:42:10', '2022-03-15 05:35:01'),
(73, 73, '<p>Alverine Citrate is indicated in-</p>\r\n\r\n<ul>\r\n	<li>Irritable Bowel Syndrome</li>\r\n	<li>Bowel movement disturbances caused by small sacs or pouches in the wall of the gut (diverticular disease)</li>\r\n	<li>Abdominal pain associated with menstrual periods (Primary dysmenorrhea)</li>\r\n	<li>Relief of other conditions associated with spasm of involuntary muscle</li>\r\n</ul>', '<p>Alverine Citrate is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine Citrate acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasm which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Alverine Citrate also relaxes the smooth muscle in the uterus. It is therefore also used to treat painful menstruation, which is caused by muscle spasm in the uterus (dysmenorrhea).</p>', '<p><strong>Adult</strong>: Orally: 60-120 mg 1-3 times daily.</p>', '<p>There are no drug interactions reported with this medicine.</p>', '<p>Paralytic ileus or known hypersensitivity to any of the ingredients.</p>', '<p>Possible side effects may include nausea, headache, dizziness, itching, rash and allergic reactions.</p>', '<p>Although no teratogenic effects have been reported, use during pregnancy or lactation is not recommended as evidence of safety in preclinical studies are limited.</p>', '<p>Avoid Alverine Citrate in patients with intestinal obstruction or paralytic ileus.</p>', '<p>Can produce hypotension and atropine like-toxic effects. Management for overdose is as like as atropine poisoning with continuation of supportive therapy for hypotension.</p>', '<p>Anticholinergics</p>', '<p>Store in a cool and dry place, away from light. Keep all medicines out of the reach of children. Store below 25&deg;C temperature.</p>', '<p>Children under 12 years: Not recommended</p>', '2022-02-14 06:42:34', '2022-03-15 05:39:45');
